

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number  
**WO 02/44426 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

Avenue, #3, Chicago, IL 60637 (US). **BONEN, Denise**  
[US/US]; 1141 S. Bell Avenue, Chicago, IL 60643 (US).

(21) International Application Number: **PCT/US01/51068**

(74) Agents: **CARROLL, Peter, G. et al.**; Medlen & Carroll,  
LLP, Suite 350, 101 Howard Street, San Francisco, CA  
94105 (US).

(22) International Filing Date: 26 October 2001 (26.10.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(26) Publication Language: English

(30) Priority Data:  
60/244,266 30 October 2000 (30.10.2000) US  
60/286,316 25 April 2001 (25.04.2001) US  
Not furnished 26 October 2001 (26.10.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(71) Applicants (*for all designated States except US*): **RE-  
GENTS OF THE UNIVERSITY OF MICHIGAN**  
[US/US]; 3003 S. State Street, Ann Arbor, MI 48109 (US).  
**THE UNIVERSITY OF CHICAGO** [US/US]; 5640  
South Ellis Avenue, Chicago, IL 60637 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **NUNEZ, Gabriel**  
[US/US]; 2121 Crestland, Ann Arbor, MI 48104 (US).  
**INOHARA, Naohiro** [JP/US]; 931 Sunnyside, Ann  
Arbor, MI 48103 (US). **OGURA, Yasunori** [JP/US];  
2200 Fuller Ct., #814B, Ann Arbor, MI 48105 (US).  
**CHO, Judy** [US/US]; 1833 N. Dayton, Chicago, IL 60614  
(US). **NICOLAE, Dan, L.** [US/US]; 5547 S. Dorchester

Published:

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



**WO 02/44426 A2**

(54) Title: **NOD2 NUCLEIC ACIDS AND PROTEINS**

(57) Abstract: The present invention relates to intracellular signalling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides isolated nucleotide sequence encoding Nod2, isolated Nod2 peptides, antibodies that specifically bind Nod2, methods for the detection of Nod2, and methods for screening compounds for the ability to alter Nod2 associated signal transduction. The present invention also provides Nod2 variant alleles. The present invention further provides methods of identifying individuals at increased risk of developing Crohn's disease.

## NOD2 NUCLEIC ACIDS AND PROTEINS

This application claims priority to U.S. provisional patent applications serial numbers 60/244,266 and 60/286,316 and US application serial number not assigned, filed 10/26/01, each of which is herein incorporated by reference in its entirety. This patent  
5 application was supported in part by grant CA-64556 from the National Institutes of Health. The government has certain rights in the invention.

### FIELD OF THE INVENTION

The present invention relates to intracellular signaling molecules, in particular the  
10 Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides assays for the detection of Nod2 and Nod2 polymorphisms associated with disease states. The present invention further provides inhibitors of Nod2 signaling and methods for identifying Nod2 pathway components. The present invention additionally provides methods of determining an individual's risk of developing disease states.

### 15 BACKGROUND OF THE INVENTION

Inflammatory bowel diseases (IBD) are defined by chronic, relapsing intestinal inflammation of obscure origin. IBD refers to two distinct disorders, Crohn's disease and ulcerative colitis (UC). Both diseases appear to involve either a dysregulated immune response to GI tract antigens, a mucosal barrier breach, and/or an adverse inflammatory  
20 reaction to a persistent intestinal infection. The GI tract luminal contents and bacteria constantly stimulate the mucosal immune system, and a delicate balance of proinflammatory and anti-inflammatory cells and molecules maintains the integrity of the GI tract, without eliciting severe and damaging inflammation. It is unknown how the IBD inflammatory cascade begins, but constant GI antigen-dependent stimulation of the  
25 mucosal and systemic immune systems perpetuates the inflammatory cascade and drives lesion formation.

There is no known cure for IBD, which afflicts 2 million Americans. Current methods of managing IBD symptoms cost an estimated \$1.2 billion annually in the United States alone.

30 In patients with IBD, ulcers and inflammation of the inner lining of the intestines lead to symptoms of abdominal pain, diarrhea, and rectal bleeding. Ulcerative colitis

occurs in the large intestine, while in Crohn's disease, the disease can involve the entire GI tract as well as the small and large intestines. For most patients, IBD is a chronic condition with symptoms lasting for months to years. It is most common in young adults, but can occur at any age. It is found worldwide, but is most common in industrialized countries such as the United States, England, and northern Europe. It is especially common in people of Jewish descent and has racial differences in incidence as well. The clinical symptoms of IBD are intermittent rectal bleeding, crampy abdominal pain, weight loss and diarrhea. Diagnosis of IBD is based on the clinical symptoms, the use of a barium enema, but direct visualization (sigmoidoscopy or colonoscopy) is the most accurate test. Protracted IBD is a risk factor for colon cancer. The risk for cancer begins to rise significantly after eight to ten years of IBD.

Some patients with UC only have disease in the rectum (proctitis). Others with UC have disease limited to the rectum and the adjacent left colon (proctosigmoiditis). Yet others have UC of the entire colon (universal IBD). Symptoms of UC are generally more severe with more extensive disease (larger portion of the colon involved with disease).

The prognosis for patients with disease limited to the rectum (proctitis) or UC limited to the end of the left colon (proctosigmoiditis) is better than that of full colon UC. Brief periodic treatments using oral medications or enemas may be sufficient. In those with more extensive disease, blood loss from the inflamed intestines can lead to anemia, and may require treatment with iron supplements or even blood transfusions. Rarely, the colon can acutely dilate to a large size when the inflammation becomes very severe. This condition is called toxic megacolon. Patients with toxic megacolon are extremely ill with fever, abdominal pain and distention, dehydration, and malnutrition. Unless the patient improves rapidly with medication, surgery is usually necessary to prevent colon rupture.

Crohn's disease can occur in all regions of the gastrointestinal tract. With this disease intestinal obstruction due to inflammation and fibrosis occurs in a large number of patients. Granulomas and fistula formation are frequent complications of Crohn's disease. Disease progression consequences include intravenous feeding, surgery and colostomy.

The most commonly used medications to treat IBD are anti-inflammatory drugs such as the salicylates. The salicylate preparations have been effective in treating mild to

moderate disease. They can also decrease the frequency of disease flares when the medications are taken on a prolonged basis. Examples of salicylates include sulfasalazine, olsalazine, and mesalamine. All of these medications are given orally in high doses for maximal therapeutic benefit. These medicines are not without side effects.

5 Azulfidine can cause upset stomach when taken in high doses, and rare cases of mild kidney inflammation have been reported with some salicylate preparations.

Corticosteroids are more potent and faster-acting than salicylates in the treatment of IBD, but potentially serious side effects limit the use of corticosteroids to patients with more severe disease. Side effects of corticosteroids usually occur with long-term use.

10 They include thinning of the bone and skin, infections, diabetes, muscle wasting, rounding of faces, psychiatric disturbances, and, on rare occasions, destruction of hip joints.

In IBD patients that do not respond to salicylates or corticosteroids, medications that suppress the immune system are used. Examples of immunosuppressants include

15 azathioprine and 6-mercaptopurine. Immunosuppressants used in this situation help to control IBD and allow gradual reduction or elimination of corticosteroids. However, immunosuppressants cause increased risk of infection, renal insufficiency, and the need for hospitalization.

Clearly there is a great need for identification of the molecular basis of IBD, or its

20 associated disorders Crohn's disease and ulcerative colitis.

## SUMMARY OF THE INVENTION

The present invention relates to intracellular signaling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention

25 provides assays for the detection of Nod2 and Nod2 polymorphisms associated with disease states. The present invention further provides inhibitors of Nod2 signaling and methods for identifying Nod2 pathway components.

Thus, in some embodiments, the present invention provides an isolated and purified nucleic acid comprising a sequence encoding a protein selected from the group

30 consisting of SEQ ID NOs: 2, 3, and 34. In some embodiments, the nucleic acid sequence is operably linked to a heterologous promoter. In some embodiments, the



nucleic acid sequence is contained within a vector. In some further embodiments, the vector is within a host cell.

5 In other embodiments, the present invention provides an isolated and purified nucleic acid sequence that hybridizes under conditions of low stringency to a nucleic acid selected from the group consisting of SEQ ID NOs: 1 and 33. In some embodiments, the nucleic acid sequence encodes a protein that activates NF- $\kappa$ B. In other embodiments, the present invention provides a vector comprising the nucleic acid sequence. In still other embodiments, the vector is within a host cell. In some embodiments, the host cell is located in an organism selected from the group consisting of a plant and an animal.

10 In yet other embodiments the present invention provides a protein encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 1, 33 and variants thereof that are at least 80% identical to SEQ ID NOs: 1 and 33 and wherein the protein has at least one activity of Nod2. In some embodiments, the activity is activation of NF- $\kappa$ B. In other embodiments, the activity is binding to RICK. In some embodiments, the protein is at least 90% identical to SEQ ID NOs: 1 and 33. In other embodiments, the protein is at least 95% identical to SEQ ID NOs: 1 and 33.

15 In still further embodiments, the present invention provides a method for producing variants of Nod2 comprising: providing a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 and 33; mutagenizing the nucleic acid sequence; and screening the variant for Nod2 activity.

20 In additional embodiments, the present invention provides a nucleic acid encoding Nod2, wherein the Nod2 competes for binding to RICK with a protein encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 and 33.

25 In other embodiments, the present invention provides a composition comprising a nucleic acid that inhibits the binding of at least a portion of a nucleic acid selected from the group consisting of SEQ ID NOs: 1 and 33 to their complementary sequences. In yet other embodiments, the present invention provides a polynucleotide sequence comprising at least fifteen nucleotides capable of hybridizing under stringent conditions to the isolated nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 and 33.

The present invention also provides a method for detection of a polynucleotide encoding Nod2 protein in a biological sample suspected of containing a polynucleotide encoding Nod2. The method includes hybridizing the polynucleotide sequence selected from the group consisting of SEQ ID NOs: 1 and 33 and variants thereof that are at least  
5 80% identical to SEQ ID NOs: 1 and 33 (and wherein the protein has at least one activity of Nod2) to the nucleic acid of the biological sample to produce a hybridization complex. In some embodiments, the method further includes the step of detecting the hybridization complex, wherein the presence of the hybridization complex indicates the presence of a polynucleotide encoding Nod2 in the biological sample. In some embodiments, prior to  
10 hybridization, the nucleic acid of the biological sample is amplified.

The present invention further provides a method for screening compounds for the ability to alter Nod2 activity, comprising: providing: a first polypeptide sequence comprising at least a portion of Nod2; ii) a second polypeptide sequence comprising at least a portion of a protein known to interact with Nod2; and iii) one or more test  
15 compounds; combining in any order, the first polypeptide sequence comprising at least a portion of Nod2, the second polypeptide sequence comprising at least a portion of a protein known to interact with Nod2, and one or more test compounds under conditions such that the first polypeptide sequence, the second polypeptide sequence, and the test compound interact; and detecting the presence or absence of an interaction between the  
20 polypeptide sequence comprising at least a portion of Nod2 and the polypeptide sequence comprising at least a portion of a protein known to interact with Nod2. In some embodiments, the first polypeptide sequence is selected from the group consisting of SEQ ID NOs: 2-17 and 34. In some embodiments, the second polypeptide comprises RICK.

25 The present invention also provides a purified polypeptide selected from the group consisting of SEQ ID NOs: 2, 3, and 34.

The present invention additionally provides a compound capable of inhibiting the binding of a Nod2 to a RICK polypeptide.

In some embodiments, the present invention provides a method of identifying  
30 subjects at risk of developing Crohn's disease comprising: providing nucleic acid from a subject, wherein said nucleic acid comprises a Nod2 gene; and detecting the presence or

absence of one or more variations in the Nod2 gene. In some embodiments, the method further comprises determining if the subject is at risk of developing Crohn's disease based on the presence or absence of the one or more variations. In some embodiments, the determining comprises determining a genotype relative risk for said subject. In other  
5       embodiments, the determining comprises determining a population attributable risk for said subject. In some embodiments, the variation is a mutation. In other embodiments, the variation is a polymorphism. In some embodiments, the mutation is a cytosine residue insertion. In some embodiments, the mutation causes a deletion of at least one LRR repeat of Nod2. The present invention is not limited to the detection of a specific  
10       variation. Any variation may be detected, including but not limited to, those selected from the group consisting of the nucleic acid sequences described by SEQ ID NOs: 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88. In some embodiments, the detecting step is accomplished by hybridization analysis. In some embodiments, the detecting step comprises comparing the sequence of the nucleic acid to the sequence of a wild-type  
15       Nod2 nucleic acid.

      The present invention further provides a kit for determining if a subject is at risk of developing Crohn's disease comprising: a detection assay capable of specifically detecting a variant Nod2 allele; and instructions for determining if the subject is at increased risk of developing Crohn's disease. In some embodiments, the detection assay  
20       comprises a nucleic acid probe that hybridizes under stringent conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 70-83.

      In still further embodiments, the present invention provides an isolated nucleic acid comprising a sequence encoding a polypeptide selected from the group consisting of SEQ ID NOs: 55, 57, 59, 61, 63, 65, 67, 69, 85, 87, and 89. In some embodiments, the  
25       sequence is operably linked to a heterologous promoter. In some embodiments, the sequence is contained within a vector. In some embodiments, the vector is contained in a host cell. In some embodiments, the host cell is located in an organism selected from the group consisting of a plant and an animal.

      In yet other embodiments, the present invention provides an isolated nucleic acid  
30       sequence selected from the group consisting of SEQ ID NOs: 54, 56, 58, 60, 62, 64, 66,

68, 84, 86, and 88. In some embodiments, the present invention provides a computer readable medium encoding a representation of the nucleic acid sequence.

In still other embodiments, the present invention provides an isolated polypeptide selected from the group consisting of SEQ ID NOs: 55, 57, 59, 61, 63, 65, 67, 69, 85, 87,  
5 and 89.

In some embodiments, the present invention provides a computer readable medium encoding a representation of the polypeptide.

The present invention also provides a computer implemented method of  
determining a patient's risk of developing Crohn's disease comprising providing nucleic  
10 acid from a patient, wherein the nucleic acid comprises a Nod2 gene; and a computer  
comprising software for the prediction of a patient's risk of developing Crohn's disease;  
and detecting the presence of one or more variations in the patient's Nod2 gene to  
generate genetic variation information; entering the genetic variation information into  
said computer; and calculating the patient's risk with the software. In some  
15 embodiments, the method further provides the step of displaying the patient's risk. In  
some embodiments, the risk comprises a genotype relative risk. In other embodiments,  
the risk comprises a population attributable risk. In other embodiments, the determining  
comprises determining a population attributable risk for said subject. In some  
embodiments, the variation is a mutation. In other embodiments, the variation is a  
20 polymorphism. In some embodiments, the mutation is a cytosine residue insertion. In  
some embodiments, the mutation causes a deletion of at least one LRR repeat of Nod2.  
The present invention is not limited to the detection of a specific variation. Any variation  
may be detected, including but not limited to, those selected from the group consisting of  
the nucleic acid sequences described by SEQ ID NOs: 33, 54, 56, 58, 60, 62, 64, 66, 68,  
25 84, 86, and 88. In some embodiments, the detecting step comprises comparing the  
sequence of the nucleic acid to the sequence of a wild-type Nod2 nucleic acid.

## DESCRIPTION OF THE FIGURES

Figure 1 shows the deduced amino acid sequence and domain structure of human  
30 Nod2. Figure 1A shows the amino acid sequence of Nod2 (SEQ ID NO: 4). Caspase  
recruitment domains (CARD 1 and 2; SEQ ID NOs: 5 and 6), nucleotide binding domain

(NBD; SEQ ID NO: 7) and leucine-rich repeats (LRRs; SEQ ID NOs: 8-17) are indicated by reverse highlight, underline and arrows, respectively. The consensus sequence of the P-loop (Walker A box; SEQ ID NO: 18) and the  $Mg^{2+}$  binding site (Walker B box; SEQ ID NO: 19) are indicated by boxes. Figure 1B shows the domain structure of Nod2.

- 5 Numbers correspond to amino acid residues shown in panel A. The region homologous to the CARDS, NBD and LRRs are indicated by black closed, dark closed, and hatched boxes, respectively.

Figure 2 an alignment of human Nod2 and related proteins. Figure 2A shows an alignment of CARDs of Nod2 (SEQ ID NOs: 5 and 6), Nod1 (GeneBank accession  
10 number AF113925; SEQ ID NO: 20), RICK (AF027706; SEQ ID NO: 21), ARC (AF043244; SEQ ID NO: 22), RAIDD (U79115; SEQ ID NO: 23), Caspase-2 (U13021; SEQ ID NO: 24), Ced-3 (L29052; SEQ ID NO: 25), Ced-4 (X69016; SEQ ID NO: 26), Caspase-9 (U56390; SEQ ID NO: 27), Apaf-I (AF013263; SEQ ID NO: 28) and c-IAP-1 (L49431; SEQ ID NO: 29). Hydrophobic residues are shown in reverse highlighting.  
15 Negatively and positively charged residues are highlighted in light and dark gray, respectively. Proline and glycine residues ( $\alpha\beta$  breaker) are bolded. The putative  $\alpha$  helices, H1 to H5, are shown according to the three dimensional structure of the CARD of RAIDD (Chou *et al.*, Cell, 94:171 [1998]). Figure 2B shows an alignment of NBDs of Nod2 (SEQ ID NO: 7), Nod1 (SEQ ID NO: 30), Apaf-I (SEQ ID NO: 31) and Ced-4  
20 (SEQ ID NO: 32). The residues identical and similar to those of Nod2 are shown by reverse and dark highlighting, respectively. The consensus sequence of the P-loop (Walker A box) and the  $Mg^{2+}$  binding site (Walker B box) are indicated by boxes. The residues identical and similar to those of Nod2 are shown by reverse and dark highlighting, respectively. Figure 2C shows an alignment of LRRs of Nod2 (SEQ ID  
25 NOs: 8-17). The conserved positions with leucine and other hydrophobic residues are indicated by dark and light gray highlighting, respectively. The putative ( $\alpha$ helix and  $\beta$ sheet are shown according to the three dimensional structure of the ribonuclease inhibitor (Kobe and Deisenhofer, Curr. Opin. Struct Biol., 5:409-416 [1995]).

Figure 3 shows an expression analysis of Nod2. Figure 3A shows a northern blot  
30 analysis of Nod2 expression in human tissues; PBL (peripheral blood leukocytes). Figure 3B shows RT-PCR analysis of Nod2 expression in granulocyte, monocyte and

lymphocyte enriched populations. Two sets of Nod2 oligonucleotide primers (P1-P2 and P3-P4) were used to amplify the nucleotide sequences of the CARDs and LRRs, respectively. Figure 3C shows the nucleotide sequence of the 5' region of nod2. Two potential in-frame translation initiation sites separated by 81 nucleotides are indicated by arrows. Figure 3D shows immunoblotting of nod2 gene products expressed in HEK293T cells. Cells were transfected with control plasmid (lane 1), or constructs containing both potential translation initiator sites of Nod2 (lane 2), or as a control the second translation initiation site corresponding to that of Nod2b (lane 3) or the most NH<sub>2</sub>-terminal translation initiation site (lane 4) in the context of a canonical translation initiation motif. In all cases, a Nod2 protein lacking residues 302-1040 and HA tagged at its COOH terminus was expressed to facilitate detection of nod2 gene products. Nod2 proteins were detected by immunoblotting with anti-HA antibody and indicated by a and b.

Figure 4 shows a mutational analysis of Nod2. Figure 4A shows wt and mutant Nod2 proteins. CARDs, NBD and LRRs are indicated by black closed, dark closed, and hatched boxes, respectively. Numbers represent amino acid residue in Nod2 protein. Figure 4B shows expression analysis of wt and mutant Nod2 proteins. HEK293T cells were transfected with control plasmid (-) or 5 µg of plasmids producing the indicated HA-tagged Nod2 proteins. Extracts from equal number of cells were immunoprecipitated with rabbit anti-HA antibody and immunoblotted with mouse monoclonal anti-HA antibody. The expected size of CARDs, CARD1 and LRRs mutant proteins are indicated by black arrowheads. Figure 4C shows NF-κB Activation by Nod2 proteins. Induction of NF-κB activation was determined from triplicate culture of HEK293T cells co-transfected with the indicated amount of wt or mutant Nod2 expression plasmids in the presence of pBVix-Luc and pEF-BOS-βgal as described below. Values represent mean ± SD of triplicate cultures.

Figure 5 shows that Nod2 acts through the IKK complex to activate NF-κB. Figure 5A shows inhibition of Nod2 and TNFα-induced NF-κB activation by dominant negative mutant proteins of the NF-κB pathway. Induction of NF-κB activation was determined in triplicate cultures of HEK293T cells transfected with 30 ng of Nod2 plasmid (open bars) or stimulated with 10 ng/ml of TNFα for 4 h (closed bars) and 70 ng of I-κBα S32A/S36A, IKKα K44A, IKKβ K44A, RICK (406-540) or RIP (558-671)

expression plasmid in the presence of pBVluc and pEF-BOS- $\beta$ -gal. Results are presented as a percent of values obtained with Nod2 and control plasmid. In the experiment shown, Nod2 and TNF $\alpha$  induced  $58 \pm 8$ -fold and  $14 \pm 1$ -fold activation of NF- $\kappa$ B, respectively. Values represent mean  $\pm$  SD of triplicate cultures. Figure 5B shows induction of NF- $\kappa$ B in parental Rat-1 and derivative 5R cells. Induction of NF- $\kappa$ B activation was determined from triplicate cultures of  $1 \times 10^5$  HEK293T cells co-transfected with the indicated plasmids and pBVluc in the presence of control plasmid pEF-BOS- $\beta$ -gal. Values represent mean  $\pm$  SD of triplicate cultures.

Figure 6 shows the interaction of Nod2 with RICK. Figures 6A and B show the interaction between wt and mutant Nod2 with RICK. HEK293T cells were co-transfected with wt or mutant Nod2 and RICK expression plasmid. The co-immunoprecipitated RICK was detected by immunoblotting with anti-Flag antibody (upper panel). Nod2 immunoprecipitates are shown in lower panel. Total lysates were blotted with anti-Flag antibody (middle panel). Figure 6C shows the interaction between Nod2 and wt and mutant RICK. HEK293T cells were co-transfected with wt Nod2 and wt or mutant RICK $\Delta$ CARD (residues 1-374) or RICK-CARD (residues 374-540) expression plasmid. The co-immunoprecipitated Nod2 was detected by immunoblotting with anti-HA antibody (upper panel). Total lysates were blotted with anti-Flag (middle panel) or anti-HA (lower panel) antibody. A background band is shown by asterisk.

Figure 7 shows that enforced oligomerization of Nod2 induces NF- $\kappa$ B activation. Figure 7A shows an expression analysis of wt and mutant Fpk3-Nod2 chimeric proteins. HEK293T cells were transfected with of control plasmid (-) or plasmids producing the indicated Myc-tagged Fpk3Nod2 proteins. Extracts from equal number of cells was immunoprecipitated and immunoblotted with rabbit anti-Myc antibody. Figure 7B shows that enforced oligomerization of Nod2 induces NF- $\kappa$ B activation.  $2 \times 10^5$  HEK293T cells were transfected with 1 ng of the indicated plasmids in the presence of pBVluc and pEF-BOS- $\beta$ -gal. 8 hr post-transfection, cells were treated with 500 nM AP1510 (black bars) or left untreated (white bars). 24 hr post-transfection, the B-dependent transcription was determined as described below. Values represent mean  $\pm$  SD of triplicate cultures.

Figure 8 shows the response of HEK293T cells expressing Nod1 to bacterial and fungal pathogen components. Figure 8A shows data from  $1 \times 10^5$  HEK293T cells that

were transfected with 0.3 ng of pcDNA3-Flag (white bars) or pcDNA3Nod1-Flag (black bars) in the presence of 600 ng of pcDNA3, 73 ng pEF1BOS- $\beta$ gal and 7.3 ng pBXIV-luc. 8 hr post-transfection, cells were treated with 10  $\mu$ g/ml of each pathogen product, lipoteichoic acid (LTA) or peptidoglycan (PGN) from *Staphylococcus aureus*,  
 5 lipopolysaccharide (LPS) from *Escherichia coli* 055:B5, mannan from *Candida albicans* 20A, synthetic soluble bacterial lipoprotein (SBLP) or left untreated (Control). 24 hr post-transfection, B-dependent transcription was determined by luciferase activity relative and values normalized to  $\beta$ -galactosidase in triplicate cultures. As control, the inset showed Nod1 proteins immunodetected with anti-FLAG Ab in lysates from cells  
 10 transfected with 10 ng pcDNA3-Nod1 in presence (right) and absence (left) of 10  $\mu$ g/ml LPS. Figure 8B shows data from  $1 \times 10^5$  HEK293T cells that were transfected with 0.3 ng of pcDNA3-Flag (-), pcDNA3-Nod1-Flag (Nod1) or pcDNA3-Nod1 (1-648)-Flag (Nod1 $\Delta$ LRR), 300 ng pcDNA3-FLAG-TLR4, 3 ng pCMVIL1R1 plus 100 ng pcDNA3-IL1 $\beta$ -HA (IL1) or 1 ng pcDNA3-RIP-Flag (RIP) in the presence of 600 ng of  
 15 pcDNA3, 73 ng pEF1BOS- $\beta$ gal and 7.3 ng pBXIV-luc. Eight hr post-transfection, cells were treated with 10  $\mu$ g/n-A LPS (black bars) or left untreated (white bars). Twenty-four hr post-transfection,  $\kappa$ B-dependent transcription was determined as described above.

Figure 9 shows differential responsiveness of Nod1 and Nod2 to LPS from various sources.  $1 \times 10^5$  HEK293T cells were transfected with 0.3 ng of pcDNA3-Flag (-), pcDNA3-Nod1-Flag (Nod1) or pcDNA3-Nod1 (1-648)-Flag (Nod1 $\Delta$ LRR), 0.03ng of  
 20 pcDNA3-Nod2 or pcDNA3-Nod2 (1-744)-Flag (Nod2 $\Delta$ LRR) in the presence of 600 ng of pcDNA3, 73 ng pEF1BOS- $\beta$ gal and 7.3 ng pBXIV-luc. 8 hr post-transfection, cells were treated with 10  $\mu$ g/ml each pathogen, LTA from *S. aureus* or *S. sanguis*, PGN from *S. aureus*, LPS from *Pseudomonas aeruginosa*, *Shigella flexneri* 1A, *Serratia marcescens*, *Salmonella typhimurium*, *Klebsiella pneumoniae* or *E. coli* 055:B5, or left  
 25 alone without treatment. For TNF $\alpha$  stimulation, 22 hrs after transfection, cells were incubated with 10 ng/ml of TNF $\alpha$  for 2 hr.

Figure 10 shows the physical interaction between Nod1 and LPS.  $1 \times 10^8$  HEK293T cells were transfected with 30  $\mu$ g of pcDNA3-Flag-Nod1, pRK7-FLAG-IKK $\beta$ ,  
 30 pcDNA3-FLAG-IKK $\alpha$ , pcDNA3-FLAG-IKK $\gamma$  or pcDNA3-CIPER-FLAG (Takeuchi *et al.*, Immunity, 4:443 [1999]). 24 hr post-transfection, S100 fractions were prepared from



transfected cells as described below. The radioactivity of [ $^3\text{H}$ ] LPS co-immunoprecipitated with anti-FLAG Ab was determined as described below. Figure 10A shows S100 lysate from transfected cells was incubated with [ $^3\text{H}$ ] LPS, anti-FLAG M2 Ab, Protein A-Sepharose and Protein G-Sepharose. Figure 10B shows data for proteins that were immunopurified first from 20 mg of S100 lysate and incubated with [ $^3\text{H}$ ] LPS in the presence of 10 mg BSA. The co-immunoprecipitated radioactivity was determined as described in detail below. Expression of each protein in 50  $\mu\text{g}$  of S100 lysate was immunodetected with anti-FLAG Ab.

Figure 11 shows the nucleic acid sequence of SEQ ID NO: 33.

Figure 12 shows the nucleic acid sequence of SEQ ID NO: 1.

Figure 13 shows the polypeptide sequence of SEQ ID NO: 2.

Figure 14 shows the polypeptide sequence of SEQ ID NO: 3.

Figure 15 shows the polypeptide sequence of SEQ ID NO: 34.

Figure 16 shows the nucleic acid (SEQ ID NOs: 35 (wild type) and 36 (mutant)) and polypeptide (SEQ ID NO: 98 (wild type) and SEQ ID NO: 99 (mutant)) of Nod2 Exon 11.

Figure 17 shows the identification of a frameshift Nod2 mutation in affected individuals from CD families. Figure 17a shows a physical map of the region of interest at 16ql2. Approximate positions of chromosomal and genetic markers are shown based on ref. 23. Human genomic BAC clone RP 11-32722 contains the *Nod2* gene and markers stSG46415 and SGC32374. The exon-intron organization of the human *Nod2* gene is shown underneath. Figure 17b shows DNA sequence electropherograms (exon 11) from control and three affected individuals from CD families. Patients from families 1 and 6 are heterozygous, whereas the patient from family 7 is homozygous for 3020InsC. The C insertion is shown by arrow. Figure 17c shows nucleotide and predicted amino acid sequence of exon 11 and flanking introns from normal control and patients with 3020CIns. Exon sequence is shown in bold. The site of C insertion is indicated by arrow. The residue (W) indicates that a nucleotide from exon 12 contributes to the codon. Figure 17d shows a schematic of the domain structure of Nod2 to illustrate the site of protein truncation. Caspase recruitment domains (CARDs), nucleotide binding

domain (NBD) and ten LRRs are shown. Residues of the tenth LRR are underlined. Numbers indicate residue positions.

Figure 18 shows the determination of transmission of the 3020InsC mutation in a CD family by allele-specific PCR. Multiplex PCR was used to generate a non-specific 533 bp product, along with allele-specific amplicons: a 319 bp fragment (wild-type) and a 214 bp fragment (3020InsC). In this family, both parents (lanes 1 and 4) are heterozygous for 3020InsC, whereas both children (lanes 2 and 3) have CD and are homozygous for 3020 InsC. Lane 5, wild type control. Lane 6, pBR322 DNA-Mspl markers. Numbers on the gel indicate the size of fragments.

Figure 19 shows the differential responsiveness of wild-type and mutant Nod2 to LPS. Figure 19a shows HEK293T cells that were co-transfected with the indicated amounts of pcDNA3-Nod2, pcDNA3-Nod2 3020InsC or pcDNA3 (vector) and pEF-BOS- $\beta$ -gal and pBVI-luc reporter plasmids in triplicate. Values represent means  $\pm$  s. d. Expression of wild-type and mutant Nod2 proteins in cell extracts is shown on top.

Figure 19b shows HEK293T cells that were cotransfected with 0.3 ng of pcDNA3-Nod2, 3 ng of pcDNA3-Nod2 3020InsC, 3 ng of pcDNA3-TLR4 plus 3 ng of pcDNA3-MD-2 (indicated by TLR4) or pcDNA3 (vector) and pEF1BOS- $\beta$ -gal and pBMV-luc in triplicate. Under these conditions, both wild-type and mutant Nod2 constructs induced similar levels of basal NF- $\kappa$ B activity. 8 hr post transfection, cells were treated with 10  $\mu$ g/ml of LPS from indicated bacteria. Values represent means  $\pm$  s.d. The results are representative of at least 3 independent experiments.

Figure 20 shows the nucleic acid sequence of SEQ ID NO: 53.

Figure 21 shows the nucleic acid sequence of SEQ ID NO: 54.

Figure 22 shows the amino acid sequence of SEQ ID NO: 55.

Figure 23 shows the nucleic acid sequence of SEQ ID NO: 56.

Figure 24 shows the amino acid sequence of SEQ ID NO: 57.

Figure 25 shows the nucleic acid sequence of SEQ ID NO: 58.

Figure 26 describes polymorphisms in the Nod2 gene. Table 1 describes the alleles and their corresponding SEQ ID Nos.

Figure 27 describes allele frequencies for the polymorphisms described in Figure 26.

- Figure 28 shows the amino acid sequence of SEQ ID NO: 59.  
Figure 29 shows the nucleic acid sequence of SEQ ID NO: 60.  
Figure 30 shows the amino acid sequence of SEQ ID NO: 61.  
Figure 31 shows the nucleic acid sequence of SEQ ID NO: 62.  
5 Figure 32 shows the amino acid sequence of SEQ ID NO: 63.  
Figure 33 shows the nucleic acid sequence of SEQ ID NO: 64.  
Figure 34 shows the amino acid sequence of SEQ ID NO: 65.  
Figure 35 shows the nucleic acid sequence of SEQ ID NO: 66.  
Figure 36 shows the amino acid sequence of SEQ ID NO: 67.  
10 Figure 37 shows the nucleic acid sequence of SEQ ID NO: 68.  
Figure 38 shows the amino acid sequence of SEQ ID NO: 69.  
Figure 39 shows the nucleic acid sequence of SEQ ID NO: 84.  
Figure 40 shows the amino acid sequence of SEQ ID NO: 85.  
Figure 41 shows the nucleic acid sequence of SEQ ID NO: 86.  
15 Figure 42 shows the amino acid sequence of SEQ ID NO: 87.  
Figure 43 shows the nucleic acid sequence of SEQ ID NO: 88.  
Figure 44 shows the amino acid sequence of SEQ ID NO: 89.

#### GENERAL DESCRIPTION OF THE INVENTION

- 20 The present invention relates to intracellular signaling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The Nod2 protein was found to have structural homology to the Nod1 protein. Apaf-1 and Nod1 (also called CARD4) are members of a family of intracellular proteins that are composed of an NH<sub>2</sub>-terminal caspase-recruitment domain (CARD), a centrally located nucleotide-binding domain  
25 (NBD) and a COOH-terminal regulatory domain (Bertin *et al.*, J. Biol. Chem. 274: 12955-12958 [1999], Inohara *et al.*, J. Biol. Chem. 274: 14560-14568 [1999]). While Apaf-1 possesses WD40 repeats, Nod1 contains leucine-rich repeats (LRRs) in its C-terminus. The structural and functional similarities between Apaf-1 and Nod1 suggest that these proteins share a common molecular mechanism for activation and effector  
30 function. In the case of Apaf-1, the WD-40 repeats act as a recognition domain for mitochondrial damage through binding to cytochrome c, allowing Apaf-1 to oligomerize

and interact with procaspase-9 through a CARD-CARD homophilic interaction (Li *et al.*, Cell 91: 479-489 [1997], Zou *et al.*, J. Bio. Chem. 274: 11549-11556 [1999]). Apaf-1 oligomerization is mediated by the NBD and is thought to induce the proximity and proteolytic activation of procaspase-9 molecules in the apoptosome complex (Srinivasula  
5 *et al.*, Mol. Cell 1: 949-957 [1998], Hu *et al.*, J. Bio. Chem. 273: 33489-34494 [1998]).

Previous studies showed that Nod1 promotes apoptosis when overexpressed in cells, but unlike Apaf-1, it induces NF- $\kappa$ B activation (Bertin *et al.*, *supra*, Inohara *et al.*, *supra*). NF- $\kappa$ B activation induced by Nod1 is mediated by the association of the CARD of Nod1 with the corresponding CARD of RICK (also called RIP2 and CARDIAK), a  
10 protein kinase that activates NF- $\kappa$ B (Bertin *et al.*, *supra*, Inohara *et al.*, *supra*, Inohara *et al.*, J. Biol. Chem. 273: 12296-12300 [1998], McCarthy *et al.*, J. Bio. Chem. 273, 16968-16975 [1998], Thome *et al.*, Curr. Biol. 8: 885-888 [1998]). Analyses with wild-type (wt) and mutant forms of both Nod1 and RICK have suggested that Nod1 and RICK act in the same pathway of NF- $\kappa$ B activation, where RICK functions as a  
15 downstream mediator of Nod1 signaling (Bertin *et al.*, *supra*, Inohara *et al.*, [1999] *supra*, Inohara *et al.*, J. Biol. Chem. 275: 27823-27831 [2000]). Nod1 self-associates through its NBD and Nod1 oligomerization promotes proximity of RICK molecules and NF- $\kappa$ B activation (Inohara *et al.*, [2000], *supra*). Nod1 also displays similarity to a class of disease resistance (R) proteins found in plants (Parniske *et al.*, Cell 91: 821-832  
20 [1997], Dixon *et al.*, Proc. Natl. Acad. Sci. U. S. A. 97: 8807-8814 [2000]). Like Nod1, these intracellular R proteins contain N-terminal effector domains linked to a NBD and share with Nod1 the presence of multiple LRRs located C-terminally of the NBD (Bertin *et al.*, *supra*, Dixon *et al.*, *supra*). After specific recognition of pathogen products, these R proteins mediate a defense response associated with metabolic alterations and localized  
25 cell death at the site of pathogen invasion (Dixon *et al.*, *supra*). The LRRs of R proteins are highly diverse and appear to be involved in the recognition of a wide array of pathogen components (Parniske *et al.*, *supra*, Dixon *et al.*, *supra*). The binding partner of the LRRs of Nod1 remains unknown. The structural homology of Nod1 with plant R proteins suggest that other LRR-containing Nod1-like molecules may exist in the human  
30 genome to allow activation of these molecules by different sets of intracellular stimuli.

The identification and characterization of Nod2, a LRR-containing protein with structural and functional similarity to Nod1 is disclosed herein. These studies indicate that Nod2 activates NF- $\kappa$ B, but unlike Nod1, this new homologue is primarily expressed in monocytes. The present invention is not limited to any particular mechanism of action.

5 Indeed, an understanding of the mechanism of action is not necessary to practice the present invention. Nevertheless, Nod2 is a member of the Nod1/Apaf-1 family that activates NF- $\kappa$ B through interactions with its NH<sub>2</sub>-terminal CARDS, as these domains were found to be necessary and sufficient for NF- $\kappa$ B activation. Nod2 associated with RICK via a homophilic CARD-CARD interaction. The NF- $\kappa$ B-inducing activity of Nod2  
10 correlated with its ability to associate with RICK and was inhibited by a RICK mutant, suggesting that RICK is a direct downstream target of Nod2. Thus, the signaling pathways of both Nod1 and Nod2 appear to utilize RICK as a downstream mediator of NF- $\kappa$ B activation. In contrast to Nod1, two tandem CARDS are present in the NH<sub>2</sub>-terminus of Nod2 and both were required for association with RICK and NF- $\kappa$ B  
15 activation.

Nod2 is the first molecule known to contain two CARDS. The molecular basis underlying the requirement of both CARDS of Nod2 for RICK binding remains unclear. The present invention is not limited to any particular mechanism of action. Indeed, an understanding of the mechanism of action is not necessary to practice the present  
20 invention. Nevertheless, it is contemplated that the presence of both CARDS may enhance the affinity for the CARD of RICK. Another possibility is that upon an initial interaction involving a CARD of Nod2 and the CARD of RICK, Nod2 may undergo a conformational change that allows the second CARD to associate with high affinity to RICK. The intermediate region of RICK associates with IKK $\gamma$  (Inohara *et al.*, [2000],  
25 *supra*), providing a direct link between Nod1/Nod2 and the IKK complex. Consistent with this model, NF- $\kappa$ B activation induced by Nod2 as well as that induced by Nod1 required IKK $\gamma$  and was inhibited by dominant negative forms of IKK $\gamma$ , IKK $\alpha$  and IKK $\beta$ . The functional role for the LRRs of Nod1 and Nod2 remains unclear. The LRR is a repeated protein-protein interaction module that is presumably involved in the activation  
30 of Nod1 and Nod2 by upstream signals. In the case of plant NBD/LRR-containing R proteins, their LRRs appear to be important for the recognition of pathogen components

and their N-terminal domains appear to mediate a signaling cascade that regulates gene expression (Parniske *et al.*, *supra*, Dixon *et al.*, *supra*). Because both Nod1 and Nod2 activate NF- $\kappa$ B, their LRRs may act to recognize a different set of intracellular stimuli that mediate Nod1 and Nod2 oligomerization and association with RICK. Because Nod2  
5 is expressed primarily in monocytes, Nod2 might serve as an intracellular receptor that transduces signals in the monocyte/macrophage that lead to activation of and transcription of regulatory genes.

The Nod2 proteins of the present invention are also involved in the recognition of microbial pathogens. The innate immune system regulates the immediate response to  
10 microbial pathogens in multiple organisms including humans. The innate immune response is initiated by recognition of specific pathogen components by host immune cells. Mammalian cells have cell surface receptors and intracellular mechanisms that initiate the defense response against microbial pathogens (Aderem and Ulevitch, *Nature*, 406:785-787 [2000]; Philpott *et al.*, *J. Immunol.*, 165:903-914 [2000]). Toll like  
15 receptors (TLRs) comprise a family of cell surface receptors that are related to the *Drosophila* Toll protein, a molecule involved in defense against fungal infection in the fly (Aderem and Ulevitch, *Supra*). Ten mammalian TLRs have been identified (Aderem and Ulevitch, *Supra*). Two members of the family, TLR2 and TLR4, have been better characterized and shown to mediate the response to multiple bacterial cell-wall  
20 components including lipopolysaccharide (LPS), lipopeptides, peptidoglycans (PGN) and lipoteichoic acid (LTA) (Yang *et al.*, *Nature*, 395:284-288 [1998]; Poltorak *et al.*, *Science*, 282:2085-2088 [1998]; Aliprantis *et al.*, *Science*, 285:736-739 [1999]; Chow *et al.*, *J. Biol. Chem.*, 274:10689-10692 [2000]; and Schwandner *et al.*, *J. Biol. Chem.*, 274: 17406-17409 [2000]). Mammalian TLRs have multiple leucine-rich repeats in the  
25 ectodomain and an intracellular Toll-IL1 receptor (TIR) domain that mediates a signaling cascade to the nucleus (Aderem and Ulevitch, *Supra*). Stimulation of TLR2 and TLR4 leads to the recruitment of the adaptor molecule MyD88 and the serine kinase IL-1R-associated kinase (IRAK), two signaling components that together with TRAF-6 mediate activation of NF- $\kappa$ B (Aderem and Ulevitch, *Supra*).

30 Plants have several classes of genes that regulate the defense against invading pathogens. An important class of these molecules is termed disease resistance (R)

proteins, and members include both membrane-bound and cytosolic proteins. These are essential for the defense against multiple pathogens including bacteria, fungi and viruses (Dixon *et al.*, PNAS, 97:8807-8814 [2000]). The cytosolic type of R proteins which include the Tobacco N gene product and up to 200 gene products in *Arabidopsis thaliana* are comprised of an N-terminal TIR or zinc finger effector domain, a centrally located nucleotide-binding domain (NBD) and C-terminal leucine-rich repeats (LRRs) (Dixon *et al.*, *Supra*). The LRRs of cytosolic R proteins are highly diverse and appear to be involved in the recognition of a wide array of microbial components (Dixon *et al.*, *Supra*). This class of disease resistant proteins mediates the hypersensitive (HS) response in plants that includes metabolic alterations and localized cell death at the site of pathogen invasion (Dixon *et al.*, *Supra*). The cytosolic R proteins of plants have remarkable structural homology to Nod1/CARD4, a recently described protein related to the apoptosis regulator Apaf-1 (Zou *et al.*, Cell, 90:405-413 [1997]; Bertin *et al.*, J. Biol. Chem., 274:12955-12958; and Inohara *et al.*, J. Biol. Chem., 274:14560-14568 [1999]). Like plant R proteins, Nod1 is comprised of an N-terminal effector domain, a centrally located NBD and multiple LRRs at the C-terminus (Bertin *et al.*, *Supra*; Inohara *et al.*, *Supra*). Nod1 induces NF- $\kappa$ B activation which is mediated through the association of its N-terminal caspase-recruitment domain (CARD) with that of RICK, a protein kinase that also activates NF- $\kappa$ B (Bertin *et al.*, *Supra*; Inohara *et al.*, *Supra*; Inohara *et al.*, J. Biol. Chem., 273:12296 [1998]; McCarthy *et al.*, J. Biol. Chem., 273:16968; Thome *et al.*, Curr. Biol., 8:885 [1998]; Inohara *et al.*, J. Biol. Chem., 275:27823 [2000]). However, the trigger molecule(s) that activates Nod1 to mediate NF- $\kappa$ B activation remains unknown.

The present invention also demonstrates that lipopolysaccharide (LPS) induces NF- $\kappa$ B activation in HEK293T cell expressing Nod1, whereas parental HEK293T cells are insensitive to LPS. The present invention is not limited to a particular mechanism of action. Indeed, an understanding of the mechanism of action is not necessary to practice the present invention. Nevertheless, in the human system, the TLR4/MD2/CD14 complex has been demonstrated to serve as a surface receptor for LPS (Aderem and Ulevitch, *Supra*). In addition to the cell surface TLR4 complex, there is mounting evidence that mammalian cells have an intracellular receptor that detects LPS in the

cytoplasm of bacteria infected cells (Philpott *et al.*, *Supra*). For example, epithelial cells are unresponsive to extracellular LPS either purified or presented in the context of non-invasive Gram-negative bacterial strains (Philpott *et al.*, *Supra*). Yet, LPS introduced inside of the epithelial cells activates NF- $\kappa$ B (Philpott *et al.*, *Supra*).

5 However, to date, the identification of an intracellular recognition system for LPS and/or other microbial products remains elusive. Because Nod1 can confer responsiveness to LPS, Nod1 may act as an intracellular receptor for LPS. Nod1 function might be important in the intracellular response of epithelial cells against invading bacteria, as Nod1 is expressed in intestinal, lung and nasal epithelial surfaces in the late mouse  
10 embryo (Inohara *et al.*, *Supra*). The presence of an intracellular detection system for bacterial LPS would be expected in epithelial surfaces such as those of the gut that are highly exposed to bacteria and bacterial products. In such organs, triggering of an inflammatory response to bacterial products through surface receptors such as TLR4 would be detrimental to the organism. HEK293T cells expressing Nod2, another member  
15 of Nod family, respond to LPS but Nod1 and Nod2 appear to have different preferences for LPS preparations from different bacteria. These observations suggest that in addition to TLRs, Nod family members may represent another innate immune system for the recognition of a wide array of pathogen products. For example, the genome of the plant *Arabidopsis thaliana* contains approximately 200 disease resistance genes encoding  
20 intracellular NBD-LRR proteins related to Nod1 and Nod2 (Dixon *et al.*, *Supra*).

The innate immune system regulates the immediate response to microbial pathogens and is initiated by recognition of specific pathogen components by receptors located in host immune cells (Aderem and Ulevitch, *Nature* 406:785 [2000]). Mammalian cells have cell surface receptors (*e.g.* TLRs) and intracellular mechanisms that initiate the  
25 defense response against microbial pathogens (Aderem and Ulevitch, *supra*). Nod1 and Nod2 appear to function as intracellular receptors for LPS with the LRRs required for responsiveness (See Example 8). The results described herein suggest that a premature truncation of the tenth LRR in Nod2 is associated with development of CD. Consistent with published linkage analysis data (Ohmen *et al.*, *Hum Mol Genet.* 5:1679 [1996]; Cho  
30 *et al.*, *Proc Natl Acad Sci U S A.* 95:7502 [1998]) this genetic variant was associated solely with CD, and not with UC. Functional analyses indicate that the truncated LRR



Nod2 mutant is less active than the wild-type protein in conferring responsiveness to bacterial LPS. In plant Nod2 homologues, the LRRs appear to determine the specificity for pathogen products and alterations in their LRRs can result in unresponsiveness to particular pathogens and disease (Pamiske *et al.*, Cell 91:821 [1997]; Ellis *et al.*, Plant Cell 11:495 [1999]; Dixon *et al.*, Proc. Natl. Acad. Sci. U.S.A. 97:8807 [2000]).

Similarly, genetic variation in the LRRs of TLR4 account for inter-individual differences in bronchial responsiveness to aerosolized LPS (Arbour *et al.*, Nat Genet. 25:187 [2000]).

The present invention is not limited to any one mechanism. Indeed, an understanding of the mechanism is not necessary to practice the present invention. Nonetheless, several mechanisms can be envisioned which may account for susceptibility to CD in individuals harboring the 3020InsC mutation or other Nod2 variant. Nod2 is a cytosolic protein whose expression is restricted to monocytes with no expression detected in lymphocytes (See Example 3 below). A deficit in sensing bacteria within monocytes/macrophages might result in an exaggerated inflammatory response by the adaptive immune system.

An alternative possibility is that wild-type Nod2 may mediate the induction of cytokine genes such as interleukin-10 that can downregulate the inflammatory response (Moore *et al.*, Ann. Rev. Immunol. 11:165 [1993]; Berg *et al.*, J. Clin. Invest. 98:1010 [1996]).

In this scenario, a deficiency in Nod2 function may lead to relative overproduction of pro-inflammatory cytokines in the gut. Finally, variation in the LRRs of plant Nod2 homologues have been shown to result in the recognition of new specificities for pathogen components (Pamiske *et al.*, Cell 91:821 [1997]; Ellis *et al.*, Plant Cell 11:495 [1999]). Thus, it is also possible that 3020InsC could act as a gain of function mutant for an unknown pathogen. The present studies implicate Nod2 in susceptibility to CD and suggest a link between an innate response to bacterial components and development of disease. The results may explain the observation that decreasing intestinal bacteria flora can lead to clinical improvement and decreased gut inflammation (Fiocchi, Gastroenterology 115:182 [1998]).

Experiments performed during the development of the present invention (See e.g., Examples 9 and 10) identified several polymorphisms of Nod2 that are found in a higher prevalence in individuals with Crohn's disease. In addition, several polymorphisms were found to be associated with an increased risk of developing Crohn's disease.

Accordingly, in some embodiments, the present invention provides methods for determining an individual's susceptibility to Crohn's disease. In some embodiments, the methods include bioinformatics methods.

## 5 DEFINITIONS

To facilitate understanding of the invention, a number of terms are defined below.

As used herein, the term "Nod2" when used in reference to a protein or nucleic acid refers to a protein or nucleic acid encoding a protein that, in its wild type form, activates NF- $\kappa$ B and contains two CARDs (caspase recruitment domains). The term  
10 Nod2 encompasses both proteins that are identical to wild-type Nod2 and those that are derived from wild type Nod2 (*e.g.*, variants of Nod2 or chimeric genes constructed with portions of Nod2 coding regions).

As used herein, the term "activates NF- $\kappa$ B," when used in reference to any molecule that activates NF- $\kappa$ B, refers to a molecule (*e.g.*, a protein) that induces the  
15 activity of the NF- $\kappa$ B transcription factor through a cell signaling pathway. Assays for determining if a molecule activates NF- $\kappa$ B utilize, for example, NF- $\kappa$ B responsive reporter gene constructs. Suitable assays include, but are not limited to, those described in Examples 4 and 5.

As used herein, the term "activity of Nod2" refers to any activity of wild type  
20 Nod2. The term is intended to encompass all activities of Nod2 (*e.g.*, including, but not limited to, activating NF- $\kappa$ B, binding to RICK, and enhancing apoptosis).

As used herein, the term "individual at an increased risk of developing Crohn's disease," refers to an individual for whom the "genotype relative risk" or the "population attributable risk" of developing Crohn's disease is greater than the average risk in a given  
25 population (*e.g.*, an ethnic group).

As used herein, the term "genotype relative risk" and "population attributable risk" refer to relative measurements of the risk of developing a disease state (*e.g.*, Crohn's disease). Examples of how to calculate "genotype relative risk" and "population attributable risk" are given in Example 10.

30 The term "apoptosis" means non-necrotic cell death that takes place in metazoan animal cells following activation of an intrinsic cell suicide program. Apoptosis is a

normal process in the development and homeostasis of metazoan animals. Apoptosis involves characteristic morphological and biochemical changes, including cell shrinkage, zeiosis, or blebbing, of the plasma membrane, and nuclear collapse and fragmentation of the nuclear chromatin, at intranucleosomal sites, due to activation of an endogenous  
5 nuclease.

The term "gene" refers to a nucleic acid (*e.g.*, DNA) sequence that comprises coding sequences necessary for the production of a polypeptide, RNA (*e.g.*, including but not limited to, mRNA, tRNA and rRNA) or precursor (*e.g.*, Nod2). The polypeptide, RNA, or precursor can be encoded by a full length coding sequence or by any portion of  
10 the coding sequence so long as the desired activity or functional properties (*e.g.*, enzymatic activity, ligand binding, signal transduction, etc.) of the full-length or fragment are retained. The term also encompasses the coding region of a structural gene and the including sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 1 kb on either end such that the gene corresponds to the length of the  
15 full-length mRNA. The sequences that are located 5' of the coding region and which are present on the mRNA are referred to as 5' untranslated sequences. The sequences that are located 3' or downstream of the coding region and that are present on the mRNA are referred to as 3' untranslated sequences. The term "gene" encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene contains the coding region  
20 interrupted with non-coding sequences termed "introns" or "intervening regions" or "intervening sequences." Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or "spliced out" from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during  
25 translation to specify the sequence or order of amino acids in a nascent polypeptide.

In particular, the term "Nod2 gene" refers to the full-length Nod2 nucleotide sequence (*e.g.*, contained in SEQ ID NO: 1). However, it is also intended that the term encompass fragments of the Nod2 sequence, as well as other domains within the full-length Nod2 nucleotide sequence. Furthermore, the terms "Nod2 nucleotide sequence" or  
30 "Nod2 polynucleotide sequence" encompasses DNA, cDNA, and RNA (*e.g.*, mRNA) sequences.

Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms, such as "polypeptide" or "protein" are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

5 In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' end of the sequences that are present on the RNA transcript. These sequences are referred to as "flanking" sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as  
10 promoters and enhancers that control or influence the transcription of the gene. The 3' flanking region may contain sequences that direct the termination of transcription, post-transcriptional cleavage and polyadenylation.

The term "wild-type" refers to a gene or gene product that has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-  
15 type gene is that which is most frequently observed in a population and is thus arbitrarily designed the "normal" or "wild-type" form of the gene. In contrast, the terms "modified," "mutant," "polymorphism," and "variant" refer to a gene or gene product that displays modifications in sequence and/or functional properties (*i.e.*, altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring  
20 mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

As used herein, the terms "nucleic acid molecule encoding," "DNA sequence encoding," and "DNA encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides  
25 determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.

DNA molecules are said to have "5' ends" and "3' ends" because mononucleotides are reacted to make oligonucleotides or polynucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor  
30 in one direction via a phosphodiester linkage. Therefore, an end of an oligonucleotides or polynucleotide, referred to as the "5' end" if its 5' phosphate is not linked to the 3' oxygen

of a mononucleotide pentose ring and as the "3' end" if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide or polynucleotide, also may be said to have 5' and 3' ends. In either a linear or circular DNA molecule, discrete elements are referred to as being "upstream" or 5' of the "downstream" or 3' elements. This terminology reflects the fact that transcription proceeds in a 5' to 3' fashion along the DNA strand. The promoter and enhancer elements that direct transcription of a linked gene are generally located 5' or upstream of the coding region. However, enhancer elements can exert their effect even when located 3' of the promoter element and the coding region. Transcription termination and polyadenylation signals are located 3' or downstream of the coding region.

As used herein, the terms "an oligonucleotide having a nucleotide sequence encoding a gene" and "polynucleotide having a nucleotide sequence encoding a gene," means a nucleic acid sequence comprising the coding region of a gene or, in other words, the nucleic acid sequence that encodes a gene product. The coding region may be present in a cDNA, genomic DNA, or RNA form. When present in a DNA form, the oligonucleotide or polynucleotide may be single-stranded (*i.e.*, the sense strand) or double-stranded. Suitable control elements such as enhancers/promoters, splice junctions, polyadenylation signals, *etc.* may be placed in close proximity to the coding region of the gene if needed to permit proper initiation of transcription and/or correct processing of the primary RNA transcript. Alternatively, the coding region utilized in the expression vectors of the present invention may contain endogenous enhancers/promoters, splice junctions, intervening sequences, polyadenylation signals, *etc.* or a combination of both endogenous and exogenous control elements.

As used herein, the term "regulatory element" refers to a genetic element that controls some aspect of the expression of nucleic acid sequences. For example, a promoter is a regulatory element that facilitates the initiation of transcription of an operably linked coding region. Other regulatory elements include splicing signals, polyadenylation signals, termination signals, *etc.*

As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (*i.e.*, a sequence of nucleotides) related by the base-pairing

rules. For example, for the sequence "A-G-T," is complementary to the sequence "T-C-A." Complementarity may be "partial," in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between  
5 nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods that depend upon binding between nucleic acids.

The term "homology" refers to a degree of complementarity. There may be partial homology or complete homology (*i.e.*, identity). A partially complementary  
10 sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid and is referred to using the functional term "substantially homologous." The term "inhibition of binding," when used in reference to nucleic acid binding, refers to inhibition of binding caused by competition of homologous sequences for binding to a target sequence. The inhibition of hybridization of the  
15 completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous to a target under conditions of low stringency. This is not to say that conditions of low  
20 stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding may be tested by the use of a second target that lacks even a partial degree of complementarity (*e.g.*, less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the  
25 second non-complementary target.

The art knows well that numerous equivalent conditions may be employed to comprise low stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other  
30 components (*e.g.*, the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate

conditions of low stringency hybridization different from, but equivalent to, the above listed conditions. In addition, the art knows conditions that promote hybridization under conditions of high stringency (*e.g.*, increasing the temperature of the hybridization and/or wash steps, the use of formamide in the hybridization solution, etc.).

5           When used in reference to a double-stranded nucleic acid sequence such as a cDNA or genomic clone, the term "substantially homologous" refers to any probe that can hybridize to either or both strands of the double-stranded nucleic acid sequence under conditions of low stringency as described above.

10           A gene may produce multiple RNA species that are generated by differential splicing of the primary RNA transcript. cDNAs that are splice variants of the same gene will contain regions of sequence identity or complete homology (representing the presence of the same exon or portion of the same exon on both cDNAs) and regions of complete non-identity (for example, representing the presence of exon "A" on cDNA 1 wherein cDNA 2 contains exon "B" instead). Because the two cDNAs contain regions of  
15           sequence identity they will both hybridize to a probe derived from the entire gene or portions of the gene containing sequences found on both cDNAs; the two splice variants are therefore substantially homologous to such a probe and to each other.

          When used in reference to a single-stranded nucleic acid sequence, the term "substantially homologous" refers to any probe that can hybridize (*i.e.*, it is the  
20           complement of) the single-stranded nucleic acid sequence under conditions of low stringency as described above.

          As used herein, the term "competes for binding" is used in reference to a first polypeptide with an activity which binds to the same substrate as does a second polypeptide with an activity, where the second polypeptide is a variant of the first  
25           polypeptide or a related or dissimilar polypeptide. The efficiency (*e.g.*, kinetics or thermodynamics) of binding by the first polypeptide may be the same as or greater than or less than the efficiency substrate binding by the second polypeptide. For example, the equilibrium binding constant ( $K_D$ ) for binding to the substrate may be different for the two polypeptides. The term " $K_m$ " as used herein refers to the Michaelis-Menton constant  
30           for an enzyme and is defined as the concentration of the specific substrate at which a given enzyme yields one-half its maximum velocity in an enzyme catalyzed reaction.

As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (*i.e.*, the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementary between the nucleic acids, stringency of the conditions  
5 involved, the  $T_m$  of the formed hybrid, and the G:C ratio within the nucleic acids.

As used herein, the term " $T_m$ " is used in reference to the "melting temperature." The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. The equation for calculating the  $T_m$  of nucleic acids is well known in the art. As indicated by standard  
10 references, a simple estimate of the  $T_m$  value may be calculated by the equation:  $T_m = 81.5 + 0.41(\% G + C)$ , when a nucleic acid is in aqueous solution at 1 M NaCl (*See e.g.*, Anderson and Young, Quantitative Filter Hybridization, in *Nucleic Acid Hybridization* [1985]). Other references include more sophisticated computations that take structural as well as sequence characteristics into account for the calculation of  $T_m$ .

As used herein the term "stringency" is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. Those skilled in the art will recognize that "stringency" conditions may be altered by varying the parameters just described either individually or in concert. With "high stringency" conditions, nucleic  
20 acid base pairing will occur only between nucleic acid fragments that have a high frequency of complementary base sequences (*e.g.*, hybridization under "high stringency" conditions may occur between homologs with about 85-100% identity, preferably about 70-100% identity). With medium stringency conditions, nucleic acid base pairing will occur between nucleic acids with an intermediate frequency of complementary base  
25 sequences (*e.g.*, hybridization under "medium stringency" conditions may occur between homologs with about 50-70% identity). Thus, conditions of "weak" or "low" stringency are often required with nucleic acids that are derived from organisms that are genetically diverse, as the frequency of complementary sequences is usually less.

"High stringency conditions" when used in reference to nucleic acid hybridization  
30 comprise conditions equivalent to binding or hybridization at 42 C in a solution



consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH<sub>2</sub>PO<sub>4</sub> H<sub>2</sub>O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, 1.0% SDS at 42 C when a probe of about 500 nucleotides in length is employed.

5 "Medium stringency conditions" when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42 C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH<sub>2</sub>PO<sub>4</sub> H<sub>2</sub>O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 1.0X SSPE,  
10 1.0% SDS at 42 C when a probe of about 500 nucleotides in length is employed.

"Low stringency conditions" comprise conditions equivalent to binding or hybridization at 42 C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH<sub>2</sub>PO<sub>4</sub> H<sub>2</sub>O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5X Denhardt's reagent [50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400,  
15 Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42 C when a probe of about 500 nucleotides in length is employed.

The following terms are used to describe the sequence relationships between two or more polynucleotides: "reference sequence", "sequence identity", "percentage of  
20 sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA sequence given in a sequence listing or may comprise a complete gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides  
25 in length, and often at least 50 nucleotides in length. Since two polynucleotides may each (1) comprise a sequence (*i.e.*, a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) may further comprise a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two  
30 polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window", as used herein, refers to a conceptual

segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a reference sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman [Smith and Waterman, *Adv. Appl. Math.* 2: 482 (1981)] by the homology alignment algorithm of Needleman and Wunsch [Needleman and Wunsch, *J. Mol. Biol.* 48:443 (1970)], by the search for similarity method of Pearson and Lipman [Pearson and Lipman, *Proc. Natl. Acad. Sci. (U.S.A.)* 85:2444 (1988)], by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection, and the best alignment (*i.e.*, resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected. The term "sequence identity" means that two polynucleotide sequences are identical (*i.e.*, on a nucleotide-by-nucleotide basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 25-50 nucleotides, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the

window of comparison. The reference sequence may be a subset of a larger sequence, for example, as a segment of the full-length sequences of the compositions claimed in the present invention (*e.g.*, Nod2).

As applied to polypeptides, the term "substantial identity" means that two peptide  
5 sequences, when optimally aligned, such as by the programs GAP or BESTFIT using  
default gap weights, share at least 80 percent sequence identity, preferably at least 90  
percent sequence identity, more preferably at least 95 percent sequence identity or more  
(*e.g.*, 99 percent sequence identity). Preferably, residue positions that are not identical  
10 differ by conservative amino acid substitutions. Conservative amino acid substitutions  
refer to the interchangeability of residues having similar side chains. For example, a  
group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and  
isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and  
threonine; a group of amino acids having amide-containing side chains is asparagine and  
15 glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine,  
and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and  
histidine; and a group of amino acids having sulfur-containing side chains is cysteine and  
methionine. Preferred conservative amino acids substitution groups are: valine-leucine-  
isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-  
glutamine.

20 The term "fragment" as used herein refers to a polypeptide that has an amino-  
terminal and/or carboxy-terminal deletion as compared to the native protein, but where  
the remaining amino acid sequence is identical to the corresponding positions in the  
amino acid sequence deduced from a full-length cDNA sequence. Fragments typically  
are at least 4 amino acids long, preferably at least 20 amino acids long, usually at least 50  
25 amino acids long or longer, and span the portion of the polypeptide required for  
intermolecular binding of the compositions (claimed in the present invention) with its  
various ligands and/or substrates.

The term "polymorphic locus" is a locus present in a population that shows  
variation between members of the population (*i.e.*, the most common allele has a  
30 frequency of less than 0.95). In contrast, a "monomorphic locus" is a genetic locus at  
little or no variations seen between members of the population (generally taken to be a

locus at which the most common allele exceeds a frequency of 0.95 in the gene pool of the population).

As used herein, the term "genetic variation information" or "genetic variant information" refers to the presence or absence of one or more variant nucleic acid sequences (*e.g.*, polymorphism or mutations) in a given allele of a particular gene (*e.g.*, the Nod2 gene).

As used herein, the term "detection assay" refers to an assay for detecting the presence or absence of variant nucleic acid sequences (*e.g.*, polymorphism or mutations) in a given allele of a particular gene (*e.g.*, the Nod2 gene). Examples of suitable detection assays include, but are not limited to, those described below in Section III B.

The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.

"Amplification" is a special case of nucleic acid replication involving template specificity. It is to be contrasted with non-specific template replication (*i.e.*, replication that is template-dependent but not dependent on a specific template). Template specificity is here distinguished from fidelity of replication (*i.e.*, synthesis of the proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-) specificity. Template specificity is frequently described in terms of "target" specificity. Target sequences are "targets" in the sense that they are sought to be sorted out from other nucleic acid. Amplification techniques have been designed primarily for this sorting out.

Template specificity is achieved in most amplification techniques by the choice of enzyme. Amplification enzymes are enzymes that, under conditions they are used, will process only specific sequences of nucleic acid in a heterogeneous mixture of nucleic acid. For example, in the case of Q $\beta$  replicase, MDV-1 RNA is the specific template for the replicase (D.L. Kacian *et al.*, Proc. Natl. Acad. Sci. USA 69:3038 [1972]). Other nucleic acid will not be replicated by this amplification enzyme. Similarly, in the case of T7 RNA polymerase, this amplification enzyme has a stringent specificity for its own promoters (Chamberlin *et al.*, Nature 228:227 [1970]). In the case of T4 DNA ligase, the

enzyme will not ligate the two oligonucleotides or polynucleotides, where there is a mismatch between the oligonucleotide or polynucleotide substrate and the template at the ligation junction (D.Y. Wu and R. B. Wallace, Genomics 4:560 [1989]). Finally, *Taq* and *Pfu* polymerases, by virtue of their ability to function at high temperature, are found to display high specificity for the sequences bounded and thus defined by the primers; the high temperature results in thermodynamic conditions that favor primer hybridization with the target sequences and not hybridization with non-target sequences (H.A. Erlich (ed.), *PCR Technology*, Stockton Press [1989]).

As used herein, the term "amplifiable nucleic acid" is used in reference to nucleic acids that may be amplified by any amplification method. It is contemplated that "amplifiable nucleic acid" will usually comprise "sample template."

As used herein, the term "sample template" refers to nucleic acid originating from a sample that is analyzed for the presence of "target" (defined below). In contrast, "background template" is used in reference to nucleic acid other than sample template that may or may not be present in a sample. Background template is most often inadvertent. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.

As used herein, the term "primer" refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, (*i.e.*, in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the

primers will depend on many factors, including temperature, source of primer and the use of the method.

As used herein, the term "probe" refers to an oligonucleotide (*i.e.*, a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, that is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. It is contemplated that any probe used in the present invention will be labeled with any "reporter molecule," so that is detectable in any detection system, including, but not limited to enzyme (*e.g.*, ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.

As used herein, the term "target," refers to a nucleic acid sequence or structure to be detected or characterized. Thus, the "target" is sought to be sorted out from other nucleic acid sequences. A "segment" is defined as a region of nucleic acid within the target sequence.

As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of K.B. Mullis U.S. Patent Nos. 4,683,195, 4,683,202, and 4,965,188, hereby incorporated by reference, that describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the

amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the "polymerase chain reaction" (hereinafter "PCR"). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified."

With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (*e.g.*, hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of <sup>32</sup>P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide or polynucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.

As used herein, the terms "PCR product," "PCR fragment," and "amplification product" refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.

As used herein, the term "amplification reagents" refers to those reagents (deoxyribonucleotide triphosphates, buffer, etc.), needed for amplification except for primers, nucleic acid template, and the amplification enzyme. Typically, amplification reagents along with other reaction components are placed and contained in a reaction vessel (test tube, microwell, etc.).

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

As used herein, the term "recombinant DNA molecule" as used herein refers to a DNA molecule that is comprised of segments of DNA joined together by means of molecular biological techniques.

As used herein, the term "antisense" is used in reference to RNA sequences that are complementary to a specific RNA sequence (*e.g.*, mRNA). Included within this definition are antisense RNA ("asRNA") molecules involved in gene regulation by bacteria. Antisense RNA may be produced by any method, including synthesis by  
5 splicing the gene(s) of interest in a reverse orientation to a viral promoter that permits the synthesis of a coding strand. Once introduced into an embryo, this transcribed strand combines with natural mRNA produced by the embryo to form duplexes. These duplexes then block either the further transcription of the mRNA or its translation. In this manner, mutant phenotypes may be generated. The term "antisense strand" is used in reference to  
10 a nucleic acid strand that is complementary to the "sense" strand. The designation (-) (*i.e.*, "negative") is sometimes used in reference to the antisense strand, with the designation (+) sometimes used in reference to the sense (*i.e.*, "positive") strand.

The term "isolated" when used in relation to a nucleic acid, as in "an isolated oligonucleotide" or "isolated polynucleotide" refers to a nucleic acid sequence that is  
15 identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. Isolated nucleic acid is present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acids are nucleic acids such as DNA and RNA found in the state they exist in nature. For example, a given DNA sequence (*e.g.*, a gene) is found on the host cell  
20 chromosome in proximity to neighboring genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, are found in the cell as a mixture with numerous other mRNAs that encode a multitude of proteins. However, isolated nucleic acid encoding Nod2 includes, by way of example, such nucleic acid in cells ordinarily expressing Nod2 where the nucleic acid is in a chromosomal location different from that  
25 of natural cells, or is otherwise flanked by a different nucleic acid sequence than that found in nature. The isolated nucleic acid, oligonucleotide, or polynucleotide may be present in single-stranded or double-stranded form. When an isolated nucleic acid, oligonucleotide or polynucleotide is to be utilized to express a protein, the oligonucleotide or polynucleotide will contain at a minimum the sense or coding strand  
30 (*i.e.*, the oligonucleotide or polynucleotide may single-stranded), but may contain both



the sense and anti-sense strands (*i.e.*, the oligonucleotide or polynucleotide may be double-stranded).

As used herein, a "portion of a chromosome" refers to a discrete section of the chromosome. Chromosomes are divided into sites or sections by cytogeneticists as follows: the short (relative to the centromere) arm of a chromosome is termed the "p" arm; the long arm is termed the "q" arm. Each arm is then divided into 2 regions termed region 1 and region 2 (region 1 is closest to the centromere). Each region is further divided into bands. The bands may be further divided into sub-bands. For example, the 11p15.5 portion of human chromosome 11 is the portion located on chromosome 11 (11) on the short arm (p) in the first region (1) in the 5th band (5) in sub-band 5 (.5). A portion of a chromosome may be "altered;" for instance the entire portion may be absent due to a deletion or may be rearranged (*e.g.*, inversions, translocations, expanded or contracted due to changes in repeat regions). In the case of a deletion, an attempt to hybridize (*i.e.*, specifically bind) a probe homologous to a particular portion of a chromosome could result in a negative result (*i.e.*, the probe could not bind to the sample containing genetic material suspected of containing the missing portion of the chromosome). Thus, hybridization of a probe homologous to a particular portion of a chromosome may be used to detect alterations in a portion of a chromosome.

The term "sequences associated with a chromosome" means preparations of chromosomes (*e.g.*, spreads of metaphase chromosomes), nucleic acid extracted from a sample containing chromosomal DNA (*e.g.*, preparations of genomic DNA); the RNA that is produced by transcription of genes located on a chromosome (*e.g.*, hnRNA and mRNA), and cDNA copies of the RNA transcribed from the DNA located on a chromosome. Sequences associated with a chromosome may be detected by numerous techniques including probing of Southern and Northern blots and *in situ* hybridization to RNA, DNA, or metaphase chromosomes with probes containing sequences homologous to the nucleic acids in the above listed preparations.

As used herein the term "portion" when in reference to a nucleotide sequence (as in "a portion of a given nucleotide sequence") refers to fragments of that sequence. The fragments may range in size from four nucleotides to the entire nucleotide sequence minus one nucleotide (10 nucleotides, 20, 30, 40, 50, 100, 200, etc.).

As used herein the term "coding region" when used in reference to structural gene refers to the nucleotide sequences that encode the amino acids found in the nascent polypeptide as a result of translation of a mRNA molecule. The coding region is bounded, in eukaryotes, on the 5' side by the nucleotide triplet "ATG" that encodes the initiator methionine and on the 3' side by one of the three triplets, which specify stop codons (*i.e.*, TAA, TAG, TGA).

As used herein, the term "purified" or "to purify" refers to the removal of contaminants from a sample. For example, Nod2 antibodies are purified by removal of contaminating non-immunoglobulin proteins; they are also purified by the removal of immunoglobulin that does not bind Nod2. The removal of non-immunoglobulin proteins and/or the removal of immunoglobulins that do not bind Nod2 results in an increase in the percent of Nod2-reactive immunoglobulins in the sample. In another example, recombinant Nod2 polypeptides are expressed in bacterial host cells and the polypeptides are purified by the removal of host cell proteins; the percent of recombinant Nod2 polypeptides is thereby increased in the sample.

The term "recombinant DNA molecule" as used herein refers to a DNA molecule that is comprised of segments of DNA joined together by means of molecular biological techniques.

The term "recombinant protein" or "recombinant polypeptide" as used herein refers to a protein molecule that is expressed from a recombinant DNA molecule.

The term "native protein" as used herein to indicate that a protein does not contain amino acid residues encoded by vector sequences; that is the native protein contains only those amino acids found in the protein as it occurs in nature. A native protein may be produced by recombinant means or may be isolated from a naturally occurring source.

As used herein the term "portion" when in reference to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four consecutive amino acid residues to the entire amino acid sequence minus one amino acid.

The term "Southern blot," refers to the analysis of DNA on agarose or acrylamide gels to fractionate the DNA according to size followed by transfer of the DNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized

DNA is then probed with a labeled probe to detect DNA species complementary to the probe used. The DNA may be cleaved with restriction enzymes prior to electrophoresis. Following electrophoresis, the DNA may be partially depurinated and denatured prior to or during transfer to the solid support. Southern blots are a standard tool of molecular biologists (J. Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, NY, pp 9.31-9.58 [1989]).

The term "Northern blot," as used herein refers to the analysis of RNA by electrophoresis of RNA on agarose gels to fractionate the RNA according to size followed by transfer of the RNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized RNA is then probed with a labeled probe to detect RNA species complementary to the probe used. Northern blots are a standard tool of molecular biologists (J. Sambrook, *et al.*, *supra*, pp 7.39-7.52 [1989]).

The term "Western blot" refers to the analysis of protein(s) (or polypeptides) immobilized onto a support such as nitrocellulose or a membrane. The proteins are run on acrylamide gels to separate the proteins, followed by transfer of the protein from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized proteins are then exposed to antibodies with reactivity against an antigen of interest. The binding of the antibodies may be detected by various methods, including the use of radiolabelled antibodies.

The term "antigenic determinant" as used herein refers to that portion of an antigen that makes contact with a particular antibody (*i.e.*, an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies that bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (*i.e.*, the "immunogen" used to elicit the immune response) for binding to an antibody.

The term "transgene" as used herein refers to a foreign, heterologous, or autologous gene that is placed into an organism by introducing the gene into newly fertilized eggs or early embryos. The term "foreign gene" refers to any nucleic acid (*e.g.*, gene sequence) that is introduced into the genome of an animal by experimental manipulations and may include gene sequences found in that animal so long as the

introduced gene does not reside in the same location as does the naturally-occurring gene. The term "autologous gene" is intended to encompass variants (*e.g.*, polymorphisms or mutants) of the naturally occurring gene. The term transgene thus encompasses the replacement of the naturally occurring gene with a variant form of the gene.

5           As used herein, the term "vector" is used in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another. The term "vehicle" is sometimes used interchangeably with "vector."

          The term "expression vector" as used herein refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences  
10       necessary for the expression of the operably linked coding sequence in a particular host organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.

15           As used herein, the term "host cell" refers to any eukaryotic or prokaryotic cell (*e.g.*, bacterial cells such as *E. coli*, yeast cells, mammalian cells, avian cells, amphibian cells, plant cells, fish cells, and insect cells), whether located *in vitro* or *in vivo*. For example, host cells may be located in a transgenic animal.

          The terms "overexpression" and "overexpressing" and grammatical equivalents,  
20       are used in reference to levels of mRNA to indicate a level of expression approximately 3-fold higher than that typically observed in a given tissue in a control or non-transgenic animal. Levels of mRNA are measured using any of a number of techniques known to those skilled in the art including, but not limited to Northern blot analysis (*See*, Example 10, for a protocol for performing Northern blot analysis). Appropriate controls are  
25       included on the Northern blot to control for differences in the amount of RNA loaded from each tissue analyzed (*e.g.*, the amount of 28S rRNA, an abundant RNA transcript present at essentially the same amount in all tissues, present in each sample can be used as a means of normalizing or standardizing the RAD50 mRNA-specific signal observed on Northern blots). The amount of mRNA present in the band corresponding in size to  
30       the correctly spliced Nod2 transgene RNA is quantified; other minor species of RNA

which hybridize to the transgene probe are not considered in the quantification of the expression of the transgenic mRNA.

The term "transfection" as used herein refers to the introduction of foreign DNA into eukaryotic cells. Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated  
5 transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.

The term "stable transfection" or "stably transfected" refers to the introduction and integration of foreign DNA into the genome of the transfected cell. The term "stable  
10 transfectant" refers to a cell that has stably integrated foreign DNA into the genomic DNA.

The term "transient transfection" or "transiently transfected" refers to the introduction of foreign DNA into a cell where the foreign DNA fails to integrate into the genome of the transfected cell. The foreign DNA persists in the nucleus of the  
15 transfected cell for several days. During this time the foreign DNA is subject to the regulatory controls that govern the expression of endogenous genes in the chromosomes. The term "transient transfectant" refers to cells that have taken up foreign DNA but have failed to integrate this DNA.

The term "calcium phosphate co-precipitation" refers to a technique for the  
20 introduction of nucleic acids into a cell. The uptake of nucleic acids by cells is enhanced when the nucleic acid is presented as a calcium phosphate-nucleic acid co-precipitate. The original technique of Graham and van der Eb (Graham and van der Eb, Virol., 52:456 [1973]), has been modified by several groups to optimize conditions for particular types of cells. The art is well aware of these numerous modifications.

A "composition comprising a given polynucleotide sequence" as used herein  
25 refers broadly to any composition containing the given polynucleotide sequence. The composition may comprise an aqueous solution. Compositions comprising polynucleotide sequences encoding Nod2 (e.g., SEQ ID NO:1) or fragments thereof may be employed as hybridization probes. In this case, the Nod2 encoding polynucleotide  
30 sequences are typically employed in an aqueous solution containing salts (e.g., NaCl),

detergents (*e.g.*, SDS), and other components (*e.g.*, Denhardt's solution, dry milk, salmon sperm DNA, etc.).

The term "test compound" refers to any chemical entity, pharmaceutical, drug, and the like that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function, or otherwise alter the physiological or cellular status of a sample. Test compounds comprise both known and potential therapeutic compounds. A test compound can be determined to be therapeutic by screening using the screening methods of the present invention. A "known therapeutic compound" refers to a therapeutic compound that has been shown (*e.g.*, through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention.

The term "sample" as used herein is used in its broadest sense. A sample suspected of containing a human chromosome or sequences associated with a human chromosome may comprise a cell, chromosomes isolated from a cell (*e.g.*, a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern blot analysis), RNA (in solution or bound to a solid support such as for Northern blot analysis), cDNA (in solution or bound to a solid support) and the like. A sample suspected of containing a protein may comprise a cell, a portion of a tissue, an extract containing one or more proteins and the like.

As used herein, the term "response," when used in reference to an assay, refers to the generation of a detectable signal (*e.g.*, accumulation of reporter protein, increase in ion concentration, accumulation of a detectable chemical product).

As used herein, the term "membrane receptor protein" refers to membrane spanning proteins that bind a ligand (*e.g.*, a hormone or neurotransmitter). As is known in the art, protein phosphorylation is a common regulatory mechanism used by cells to selectively modify proteins carrying regulatory signals from outside the cell to the nucleus. The proteins that execute these biochemical modifications are a group of enzymes known as protein kinases. They may further be defined by the substrate residue that they target for phosphorylation. One group of protein kinases is the tyrosine kinases (TKs), which selectively phosphorylate a target protein on its tyrosine residues. Some tyrosine kinases are membrane-bound receptors (RTKs), and, upon activation by a ligand, can autophosphorylate as well as modify substrates. The initiation of sequential

phosphorylation by ligand stimulation is a paradigm that underlies the action of such effectors as, for example, epidermal growth factor (EGF), insulin, platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). The receptors for these ligands are tyrosine kinases and provide the interface between the binding of a ligand (hormone, growth factor) to a target cell and the transmission of a signal into the cell by the activation of one or more biochemical pathways. Ligand binding to a receptor tyrosine kinase activates its intrinsic enzymatic activity. Tyrosine kinases can also be cytoplasmic, non-receptor-type enzymes and act as a downstream component of a signal transduction pathway.

As used herein, the term "signal transduction protein" refers to proteins that are activated or otherwise affected by ligand binding to a membrane or cytosolic receptor protein or some other stimulus. Examples of signal transduction protein include adenylyl cyclase, phospholipase C, and G-proteins. Many membrane receptor proteins are coupled to G-proteins (*i.e.*, G-protein coupled receptors (GPCRs); for a review, *see* Neer, 1995, Cell 80:249-257 [1995]). Typically, GPCRs contain seven transmembrane domains. Putative GPCRs can be identified on the basis of sequence homology to known GPCRs.

GPCRs mediate signal transduction across a cell membrane upon the binding of a ligand to an extracellular portion of a GPCR. The intracellular portion of a GPCR interacts with a G-protein to modulate signal transduction from outside to inside a cell. A GPCR is therefore said to be "coupled" to a G-protein. G-proteins are composed of three polypeptide subunits: an  $\alpha$  subunit, which binds and hydrolyses GTP, and a dimeric  $\beta\gamma$  subunit. In the basal, inactive state, the G-protein exists as a heterotrimer of the  $\alpha$  and  $\beta\gamma$  subunits. When the G-protein is inactive, guanosine diphosphate (GDP) is associated with the  $\alpha$  subunit of the G-protein. When a GPCR is bound and activated by a ligand, the GPCR binds to the G-protein heterotrimer and decreases the affinity of the  $G\alpha$  subunit for GDP. In its active state, the  $G$  subunit exchanges GDP for guanine triphosphate (GTP) and active  $G\alpha$  subunit disassociates from both the receptor and the dimeric  $\beta\gamma$  subunit. The disassociated, active  $G\alpha$  subunit transduces signals to effectors that are "downstream" in the G-protein signaling pathway within the cell. Eventually, the G-protein's endogenous GTPase activity returns active  $G$  subunit to its inactive state, in which it is associated with GDP and the dimeric  $\beta\gamma$  subunit.

Numerous members of the heterotrimeric G-protein family have been cloned, including more than 20 genes encoding various  $G\alpha$  subunits. The various G subunits have been categorized into four families, on the basis of amino acid sequences and functional homology. These four families are termed  $G\alpha_s$ ,  $G\alpha_i$ ,  $G\alpha_q$ , and  $G\alpha_{12}$ .

- 5 Functionally, these four families differ with respect to the intracellular signaling pathways that they activate and the GPCR to which they couple.

For example, certain GPCRs normally couple with  $G\alpha_s$  and, through  $G\alpha_s$ , these GPCRs stimulate adenylyl cyclase activity. Other GPCRs normally couple with  $G\alpha_q$ , and through  $G\alpha_q$ , these GPCRs can activate phospholipase C (PLC), such as the  $\beta$  isoform of phospholipase C (*i.e.*, PLC $\beta$ , Sternweis and Smrcka, Trends in Biochem. Sci. 17:502-506 [1992]).

As used herein, the term "nucleic acid binding protein" refers to proteins that bind to nucleic acid, and in particular to proteins that cause increased (*i.e.*, activators or transcription factors) or decreased (*i.e.*, inhibitors) transcription from a gene.

- 15 As used herein, the term "ion channel protein" refers to proteins that control the ingress or egress of ions across cell membranes. Examples of ion channel proteins include, but are not limited to, the Na<sup>+</sup>-K<sup>+</sup> ATPase pump, the Ca<sup>2+</sup> pump, and the K<sup>+</sup> leak channel.

- As used herein, the term "protein kinase" refers to proteins that catalyze the addition of a phosphate group from a nucleoside triphosphate to an amino acid side chain in a protein. Kinases comprise the largest known enzyme superfamily and vary widely in their target proteins. Kinases may be categorized as protein tyrosine kinases (PTKs), which phosphorylate tyrosine residues, and protein serine/threonine kinases (STKs), which phosphorylate serine and/or threonine residues. Some kinases have dual specificity for both serine/threonine and tyrosine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain. This domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure that binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VI-XI bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Each of the 11
- 20  
25  
30



subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI through IX comprise the highly conserved catalytic core. STKs and PTKs also contain distinct sequence motifs in subdomains VI and VIII, which may confer hydroxyamino acid specificity. Some STKs and PTKs possess structural characteristics of both families. In addition, kinases may also be classified by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain.

Non-transmembrane PTKs form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that signal through non-transmembrane PTKs include cytokine, hormone, and antigen-specific lymphocytic receptors. Many PTKs were first identified as oncogene products in cancer cells in which PTK activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (*See, e.g., Carbonneau, H. and Tonks, Annu. Rev. Cell Biol. 8:463-93 [1992]*). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

As used herein, the term "protein phosphatase" refers to proteins that remove a phosphate group from a protein. Protein phosphatases are generally divided into two groups, receptor and non-receptor type proteins. Most receptor-type protein tyrosine phosphatases contain two conserved catalytic domains, each of which encompasses a segment of 240 amino acid residues. (*See, e.g., Saito et al., Cell Growth and Diff. 2:59-65 [1991]*). Receptor protein tyrosine phosphatases can be subclassified further based upon the amino acid sequence diversity of their extracellular domains (*See, e.g., Krueger et al., Proc. Natl. Acad. Sci. USA 89:7417-7421 [1992]*).

As used herein, the term "reporter gene" refers to a gene encoding a protein that may be assayed. Examples of reporter genes include, but are not limited to, luciferase (*See, e.g., deWet et al., Mol. Cell. Biol. 7:725 [1987]* and U.S. Pat Nos., 6,074,859; 5,976,796; 5,674,713; and 5,618,682; all of which are incorporated herein by reference), green fluorescent protein (*e.g., GenBank Accession Number U43284; a number of GFP*

variants are commercially available from CLONTECH Laboratories, Palo Alto, CA), chloramphenicol acetyltransferase,  $\beta$ -galactosidase, alkaline phosphatase, and horse radish peroxidase.

As used herein, the term "purified" refers to molecules, either nucleic or amino acid sequences that are removed from their natural environment, isolated or separated. An "isolated nucleic acid sequence" is therefore a purified nucleic acid sequence. "Substantially purified" molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are naturally associated.

As used herein, the terms "computer memory" and "computer memory device" refer to any storage media readable by a computer processor. Examples of computer memory include, but are not limited to, RAM, ROM, computer chips, digital video disc (DVDs), compact discs (CDs), hard disk drives (HDD), and magnetic tape.

As used herein, the term "computer readable medium" refers to any device or system for storing and providing information (*e.g.*, data and instructions) to a computer processor. Examples of computer readable media include, but are not limited to, DVDs, CDs, hard disk drives, magnetic tape and servers for streaming media over networks.

As used herein, the term "entering" as in "entering said genetic variation information into said computer" refers to transferring information to a "computer readable medium." Information may be transferred by any suitable method, including but not limited to, manually (*e.g.*, by typing into a computer) or automated (*e.g.*, transferred from another "computer readable medium" via a "processor").

As used herein, the terms "processor" and "central processing unit" or "CPU" are used interchangeably and refer to a device that is able to read a program from a computer memory (*e.g.*, ROM or other computer memory) and perform a set of steps according to the program.

As used herein, the term "computer implemented method" refers to a method utilizing a "CPU" and "computer readable medium."

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to intracellular signaling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention encompasses both native and recombinant wild-type forms of Nod2, as well as mutant and variant forms, some of which possess altered characteristics relative to the wild-type Nod2. The present invention also relates to methods of using Nod2, including altered expression in transgenic organisms and expression in prokaryotes and cell culture systems. The present invention also encompasses methods for screening for drugs that inhibit or potentiate Nod2 action. The present invention also relates to methods for screening for susceptibility to intestinal bowel disease and Crohn's disease.

### I. Nod2 Polynucleotides

As described above, a new family of proteins that activate NF- $\kappa$ B has been discovered. This family was identified by screening public databases for nucleic acid sequences having homology to Nod1. Accordingly, the present invention provides nucleic acids encoding Nod2 genes, homologs, variants (*e.g.*, polymorphisms and mutants), including but not limited to, those described in SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88. In some embodiments, the present invention provide polynucleotide sequences that are capable of hybridizing to SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88 under conditions of low to high stringency as long as the polynucleotide sequence capable of hybridizing encodes a protein that retains a biological activity of the naturally occurring Nod2. In some embodiments, the protein that retains a biological activity of naturally occurring Nod2 is 70% homologous to wild-type Nod2, preferably 80% homologous to wild-type Nod2, more preferably 90% homologous to wild-type Nod2, and most preferably 95% homologous to wild-type Nod2. In preferred embodiments, hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex and confer a defined "stringency" as explained above (*See e.g.*, Wahl, *et al.*, Meth. Enzymol., 152:399-407 [1987], incorporated herein by reference).

In other embodiments of the present invention, additional alleles of Nod2 are provided. In preferred embodiments, alleles result from a polymorphism or mutation

(i.e., a change in the nucleic acid sequence) and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes that give rise to alleles are generally ascribed to deletions, additions or substitutions of nucleic acids.

- 5 Each of these types of changes may occur alone, or in combination with the others, and at the rate of one or more times in a given sequence. Examples of the alleles of the present invention include those encoded by SEQ ID NOs:1 (wild type) and 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88 (variant) alleles.

- 10 In some embodiments of the present invention, the nucleic acids encode two CARD domains corresponding (e.g., nucleic acid sequences encoding the peptides SEQ ID NOs: 5 and 6). In other embodiments, the nucleic acids encode at least one domain selected from the group consisting of an NBD domain (e.g., SEQ ID NO:7), an LRR domain (e.g., SEQ ID NOs: 8-17), and P-loop and  $Mg^{2+}$  binding domains (SEQ ID NO:18-19)

- 15 In still other embodiments of the present invention, the nucleotide sequences of the present invention may be engineered in order to alter an Nod2 coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques that are well known in the art (e.g., site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, etc.).

- 20 In some embodiments of the present invention, the polynucleotide sequence of Nod2 may be extended utilizing the nucleotide sequences (e.g., SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88) in various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, it is contemplated that restriction-site polymerase chain reaction (PCR) will find use in the present invention. This is a direct method that uses universal primers to retrieve unknown sequence adjacent to a known locus (Gobinda *et al.*, PCR Methods Applic., 2:318-22 [1993]). First, genomic DNA is amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific
- 25  
30

primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

In another embodiment, inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia *et al.*, Nucleic Acids Res., 16:8186 [1988]). The primers may be designed using Oligo 4.0 (National Biosciences Inc, Plymouth Minn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template. In still other embodiments, walking PCR is utilized. Walking PCR is a method for targeted gene walking that permits retrieval of unknown sequence (Parker *et al.*, Nucleic Acids Res., 19:3055-60 [1991]). The PROMOTERFINDER kit (Clontech) uses PCR, nested primers and special libraries to "walk in" genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

Preferred libraries for screening for full length cDNAs include mammalian libraries that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred, in that they will contain more sequences that contain the 5' and upstream gene regions. A randomly primed library may be particularly useful in case where an oligo d(T) library does not yield full-length cDNA. Genomic mammalian libraries are useful for obtaining introns and extending 5' sequence.

In other embodiments of the present invention, variants of the disclosed Nod2 sequences are provided. In preferred embodiments, variants result from polymorphisms or mutations (*i.e.*, a change in the nucleic acid sequence) and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many variant forms. Common mutational changes that give rise to variants are generally ascribed to deletions, additions or substitutions of nucleic acids. Each of these types of changes may occur alone, or in combination with the others, and at the rate of one or more times in a given sequence.

It is contemplated that it is possible to modify the structure of a peptide having a function (*e.g.*, Nod2 function) for such purposes as altering (*e.g.*, increasing or

decreasing) the binding affinity of the Nod2 for RICK or another regulator. Such modified peptides are considered functional equivalents of peptides having an activity of Nod2 as defined herein. A modified peptide can be produced in which the nucleotide sequence encoding the polypeptide has been altered, such as by substitution, deletion, or addition. In particularly preferred embodiments, these modifications do not significantly reduce the synthetic activity of the modified Nod2. In other words, construct "X" can be evaluated in order to determine whether it is a member of the genus of modified or variant Nod2's of the present invention as defined functionally, rather than structurally. In preferred embodiments, the activity of variant Nod2 polypeptides is evaluated by the methods described in Example 4. Accordingly, in some embodiments, the present invention provides nucleic acids encoding a Nod2 that activates NF- $\kappa$ B (*e.g.*, activates an inflammatory response). In preferred embodiments, the activity of a Nod2 variant is evaluated by transfecting HEK293T cells with and expression construct encoded the variant or mutant Nod2. In particularly preferred embodiments, the cells contain a reporter luciferase construct containing enhancer regions that are responsive to NF- $\kappa$ B. In other embodiments, the Nod2 variant may be capable of binding a protein (*e.g.*, RICK) but not activating NF- $\kappa$ B. These variants can be screened for by the immunoprecipitation methods described in Example 6.

Moreover, as described above, variant forms of Nod2 are also contemplated as being equivalent to those peptides and DNA molecules that are set forth in more detail herein. For example, it is contemplated that isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (*i.e.*, conservative mutations) will not have a major effect on the biological activity of the resulting molecule. Accordingly, some embodiments of the present invention provide variants of Nod2 disclosed herein containing conservative replacements. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids can be divided into four families: (1) acidic (aspartate, glutamate); (2) basic (lysine, arginine, histidine); (3) nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan); and (4) uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine).

Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In similar fashion, the amino acid repertoire can be grouped as (1) acidic (aspartate, glutamate); (2) basic (lysine, arginine, histidine), (3) aliphatic (glycine, alanine, valine, leucine, isoleucine, serine, threonine), with serine and threonine  
5 optionally be grouped separately as aliphatic-hydroxyl; (4) aromatic (phenylalanine, tyrosine, tryptophan); (5) amide (asparagine, glutamine); and (6) sulfur -containing (cysteine and methionine) (*e.g.*, Stryer ed., *Biochemistry*, pg. 17-21, 2nd ed, WH Freeman and Co., 1981). Whether a change in the amino acid sequence of a peptide results in a functional polypeptide can be readily determined by assessing the ability of  
10 the variant peptide to function in a fashion similar to the wild-type protein. Peptides having more than one replacement can readily be tested in the same manner.

More rarely, a variant includes "nonconservative" changes (*e.g.*, replacement of a glycine with a tryptophan). Analogous minor variations can also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues can  
15 be substituted, inserted, or deleted without abolishing biological activity can be found using computer programs (*e.g.*, LASERGENE software, DNASTAR Inc., Madison, Wis.).

As described in more detail below, variants may be produced by methods such as directed evolution or other techniques for producing combinatorial libraries of variants,  
20 described in more detail below. In still other embodiments of the present invention, the nucleotide sequences of the present invention may be engineered in order to alter a Nod2 coding sequence including, but not limited to, alterations that modify the cloning, processing, localization, secretion, and/or expression of the gene product. For example, mutations may be introduced using techniques that are well known in the art (*e.g.*,  
25 site-directed mutagenesis to insert new restriction sites, alter glycosylation patterns, or change codon preference, etc.).

## II. Nod2 Polypeptides

In other embodiments, the present invention provides Nod2 polynucleotide sequences that encode Nod2 polypeptide sequences. Nod2 polypeptides (*e.g.*, SEQ ID NOs: 2, 3, 34, 55, 57, 59, 61, 63, 65, 67, 69, 85, 87, and 89) are described in Figures 13, 14, 15, 22, 24, 28, 30, 32, 34, 36, 38, 40, 42, and 44. Other embodiments of the present invention provide fragments, fusion proteins or functional equivalents of these Nod2 proteins. In still other embodiment of the present invention, nucleic acid sequences corresponding to Nod2 variants, homologs, and mutants may be used to generate recombinant DNA molecules that direct the expression of the Nod2 variants, homologs, and mutants in appropriate host cells. In some embodiments of the present invention, the polypeptide may be a naturally purified product, in other embodiments it may be a product of chemical synthetic procedures, and in still other embodiments it may be produced by recombinant techniques using a prokaryotic or eukaryotic host (*e.g.*, by bacterial, yeast, higher plant, insect and mammalian cells in culture). In some embodiments, depending upon the host employed in a recombinant production procedure, the polypeptide of the present invention may be glycosylated or may be non-glycosylated. In other embodiments, the polypeptides of the invention may also include an initial methionine amino acid residue.

In one embodiment of the present invention, due to the inherent degeneracy of the genetic code, DNA sequences other than the polynucleotide sequences of SEQ ID NO:1 that encode substantially the same or a functionally equivalent amino acid sequence, may be used to clone and express Nod2. In general, such polynucleotide sequences hybridize to SEQ ID NO:1 under conditions of high to medium stringency as described above. As will be understood by those of skill in the art, it may be advantageous to produce Nod2-encoding nucleotide sequences possessing non-naturally occurring codons. Therefore, in some preferred embodiments, codons preferred by a particular prokaryotic or eukaryotic host (Murray *et al.*, Nucl. Acids Res., 17 [1989]) are selected, for example, to increase the rate of Nod2 expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.



## 1. Vectors for Production of Nod2

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. In some embodiments of the present invention, vectors include, but are not limited to, chromosomal, nonchromosomal and synthetic DNA sequences (*e.g.*, derivatives of SV40, bacterial plasmids, phage DNA; baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies). It is contemplated that any vector may be used as long as it is replicable and viable in the host.

In particular, some embodiments of the present invention provide recombinant constructs comprising one or more of the sequences as broadly described above (*e.g.*, SEQ ID NOS: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88). In some embodiments of the present invention, the constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In still other embodiments, the heterologous structural sequence (*e.g.*, SEQ ID NO:1) is assembled in appropriate phase with translation initiation and termination sequences. In preferred embodiments of the present invention, the appropriate DNA sequence is inserted into the vector using any of a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art.

Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. Such vectors include, but are not limited to, the following vectors: 1) Bacterial -- pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pBSKS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); 2) Eukaryotic -- pWLNEO, pSV2CAT, pOG44, PXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia); and 3) Baculovirus -- pPbac and pMbac (Stratagene). Any other plasmid or vector may be used as long as they are replicable and viable in the host. In some preferred embodiments of the present invention, mammalian expression vectors comprise

an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation sites, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking non-transcribed sequences. In other embodiments, DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

In certain embodiments of the present invention, the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. Promoters useful in the present invention include, but are not limited to, the LTR or SV40 promoter, the *E. coli lac* or *trp*, the phage lambda P<sub>L</sub> and P<sub>R</sub>, T3 and T7 promoters, and the cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, and mouse metallothionein-I promoters and other promoters known to control expression of gene in prokaryotic or eukaryotic cells or their viruses. In other embodiments of the present invention, recombinant expression vectors include origins of replication and selectable markers permitting transformation of the host cell (e.g., dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or tetracycline or ampicillin resistance in *E. coli*).

In some embodiments of the present invention, transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are *cis*-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Enhancers useful in the present invention include, but are not limited to, the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

In other embodiments, the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. In still other embodiments of the present invention, the vector may also include appropriate sequences for amplifying expression.

30

## 2. Host Cells for Production of Nod2

In a further embodiment, the present invention provides host cells containing the above-described constructs. In some embodiments of the present invention, the host cell is a higher eukaryotic cell (e.g., a mammalian or insect cell). In other embodiments of the present invention, the host cell is a lower eukaryotic cell (e.g., a yeast cell). In still other embodiments of the present invention, the host cell can be a prokaryotic cell (e.g., a bacterial cell). Specific examples of host cells include, but are not limited to, *Escherichia coli*, *Salmonella typhimurium*, *Bacillus subtilis*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, as well as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Drosophila* S2 cells, *Spodoptera* Sf9 cells, Chinese hamster ovary (CHO) cells, COS-7 lines of monkey kidney fibroblasts, (Gluzman, Cell 23:175 [1981]), C127, 3T3, 293, 293T, HeLa and BHK cell lines.

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. In some embodiments, introduction of the construct into the host cell can be accomplished by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (See e.g., Davis *et al.*, Basic Methods in Molecular Biology, [1986]). Alternatively, in some embodiments of the present invention, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

Proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., [1989].

In some embodiments of the present invention, following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. In other embodiments of the present invention, cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. In still

other embodiments of the present invention, microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

5           **3. Purification of Nod2**

The present invention also provides methods for recovering and purifying Nod2 from recombinant cell cultures including, but not limited to, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity  
10 chromatography, hydroxylapatite chromatography and lectin chromatography. In other embodiments of the present invention, protein-refolding steps can be used as necessary, in completing configuration of the mature protein. In still other embodiments of the present invention, high performance liquid chromatography (HPLC) can be employed for final purification steps.

15           The present invention further provides polynucleotides having the coding sequence (*e.g.*, SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88) fused in frame to a marker sequence that allows for purification of the polypeptide of the present invention. A non-limiting example of a marker sequence is a hexahistidine tag which may be supplied by a vector, preferably a pQE-9 vector, which provides for purification  
20 of the polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host (*e.g.*, COS-7 cells) is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson *et al.*, Cell, 37:767 [1984]).

#### 4. Truncation Mutants of Nod2

In addition, the present invention provides fragments of Nod2 (*i.e.*, truncation mutants, *e.g.*, SEQ ID NO:3). In some embodiments of the present invention, when expression of a portion of the Nod2 protein is desired, it may be necessary to add a start codon (ATG) to the oligonucleotide fragment containing the desired sequence to be expressed. It is well known in the art that a methionine at the N-terminal position can be enzymatically cleaved by the use of the enzyme methionine aminopeptidase (MAP). MAP has been cloned from *E. coli* (Ben-Bassat *et al.*, J. Bacteriol., 169:751 [1987]) and *Salmonella typhimurium* and its *in vitro* activity has been demonstrated on recombinant proteins (Miller *et al.*, Proc. Natl. Acad. Sci. USA 84:2718 [1990]). Therefore, removal of an N-terminal methionine, if desired, can be achieved either *in vivo* by expressing such recombinant polypeptides in a host which produces MAP (*e.g.*, *E. coli* or CM89 or *S. cerevisiae*), or *in vitro* by use of purified MAP.

#### 5. Fusion Proteins Containing Nod2

The present invention also provides fusion proteins incorporating all or part of Nod2. Accordingly, in some embodiments of the present invention, the coding sequences for the polypeptide can be incorporated as a part of a fusion gene including a nucleotide sequence encoding a different polypeptide. It is contemplated that this type of expression system will find use under conditions where it is desirable to produce an immunogenic fragment of a Nod2 protein. In some embodiments of the present invention, the VP6 capsid protein of rotavirus is used as an immunologic carrier protein for portions of the Nod2 polypeptide, either in the monomeric form or in the form of a viral particle. In other embodiments of the present invention, the nucleic acid sequences corresponding to the portion of Nod2 against which antibodies are to be raised can be incorporated into a fusion gene construct which includes coding sequences for a late vaccinia virus structural protein to produce a set of recombinant viruses expressing fusion proteins comprising a portion of Nod2 as part of the virion. It has been demonstrated with the use of immunogenic fusion proteins utilizing the hepatitis B surface antigen fusion proteins that recombinant hepatitis B virions can be utilized in this role as well. Similarly, in other embodiments of the present invention, chimeric constructs coding for fusion proteins

containing a portion of Nod2 and the poliovirus capsid protein are created to enhance immunogenicity of the set of polypeptide antigens (*See e.g.*, EP Publication No. 025949; and Evans *et al.*, Nature 339:385 [1989]; Huang *et al.*, J. Virol., 62:3855 [1988]; and Schlienger *et al.*, J. Virol., 66:2 [1992]).

5           In still other embodiments of the present invention, the multiple antigen peptide system for peptide-based immunization can be utilized. In this system, a desired portion of Nod2 is obtained directly from organo-chemical synthesis of the peptide onto an oligomeric branching lysine core (*see e.g.*, Posnett *et al.*, J. Biol. Chem., 263:1719 [1988]; and Nardelli *et al.*, J. Immunol., 148:914 [1992]). In other embodiments of the  
10       present invention, antigenic determinants of the Nod2 proteins can also be expressed and presented by bacterial cells.

          In addition to utilizing fusion proteins to enhance immunogenicity, it is widely appreciated that fusion proteins can also facilitate the expression of proteins, such as the Nod2 protein of the present invention. Accordingly, in some embodiments of the present  
15       invention, Nod2 can be generated as a glutathione-S-transferase (*i.e.*, GST fusion protein). It is contemplated that such GST fusion proteins will enable easy purification of Nod2, such as by the use of glutathione-derivatized matrices (*See e.g.*, Ausabel *et al.* (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY [1991]). In another embodiment of the present invention, a fusion gene coding for a purification  
20       leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of Nod2, can allow purification of the expressed Nod2 fusion protein by affinity chromatography using a Ni<sup>2+</sup> metal resin. In still another embodiment of the present invention, the purification leader sequence can then be subsequently removed by treatment with enterokinase (*See e.g.*, Hochuli *et al.*, J.  
25       Chromatogr., 411:177 [1987]; and Janknecht *et al.*, Proc. Natl. Acad. Sci. USA 88:8972).

          Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini,  
30       filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment of the present

invention, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, in other embodiments of the present invention, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments  
5 which can subsequently be annealed to generate a chimeric gene sequence (*See e.g.*, Current Protocols in Molecular Biology, *supra*).

## 6. Variants of Nod2

Still other embodiments of the present invention provide mutant or variant forms  
10 of Nod2 (*i.e.*, muteins). It is possible to modify the structure of a peptide having an activity of Nod2 for such purposes as enhancing therapeutic or prophylactic efficacy, or stability (*e.g.*, *ex vivo* shelf life, and/or resistance to proteolytic degradation *in vivo*). Such modified peptides are considered functional equivalents of peptides having an activity of the subject Nod2 proteins as defined herein. A modified peptide can be  
15 produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition.

Moreover, as described above, variant forms (*e.g.*, mutants or polymorphic sequences) of the subject Nod2 proteins are also contemplated as being equivalent to those peptides and DNA molecules that are set forth in more detail. For example, as  
20 described above, the present invention encompasses mutant and variant proteins that contain conservative or non-conservative amino acid substitutions.

This invention further contemplates a method of generating sets of combinatorial mutants of the present Nod2 proteins, as well as truncation mutants, and is especially useful for identifying potential variant sequences (*i.e.*, mutants or polymorphic  
25 sequences) that are functional in binding to RICK or other regulators in the NF- $\kappa$ B signalling pathway and signalling an inflammatory response. The purpose of screening such combinatorial libraries is to generate, for example, novel Nod2 variants that can act as either agonists or antagonists, or alternatively, possess novel activities all together.

Therefore, in some embodiments of the present invention, Nod2 variants are  
30 engineered by the present method to provide altered (*e.g.*, increased or decreased) activation of NF- $\kappa$ B (*i.e.*, generating an inflammatory response). In other embodiments

of the present invention, combinatorially-derived variants are generated which have a selective potency relative to a naturally occurring Nod2. Such proteins, when expressed from recombinant DNA constructs, can be used in gene therapy protocols.

Still other embodiments of the present invention provide Nod2 variants that have  
5 intracellular half-lives dramatically different than the corresponding wild-type protein. For example, the altered protein can be rendered either more stable or less stable to proteolytic degradation or other cellular process that result in destruction of, or otherwise inactivate Nod2. Such variants, and the genes which encode them, can be utilized to alter the location of Nod2 expression by modulating the half-life of the protein. For instance,  
10 a short half-life can give rise to more transient Nod2 biological effects and, when part of an inducible expression system, can allow tighter control of Nod2 levels within the cell. As above, such proteins, and particularly their recombinant nucleic acid constructs, can be used in gene therapy protocols.

In still other embodiments of the present invention, Nod2 variants are generated  
15 by the combinatorial approach to act as antagonists, in that they are able to interfere with the ability of the corresponding wild-type protein to regulate cell function.

In some embodiments of the combinatorial mutagenesis approach of the present invention, the amino acid sequences for a population of Nod2 homologs, variants or other related proteins are aligned, preferably to promote the highest homology possible. Such a  
20 population of variants can include, for example, Nod2 homologs from one or more species, or Nod2 variants from the same species but which differ due to mutation or polymorphisms. Amino acids that appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences.

In a preferred embodiment of the present invention, the combinatorial Nod2  
25 library is produced by way of a degenerate library of genes encoding a library of polypeptides which each include at least a portion of potential Nod2 protein sequences. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential Nod2 sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for  
30 phage display) containing the set of Nod2 sequences therein.



There are many ways by which the library of potential Nod2 homologs and variants can be generated from a degenerate oligonucleotide sequence. In some embodiments, chemical synthesis of a degenerate gene sequence is carried out in an automatic DNA synthesizer, and the synthetic genes are ligated into an appropriate gene  
5 for expression. The purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential Nod2 sequences. The synthesis of degenerate oligonucleotides is well known in the art (*See e.g.*, Narang, *Tetrahedron Lett.*, 39:39 [1983]; Itakura *et al.*, *Recombinant DNA*, in Walton (ed.), *Proceedings of the 3rd Cleveland Symposium on Macromolecules*, Elsevier, Amsterdam, pp 273-289 [1981];  
10 Itakura *et al.*, *Annu. Rev. Biochem.*, 53:323 [1984]; Itakura *et al.*, *Science* 198:1056 [1984]; Ike *et al.*, *Nucl. Acid Res.*, 11:477 [1983]). Such techniques have been employed in the directed evolution of other proteins (*See e.g.*, Scott *et al.*, *Science* 249:386 [1980]; Roberts *et al.*, *Proc. Natl. Acad. Sci. USA* 89:2429 [1992]; Devlin *et al.*, *Science* 249:404 [1990]; Cwirla *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 6378 [1990]; as well as U.S.  
15 Pat. Nos. 5,223,409, 5,198,346, and 5,096,815; each of which is incorporated herein by reference).

It is contemplated that the Nod2 nucleic acids (*e.g.*, SEQ ID NO:1, and fragments and variants thereof) can be utilized as starting nucleic acids for directed evolution. These techniques can be utilized to develop Nod2 variants having desirable properties  
20 such as increased or decreased binding affinity for RICK.

In some embodiments, artificial evolution is performed by random mutagenesis (*e.g.*, by utilizing error-prone PCR to introduce random mutations into a given coding sequence). This method requires that the frequency of mutation be finely tuned. As a general rule, beneficial mutations are rare, while deleterious mutations are common. This  
25 is because the combination of a deleterious mutation and a beneficial mutation often results in an inactive enzyme. The ideal number of base substitutions for targeted gene is usually between 1.5 and 5 (Moore and Arnold, *Nat. Biotech.*, 14, 458 [1996]; Leung *et al.*, *Technique*, 1:11 [1989]; Eckert and Kunkel, *PCR Methods Appl.*, 1:17-24 [1991]; Caldwell and Joyce, *PCR Methods Appl.*, 2:28 [1992]; and Zhao and Arnold, *Nuc. Acids.*  
30 *Res.*, 25:1307 [1997]). After mutagenesis, the resulting clones are selected for desirable activity (*e.g.*, screened for Nod2 activity). Successive rounds of mutagenesis and

selection are often necessary to develop enzymes with desirable properties. It should be noted that only the useful mutations are carried over to the next round of mutagenesis.

In other embodiments of the present invention, the polynucleotides of the present invention are used in gene shuffling or sexual PCR procedures (*e.g.*, Smith, *Nature*, 370:324 [1994]; U.S. Pat. Nos. 5,837,458; 5,830,721; 5,811,238; 5,733,731; all of which are herein incorporated by reference). Gene shuffling involves random fragmentation of several mutant DNAs followed by their reassembly by PCR into full length molecules. Examples of various gene shuffling procedures include, but are not limited to, assembly following DNase treatment, the staggered extension process (STEP), and random priming in vitro recombination. In the DNase mediated method, DNA segments isolated from a pool of positive mutants are cleaved into random fragments with DNaseI and subjected to multiple rounds of PCR with no added primer. The lengths of random fragments approach that of the uncleaved segment as the PCR cycles proceed, resulting in mutations in present in different clones becoming mixed and accumulating in some of the resulting sequences. Multiple cycles of selection and shuffling have led to the functional enhancement of several enzymes (Stemmer, *Nature*, 370:398 [1994]; Stemmer, *Proc. Natl. Acad. Sci. USA*, 91:10747 [1994]; Cramer *et al.*, *Nat. Biotech.*, 14:315 [1996]; Zhang *et al.*, *Proc. Natl. Acad. Sci. USA*, 94:4504 [1997]; and Cramer *et al.*, *Nat. Biotech.*, 15:436 [1997]). Variants produced by directed evolution can be screened for Nod2 activity by the methods described in Examples 4-8.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations, and for screening cDNA libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis or recombination of Nod2 homologs or variants. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected.

## 7. Chemical Synthesis of Nod2

In an alternate embodiment of the invention, the coding sequence of Nod2 is synthesized, whole or in part, using chemical methods well known in the art (*See e.g.*, Caruthers *et al.*, Nucl. Acids Res. Symp. Ser., 7:215 [1980]; Crea and Horn, Nucl. Acids Res., 9:2331 [1980]; Matteucci and Caruthers, Tetrahedron Lett., 21:719 [1980]; and Chow and Kempe, Nucl. Acids Res., 9:2807 [1981]). In other embodiments of the present invention, the protein itself is produced using chemical methods to synthesize either an entire Nod2 amino acid sequence or a portion thereof. For example, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (*See e.g.*, Creighton, *Proteins Structures And Molecular Principles*, W H Freeman and Co, New York N.Y. [1983]). In other embodiments of the present invention, the composition of the synthetic peptides is confirmed by amino acid analysis or sequencing (*See e.g.*, Creighton, *supra*).

Direct peptide synthesis can be performed using various solid-phase techniques (Roberge *et al.*, Science 269:202 [1995]) and automated synthesis may be achieved, for example, using ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. Additionally, the amino acid sequence of Nod2, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with other sequences to produce a variant polypeptide.

20

## III. Detection of Nod2 Alleles

### A. Nod2 Alleles

In some embodiments, the present invention includes alleles of Nod2 that increase a patient's susceptibility to Crohn's disease (*e.g.*, including, but not limited to, SEQ ID NO: 33. Analysis of naturally occurring human Nod2 alleles revealed that patients with increased susceptibility to Crohn's disease have a mutant Nod2 allele that, for example, contains an additional cytosine residue (*e.g.*, SEQ ID NO: 33; 3020InsC or Nod $\Delta$ 33). The additional cytosine residue causes a frameshift mutation resulting in the generation of a stop codon that causes deletion of a portion of the LRR domain. Expression of the Crohn's disease Nod2 allele of SEQ ID NO:33 in the absence of LPS induced NF- $\kappa$ B

25

30

activation (Fig. 19a). The ability of Nod2 proteins to enhance NF- $\kappa$ B activation after incubation with LPS from several bacteria was also tested. LPS from various bacteria induced NF- $\kappa$ B activation in cells expressing wild-type Nod2, whereas no significant induction of reporter gene activity was observed in cells transfected with control plasmid (Fig. 19b). Significantly, the ability of Nod2 mutant to confer responsiveness to LPS was greatly diminished when compared to wild-type Nod2 (Fig. 19b).

The present invention is not limited to a particular mechanism of action. Indeed, an understanding of the mechanism of action is not necessary to practice the present invention. Nevertheless, it is contemplated that the signaling system of which Nod2 is a component recognizes bacterial and viral pathogens and initiates a response to kill the pathogen or infected cell (*i.e.*, cell signalling that activates a transcription factor, that in turn, activates an inflammatory response). It is contemplated that in Crohn's disease the activation of the signalling pathway occurs in the absence of pathogen stimulation because of the presence of the truncated form of Nod2. This leads to the inflammation associated with Crohn's disease.

However, the present invention is not limited to the mutation described in SEQ ID NOs: 3 and 33. Any mutation that results in the undesired phenotype (*e.g.*, a high degree of NF- $\kappa$ B activation in the absence of other signalling stimuli or increased susceptibility to Crohn's disease) is within the scope of the present invention. Assays for determining if a given polypeptide has such activities are provided in Examples 4 and 5.

For example, in some embodiments, the present invention provides alleles containing one or more single-nucleotide changes of Nod2 (*e.g.*, mutants or polymorphic sequences) (*e.g.*, including but not limited to the nucleic acid sequences described in SEQ ID NOs: 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88. Example 10 and Figures 26 and 27 describe exemplary polymorphisms and their prevalence alone and in combination. Examples 9 and 10 describe the association of three Nod2 polymorphisms with Crohn's disease. Example 10 describes the association of one or more of the mutations described above with an increased risk of developing Crohn's disease. Table 1 describes Nod2 sequences for wild type and mutant nucleic acids and polypeptides.

**Table 1**

Sequence	SEQ ID Number	Figure Number
Nod2 cDNA Wild-type	1	12
Nod2 cDNA cytosine insertion	33	11
Nod2a Amino Acid Wild Type	2	13
Nod2b Amino Acid Wild Type	3	14
Nod2a Amino Acid $\Delta 33$	34	15
Nod2 Exon 11 Wild Type	35	16
Nod2 Exon 11 $\Delta 33$	36	16
Nod2 cDNA wild type	53	20
Nod2 c802t + 3020Insc nucleic acid	54	21
Nod2a P268S + Frameshift 1007 amino acid	55	22
Nod2 c2104t nucleic acid (SNP 20)	56	23
Nod2a R702W amino acid (SNP 20)	57	24
Nod2 g2722c nucleic acid (SNP 17)	58	25
Nod2a G908R (SNP 17)	59	28
Nod2 c802t nucleic acid (SNP 4)	60	29
Nod2a P268S amino acid (SNP4)	61	30
Nod2 g2377a nucleic acid (SNP 7)	62	31
Nod2a V793M amino acid (SNP 7)	63	32
Nod2 a2555g nucleic acid (SNP 18)	64	33
Nod2a N852S amino acid (SNP 18)	65	34
Nod2 g2863a nucleic acid (SNP 23)	66	35
Nod2a V955I amino acid (SNP 23)	67	36
Nod2 a2587g nucleic acid (SNP 25)	68	37
Nod2a M863V amino acid (SNP25)	69	38
Nod2 c802t + g2722c nucleic acid (SNP 4 + SNP 17)	84	39
Nod2a P268S + G908R amino acid (SNP 4	85	40

+ SNP 17)		
Nod2 c802t + a2555g nucleic acid (SNP 4 + SNP 18)	86	41
Nod2a P268S + N852S amino acid (SNP 4 + SNP 18)	87	42
Nod2 c802t + c2104t nucleic acid (SNP 4 + SNP 20)	88	43
Nod2a P268S + R702W amino acid (SNP 4 + SNP 20)	89	44

### B. Detection of Nod2 Alleles

Accordingly, the present invention provides methods for determining whether a patient has an increased susceptibility to inflammatory bowel disease or Crohn's disease by determining whether the individual has a variant Nod2 allele. In other embodiments, the present invention provides methods for providing a prognosis of increased risk for Crohn's disease to an individual based on the presence or absence of one or more variant alleles of Nod2. In preferred embodiments, the variation causes a truncation of the LRR domain. In other preferred embodiments, the variation results in increased activation of NF- $\kappa$ B and consequent inflammatory response. In particularly preferred embodiments, the variation is a single nucleotide polymorphism caused by an insertion of a cytosine residue or a single nucleotide substitution).

A number of methods are available for analysis of variant (*e.g.*, mutant or polymorphic) nucleic acid sequences. Assays for detection variants (*e.g.*, polymorphisms or mutations) fall into several categories, including, but not limited to direct sequencing assays, fragment polymorphism assays, hybridization assays, and computer based data analysis. Protocols and commercially available kits or services for performing multiple variations of these assays are available. In some embodiments, assays are performed in combination or in hybrid (*e.g.*, different reagents or technologies from several assays are combined to yield one assay). The following assays are useful in the present invention.

### 1. Direct sequencing Assays

In some embodiments of the present invention, variant sequences are detected using a direct sequencing technique. In these assays, DNA samples are first isolated from a subject using any suitable method. In some embodiments, the region of interest is  
5 cloned into a suitable vector and amplified by growth in a host cell (*e.g.*, a bacteria). In other embodiments, DNA in the region of interest is amplified using PCR.

Following amplification, DNA in the region of interest (*e.g.*, the region containing the SNP or mutation of interest) is sequenced using any suitable method, including but not limited to manual sequencing using radioactive marker nucleotides, or automated  
10 sequencing. The results of the sequencing are displayed using any suitable method. The sequence is examined and the presence or absence of a given SNP or mutation is determined.

### 2. PCR Assay

15 In some embodiments of the present invention, variant sequences are detected using a PCR-based assay. In some embodiments, the PCR assay comprises the use of oligonucleotide primers that hybridize only to the variant or wild type allele of Nod2 (*e.g.*, to the region of polymorphism or mutation). Both sets of primers are used to amplify a sample of DNA. If only the mutant primers result in a PCR product, then the  
20 patient has the mutant Nod2 allele. If only the wild-type primers result in a PCR product, then the patient has the wild type allele of Nod2.

### 3. Fragment Length Polymorphism Assays

In some embodiments of the present invention, variant sequences are detected  
25 using a fragment length polymorphism assay. In a fragment length polymorphism assay, a unique DNA banding pattern based on cleaving the DNA at a series of positions is generated using an enzyme (*e.g.*, a restriction enzyme or a CLEAVASE I [Third Wave Technologies, Madison, WI] enzyme). DNA fragments from a sample containing a SNP or a mutation will have a different banding pattern than wild type.

30

**a. RFLP Assay**

In some embodiments of the present invention, variant sequences are detected using a restriction fragment length polymorphism assay (RFLP). The region of interest is first isolated using PCR. The PCR products are then cleaved with restriction enzymes known to give a unique length fragment for a given polymorphism. The restriction-enzyme digested PCR products are separated by agarose gel electrophoresis and visualized by ethidium bromide staining. The length of the fragments is compared to molecular weight markers and fragments generated from wild-type and mutant controls.

**b. CFLP Assay**

In other embodiments, variant sequences are detected using a CLEAVASE fragment length polymorphism assay (CFLP; Third Wave Technologies, Madison, WI; See e.g., U.S. Patent Nos. 5,843,654; 5,843,669; 5,719,208; and 5,888,780; each of which is herein incorporated by reference). This assay is based on the observation that when single strands of DNA fold on themselves, they assume higher order structures that are highly individual to the precise sequence of the DNA molecule. These secondary structures involve partially duplexed regions of DNA such that single stranded regions are juxtaposed with double stranded DNA hairpins. The CLEAVASE I enzyme, is a structure-specific, thermostable nuclease that recognizes and cleaves the junctions between these single-stranded and double-stranded regions.

The region of interest is first isolated, for example, using PCR. Then, DNA strands are separated by heating. Next, the reactions are cooled to allow intrastrand secondary structure to form. The PCR products are then treated with the CLEAVASE I enzyme to generate a series of fragments that are unique to a given SNP or mutation. The CLEAVASE enzyme treated PCR products are separated and detected (e.g., by agarose gel electrophoresis) and visualized (e.g., by ethidium bromide staining). The length of the fragments is compared to molecular weight markers and fragments generated from wild-type and mutant controls.



#### 4. Hybridization Assays

In preferred embodiments of the present invention, variant sequences are detected a hybridization assay. In a hybridization assay, the presence or absence of a given SNP or mutation is determined based on the ability of the DNA from the sample to hybridize to a complementary DNA molecule (*e.g.*, a oligonucleotide probe). A variety of hybridization assays using a variety of technologies for hybridization and detection are available. A description of a selection of assays is provided below.

##### a. Direct Detection of Hybridization

In some embodiments, hybridization of a probe to the sequence of interest (*e.g.*, a SNP or mutation) is detected directly by visualizing a bound probe (*e.g.*, a Northern or Southern assay; *See e.g.*, Ausabel *et al.* (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY [1991]). In these assays, genomic DNA (Southern) or RNA (Northern) is isolated from a subject. The DNA or RNA is then cleaved with a series of restriction enzymes that cleave infrequently in the genome and not near any of the markers being assayed. The DNA or RNA is then separated (*e.g.*, on an agarose gel) and transferred to a membrane. A labeled (*e.g.*, by incorporating a radionucleotide) probe or probes specific for the SNP or mutation being detected is allowed to contact the membrane under a condition of low, medium, or high stringency conditions. Unbound probe is removed and the presence of binding is detected by visualizing the labeled probe.

##### b. Detection of Hybridization Using "DNA Chip" Assays

In some embodiments of the present invention, variant sequences are detected using a DNA chip hybridization assay. In this assay, a series of oligonucleotide probes are affixed to a solid support. The oligonucleotide probes are designed to be unique to a given SNP or mutation. The DNA sample of interest is contacted with the DNA "chip" and hybridization is detected.

In some embodiments, the DNA chip assay is a GeneChip (Affymetrix, Santa Clara, CA; *See e.g.*, U.S. Patent Nos. 6,045,996; 5,925,525; and 5,858,659; each of which is herein incorporated by reference) assay. The GeneChip technology uses miniaturized,

high-density arrays of oligonucleotide probes affixed to a "chip." Probe arrays are manufactured by Affymetrix's light-directed chemical synthesis process, which combines solid-phase chemical synthesis with photolithographic fabrication techniques employed in the semiconductor industry. Using a series of photolithographic masks to define chip exposure sites, followed by specific chemical synthesis steps, the process constructs high-density arrays of oligonucleotides, with each probe in a predefined position in the array. Multiple probe arrays are synthesized simultaneously on a large glass wafer. The wafers are then diced, and individual probe arrays are packaged in injection-molded plastic cartridges, which protect them from the environment and serve as chambers for hybridization.

The nucleic acid to be analyzed is isolated, amplified by PCR, and labeled with a fluorescent reporter group. The labeled DNA is then incubated with the array using a fluidics station. The array is then inserted into the scanner, where patterns of hybridization are detected. The hybridization data are collected as light emitted from the fluorescent reporter groups already incorporated into the target, which is bound to the probe array. Probes that perfectly match the target generally produce stronger signals than those that have mismatches. Since the sequence and position of each probe on the array are known, by complementarity, the identity of the target nucleic acid applied to the probe array can be determined.

In other embodiments, a DNA microchip containing electronically captured probes (Nanogen, San Diego, CA) is utilized (*See e.g.*, U.S. Patent Nos. 6,017,696; 6,068,818; and 6,051,380; each of which are herein incorporated by reference). Through the use of microelectronics, Nanogen's technology enables the active movement and concentration of charged molecules to and from designated test sites on its semiconductor microchip. DNA capture probes unique to a given SNP or mutation are electronically placed at, or "addressed" to, specific sites on the microchip. Since DNA has a strong negative charge, it can be electronically moved to an area of positive charge.

First, a test site or a row of test sites on the microchip is electronically activated with a positive charge. Next, a solution containing the DNA probes is introduced onto the microchip. The negatively charged probes rapidly move to the positively charged sites, where they concentrate and are chemically bound to a site on the microchip. The

microchip is then washed and another solution of distinct DNA probes is added until the array of specifically bound DNA probes is complete.

A test sample is then analyzed for the presence of target DNA molecules by determining which of the DNA capture probes hybridize, with complementary DNA in the test sample (*e.g.*, a PCR amplified gene of interest). An electronic charge is also used to move and concentrate target molecules to one or more test sites on the microchip. The electronic concentration of sample DNA at each test site promotes rapid hybridization of sample DNA with complementary capture probes (hybridization may occur in minutes). To remove any unbound or nonspecifically bound DNA from each site, the polarity or charge of the site is reversed to negative, thereby forcing any unbound or nonspecifically bound DNA back into solution away from the capture probes. A laser-based fluorescence scanner is used to detect binding,

In still further embodiments, an array technology based upon the segregation of fluids on a flat surface (chip) by differences in surface tension (ProtoGene, Palo Alto, CA) is utilized (*See e.g.*, U.S. Patent Nos. 6,001,311; 5,985,551; and 5,474,796; each of which is herein incorporated by reference). Protogene's technology is based on the fact that fluids can be segregated on a flat surface by differences in surface tension that have been imparted by chemical coatings. Once so segregated, oligonucleotide probes are synthesized directly on the chip by ink-jet printing of reagents. The array with its reaction sites defined by surface tension is mounted on a X/Y translation stage under a set of four piezoelectric nozzles, one for each of the four standard DNA bases. The translation stage moves along each of the rows of the array and the appropriate reagent is delivered to each of the reaction site. For example, the A amidite is delivered only to the sites where amidite A is to be coupled during that synthesis step and so on. Common reagents and washes are delivered by flooding the entire surface and then removing them by spinning.

DNA probes unique for the SNP or mutation of interest are affixed to the chip using Protogene's technology. The chip is then contacted with the PCR-amplified genes of interest. Following hybridization, unbound DNA is removed and hybridization is detected using any suitable method (*e.g.*, by fluorescence de-quenching of an incorporated fluorescent group).

In yet other embodiments, a "bead array" is used for the detection of polymorphisms (Illumina, San Diego, CA; *See e.g.*, PCT Publications WO 99/67641 and WO 00/39587, each of which is herein incorporated by reference). Illumina uses a BEAD ARRAY technology that combines fiber optic bundles and beads that  
5 self-assemble into an array. Each fiber optic bundle contains thousands to millions of individual fibers depending on the diameter of the bundle. The beads are coated with an oligonucleotide specific for the detection of a given SNP or mutation. Batches of beads are combined to form a pool specific to the array. To perform an assay, the BEAD ARRAY is contacted with a prepared subject sample (*e.g.*, DNA). Hybridization is  
10 detected using any suitable method.

**c. Enzymatic Detection of Hybridization**

In some embodiments of the present invention, hybridization is detected by enzymatic cleavage of specific structures (INVADER assay, Third Wave Technologies;  
15 *See e.g.*, U.S. Patent Nos. 5,846,717, 6,090,543; 6,001,567; 5,985,557; and 5,994,069; each of which is herein incorporated by reference). The INVADER assay detects specific DNA and RNA sequences by using structure-specific enzymes to cleave a complex formed by the hybridization of overlapping oligonucleotide probes. Elevated temperature and an excess of one of the probes enable multiple probes to be cleaved for each target  
20 sequence present without temperature cycling. These cleaved probes then direct cleavage of a second labeled probe. The secondary probe oligonucleotide can be 5'-end labeled with fluorescein that is quenched by an internal dye. Upon cleavage, the de-quenched fluorescein labeled product may be detected using a standard fluorescence plate reader.

The INVADER assay detects specific mutations and SNPs in unamplified  
25 genomic DNA. The isolated DNA sample is contacted with the first probe specific either for a SNP/mutation or wild type sequence and allowed to hybridize. Then a secondary probe, specific to the first probe, and containing the fluorescein label, is hybridized and the enzyme is added. Binding is detected by using a fluorescent plate reader and comparing the signal of the test sample to known positive and negative controls.

30 In some embodiments, hybridization of a bound probe is detected using a TaqMan assay (PE Biosystems, Foster City, CA; *See e.g.*, U.S. Patent Nos. 5,962,233 and

5,538,848, each of which is herein incorporated by reference). The assay is performed during a PCR reaction. The TaqMan assay exploits the 5'-3' exonuclease activity of the AMPLITAQ GOLD DNA polymerase. A probe, specific for a given allele or mutation, is included in the PCR reaction. The probe consists of an oligonucleotide with a 5'-  
5 reporter dye (*e.g.*, a fluorescent dye) and a 3'-quencher dye. During PCR, if the probe is bound to its target, the 5'-3' nucleolytic activity of the AMPLITAQ GOLD polymerase cleaves the probe between the reporter and the quencher dye. The separation of the reporter dye from the quencher dye results in an increase of fluorescence. The signal accumulates with each cycle of PCR and can be monitored with a fluorimeter.

10 In still further embodiments, polymorphisms are detected using the SNP-IT primer extension assay (Orchid Biosciences, Princeton, NJ; *See e.g.*, U.S. Patent Nos. 5,952,174 and 5,919,626, each of which is herein incorporated by reference). In this assay, SNPs are identified by using a specially synthesized DNA primer and a DNA  
15 polymerase to selectively extend the DNA chain by one base at the suspected SNP location. DNA in the region of interest is amplified and denatured. Polymerase reactions are then performed using miniaturized systems called microfluidics. Detection is accomplished by adding a label to the nucleotide suspected of being at the SNP or mutation location. Incorporation of the label into the DNA can be detected by any suitable method (*e.g.*, if the nucleotide contains a biotin label, detection is via a  
20 fluorescently labelled antibody specific for biotin).

## 5. Mass Spectroscopy Assay

In some embodiments, a MassARRAY system (Sequenom, San Diego, CA.) is used to detect variant sequences (*See e.g.*, U.S. Patent Nos. 6,043,031; 5,777,324; and  
25 5,605,798; each of which is herein incorporated by reference). DNA is isolated from blood samples using standard procedures. Next, specific DNA regions containing the mutation or SNP of interest, about 200 base pairs in length, are amplified by PCR. The amplified fragments are then attached by one strand to a solid surface and the non-immobilized strands are removed by standard denaturation and washing. The  
30 remaining immobilized single strand then serves as a template for automated enzymatic reactions that produce genotype specific diagnostic products.

Very small quantities of the enzymatic products, typically five to ten nanoliters, are then transferred to a SpectroCHIP array for subsequent automated analysis with the SpectroREADER mass spectrometer. Each spot is preloaded with light absorbing crystals that form a matrix with the dispensed diagnostic product. The MassARRAY  
5 system uses MALDI-TOF (Matrix Assisted Laser Desorption Ionization - Time of Flight) mass spectrometry. In a process known as desorption, the matrix is hit with a pulse from a laser beam. Energy from the laser beam is transferred to the matrix and it is vaporized resulting in a small amount of the diagnostic product being expelled into a flight tube. As the diagnostic product is charged when an electrical field pulse is subsequently applied to  
10 the tube they are launched down the flight tube towards a detector. The time between application of the electrical field pulse and collision of the diagnostic product with the detector is referred to as the time of flight. This is a very precise measure of the product's molecular weight, as a molecule's mass correlates directly with time of flight with smaller molecules flying faster than larger molecules. The entire assay is completed in less than  
15 one thousandth of a second, enabling samples to be analyzed in a total of 3-5 second including repetitive data collection. The SpectroTYPER software then calculates, records, compares and reports the genotypes at the rate of three seconds per sample.

#### **6. Variant Analysis by Differential Antibody Binding**

20 In other embodiments of the present invention, antibodies (See below for antibody production) are used to determine if an individual contains an allele encoding a variant Nod2 gene. In preferred embodiments, antibodies are utilized that discriminate between variant (*i.e.*, truncated proteins); and wild-type proteins (SEQ ID NOs:2 and 3). In some particularly preferred embodiments, the antibodies are directed to the C-terminus of  
25 Nod2.

#### **7. Kits for Analyzing Risk of Crohn's Disease**

The present invention also provides kits for determining whether an individual contains a wild-type or variant (*e.g.*, mutant or polymorphic) allele of Nod2. In some  
30 embodiments, the kits are useful determining whether the subject is at risk of developing Crohn's disease. The diagnostic kits are produced in a variety of ways. In some

embodiments, the kits contain at least one reagent for specifically detecting a mutant Nod2 allele or protein. In preferred embodiments, the kits contain reagents for detecting a SNP caused by an insertion of a cytosine residue or a single nucleotide substitution of the wild-type gene. In preferred embodiments, the reagent is a nucleic acid that

5 hybridizes to nucleic acids containing the SNP and that does not bind to nucleic acids that do not contain the SNP. In other preferred embodiments, the reagents are primers for amplifying the region of DNA containing the SNP. In still other embodiments, the reagents are antibodies that preferentially bind either the wild-type or truncated Nod2 proteins. In some embodiments, the kit contains instructions for determining whether the

10 subject is at risk for developing Crohn's disease. In preferred embodiments, the instructions specify that risk for developing Crohn's disease is determined by detecting the presence or absence of a mutant Nod2 allele in the subject, wherein subjects having an allele containing a cytosine insertion or single nucleotide substitution mutation have an increased risk of developing Crohn's disease. In some embodiments, the kits include

15 ancillary reagents such as buffering agents, nucleic acid stabilizing reagents, protein stabilizing reagents, and signal producing systems (*e.g.*, florescence generating systems as Fret systems). The test kit may be packages in any suitable manner, typically with the elements in a single container or various containers as necessary along with a sheet of instructions for carrying out the test. In some embodiments, the kits also preferably

20 include a positive control sample.

## 8. Bioinformatics

In some embodiments, the present invention provides methods of determining an individual's risk of developing Crohn's disease based on the presence of one or more

25 variant alleles of Nod2. In some embodiments, the analysis of variant data is processed by a computer using information stored on a computer (*e.g.*, in a database). For example, in some embodiments, the present invention provides a bioinformatics research system comprising a plurality of computers running a mulit-platform object oriented programming language (*See e.g.*, U.S. Patent 6,125,383; herein incorporated by

30 reference). In some embodiments, one of the computers stores genetics data (*e.g.*, the risk of contacting Crohn's disease associated with a given polymorphism, as well as the

sequences). In some embodiments, one of the computers stores application programs (e.g., for analyzing transmission disequilibrium data or determining genotype relative risks and population attributable risks (See examples 9 and 10). Results are then delivered to the user (e.g., via one of the computers or via the internet).

5

#### IV. Generation of Nod2 Antibodies

Antibodies can be generated to allow for the detection of Nod2 protein. The antibodies may be prepared using various immunogens. In one embodiment, the immunogen is a human Nod2 peptide to generate antibodies that recognize human Nod2.

10 Such antibodies include, but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and Fab expression libraries.

Various procedures known in the art may be used for the production of polyclonal antibodies directed against Nod2. For the production of antibody, various host animals can be immunized by injection with the peptide corresponding to the Nod2 epitope  
15 including but not limited to rabbits, mice, rats, sheep, goats, etc. In a preferred embodiment, the peptide is conjugated to an immunogenic carrier (e.g., diphtheria toxoid, bovine serum albumin (BSA), or keyhole limpet hemocyanin (KLH)). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels (e.g.,  
20 aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (Bacille Calmette-Guerin) and *Corynebacterium parvum*).

For preparation of monoclonal antibodies directed toward Nod2, it is  
25 contemplated that any technique that provides for the production of antibody molecules by continuous cell lines in culture will find use with the present invention (See e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). These include but are not limited to the hybridoma technique originally developed by Köhler and Milstein (Köhler and Milstein, *Nature*  
30 256:495-497 [1975]), as well as the trioma technique, the human B-cell hybridoma technique (See e.g., Kozbor *et al.*, *Immunol. Tod.*, 4:72 [1983]), and the EBV-hybridoma



technique to produce human monoclonal antibodies (Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 [1985]).

In an additional embodiment of the invention, monoclonal antibodies are produced in germ-free animals utilizing technology such as that described in  
5 PCT/US90/02545). Furthermore, it is contemplated that human antibodies will be generated by human hybridomas (Cote *et al.*, Proc. Natl. Acad. Sci. USA 80:2026-2030 [1983]) or by transforming human B cells with EBV virus *in vitro* (Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96 [1985]).

In addition, it is contemplated that techniques described for the production of  
10 single chain antibodies (U.S. Patent 4,946,778; herein incorporated by reference) will find use in producing Nod2 specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse *et al.*, Science 246:1275-1281 [1989]) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for Nod2.

15 It is contemplated that any technique suitable for producing antibody fragments will find use in generating antibody fragments that contain the idiotype (antigen binding region) of the antibody molecule. For example, such fragments include but are not limited to: F(ab')<sub>2</sub> fragment that can be produced by pepsin digestion of the antibody molecule; Fab' fragments that can be generated by reducing the disulfide bridges of the  
20 F(ab')<sub>2</sub> fragment, and Fab fragments that can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, it is contemplated that screening for the desired antibody will be accomplished by techniques known in the art (*e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays,  
25 immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, *in situ* immunoassays (*e.g.*, using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc.

30 In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting

binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. As is well known in the art, the immunogenic peptide should be provided free of the carrier molecule used in any immunization protocol. For example, if the peptide was conjugated to KLH, it may be conjugated to BSA, or used directly, in a screening assay.)

The foregoing antibodies can be used in methods known in the art relating to the localization and structure of Nod2 (*e.g.*, for Western blotting), measuring levels thereof in appropriate biological samples, etc. The antibodies can be used to detect Nod2 in a biological sample from an individual. The biological sample can be a biological fluid, such as, but not limited to, blood, serum, plasma, interstitial fluid, urine, cerebrospinal fluid, and the like, containing cells.

The biological samples can then be tested directly for the presence of human Nod2 using an appropriate strategy (*e.g.*, ELISA or radioimmunoassay) and format (*e.g.*, microwells, dipstick (*e.g.*, as described in International Patent Publication WO 93/03367), etc. Alternatively, proteins in the sample can be size separated (*e.g.*, by polyacrylamide gel electrophoresis (PAGE), in the presence or not of sodium dodecyl sulfate (SDS), and the presence of Nod2 detected by immunoblotting (Western blotting). Immunoblotting techniques are generally more effective with antibodies generated against a peptide corresponding to an epitope of a protein, and hence, are particularly suited to the present invention.

Another method uses antibodies as agents to alter signal transduction. Specific antibodies that bind to the binding domains of Nod2 or other proteins involved in intracellular signalling can be used to inhibit the interaction between the various proteins and their interaction with other ligands. Antibodies that bind to the complex can also be used therapeutically to inhibit interactions of the protein complex in the signal transduction pathways leading to the various physiological and cellular effects of NF- $\kappa$ B. Such antibodies can also be used diagnostically to measure abnormal expression of Nod2, or the aberrant formation of protein complexes, which may be indicative of a disease state.

## V. Gene Therapy Using Nod2

The present invention also provides methods and compositions suitable for gene therapy to alter Nod2 expression, production, or function. As described above, the present invention provides human Nod2 genes and provides methods of obtaining Nod2 genes from other species. Thus, the methods described below are generally applicable across many species. In some embodiments, it is contemplated that the gene therapy is performed by providing a subject with a wild-type allele of Nod2 (*i.e.*, an allele that does not contain a cytosine insertion mutation or other nucleic acid change (*e.g.*, polymorphisms or mutations). Subjects in need of such therapy are identified by the methods described above. As described above, Nod2 is primarily expressed in the monocytes. Accordingly, a preferred method of gene therapy is to ablate the subject's monocytes (*e.g.*, via radiation) and replace the defective monocytes with monocytes expressing wild-type Nod2 via a bone marrow transplant. In some embodiments, the subjects defective monocytes may be harvested prior to radiation treatment, transfected with a vector (described below) encoding wild-type monocytes, amplified through *in vitro* cultured, and reintroduced into the subject.

Viral vectors commonly used for *in vivo* or *ex vivo* targeting and therapy procedures are DNA-based vectors and retroviral vectors. Methods for constructing and using viral vectors are known in the art (*See e.g.*, Miller and Rosman, BioTech., 7:980-990 [1992]). Preferably, the viral vectors are replication defective, that is, they are unable to replicate autonomously in the target cell. In general, the genome of the replication defective viral vectors that are used within the scope of the present invention lack at least one region that is necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), or be rendered non-functional by any technique known to a person skilled in the art. These techniques include the total removal, substitution (by other sequences, in particular by the inserted nucleic acid), partial deletion or addition of one or more bases to an essential (for replication) region. Such techniques may be performed *in vitro* (*i.e.*, on the isolated DNA) or *in situ*, using the techniques of genetic manipulation or by treatment with mutagenic agents.

Preferably, the replication defective virus retains the sequences of its genome that are necessary for encapsidating the viral particles. DNA viral vectors include an attenuated or defective DNA viruses, including, but not limited to, herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, that entirely or almost entirely lack viral genes, are preferred, as defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, a specific tissue can be specifically targeted. Examples of particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector (Kaplitt *et al.*, Mol. Cell. Neurosci., 2:320-330 [1991]), defective herpes virus vector lacking a glycoprotein L gene (*See e.g.*, Patent Publication RD 371005 A), or other defective herpes virus vectors (*See e.g.*, WO 94/21807; and WO 92/05263); an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet *et al.* (J. Clin. Invest., 90:626-630 [1992]; *See also*, La Salle *et al.*, Science 259:988-990 [1993]); and a defective adeno-associated virus vector (Samulski *et al.*, J. Virol., 61:3096-3101 [1987]; Samulski *et al.*, J. Virol., 63:3822-3828 [1989]; and Lebkowski *et al.*, Mol. Cell. Biol., 8:3988-3996 [1988]).

Preferably, for *in vivo* administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector (*e.g.*, adenovirus vector), to avoid immuno-deactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as interleukin-12 (IL-12), interferon-gamma (IFN- $\gamma$ ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors. In addition, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

In a preferred embodiment, the vector is an adenovirus vector. Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types. Various serotypes of adenovirus exist. Of these serotypes, preference is given, within the scope of the present invention, to type 2 or type 5 human adenoviruses (Ad 2 or Ad 5), or adenoviruses of animal origin (*See e.g.*, WO 94/26914). Those adenoviruses of animal origin that can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (*e.g.*, Mav1, Beard *et*

*al.*, Virol., 75-81 [1990]), ovine, porcine, avian, and simian (*e.g.*, SAV) origin.

Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (*e.g.* Manhattan or A26/61 strain (ATCC VR-800)).

Preferably, the replication defective adenoviral vectors of the invention comprise  
5 the ITRs, an encapsidation sequence and the nucleic acid of interest. Still more preferably, at least the E1 region of the adenoviral vector is non-functional. The deletion in the E1 region preferably extends from nucleotides 455 to 3329 in the sequence of the Ad5 adenovirus (*PvuII-BglII* fragment) or 382 to 3446 (*HinfII-Sau3A* fragment). Other regions may also be modified, in particular the E3 region (*e.g.*, WO 95/02697), the E2  
10 region (*e.g.*, WO 94/28938), the E4 region (*e.g.*, WO 94/28152, WO 94/12649 and WO 95/02697), or in any of the late genes L1-L5.

In a preferred embodiment, the adenoviral vector has a deletion in the E1 region (Ad 1.0). Examples of E1-deleted adenoviruses are disclosed in EP 185,573, the contents of which are incorporated herein by reference. In another preferred  
15 embodiment, the adenoviral vector has a deletion in the E1 and E4 regions (Ad 3.0). Examples of E1/E4-deleted adenoviruses are disclosed in WO 95/02697 and WO 96/22378. In still another preferred embodiment, the adenoviral vector has a deletion in the E1 region into which the E4 region and the nucleic acid sequence are inserted.

The replication defective recombinant adenoviruses according to the invention  
20 can be prepared by any technique known to the person skilled in the art (*See e.g.*, Levero *et al.*, Gene 101:195 [1991]; EP 185 573; and Graham, EMBO J., 3:2917 [1984]). In particular, they can be prepared by homologous recombination between an adenovirus and a plasmid that carries, *inter alia*, the DNA sequence of interest. The homologous recombination is accomplished following co-transfection of the adenovirus and plasmid  
25 into an appropriate cell line. The cell line that is employed should preferably (i) be transformable by the elements to be used, and (ii) contain the sequences that are able to complement the part of the genome of the replication defective adenovirus, preferably in integrated form in order to avoid the risks of recombination. Examples of cell lines that may be used are the human embryonic kidney cell line 293 (Graham *et al.*, J. Gen. Virol.,  
30 36:59 [1977]), which contains the left-hand portion of the genome of an Ad5 adenovirus (12%) integrated into its genome, and cell lines that are able to complement the E1 and

E4 functions, as described in applications WO 94/26914 and WO 95/02697.

Recombinant adenoviruses are recovered and purified using standard molecular biological techniques that are well known to one of ordinary skill in the art.

The adeno-associated viruses (AAV) are DNA viruses of relatively small size that  
5 can integrate, in a stable and site-specific manner, into the genome of the cells that they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The AAV genome has been cloned, sequenced and characterized. It encompasses approximately 4700 bases and contains an inverted terminal repeat (ITR)  
10 region of approximately 145 bases at each end, which serves as an origin of replication for the virus. The remainder of the genome is divided into two essential regions that carry the encapsidation functions: the left-hand part of the genome, that contains the *rep* gene involved in viral replication and expression of the viral genes; and the right-hand part of the genome, that contains the *cap* gene encoding the capsid proteins of the virus.

15 The use of vectors derived from the AAVs for transferring genes *in vitro* and *in vivo* has been described (See e.g., WO 91/18088; WO 93/09239; US Pat. No. 4,797,368; US Pat. No., 5,139,941; and EP 488 528, all of which are herein incorporated by reference). These publications describe various AAV-derived constructs in which the *rep* and/or *cap* genes are deleted and replaced by a gene of interest, and the use of these  
20 constructs for transferring the gene of interest *in vitro* (into cultured cells) or *in vivo* (directly into an organism). The replication defective recombinant AAVs according to the invention can be prepared by co-transfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (*rep* and *cap* genes), into a cell line that is  
25 infected with a human helper virus (for example an adenovirus). The AAV recombinants that are produced are then purified by standard techniques.

In another embodiment, the gene can be introduced in a retroviral vector (e.g., as described in U.S. Pat. Nos. 5,399,346, 4,650,764, 4,980,289 and 5,124,263; all of which are herein incorporated by reference; Mann *et al.*, Cell 33:153 [1983]; Markowitz *et al.*,  
30 J. Virol., 62:1120 [1988]; PCT/US95/14575; EP 453242; EP178220; Bernstein *et al.* Genet. Eng., 7:235 [1985]; McCormick, BioTechnol., 3:689 [1985]; WO 95/07358; and

Kuo *et al.*, Blood 82:845 [1993]). The retroviruses are integrating viruses that infect dividing cells. The retrovirus genome includes two LTRs, an encapsidation sequence and three coding regions (*gag*, *pol* and *env*). In recombinant retroviral vectors, the *gag*, *pol* and *env* genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest. These vectors can be constructed from different types of retrovirus, such as, HIV, MoMuLV ("murine Moloney leukaemia virus" MSV ("murine Moloney sarcoma virus"), HaSV ("Harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("Rous sarcoma virus") and Friend virus. Defective retroviral vectors are also disclosed in WO 95/02697.

10 In general, in order to construct recombinant retroviruses containing a nucleic acid sequence, a plasmid is constructed that contains the LTRs, the encapsidation sequence and the coding sequence. This construct is used to transfect a packaging cell line, which cell line is able to supply in trans the retroviral functions that are deficient in the plasmid. In general, the packaging cell lines are thus able to express the *gag*, *pol* and  
15 *env* genes. Such packaging cell lines have been described in the prior art, in particular the cell line PA317 (US Pat. No. 4,861,719, herein incorporated by reference), the PsiCRIP cell line (See, WO90/02806), and the GP+envAm-12 cell line (See, WO89/07150). In addition, the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive  
20 encapsidation sequences that may include a part of the *gag* gene (Bender *et al.*, J. Virol., 61:1639 [1987]). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.

Alternatively, the vector can be introduced *in vivo* by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of  
25 nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker (Felgner *et al.*, Proc. Natl. Acad. Sci. USA 84:7413-7417 [1987]; See also, Mackey, *et al.*, Proc. Natl. Acad. Sci. USA 85:8027-8031 [1988]; Ulmer *et al.*, Science 259:1745-1748 [1993]). The use of  
30 cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes (Felgner and Ringold, Science

337:387-388 [1989]). Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in WO95/18863 and WO96/17823, and in U.S. Pat. No. 5,459,127, herein incorporated by reference.

Other molecules are also useful for facilitating transfection of a nucleic acid *in vivo*, such as a cationic oligopeptide (e.g., WO95/21931), peptides derived from DNA binding proteins (e.g., WO96/25508), or a cationic polymer (e.g., WO95/21931).

It is also possible to introduce the vector *in vivo* as a naked DNA plasmid. Methods for formulating and administering naked DNA to mammalian muscle tissue are disclosed in U.S. Pat. Nos. 5,580,859 and 5,589,466, both of which are herein incorporated by reference.

DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, including but not limited to transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (See e.g., Wu *et al.*, J. Biol. Chem., 267:963 [1992]; Wu and Wu, J. Biol. Chem., 263:14621 [1988]; and Williams *et al.*, Proc. Natl. Acad. Sci. USA 88:2726 [1991]). Receptor-mediated DNA delivery approaches can also be used (Curiel *et al.*, Hum. Gene Ther., 3:147 [1992]; and Wu and Wu, J. Biol. Chem., 262:4429 [1987]).

## **VI. Transgenic Animals Expressing Exogenous Nod2 Genes and Homologs, Mutants, and Variants Thereof**

The present invention contemplates the generation of transgenic animals comprising an exogenous Nod2 gene or homologs, mutants, or variants thereof. In preferred embodiments, the transgenic animal displays an altered phenotype as compared to wild-type animals. In some embodiments, the altered phenotype is the overexpression of mRNA for a Nod2 gene as compared to wild-type levels of Nod2 expression. In other embodiments, the altered phenotype is the decreased expression of mRNA for an endogenous Nod2 gene as compared to wild-type levels of endogenous Nod2 expression. Methods for analyzing the presence or absence of such phenotypes include Northern blotting, mRNA protection assays, and RT-PCR. In other embodiments, the transgenic mice have a knock out mutation of the Nod2 gene. In still further embodiments,



expression of a Nod2 variant gene (*e.g.*, SEQ ID NO:33 (the c insertion mutant), single nucleotide substitution variants (*e.g.*, SEQ ID NOs: 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88) or mutants containing deletions of one or more LRR repeats). In preferred embodiments, the transgenic animals display a Crohn's disease phenotype.

5           The transgenic animals of the present invention find use in dietary, drug and pathogen (*e.g.*, enteric bacteria) screens. In some embodiments, the transgenic animals (*e.g.*, animals displaying a Crohn's disease phenotype) are fed test or control diets and the response of the animals to the diets is evaluated. In other embodiments, test compounds (*e.g.*, a drug that is suspected of being useful to treat Crohn's disease) and control  
10   compounds (*e.g.*, a placebo) are administered to the transgenic animals and the control animals and the effects evaluated. In other embodiments, transgenic and control animals are infected with an enteric bacteria and the effect on Crohn's disease symptoms is assessed. In yet other embodiments, transgenic and control animals are infected with enteric bacteria found to cause or increase the severity of disease symptoms, followed by  
15   the administration of test compounds and control compounds. The effects of the test and control compounds on disease symptoms are then assessed.

          The transgenic animals can be generated via a variety of methods. In some embodiments, embryonal cells at various developmental stages are used to introduce transgenes for the production of transgenic animals. Different methods are used  
20   depending on the stage of development of the embryonal cell. The zygote is the best target for micro-injection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter, which allows reproducible injection of 1-2 picoliters (pl) of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host  
25   genome before the first cleavage (Brinster *et al.*, Proc. Natl. Acad. Sci. USA 82:4438-4442 [1985]). As a consequence, all cells of the transgenic non-human animal will carry the incorporated transgene. This will in general also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene. U.S. Patent No. 4,873,191 describes a method for the micro-  
30   injection of zygotes; the disclosure of this patent is incorporated herein in its entirety.

In other embodiments, retroviral infection is used to introduce transgenes into a non-human animal. In some embodiments, the retroviral vector is utilized to transfect oocytes by injecting the retroviral vector into the perivitelline space of the oocyte (U.S. Pat. No. 6,080,912, incorporated herein by reference). In other embodiments, the developing non-human embryo can be cultured *in vitro* to the blastocyst stage. During this time, the blastomeres can be targets for retroviral infection (Janenich, Proc. Natl. Acad. Sci. USA 73:1260 [1976]). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan *et al.*, in *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. [1986]).

The viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner *et al.*, Proc. Natl. Acad. Sci. USA 82:6927 [1985]). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, *supra*; Stewart, *et al.*, EMBO J., 6:383 [1987]). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (Jahner *et al.*, Nature 298:623 [1982]). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of cells that form the transgenic animal. Further, the founder may contain various retroviral insertions of the transgene at different positions in the genome that generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germline, albeit with low efficiency, by intrauterine retroviral infection of the midgestation embryo (Jahner *et al.*, *supra* [1982]). Additional means of using retroviruses or retroviral vectors to create transgenic animals known to the art involves the micro-injection of retroviral particles or mitomycin C-treated cells producing retrovirus into the perivitelline space of fertilized eggs or early embryos (PCT International Application WO 90/08832 [1990], and Haskell and Bowen, Mol. Reprod. Dev., 40:386 [1995]).

In other embodiments, the transgene is introduced into embryonic stem cells and the transfected stem cells are utilized to form an embryo. ES cells are obtained by culturing pre-implantation embryos *in vitro* under appropriate conditions (Evans *et al.*, Nature 292:154 [1981]; Bradley *et al.*, Nature 309:255 [1984]; Gossler *et al.*, Proc. Acad. Sci. USA 83:9065 [1986]; and Robertson *et al.*, Nature 322:445 [1986]). Transgenes can

be efficiently introduced into the ES cells by DNA transfection by a variety of methods known to the art including calcium phosphate co-precipitation, protoplast or spheroplast fusion, lipofection and DEAE-dextran-mediated transfection. Transgenes may also be introduced into ES cells by retrovirus-mediated transduction or by micro-injection. Such  
5 transfected ES cells can thereafter colonize an embryo following their introduction into the blastocoel of a blastocyst-stage embryo and contribute to the germ line of the resulting chimeric animal (for review, *See*, Jaenisch, Science 240:1468 [1988]). Prior to the introduction of transfected ES cells into the blastocoel, the transfected ES cells may be subjected to various selection protocols to enrich for ES cells which have integrated  
10 the transgene assuming that the transgene provides a means for such selection. Alternatively, the polymerase chain reaction may be used to screen for ES cells that have integrated the transgene. This technique obviates the need for growth of the transfected ES cells under appropriate selective conditions prior to transfer into the blastocoel.

In still other embodiments, homologous recombination is utilized to knock-out  
15 gene function or create deletion mutants (*e.g.*, mutants in which the LRRs of Nod2 are deleted). Methods for homologous recombination are described in U.S. Pat. No. 5,614,396, incorporated herein by reference.

## **VII. Transgenic Plants Expressing Exogenous Nod2 and Homologs, Mutants, and 20 Variants Thereof**

As described above, the plant Nod2 homologs share homology with a class of plant disease resistant R gene products. The present invention provides transgenic plants and methods for creating transgenic plants that have altered responses and or resistance to pathogens. In some embodiments, the transgenic plants express an exogenous Nod2 gene  
25 or homolog, mutant or variant thereof (*e.g.*, SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88). In preferred embodiments, the transgenic plant displays an altered phenotype as compared to wild-type plants. In some embodiments, the altered phenotype is the overexpression of mRNA for a Nod2 gene as compared to wild-type levels of Nod2 expression. In other embodiments, the altered phenotype is the decreased  
30 expression of mRNA for an endogenous Nod2 gene as compared to wild-type levels of endogenous Nod2 expression. Methods for analyzing the presence or absence of such

phenotypes include Northern blotting, mRNA protection assays, and RT-PCR. In still further embodiments, increased Nod2 gene expression in the transgenic plant confers increased resistance to pathogens. In some embodiments, the observed phenotype mimics the inflammatory response induced by Nod2 in animals. Transgenic plants  
5 expressing this phenotype may be screened by challenging plants with a pathogen and selecting plants that display resistance as compared to control, nontransgenic plants.

In some embodiments of the present invention, vectors are provided for the transfection of plant hosts to create transgenic plants. In general, these vectors comprise a Nod2 nucleic acid (*e.g.*, SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and  
10 88) operably linked to a promoter and other regulatory sequences (*e.g.*, enhancers, polyadenylation signals, etc.) required for expression in a plant. The Nod2 nucleic acid can be oriented to produce sense or antisense transcripts, depending on the desired use. In some embodiments, the promoter is a constitutive promoter (*e.g.*, superpromoter or SD promoter). In other embodiments, the promoter is a seed specific promoter (*e.g.*,  
15 phaseolin promoter [*See e.g.*, U.S. Pat. No. 5,589,616, incorporated herein by reference], napin promoter [*See e.g.*, U.S. Pat. No. 5,608,152, incorporated herein by reference], or acyl-CoA carrier protein promoter [*See e.g.*, 5,767,363, incorporated herein by reference]).

In some preferred embodiments, the vector is adapted for use in an  
20 *Agrobacterium* mediated transfection process (*See e.g.*, U.S. Pat. Nos. 5,981,839, 6,051,757, 5,981,840, 5,824,877, and 4,940,838; all of which are incorporated herein by reference). Construction of recombinant Ti and Ri plasmids in general follows methods typically used with the more common bacterial vectors, such as pBR322. Additional use can be made of accessory genetic elements sometimes found with the native plasmids and  
25 sometimes constructed from foreign sequences. These may include but are not limited to structural genes for antibiotic resistance as selection genes.

There are two systems of recombinant Ti and Ri plasmid vector systems now in use. The first system is called the "cointegrate" system. In this system, the shuttle vector containing the gene of interest is inserted by genetic recombination into a non-oncogenic  
30 Ti plasmid that contains both the cis-acting and trans-acting elements required for plant transformation as, for example, in the pMLJ1 shuttle vector and the non-oncogenic Ti

plasmid pGV3850. The second system is called the "binary" system in which two plasmids are used; the gene of interest is inserted into a shuttle vector containing the cis-acting elements required for plant transformation. The other necessary functions are provided in trans by the non-oncogenic Ti plasmid as exemplified by the pBIN19 shuttle  
5 vector and the non-oncogenic Ti plasmid PAL4404. Some of these vectors are commercially available.

It may be desirable to target the nucleic acid sequence of interest to a particular locus on the plant genome. Site-directed integration of the nucleic acid sequence of interest into the plant cell genome may be achieved by, for example, homologous  
10 recombination using *Agrobacterium*-derived sequences. Generally, plant cells are incubated with a strain of *Agrobacterium* which contains a targeting vector in which sequences that are homologous to a DNA sequence inside the target locus are flanked by *Agrobacterium* transfer-DNA (T-DNA) sequences, as previously described (U.S. Pat. No. 5,501,967, the entire contents of which are herein incorporated by reference). One of  
15 skill in the art knows that homologous recombination may be achieved using targeting vectors that contain sequences that are homologous to any part of the targeted plant gene, whether belonging to the regulatory elements of the gene, or the coding regions of the gene. Homologous recombination may be achieved at any region of a plant gene so long as the nucleic acid sequence of regions flanking the site to be targeted is known.

20 The nucleic acids of the present invention may also be utilized to construct vectors derived from plant (+) RNA viruses (*e.g.*, brome mosaic virus, tobacco mosaic virus, alfalfa mosaic virus, cucumber mosaic virus, tomato mosaic virus, and combinations and hybrids thereof). Generally, the inserted Nod2 polynucleotide can be expressed from these vectors as a fusion protein (*e.g.*, coat protein fusion protein) or from  
25 its own subgenomic promoter or other promoter. Methods for the construction and use of such viruses are described in U.S. Pat. Nos. 5,846,795, 5,500,360, 5,173,410, 5,965,794, 5,977,438, and 5,866,785; all of which are incorporated herein by reference.

Alternatively, vectors can be constructed for expression in hosts other than plants (*e.g.*, prokaryotic cells such as *E. coli*, yeast cells, *C. elegans*, and mammalian cell culture  
30 cells). In some embodiments of the present invention, vectors include, but are not limited to, chromosomal, nonchromosomal and synthetic DNA sequences (*e.g.*, derivatives of

SV40, bacterial plasmids, phage DNA; baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies). Large numbers of suitable vectors that are replicable and viable in the host are known to those of skill in the art, and are commercially  
5 available. Any other plasmid or vector may be used as long as they are replicable and viable in the host.

In some preferred embodiments of the present invention, bacterial expression vectors comprise an origin of replication, a suitable promoter and optionally an enhancer, and also any necessary ribosome binding sites, polyadenylation sites, transcriptional  
10 termination sequences, and 5' flanking nontranscribed sequences. Promoters useful in the present invention include, but are not limited to, retroviral LTRs, SV40 promoter, CMV promoter, RSV promoter, *E. coli lac* or *trp* promoters, phage lambda P<sub>L</sub> and P<sub>R</sub> promoters, T3, SP6 and T7 promoters. In other embodiments of the present invention, recombinant expression vectors include origins of replication and selectable markers,  
15 (e.g., tetracycline or ampicillin resistance in *E. coli*, or neomycin phosphotransferase gene for selection in eukaryotic cells).

The vectors described above can be utilized to express the Nod2 of the present invention in transgenic plants. A variety of methods are known for producing transgenic plants.

20 In some embodiments, *Agrobacterium* mediated transfection is utilized to create transgenic plants. Since most dicotyledonous plants are natural hosts for *Agrobacterium*, almost every dicotyledonous plant may be transformed by *Agrobacterium in vitro*. Although monocotyledonous plants, and in particular, cereals and grasses, are not natural hosts to *Agrobacterium*, work to transform them using *Agrobacterium* has also been  
25 carried out (Hooykas-Van Slogteren *et al.*, Nature 311:763-764 [1984]). Plant genera that may be transformed by *Agrobacterium* include *Arabidopsis*, *Chrysanthemum*, *Dianthus*, *Gerbera*, *Euphorbia*, *Pelargonium*, *Ipomoea*, *Passiflora*, *Cyclamen*, *Malus*, *Prunus*, *Rosa*, *Rubus*, *Populus*, *Santalum*, *Allium*, *Lilium*, *Narcissus*, *Ananas*, *Arachis*, *Phaseolus* and *Pisum*.

30 For transformation with *Agrobacterium*, disarmed *Agrobacterium* cells are transformed with recombinant Ti plasmids of *Agrobacterium tumefaciens* or Ri plasmids

of *Agrobacterium rhizogenes* (such as those described in U.S. Patent No. 4,940,838, the entire contents of which are herein incorporated by reference). The nucleic acid sequence of interest is then stably integrated into the plant genome by infection with the transformed *Agrobacterium* strain. For example, heterologous nucleic acid sequences  
5 have been introduced into plant tissues using the natural DNA transfer system of *Agrobacterium tumefaciens* and *Agrobacterium rhizogenes* bacteria (for review, see Klee *et al.*, Ann. Rev. Plant Phys. 38:467-486 [1987]).

There are three common methods to transform plant cells with *Agrobacterium*. The first method is co-cultivation of *Agrobacterium* with cultured isolated protoplasts.  
10 This method requires an established culture system that allows culturing protoplasts and plant regeneration from cultured protoplasts. The second method is transformation of cells or tissues with *Agrobacterium*. This method requires (a) that the plant cells or tissues can be transformed by *Agrobacterium* and (b) that the transformed cells or tissues can be induced to regenerate into whole plants. The third method is transformation of  
15 seeds, apices or meristems with *Agrobacterium*. This method requires micropropagation.

One of skill in the art knows that the efficiency of transformation by *Agrobacterium* may be enhanced by using a number of methods known in the art. For example, the inclusion of a natural wound response molecule such as acetosyringone (AS) to the *Agrobacterium* culture has been shown to enhance transformation efficiency  
20 with *Agrobacterium tumefaciens* [Shahla *et al.*, Plant Molec. Biol. 8:291 [1987]]. Alternatively, transformation efficiency may be enhanced by wounding the target tissue to be transformed. Wounding of plant tissue may be achieved, for example, by punching, maceration, bombardment with microprojectiles, etc. [See *e.g.*, Bidney *et al.*, Plant Molec. Biol. 18:301 [1992]].

25 In still further embodiments, the plant cells are transfected with vectors via particle bombardment (*i.e.*, with a gene gun). Particle mediated gene transfer methods are known in the art, are commercially available, and include, but are not limited to, the gas driven gene delivery instrument described in McCabe, U.S. Pat. No. 5,584,807, the entire contents of which are herein incorporated by reference. This method involves  
30 coating the nucleic acid sequence of interest onto heavy metal particles, and accelerating the coated particles under the pressure of compressed gas for delivery to the target tissue.

Other particle bombardment methods are also available for the introduction of heterologous nucleic acid sequences into plant cells. Generally, these methods involve depositing the nucleic acid sequence of interest upon the surface of small, dense particles of a material such as gold, platinum, or tungsten. The coated particles are themselves  
5 then coated onto either a rigid surface, such as a metal plate, or onto a carrier sheet made of a fragile material such as Mylar. The coated sheet is then accelerated toward the target biological tissue. The use of the flat sheet generates a uniform spread of accelerated particles that maximizes the number of cells receiving particles under uniform conditions, resulting in the introduction of the nucleic acid sample into the target tissue.

10 Plants, plant cells and tissues transformed with a heterologous nucleic acid sequence of interest are readily detected using methods known in the art including, but not limited to, restriction mapping of the genomic DNA, PCR-analysis, DNA-DNA hybridization, DNA-RNA hybridization, DNA sequence analysis and the like.

Additionally, selection of transformed plant cells may be accomplished using a  
15 selection marker gene. It is preferred, though not necessary, that a selection marker gene be used to select transformed plant cells. A selection marker gene may confer positive or negative selection.

A positive selection marker gene may be used in constructs for random integration and site-directed integration. Positive selection marker genes include  
20 antibiotic resistance genes, and herbicide resistance genes and the like. In one embodiment, the positive selection marker gene is the NPTII gene, which confers resistance to geneticin (G418) or kanamycin. In another embodiment the positive selection marker gene is the HPT gene, which confers resistance to hygromycin. The choice of the positive selection marker gene is not critical to the invention as long as it  
25 encodes a functional polypeptide product. Positive selection genes known in the art include, but are not limited to, the ALS gene (chlorsulphuron resistance), and the DHFR-gene (methothrexate resistance).

A negative selection marker gene may also be included in the constructs. The use of one or more negative selection marker genes in combination with a positive selection  
30 marker gene is preferred in constructs used for homologous recombination. Negative selection marker genes are generally placed outside the regions involved in the



homologous recombination event. The negative selection marker gene serves to provide a disadvantage (preferably lethality) to cells that have integrated these genes into their genome in an expressible manner. Cells in which the targeting vectors for homologous recombination are randomly integrated in the genome will be harmed or killed due to the presence of the negative selection marker gene. Where a positive selection marker gene is included in the construct, only those cells having the positive selection marker gene integrated in their genome will survive.

The choice of the negative selection marker gene is not critical to the invention as long as it encodes a functional polypeptide in the transformed plant cell. The negative selection gene may for instance be chosen from the *aux-2* gene from the Ti-plasmid of *Agrobacterium*, the *tk*-gene from SV40, cytochrome P450 from *Streptomyces griseolus*, the *Adh*-gene from Maize or *Arabidopsis*, etc. Any gene encoding an enzyme capable of converting a substance that is otherwise harmless to plant cells into a substance that is harmful to plant cells may be used. It is contemplated that the Nod2 polynucleotides of the present invention may be utilized to either increase or decrease the level of Nod2 mRNA and/or protein in transfected cells as compared to the levels in wild-type cells. Accordingly, in some embodiments, expression in plants by the methods described above leads to the overexpression of Nod2 in transgenic plants, plant tissues, or plant cells.

In other embodiments of the present invention, the Nod2 polynucleotides are utilized to decrease the level of Nod2 protein or mRNA in transgenic plants, plant tissues, or plant cells as compared to wild-type plants, plant tissues, or plant cells. One method of reducing Nod2 expression utilizes expression of antisense transcripts. Antisense RNA has been used to inhibit plant target genes in a tissue-specific manner (e.g., Van der Krol *et al.*, Biotechniques 6:958 [1988]). Antisense inhibition has been shown using the entire cDNA sequence as well as a partial cDNA sequence (e.g., Sheehy *et al.*, Proc. Natl. Acad. Sci. USA 85:8805 [1988]; Cannon *et al.*, Plant Mol. Biol. 15:39 [1990]). There is also evidence that 3' non-coding sequence fragment and 5' coding sequence fragments, containing as few as 41 base-pairs of a 1.87 kb cDNA, can play important roles in antisense inhibition (Ch'ng *et al.*, Proc. Natl. Acad. Sci. USA 86:10006 [1989]).

Accordingly, in some embodiments, the Nod2 nucleic acids of the present invention (e.g., SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88, and

fragments and variants thereof) are oriented in a vector and expressed so as to produce antisense transcripts. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the antisense strand of RNA will be transcribed. The expression cassette is then transformed into plants and the antisense strand of RNA is produced. The nucleic acid segment to be introduced generally will be substantially identical to at least a portion of the endogenous gene or genes to be repressed. The sequence, however, need not be perfectly identical to inhibit expression. The vectors of the present invention can be designed such that the inhibitory effect applies to other proteins within a family of genes exhibiting homology or substantial homology to the target gene.

Furthermore, for antisense suppression, the introduced sequence also need not be full length relative to either the primary transcription product or fully processed mRNA. Generally, higher homology can be used to compensate for the use of a shorter sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and homology of non-coding segments may be equally effective. Normally, a sequence of between about 30 or 40 nucleotides and about full length nucleotides should be used, though a sequence of at least about 100 nucleotides is preferred, a sequence of at least about 200 nucleotides is more preferred, and a sequence of at least about 500 nucleotides is especially preferred.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of the target gene or genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs.

A number of classes of ribozymes have been identified. One class of ribozymes is derived from a number of small circular RNAs that are capable of self-cleavage and replication in plants. The RNAs replicate either alone (viroid RNAs) or with a helper virus (satellite RNAs). Examples include RNAs from avocado sunblotch viroid and the

satellite RNAs from tobacco ringspot virus, lucerne transient streak virus, velvet tobacco mottle virus, *Solanum nodiflorum* mottle virus and subterranean clover mottle virus. The design and use of target RNA-specific ribozymes is described in Haseloff, *et al.*, Nature 334:585 [1988].

5           Another method of reducing Nod2 expression utilizes the phenomenon of cosuppression or gene silencing (*See e.g.*, U.S. Pat. No. 6,063,947, incorporated herein by reference). The phenomenon of cosuppression has also been used to inhibit plant target genes in a tissue-specific manner. Cosuppression of an endogenous gene using a full-length cDNA sequence as well as a partial cDNA sequence (730 bp of a 1770 bp  
10 cDNA) are known (*e.g.*, Napoli *et al.*, Plant Cell 2:279 [1990]; van der Krol *et al.*, Plant Cell 2:291 [1990]; Smith *et al.*, Mol. Gen. Genetics 224:477 [1990]). Accordingly, in some embodiments the Nod2 nucleic acids (*e.g.*, SEQ ID NOs: 1, 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88), and fragments and variants thereof are expressed in another species of plant to effect cosuppression of a homologous gene.

15           Generally, where inhibition of expression is desired, some transcription of the introduced sequence occurs. The effect may occur where the introduced sequence contains no coding sequence per se, but only intron or untranslated sequences homologous to sequences present in the primary transcript of the endogenous sequence. The introduced sequence generally will be substantially identical to the endogenous  
20 sequence intended to be repressed. This minimal identity will typically be greater than about 65%, but a higher identity might exert a more effective repression of expression of the endogenous sequences. Substantially greater identity of more than about 80% is preferred, though about 95% to absolute identity would be most preferred. As with antisense regulation, the effect should apply to any other proteins within a similar family  
25 of genes exhibiting homology or substantial homology.

For cosuppression, the introduced sequence in the expression cassette, needing less than absolute identity, also need not be full length, relative to either the primary transcription product or fully processed mRNA. This may be preferred to avoid concurrent production of some plants that are overexpressers. A higher identity in a  
30 shorter than full length sequence compensates for a longer, less identical sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern; and

identity of non-coding segments will be equally effective. Normally, a sequence of the size ranges noted above for antisense regulation is used.

#### VIII. Drug Screening Using Nod2

5           The present invention provides methods and compositions for using Nod2 as a target for screening drugs that can alter, for example, RICK signalling, and thus the physiological effects of NF- $\kappa$ B (*e.g.*, inflammatory response). For example, drugs that induce or inhibit NF- $\kappa$ B mediated inflammatory responses can be identified by screening for compounds that target Nod2 or regulate Nod2 gene expression.

10           The present invention is not limited to a particular mechanism of action. Indeed, an understanding of the mechanism of action is not necessary to practice the present invention. Nevertheless, it is contemplated that Nod2 binds to RICK, and this binding results in the activation of NF- $\kappa$ B. Accordingly, it is contemplated that binding assays are useful for screening for compounds that block Nod2 binding to RICK. In particular,  
15           it is contemplated that such screens are capable of identifying compounds that are useful for inhibiting NF- $\kappa$ B activity and thus for treating Crohn's disease. The binding need not employ full-length RICK and Nod2. Indeed, portions of RICK and Nod2 may be utilized in the binding assays. For example, in some embodiments, a fragment of Nod2 containing the two CARD domains is utilized in the binding assay.

20           In other embodiments, the present invention provides methods of screening for compounds that increase or decrease the binding of Nod2 to pathogens, pathogen components, or pathogen binding proteins, and consequently, affect downstream signaling and NF- $\kappa$ B activation. In some embodiments, wild-type Nod2 or a fragment thereof is utilized. In other embodiments, Nod2 containing one or more variations (*e.g.*,  
25           mutations or polymorphisms) is utilized.

          In one screening method, the two-hybrid system is used to screen for compounds (*e.g.*, drug) capable of altering (*e.g.*, inhibiting) Nod2 function(s) (*e.g.*, NF- $\kappa$ B-mediated signal transduction) *in vitro* or *in vivo*. In one embodiment, a GAL4 binding site, linked to a reporter gene such as *lacZ*, is contacted in the presence and absence of a candidate  
30           compound with a GAL4 binding domain linked to a Nod2 fragment and a GAL4 transactivation domain II linked to a NF- $\kappa$ B fragment. Expression of the reporter gene is

monitored and a decrease in the expression is an indication that the candidate compound inhibits the interaction of Nod2 with NF- $\kappa$ B. Alternately, the effect of candidate compounds on the interaction of Nod2 with other proteins (*e.g.*, proteins known to interact directly or indirectly with NF- $\kappa$ B) can be tested in a similar manner.

- 5           In another screening method, candidate compounds are evaluated for their ability to alter Nod2 signalling by contacting Nod2, NF- $\kappa$ B, NF- $\kappa$ B-associated proteins, or fragments thereof, with the candidate compound and determining binding of the candidate compound to the peptide. The protein or protein fragments is/are immobilized using methods known in the art such as binding a GST-Nod2 fusion protein to a
- 10 polymeric bead containing glutathione. A chimeric gene encoding a GST fusion protein is constructed by fusing DNA encoding the polypeptide or polypeptide fragment of interest to the DNA encoding the carboxyl terminus of GST (*See e.g.*, Smith *et al.*, Gene 67:31 [1988]). The fusion construct is then transformed into a suitable expression system (*e.g.*, *E. coli* XA90) in which the expression of the GST fusion protein can be induced
- 15 with isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG). Induction with IPTG should yield the fusion protein as a major constituent of soluble, cellular proteins. The fusion proteins can be purified by methods known to those skilled in the art, including purification by glutathione affinity chromatography. Binding of the candidate compound to the proteins or protein fragments is correlated with the ability of the compound to disrupt the signal
- 20 transduction pathway and thus regulate Nod2 physiological effects (*e.g.*, apoptosis).

- In another screening method, one of the components of the Nod2/NF- $\kappa$ B signalling system, such as Nod2 or a fragment of Nod2, is immobilized. Polypeptides can be immobilized using methods known in the art, such as adsorption onto a plastic microtiter plate or specific binding of a GST-fusion protein to a polymeric bead
- 25 containing glutathione. For example, GST-Nod2 is bound to glutathione-Sepharose beads. The immobilized peptide is then contacted with another peptide with which it is capable of binding in the presence and absence of a candidate compound. Unbound peptide is then removed and the complex solubilized and analyzed to determine the amount of bound labeled peptide. A decrease in binding is an indication that the
- 30 candidate compound inhibits the interaction of Nod2 with the other peptide. A variation of this method allows for the screening of compounds that are capable of disrupting a

previously-formed protein/protein complex. For example, in some embodiments a complex comprising Nod2 or a Nod2 fragment bound to another peptide is immobilized as described above and contacted with a candidate compound. The dissolution of the complex by the candidate compound correlates with the ability of the compound to  
5 disrupt or inhibit the interaction between Nod2 and the other peptide.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to Nod2 peptides and is described in detail in WO 84/03564, incorporated herein by reference. Briefly, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or  
10 some other surface. The peptide test compounds are then reacted with Nod2 peptides and washed. Bound Nod2 peptides are then detected by methods well known in the art.

Another technique uses Nod2 antibodies, generated as discussed above. Such antibodies capable of specifically binding to Nod2 peptides compete with a test compound for binding to Nod2. In this manner, the antibodies can be used to detect the  
15 presence of any peptide that shares one or more antigenic determinants of the Nod2 peptide.

In some embodiments of the present invention, compounds are screened for their ability to inhibit the binding of pathogen components (*e.g.*, including, but not limited to, bacterial cell surface proteins; fungi proteins, parasite proteins, and virus proteins) to  
20 Nod2. Any suitable screening assay may be utilized, including, but not limited to, those described herein.

The present invention contemplates many other means of screening compounds. The examples provided above are presented merely to illustrate a range of techniques available. One of ordinary skill in the art will appreciate that many other screening  
25 methods can be used.

In particular, the present invention contemplates the use of cell lines transfected with Nod2 and variants thereof for screening compounds for activity, and in particular to high throughput screening of compounds from combinatorial libraries (*e.g.*, libraries containing greater than  $10^4$  compounds). The cell lines of the present invention can be  
30 used in a variety of screening methods. In some embodiments, the cells can be used in second messenger assays that monitor signal transduction following activation of cell-

surface receptors. In other embodiments, the cells can be used in reporter gene assays that monitor cellular responses at the transcription/translation level. In still further embodiments, the cells can be used in cell proliferation assays to monitor the overall growth/no growth response of cells to external stimuli.

5           In second messenger assays, the host cells are preferably transfected as described above with vectors encoding Nod2 or variants or mutants thereof. The host cells are then treated with a compound or plurality of compounds (*e.g.*, from a combinatorial library) and assayed for the presence or absence of a response. It is contemplated that at least some of the compounds in the combinatorial library can serve as agonists, antagonists,  
10   activators, or inhibitors of the protein or proteins encoded by the vectors. It is also contemplated that at least some of the compounds in the combinatorial library can serve as agonists, antagonists, activators, or inhibitors of protein acting upstream or downstream of the protein encoded by the vector in a signal transduction pathway.

          In some embodiments, the second messenger assays measure fluorescent signals  
15   from reporter molecules that respond to intracellular changes (*e.g.*,  $\text{Ca}^{2+}$  concentration, membrane potential, pH,  $\text{IP}_3$ , cAMP, arachidonic acid release) due to stimulation of membrane receptors and ion channels (*e.g.*, ligand gated ion channels; *see Denyer et al.*, *Drug Discov. Today* 3:323 [1998]; and Gonzales *et al.*, *Drug. Discov. Today* 4:431-39 [1999]). Examples of reporter molecules include, but are not limited to, FRET  
20   (florescence resonance energy transfer) systems (*e.g.*, Cuo-lipids and oxonols, EDAN/DABCYL), calcium sensitive indicators (*e.g.*, Fluo-3, FURA 2, INDO 1, and FLUO3/AM, BAPTA AM), chloride-sensitive indicators (*e.g.*, SPQ, SPA), potassium-sensitive indicators (*e.g.*, PBFI), sodium-sensitive indicators (*e.g.*, SBFI), and pH sensitive indicators (*e.g.*, BCECF).

25           In general, the host cells are loaded with the indicator prior to exposure to the compound. Responses of the host cells to treatment with the compounds can be detected by methods known in the art, including, but not limited to, fluorescence microscopy, confocal microscopy (*e.g.*, FCS systems), flow cytometry, microfluidic devices, FLIPR systems (*See, e.g.*, Schroeder and Neagle, *J. Biomol. Screening* 1:75 [1996]), and plate-  
30   reading systems. In some preferred embodiments, the response (*e.g.*, increase in fluorescent intensity) caused by compound of unknown activity is compared to the

response generated by a known agonist and expressed as a percentage of the maximal response of the known agonist. The maximum response caused by a known agonist is defined as a 100% response. Likewise, the maximal response recorded after addition of an agonist to a sample containing a known or test antagonist is detectably lower than the  
5 100% response.

The cells are also useful in reporter gene assays. Reporter gene assays involve the use of host cells transfected with vectors encoding a nucleic acid comprising transcriptional control elements of a target gene (*i.e.*, a gene that controls the biological expression and function of a disease target) spliced to a coding sequence for a reporter  
10 gene. Therefore, activation of the target gene results in activation of the reporter gene product. As described above, it is contemplated that Nod2 binds to RICK, and this binding results in the activation of NF- $\kappa$ B. Therefore, in some embodiments, the reporter gene construct comprises the 5' regulatory region (*e.g.*, promoters and/or enhancers) of a protein whose expression is controlled by NF- $\kappa$ B in operable association with a reporter  
15 gene (See Example 4 and Inohara *et al.*, J. Biol. Chem. 275:27823 [2000] for a description of the luciferase reporter construct pBVix-Luc). Examples of reporter genes finding use in the present invention include, but are not limited to, chloramphenicol transferase, alkaline phosphatase, firefly and bacterial luciferases,  $\beta$ -galactosidase,  $\beta$ -lactamase, and green fluorescent protein. The production of these proteins, with the  
20 exception of green fluorescent protein, is detected through the use of chemiluminescent, colorimetric, or bioluminescent products of specific substrates (*e.g.*, X-gal and luciferin). Comparisons between compounds of known and unknown activities may be conducted as described above.

## 25 IX. Pharmaceutical Compositions Containing Nod2 Nucleic Acid, Peptides, and Analogues

The present invention further provides pharmaceutical compositions which may comprise all or portions of Nod2 polynucleotide sequences, Nod2 polypeptides, inhibitors or antagonists of Nod2 bioactivity, including antibodies, alone or in combination with at  
30 least one other agent, such as a stabilizing compound, and may be administered in any



sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.

The methods of the present invention find use in treating diseases or altering physiological states characterized by apoptosis of cells or other NF- $\kappa$ B mediated effects.

- 5 The invention provides methods for inhibiting Nod2 interaction with NF- $\kappa$ B and NF- $\kappa$ B-associated proteins by administering peptides or peptide fragments of Nod2. Peptides can be administered to the patient intravenously in a pharmaceutically acceptable carrier such as physiological saline. Standard methods for intracellular delivery of peptides can be used (*e.g.*, delivery via liposome). Such methods are well known to those of ordinary  
10 skill in the art. The formulations of this invention are useful for parenteral administration, such as intravenous, subcutaneous, intramuscular, and intraperitoneal. Therapeutic administration of a polypeptide intracellularly can also be accomplished using gene therapy as described above.

- As is well known in the medical arts, dosages for any one patient depends upon  
15 many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and interaction with other drugs being concurrently administered.

- Accordingly, in some embodiments of the present invention, Nod2 nucleotide and Nod2 amino acid sequences can be administered to a patient alone, or in combination  
20 with other nucleotide sequences, drugs or hormones or in pharmaceutical compositions where it is mixed with excipient(s) or other pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert. In another embodiment of the present invention, Nod2 polynucleotide sequences or Nod2 amino acid sequences may be administered alone to  
25 individuals subject to or suffering from a disease.

- Depending on the condition being treated, these pharmaceutical compositions may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences" (Mack Publishing Co, Easton Pa.). Suitable routes may, for example, include  
30 oral or transmucosal administration; as well as parenteral delivery, including

intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.

For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. For tissue or cellular administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

In other embodiments, the pharmaceutical compositions of the present invention can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral or nasal ingestion by a patient to be treated.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. For example, an effective amount of Nod2 may be that amount that suppresses apoptosis. Determination of effective amounts is well within the capability of those skilled in the art, especially in light of the disclosure provided herein.

In addition to the active ingredients these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known (e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes).

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection

suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

5           Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, etc;  
10 cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid or a salt thereof such as sodium alginate.

15           Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active  
20 compound, (*i.e.*, dosage).

          Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium  
25 stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

          Compositions comprising a compound of the invention formulated in a pharmaceutical acceptable carrier may be prepared, placed in an appropriate container,  
30 and labeled for treatment of an indicated condition. For polynucleotide or amino acid

sequences of Nod2, conditions indicated on the label may include treatment of condition related to apoptosis.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, *etc.* Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use.

For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. Then, preferably, dosage can be formulated in animal models (particularly murine models) to achieve a desirable circulating concentration range that adjusts Nod2 levels.

A therapeutically effective dose refers to that amount of Nod2 that ameliorates symptoms of the disease state. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Compounds that exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and additional animal studies can be used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state; age, weight, and gender of the patient; diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be

administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature (*See*, U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212, all of which are herein incorporated by reference). Those skilled in the art will employ different formulations for Nod2 than for the inhibitors of Nod2. Administration to the bone marrow may necessitate delivery in a manner different from intravenous injections.

## EXPERIMENTAL

The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

- 5 In the experimental disclosure which follows, the following abbreviations apply:  
 eq (equivalents); M (Molar);  $\mu$ M (micromolar); N (Normal); mol (moles); mmol  
 (millimoles);  $\mu$ mol (micromoles); nmol (nanomoles); g (grams); mg (milligrams);  $\mu$ g  
 (micrograms); ng (nanograms); l or L (liters); ml (milliliters);  $\mu$ l (microliters); cm  
 (centimeters); mm (millimeters);  $\mu$ m (micrometers); nm (nanometers); °C (degrees  
 10 Centigrade); U (units), mU (milliunits); min. (minutes); sec. (seconds); % (percent); kb  
 (kilobase); bp (base pair); PCR (polymerase chain reaction); BSA (bovine serum  
 albumin); Fisher (Fisher Scientific, Pittsburgh, PA); Sigma (Sigma Chemical Co., St.  
 Louis, MO.); Promega (Promega Corp., Madison, WI); Perkin-Elmer (Perkin-  
 Elmer/Applied Biosystems, Foster City, CA); Boehringer Mannheim (Boehringer  
 15 Mannheim, Corp., Indianapolis, IN); Clontech (Clontech, Palo Alto, CA); Qiagen  
 (Qiagen, Santa Clarita, CA); Stratagene (Stratagene Inc., La Jolla, CA); National  
 Biosciences (National Biosciences Inc, Plymouth Minn.) and NEB (New England  
 Biolabs, Beverly, MA), CARD (caspase-recruitment domain); EST (expressed sequence  
 tag); HA (hemagglutinin); I $\kappa$ B (inhibitor of NF- $\kappa$ B); IKK (I $\kappa$ B kinase); LRRs  
 20 (leucine-rich repeats); NBD (nucleotide-binding domain); NF- $\kappa$ B (nuclear factor  $\kappa$ B);  
 TNF $\alpha$  (tumor necrosis factor  $\alpha$ ); wt (wild-type); Ab (antibody); IL-1 (interleukin 1); IL-  
 1R (IL-1 receptor); LPS (lipopolysaccharide); LTA (lipoteichoic acid); PGN  
 (peptidoglycan); SBLP (synthetic bacterial lipoprotein); and TLR (Toll-like receptor).

## 25 METHODOLOGY

- Reagents.** LPS from various sources in this study were obtained from  
 Sigma (St. Louis, MO). PGN from *Staphylococcus aureus* was obtained from  
 Fluka-Chemie (Buchs, Germany). Mannan from *Candida albicans* 20A was a gift of P.  
 Lehmann (Medical College of Ohio). PaM3CysSerLyS4, a synthetic bacterial lipoprotein  
 30 analogue (SBLP) was a gift of A. Zychlinsky (New York University School of  
 Medicine).

**Isolation of the Nod2 cDNA.** Nucleotide sequences encoding peptides with homology to Nod1 (GeneBank accession numbers AC007728 and AQ534686) were found in the public genomic database using the TBLASTN program. The coding region of human nod2 was obtained by reverse transcriptase (RT)-PCR amplification and 5' RACE using Nod2-specific oligonucleotide primers cDNA fragments and mRNA from primary mammary tissue as a template. 5' RACE was performed using a commercial kit (Roche Molecular Biochemicals, Indianapolis, IN). For PCR, three sets of primers were used: 5'-ATGTGCTCGCAGGAGGCTTTTCAGGCA-3' (SEQ ID NO:37) and 5'-CGCCTCACCCACCACCAGCACAGTGT-3' (SEQ ID NO:38); 5'-CATGGCTGGACCCCCGCAGAAGAGCCCA-3' (SEQ ID NO:39) and 5'-CA-TGCCCGGGTTCATCTGGCTCATCCGG-3' (SEQ ID NO:40); 5'-GCCATGCCCGGGTTCATCTGGCTCATC-3' (SEQ ID NO:41) and 5'-TGAGTCGAGACATGGGGAAAGCTGCTTC-3' (SEQ ID NO:42). For 5' RACE, the initial primer 5'-AGCAGCTCGACCAGCTGGCTCCTCTGT-3' (SEQ ID NO:43) was used and the product was PCR amplified with the anchored primer and second Nod2-specific primer: 5'-GACAGGCCCAAGTACCCTTATCCAGA-3' (SEQ ID NO:44). The resulting cDNA fragments were digested with restriction enzymes and ligated to generate a unique cDNA containing the entire open reading frame of Nod2. The cDNA sequence was verified by nucleotide sequencing.

20

**Northern Blot and RT-PCR Analysis of Nod2 Expression.** A 3.7 kb fragment containing the entire Nod2 coding region was radiolabeled by random priming using a commercial kit (Roche Molecular Biochemicals) and applied for analysis of human poly(A)<sup>+</sup> RNA blots from various tissues (Clontech Laboratories, Palo Alto, CA) according to the manufacturer's instructions. Peripheral blood leukocytes were obtained from heparinized venous blood from healthy volunteers by Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation. Granulocytes were separated from red blood cells by brief incubation with hypotonic lysis buffer. The mononuclear cell population was fractionated into lymphocytes and monocytes by adherence to plastic dishes. For RT-PCR analysis, 2 µg of total RNA from each cell preparations were used to generate first strand cDNA using a commercially available kit

30

(Gibco BRL; Gaithersburg, MD). Nod2 cDNA fragments corresponding to the Nod2 coding region were amplified by PCR using two sets of specific primers; P1: 5'-ATGTGCTCGCAGGAGGCTTTTCAGGCA-3' (SEQ ID NO:45); P2: 5'-CGCCTCACCCACCACCAGCACAGTGT-3' (SEQ ID NO:46); P3: 5'-ATGTGCTCGCAGGAGGCTTTTCAGGCA-3' (SEQ ID NO:47) and P4: 5'-CG-CCTCACCCACCACCAGCACAGTGT-3' (SEQ ID NO:48). As a control, a cDNA fragment of the human glyceraldehyde-3-phosphate dehydrogenase was amplified using the primers 5'-GAGTCAACGGATTTGGTCGTAT-3' (SEQ ID NO:49) and 5'-AGTCTTCTGGGTGGCAGTGAT-3' (SEQ ID NO:50).

10

**Construction of Expression Plasmids.** The Nod2 cDNA was cloned into pcDNA3-HA and pcDNA3-Fpk3-Myc (Inohara *et al.*, [2000], *supra*). Deletion and site-directed mutants of Nod2 (129-1040, A125-214, 1-125, 1-301, 1-744, 265-1040, 126-301, 265-744, 744-1040, K305R, 1-744K305R) were constructed by a PCR method and cloned into pcDNA3-HA and pcDNA3-Fpk3-Myc (Inohara *et al.*, [2000], *supra*). The authenticity of all constructs was confirmed by sequencing. pcDNA3-Flag-RICK, pcDNA3-Flag-RICK(1-374), pcDNA3-Flag-RICK(374-540), pcDNA3-Myc-RICK(406-540), pcDNA3-Myc-RIP(558-671), pRK7-Flag-IKK $\alpha$ , pRK7-Flag-IKK $\alpha$ -K44A, RSVMad-3MSS(I $\kappa$ -B $\alpha$ -S32A/S36A), pRK7-Flag-IKK $\beta$ , pRK7-Flag-IKK $\beta$ -K44A, and pcDNA3-Flag-IKK $\gamma$  (134-419) have been described previously (Inohara *et al.*, *supra*, 10). The expression plasmids pcDNA3-Nod1-Flag, pcDNA3-Nod1 (1-648)-Flag, pcDNA3-Flag-IKKi, pcDNA3CIPER-Flag, pCMV-ILIR, pCMV-TLR4-Flag, pcDNA3-Flag-RIP, pcDNA3-MyD88 DN (amino acids 1-109), pcDNA3-CD14, pCMV-MD2-FLAG and pcDNA3- $\beta$ -gal have also been described previously (Inohara *et al.*, [1999], *Supra*; Inohara *et al.*, [1999], *Supra*; Inohara *et al.*, [2000], *supra*; Shimada *et al.*, Int. Immunol., 11:1357-1362 [1999]; Huang *et al.*, PNAS, 94:12829-12832 [1997]; Medzhitov *et al.*, Mol. Cell, 2:253-258 [1998]; Hsu *et al.*, Immunity, 4:387-396 [1996]). To construct the expression plasmid producing C-terminally HA-tagged mature interleukin-1 P (IL1 $\beta$ ), pcDNA3-mIL1 $\beta$ -HA, the mature region of mouse IL1 $\beta$  was amplified by PCR and inserted into pcDNA3-HA-pro which contains the signal sequence of protrypsin and the HA tag.

30



- Transfection, Expression, Immunoprecipitation and Immunodetection of Tagged Proteins.** HEK293T cells were co-transfected with pcDNA3-Nod2-HA and various expression plasmids as described (Inohara *et al.*, [1999] *supra*). To test the interaction between wt RICK and Nod2 mutant proteins, HEK293T cells were co-transfected with pcDNA3-Flag-RICK and wt or mutant Nod2 expression plasmids. Proteins co-immunoprecipitated with anti-HA antibody were detected with anti-Flag antibody. To test the interaction between wt Nod2 and RICK mutants, HEK293T cells were cotransfected with pcDNA3-HA-Nod2 and pcDNA3-Flag-RICK, pcDNA3-Flag-RICK(1-374) or pcDNA3-Flag-RICK(374-540) (Inohara *et al.*, [1999] *supra*). Proteins co-immunoprecipitated with anti-HA antibody were detected with anti-Flag antibody. Proteins in total lysate were detected by anti-Flag and anti-HA monoclonal antibody, respectively.
- NF- $\kappa$ B activation assays.** NF- $\kappa$ B activation assays were performed as described (Inohara *et al.*, [1999] *supra*, Inohara *et al.*, [2000], *supra*). Briefly, Rat1 fibroblasts and its derivative 5R cell line (Yamaoka *et al.*, Cell 93: 1231-1240 [1998]) as well as HEK293T cells were co-transfected with 12 ng of the reporter construct pBVIx-Luc, plus indicated amounts of each expression plasmid and 120 ng of pEF-BOS- $\beta$ -gal in triplicate as described. 24 hr post-transfection, cell extracts were prepared and its relative luciferase activity was measured as described (Inohara *et al.*, [1999] *supra*, Inohara *et al.*, [2000], *supra*). Results were normalized for transfection efficiency with values obtained with pEF-BOS- $\beta$ -gal.
- In vitro LPS binding assay.**  $1 \times 10^8$  HEK293T cells were transfected with expression plasmids indicated in figure legends as described (Inohara *et al.*, [2000], *Supra*). Twenty-four hr post-transfection, S100 fractions were prepared from transfected cells as described using Buffer A (Poltorak *et al.*, [1998], *Supra*). For Fig. 10A, S100 lysate containing 5 mg of protein was incubated with 300 ng [ $^3$ H] LPS ( $1 \times 10^5$  Bq, 347 Bq/ng, List Biological Laboratories, Campbell, CA) from *Escherichia coli* K12 KCD25, 6  $\mu$ g anti-FLAG M2 antibody (Sigma Chemical), 10  $\mu$ l Protein A-Sepharose and 10  $\mu$ l

Protein G-Sepharose at 4°C for 2 hr. Proteins bound to the matrix were washed 5 times with 1 ml of Buffer A. The bound radioactivity was measured using a Liquid Scintillation Counter Beckman LS5000LD. For Fig. 3B, proteins were immunopurified first from 20 mg of S100 lysate as described above and incubated with 300 ng [<sup>3</sup>H] LPS in the presence of 10 mg bovine serum albumin Fraction V (Sigma Chemical) at 4°C for 2 hr. After 5 washes with 1 ml of Buffer A, the bound radioactivity was measured. To monitor protein expression, proteins in 50 µg of S100 lysate were detected by immunoblotting with anti-FLAG Ab.

10

### Example 1

This Example describes the identification of Nod2. To identify novel Nod1/Apaf-I-like molecules, public genomic databases were searched for genes encoding proteins with homology to Nod1 (Inohara *et al.*, *supra*). A genomic sequence was identified in human chromosome 16 (GeneBank accession number AC007728) that encodes a peptide with significant homology to the NBD of Nod1. Analysis with GeneFinder of the genomic region predicted a gene encoding a novel protein with significant homology to Nod1. To determine the ends of the coding region, 5' RACE was performed using an oligonucleotide complementary to sequences encoding the N-terminus of the predicted protein and sequenced several EST cDNAs that contain partial sequences of the gene (GeneBank accession numbers AA775466, AA910520, A1090427). To amplify the cDNA containing the entire open reading frame, we RT-PCR was performed with three sets of primers corresponding to overlapping sequences of the coding region of the gene. The predicted open reading frame encodes a protein of 1040 amino acids. A BLAST search of protein databases indicated that the protein encoded by the new open reading frame was most homologous to Nod1 (34% amino acid identity). This protein was designated Nod2 given its high level of homology with Nod1 and thus represents a novel member of the Apaf-I/Nod1 superfamily (Fig. 1). Analysis of the nucleotide sequence revealed two potential in-frame translation initiation sites separated by 81 nucleotides. Further analysis revealed that both translation initiation sites can be utilized in cells, although the longer open reading frame is preferentially used (see below). For simplicity, the longer open reading frame is designated Nod2a and the product encoded by the

30

shorter open reading frame is designated as Nod2b. A BLAST search and domain analyses revealed that Nod2 is composed of two NH<sub>2</sub>-terminal CARDs (residues 28-220) fused to a centrally located NBD domain (residues 273-577) containing consensus nucleotide-binding motifs followed by ten tandem LRRs (residues 744-1020) (Figs. 1 and 2). Each of the 10 LRRs of Nod2 contained predicted  $\alpha$  helix and  $\beta$  sheet sequences that is consistent with the prototypical horseshoe-shaped structure of LRRs (Kobe and Deisenhofer, *Curr. Opin. Struct. Biol.* 5: 409-416 [1995]) (Fig. 2C). Nod2 is the first protein known to encode two CARDs.

10

### Example 2

This Example describes the chromosomal localization and genomic organization of the human Nod2 gene. Two human BAC clones, RP11-327F22 and RP11-40IP9, containing the genomic sequence of human Nod2 (GenBank accession numbers AC007728 and AC007608, respectively) were identified. These BAC clones mapped to chromosome 16 at q12. Comparison of Nod2 cDNA and genomic sequences revealed that the Nod2 gene contains twelve coding exons.

15

### Example 3

This Example demonstrates that the expression of Nod2 is most abundant in monocytes. Northern blot analysis showed Nod2 to be expressed as two 7.0 and 5.5 kb transcripts in peripheral blood leukocytes with little or no detectable expression in various human tissues (Fig. 3A). This highly restricted pattern of expression is in contrast to that of Nod1 and Apaf-1, which are expressed in virtually all adult tissues although at different levels (Inohara *et al.*, *supra*). To determine the cells that express Nod2, peripheral blood leukocytes were fractionated into granulocyte, lymphocyte and monocyte populations and analyzed by RT-PCR analysis with two different sets of oligonucleotide primers complementary to Nod2 coding sequences. The analysis showed that Nod2 was expressed primarily in monocytes (Fig. 3B). Because the Nod2 sequence contained two potential in-frame translation initiation sites separated by 81 nucleotides (Fig. 3C), their usage was determined by transfection of a Nod2 construct containing both translation initiation sites into HEK293T cells. Because the difference in size between

20

25

30

both predicted Nod2 products is only 27 amino acids, we expressed a COOH-terminally truncated Nod2 lacking residues 302-1040 to facilitate the identification of the translation initiation sites. As a control, Nod2 plasmids were engineered that express each translation initiation site separately within a canonical Kozak's translation initiation motif. The analysis revealed that both translation initiation sites in the Nod2 open reading frame were used, although the most NH2-terminal translation initiation codon was more efficient as assessed by immunoblotting of cell extracts with an antibody that recognizes a COOH-terminal HA tag (Fig. 3D).

10

#### Example 4

This example describes the activation of NF- $\kappa$ B by Nod2. Because of the homology between Nod1 and Nod2, tests were conducted to determine whether expression of Nod2 activates NF- $\kappa$ B by transfection of Nod2 plasmids into HEK293T cells. Transfection of the wt Nod2 cDNA induced potent activation of NF- $\kappa$ B, as measured with a reporter luciferase construct (see below). In addition, we tested the Nod2b cDNA and obtained similar results to those observed with Nod2. A panel of Nod2 mutants was generated to determine the regions of Nod2 that are required for NF- $\kappa$ B activation (Fig. 4A). Immunoblotting analysis revealed that these mutant constructs were expressed when transiently transfected into HEK293T cells (Fig. 4B).

20 Expression of as little as 3 ng of wt Nod2 induced 18-fold activation of NF- $\kappa$ B (Fig. 4C). Expression of a Nod2 mutant form lacking the LRRs resulted in enhanced NF- $\kappa$ B activation, while mutants expressing the LRRs or the NBD alone were inactive (Fig. 4C). The enhanced activity of the Nod2 mutant lacking the LRRs could not be explained by increased expression of the mutant (Fig. 4A). Consistent with these results, it was shown previously that deletion of the LRRs of Nod1 and WD-40 repeats of Apaf-1 results in enhanced NF- $\kappa$ B activation and increased ability to activate procaspase-9, respectively (Inohara *et al.*, *supra*, Srinivasula *et al.*, *supra*, Hu *et al.*, *supra*). Deletion of the CARDs of Nod2, either singly or in combination, resulted in total loss of NF- $\kappa$ B activity (Fig. 4C). However, expression of both CARDs alone, but not each CARD separately, was sufficient for NF- $\kappa$ B activation (Fig. 4C). Thus, both CARDs of Nod2 are necessary and

30 sufficient for NF- $\kappa$ B activation, suggesting that the CARDs acts as an effector domain in

Nod2 signaling. The conserved lysine residue in the P-loop of Nod1 and Apaf-I is important for the activities of these proteins (Inohara *et al.*, [1999] *supra*, Inohara *et al.*, [2000], *supra*, Hu *et al.*, EMBO J. 18: 3586-3595 [1999]). Similarly, replacement of the corresponding lysine for arginine in Nod2 resulted in diminished NF- $\kappa$ B activity that was  
5 rescued at least in part by deletion of the LRRs (Fig. 4C).

The ability of Nod2 to induce apoptosis was also investigated. Overexpression of Nod2 did not induce apoptosis by itself but enhanced apoptosis induced by caspase-9 expression. These results are similar to those reported for Nod1 and Apaf-1 (Bertin *et al.*, *supra*, Inohara *et al.*, [1999] *supra*).

10

### Example 5

This example demonstrates that NF- $\kappa$ B activation induced by Nod2 requires IKK $\gamma$  and is inhibited by dominant negative forms of IKKs and RICK. A main pathway of NF- $\kappa$ B activation is mediated by I $\kappa$ B kinases (IKKS) resulting in I $\kappa$ B phosphorylation and  
15 release of cytoplasmic NF- $\kappa$ B (Karin, J. Biol. Chem. 274: 27339-27342 [1999]). To determine whether Nod2 activates an IKK-dependent pathway, Nod2 was co-expressed with mutant forms of IKK $\alpha$ , IKK $\beta$ , and I $\kappa$ B that have been shown to act as dominant inhibitors of their corresponding endogenous counterparts and/or the IKK complex (Karin, *supra*). In addition, a truncated mutant of IKK $\gamma$ /Nemo (residues 134-419) was  
20 used that is defective in IKK $\alpha$  and IKK $\beta$  binding and acts as an inhibitor of NF- $\kappa$ B activation induced by RIP and RICK (Inohara *et al.*, [2000], *supra*). The NF- $\kappa$ B activity induced by Nod2 as well as that induced by TNF $\alpha$  stimulation were greatly inhibited by mutant IKK $\alpha$ , IKK $\gamma$ , IKK $\beta$ , and I $\kappa$ B $\alpha$  (Fig. 5A). Because RICK has been shown to serve as a downstream target of Nod1 (Bertin *et al.*, *supra*, Inohara *et al.*, [1999] *supra*, Inohara  
25 *et al.*, [2000], *supra*), a truncated form of RICK containing its CARD (residues 406-540) that acts as a dominant inhibitor of Nod1 activity (Bertin *et al.*, *supra*) was used to test whether NF- $\kappa$ B activation induced by Nod2 is similarly inhibited by this RICK mutant. NF- $\kappa$ B activation induced by Nod2 was inhibited by mutant RICK but not by a mutant form of RIP that expresses its death effector domain (Fig. 5A). The inhibition by the  
30 CARD of RICK was specific in that it did not interfere with ability of TNF $\alpha$  to induce NF- $\kappa$ B, an activity that was inhibited by the RIP mutant (Fig. 5A). To verify that Nod2

acts upstream of the IKK complex to activate NF- $\kappa$ B, we tested the ability of Nod2 to activate NF- $\kappa$ B in parental Rat1 fibroblasts and 5R cells, a Rat1 derivative cell line that is defective in IKK $\gamma$ , an essential subunit of the IKKs (Yamaoka *et al.*, *supra*). Nod2, as well as Nod1 and TNF $\alpha$ oc, induced NF- $\kappa$ B activity in parental Rat1 cells but not in 5 IKK $\gamma$ -deficient 5R cells (Fig. 5B). As a control, expression of IKK $\beta$ , which functions downstream of IKK $\gamma$ , induced NF- $\kappa$ B activation in both Rat1 and 5R cell lines (Fig. 5B). These results indicate that Nod2 acts through IKK $\gamma$ /IKK/IKK $\beta$  to activate NF- $\kappa$ B.

### Example 6

10        This Example demonstrates that Nod2 associates with RICK via a homophilic CARD-CARD interaction. The CARD motif functions as an effector domain that mediates specific homophilic interaction with downstream CARD-containing molecules (Hofmann *et al.*, Trends Biochem. Sci. 22: 155-156 [1997]). Because NF- $\kappa$ B activation induced by Nod2 was inhibited by a RICK truncated mutant, the ability of RICK to act as 15 a direct downstream mediator of Nod2 signaling was tested. To test a physical association between Nod2 and RICK, HEK293T cells were co-transfected with plasmids expressing HA-tagged wt or mutant forms of Nod2 and Flag-tagged RICK and cellular extracts were immunoprecipitated with anti-HA antibody. Immunoblotting with anti-Flag antibody revealed that RICK associated with Nod2 (Fig. 6A). The association was mediated by 20 both CARDS of Nod2, as only Nod2 proteins containing both CARDS were capable of interacting with RICK (Fig. 6A, B). The association of Nod2 with RICK was specific in that Nod2 did not associate with several CARD-containing proteins including Apaf-1, caspase-1, caspase-4, c-IAP-1, c-IAP2, procaspase-9, Bcl-10, RAIDD, and Ced-4 nor with several molecules that activate NF- $\kappa$ B including TRAF-1, TRAF-2, TRAF-5, 25 TRAF-6, RIP, NIK, TRADD, IKK $\alpha$ , IKK $\beta$  or IKK $\gamma$ . To determine the region of RICK that associates with Nod2, mutant forms of RICK expressing the CARD (residues 374-540) or lacking the CARD (residues 1-374) were co-expressed with Nod2 and the cell extracts were immunoprecipitated with anti-Flag antibody. The analysis showed that only the CARD of RICK co-immunoprecipitated with Nod2 (Fig. 6C). Thus, Nod2 and 30 RICK associate via a homophilic CARD-CARD interaction.

### Example 7

This Example demonstrates that enforced oligomerization of Nod2 induces NF- $\kappa$ B activation. Previous studies showed that the NBD of Nod1 and Apaf-1 mediates oligomerization of these molecules, an activity that is critical for NF- $\kappa$ B and caspase-9 activation, respectively (Srinivasula *et al.*, *supra*, Hu *et al.*, [1998] *supra*, Inohara *et al.*, [2000], *supra*). In the case of Nod1, its oligomerization appears to promote proximity of RICK and NF- $\kappa$ B activation. To test a similar role for Nod2, plasmids were constructed to express chimeric proteins in which wt or Nod2 mutants were fused to three tandem repeated dimerization domains of Fpk (Fpk3), which can be oligomerized by the cell-permeable ligand AP1510 (MacCorkle *et al.*, Proc. Nat. Acad. Sci. U. S. A. 95: 3655 [1998]). Immunoblotting analysis showed that the chimeric Fpk3-Nod2 constructs were expressed when transfected in HEK293T cells (Fig. 7A). Because wt Nod2 alone induces NF- $\kappa$ B activation, we expressed suboptimal amounts of the chimeric Fpk3-Nod2 constructs into HEK293T cells. Under these experimental conditions, expression of Nod2-Fpk3 induced NF- $\kappa$ B activation in a ligand-dependent manner (Fig. 7B). Consistent with the results shown in Fig. 4C, enforced oligomerization of both CARDs but not each CARD singly induced NF- $\kappa$ B activation (Fig. 7B). Similarly, NF- $\kappa$ B activation induced by a Nod2 P-loop mutant lacking the LRRs (K305RALRR), which have reduced ability to induce NF- $\kappa$ B activation, was enhanced by enforced oligomerization (Fig. 7C). A Nod2-Fpk3 construct lacking the LRRs induced NF- $\kappa$ B activation in the absence and presence of AP1510 (Fig. 7B). The latter result might be explained by our observations that Nod2 lacking the LRRs has enhanced activity to self-associate and induce NF- $\kappa$ B (Fig. 4C).

### Example 8

This Example describes the role of Nod1 in the cellular response to microbial components. Human embryonic kidney HEK293T cells were transiently co-transfected with a Nod1 expression plasmid or control plasmid and a NF- $\kappa$ B reporter construct in the presence of bacterial or fungal products. No significant induction of reporter gene activity was observed when the cells transfected with control plasmid were exposed to LPS, PGN, LTA, synthetic bacterial lipopeptide (SBLP) or mannan (Fig. 8A). These

results are in agreement with previous observations in HEK293 cells (Yang *et al.*, Nature, 395:284-288 [1998]; Aliprantis *et al.*, *Supra*; Chow *et al.*, *Supra*; Schwandner *et al.*, J. Biol. chem., 274:17406-17409 [2000]). Because overexpression of Nod1 induces NF- $\kappa$ B activation (Zou *et al.*, Cell, 90:405-413 [1997]; Bertin *et al.*, J. Biol. Chem., 274:12955-12858 [1999]), HEK293T cells were transfected with 0.3 ng of Nod1 and measured for NF- $\kappa$ B activation after incubation with various pathogen components. LPS, but not the other microbial products tested, induced significant NF- $\kappa$ B activation (about 12-fold) in cells expressing trace amounts of Nod1 (Fig. 8A). To demonstrate that NF- $\kappa$ B activation by LPS is specific for cells expressing Nod1, HEK293T cells were transfected with expression plasmids producing interleukin-1 receptor (IL1R) and its ligand interleukin-1 $\beta$  (IL1 $\beta$ ) or RIP, a mediator of the TNF $\alpha$  signaling pathway (Huang *et al.*, [1997] *Supra*; Hsu *et al.*, [1996], *Supra*). As expected, stimulation of the IL1R and expression of RIP induced NF- $\kappa$ B activation in the absence of LPS (Fig. 8B). Significantly, LPS did not enhance NF- $\kappa$ B activation induced by IL1R stimulation or RIP (Fig. 8B).

Plant disease-resistant proteins have C-terminal LRRs that are critical for pathogen-specific responses (Dixon *et al.*, [2000], *Supra*). Alterations in their LRRs results in unresponsiveness to particular pathogens (Dixon *et al.*, [2000], *Supra*), suggesting that the LRRs of Nod1 might be also required for the response to LPS. To test this hypothesis, HEK293T cells were transfected with plasmids expressing wild-type or truncated Nod1 mutant lacking the LRRs (Nod1 $\Delta$ LRR) and treated with LPS. Expression of Nod1 $\Delta$ LRR induced higher NF- $\kappa$ B activation than wild-type Nod1 in the absence of LPS, as previously reported (Inohara *et al.*, [1999], *Supra*). Significantly, LPS did not enhance NF- $\kappa$ B activation induced by Nod1 $\Delta$ LRR (Fig. 9). Thus, the LRRs are essential for Nod1 to respond to LPS.

Several studies have provided conclusive evidence that TLR4 is a cell surface receptor for LPS (Aderam and Ulevitch, *Supra*, Poltorak *et al.*, Science, 282:2085 [1998]; Chow *et al.*, *Supra*; Takeuchi *et al.*, Immunity, 4:443 [1999]). Therefore, it is possible that expression of Nod1 confers LPS responsiveness through TLR4. To test this possibility, HEK293T cells were co-transfected with a TLR4 expression plasmid and NF- $\kappa$ B activity was measured in the presence and absence of LPS. Expression of TLR4 alone did not induce NF- $\kappa$ B activation in the presence of LPS, which is consistent with



recent reports that additional cell surface molecules such as MD2 and CD14 are required for TLR4-mediated LPS responses in cells (Chow *et al.*, *Supra*; Takeuchi *et al.*, *Supra*). In accord with the latter, co-transfection of TLR4, CD14 and MD2 expression plasmids induced 8-fold activation of NF- $\kappa$ B (see figure legend of Fig. 8C). To further verify that

5 Nod1 confers LPS responsiveness independently of TLRs, a dominant negative mutant of MyD88, a common signaling molecule of IL-1 and Toll-related receptors including TLR4, was co-expressed with Nod1 or TLR4, CD14 and MD2 as a control, and transfected cells were stimulated with LPS. Co-expression of the MyD88 mutant suppressed NF- $\kappa$ B activation induced by both TLR4 and IL1R stimulation, but it did not

10 affect LPS-mediated NF- $\kappa$ B activation induced by Nod1 (Fig. 8C). Furthermore, expression of a dominant negative mutant of TRAF6, a signaling molecule of TLR signaling pathways, did not block NF- $\kappa$ B activation induced by Nod1, but inhibited TLR4-mediated NF- $\kappa$ B activation (Inohara *et al.*, [1999], *Supra*). These results indicate that NF- $\kappa$ B activation in Nod1-expressing cells induced by LPS is not mediated by the

15 TLR4 signaling pathway. Consistent with this notion are recent observations showing that the Nod1 signaling pathway leading to NF- $\kappa$ B activation is distinct to that of TLRs. Nod1 activates NF- $\kappa$ B through its association with RICK, a protein kinase that directly interacts with IKK $\gamma$ /NEMO, the regulatory subunit of the I $\kappa$ B kinase complex (Inohara *et al.*, [2000], *Supra*).

20 LPS from different gram-negative bacteria have diverse structures (Rietschel *et al.*, Curr Top. Microbiol. Immunol., 216:39-81 [1997]). To determine if Nod1 confers responsiveness to LPS from several bacterial sources, Nod1-expressing cells were stimulated with LPS from six pathogenic bacteria or TNF $\alpha$ , as a positive control. All LPS preparations induced NF- $\kappa$ B activation in Nod1-expressing cells, but different

25 sources of LPS differed in their ability to enhance Nod1-mediated NF- $\kappa$ B activation (Fig. 9). As it was found with LPS from *Escherichia coli* 055:B5 (Fig. 8B), none of the LPS preparations induced significant NF- $\kappa$ B activation in cells expressing a Nod1 mutant lacking the LRRs (Fig. 9).

Plants have numerous disease resistant R genes and mammalian as well as insect

30 cells have multiple TLR family members to respond to different pathogens (Dixon *et al.*, [2000], *supra*). Notably, Nod2, another Nod1-like protein that is homologous to Nod1

(34% amino acid identity) is comprised of N-terminal CARDS, NBD and LRRs. The presence of multiple Nod family members suggests that Nod1 and Nod2 may have different specificities for pathogen components. To test this, HEK293T cells were co-transfected with plasmids expressing wild-type or mutant Nod2 lacking the LRRs. As it was observed with Nod1, all LPS preparations including those from invasive bacteria such as *Salmonella* and *Shigella*, stimulated NF- $\kappa$ B activation in cells expressing wild-type Nod2 but not mutant Nod2 (Fig. 9). Notably, LPS from *Serratia marcescens* and *Salmonella typhimurium* was more effective in inducing NF- $\kappa$ B activation in cells expressing Nod2 than Nod1 (Fig. 9). Furthermore, PGN preparation from *Staphylococcus aureus* stimulated NF- $\kappa$ B activation in cells expressing Nod2 but not Nod1 (Fig. 9). The molecular basis for the differential response of Nod1 and Nod2 to both LPS and PGN is unclear. Further biochemical analyses and structure determination of LPS moiety recognized by Nod1 and Nod2 are required to understand the differential response of Nod proteins to bacterial components.

Apaf-1, a Nod1-like molecule that plays a central role in apoptosis, mediates responsiveness to cytochrome c leaked from mitochondria (Dixon *et al.*, *Supra*; Li *et al.*, Cell, 91:479 [1997]). Apaf-1 directly binds to cytochrome c (Li *et al.*, *Supra*). To determine if Nod1 binds to LPS, S100 cell lysates were prepared from HEK293T cells expressing Nod1 and the ability of Nod1 to bind radiolabeled LPS was tested by a modified immunoprecipitation assay. LPS was co-immunoprecipitated with Flag-tagged Nod1, but not with other Flag-tagged control proteins (Fig. 10A). Thus, Nod1 is associated with an LPS binding activity present in the cytosolic fraction of HEK293T cells. However, it is possible that Nod1 does not directly bind to LPS and that the association requires other cytosolic factors. For example, dATP or ATP is required for the response of Apaf-1 to cytochrome c (Li *et al.*, *Supra*). To begin to test this, we first immunoprecipitated Nod1 or IKK $\beta$ , as a control protein, with anti-Flag antibody and the ability of the immunoprecipitated proteins to bind LPS was tested in nucleotide-free buffer. Immunopurified Nod1 exhibited LPS binding activity, but control IKK $\beta$  did not (Fig. 10). These results suggest that Nod1 directly binds LPS. However, the possibility cannot be excluded that Nod1 interacts with LPS through an intrinsic cytosolic factor(s) that is tightly bound to Nod1 and co-immunoprecipitates with Nod1 in the absence of LPS.

In plants, the *Arabidopsis thaliana* disease resistance RPS2 gene product that is structurally related to Nod1 and Nod2 can form a protein complex *in vivo* with the product of the phytopathogenic bacterium *Pseudomonas syringae* avrRpt2 gene but the protein complex also contained at least one additional plant protein of approximately 75 kDa (Leister and Katagiri, Plant J., 22:345 [2000]).

### Example 9

#### Characterization of Crohn's Disease Alleles

This example describes the identification of mutant alleles of Nod2 in patients with Inflammatory Bowel Disease (IBD). Nod2 has been mapped to chromosome 16q12, and is tightly linked to markers D16S3396, D16S416, and D16S419 (Fig. 17a), a site that precisely overlaps with the *IBD1* peak region of linkage (Hugot *et al.*, Nature 379:821 [1996]). Thus, the possibility that Nod2 might function as a susceptibility gene for CD was investigated. The twelve-exon genomic organization of the Nod2 gene was determined by aligning the CDNA sequence (Genbank Accession No: AF178930) with one genomic BAC clone, RPI11-327F22 (Genbank Accession No: AC007728) (Fig. 17a).

#### A. Ascertainment of IBD Families

Patients were selected from the United States. IBD families were ascertained for linkage and association studies (affected child with both parents) through the University of Chicago, the Johns Hopkins Hospital, and the University of Pittsburgh. In all cases, informed consent for a molecular genetic study was obtained and the study protocol was approved by the individual institutional review boards.

Using primers complementary to intronic sequences, all coding exons and flanking introns in DNA samples from CD patients and controls were amplified. In the initial analysis, one affected individual from twelve pure CD families with increased linkage scores at D16S3396 was selected for sequencing, along with four case-controls. In three unrelated affected individuals, a cytosine insertion was observed in exon 11 at nt 3020 (3020InsC); two subjects were heterozygous and one subject was homozygous for the mutation (Fig. 17b). Confirmation of the sequencing results was performed by

subcloning the PCR amplicon from heterozygous individuals, transforming and sequencing individual clones. This insertion resulted in a frameshift at the second nucleotide of codon 1007 and a Leu1007Pro substitution in the tenth LRR, followed by a premature stop codon (Fig. 17c). The predicted truncated Nod2 protein contained 1007 amino acids instead of the 1040 amino acids of the wildtype Nod2 protein, removing 33 amino acids that included part of the most C-terminal LRR (Fig. 17d ).

### B. Allele Specific PCR

An allele-specific PCR assay was used to type the 3020InsC in patients ascertained through three U. S. centers and case-controls. A family illustrating the detection of homozygous and heterozygous 3020InsC alleles by the PCR assay is shown in Fig. 18.

Primers framing a 533 base pair region surrounding the 3020InsC allele were used to amplify by PCR genomic DNA isolated from controls and patients (sense: 5'-CTGAGCCTTTGTTGATGAGC-3'; SEQ ID NO:51 and antisense: 5'-TCTTCAACCACATCCCCATT-3'; SEQ ID NO:52). In addition, each PCR reaction contained two additional primers designed to detect the wild type allele (sense: 5'-CAGAAGCCCTCCTGCAGGCCCT-3'; SEQ ID NO:92) and another primer designed to detect the 3020InsC allele (antisense: 5'-CGCGTGTCATTCTTCATGGGGC-3'; SEQ ID NO:93). The 302InsC was confirmed by DNA sequencing. For detection of the C802T allele, four primers: two sense: 5'-AGTGCACAGCTTGTGAATGG-3' (SEQ ID NO:94) and 5'-CGCGGGCAGATGTGGGCATGGCTAGAC-3' (SEQ ID NO:95); and two antisense: 5'-GCAGCTGAATGGGAAGACA-3' (SEQ ID NO:96) and 5'-GCCGTGGCTGGGCTCTTCTGCGAGGA-3' (SEQ ID NO:97) were used. Multiplex PCR was performed with all four primers in one tube. PCR products were isolated on 2% agarose gels and visualized with ethidium bromide.

### C. Data Analysis

The allele frequencies in the CD patients were calculated both from a subsample of unrelated individuals and from the whole sample of CD patients. When all the samples were used, the frequencies were estimated using a likelihood approach. The

likelihood of the genotypes were calculated for each family (in the calculation only the CD genotypes were used and the linkage information was ignored). The solution of the score function was estimated numerically. The p-values for the TDT test were calculated using a binomial exact test. Sib-TDT for 500,000 replicates was used to calculate  
5 empirical probabilities for chi-squared statistics when all independent families were counted (Teng and Risch, Genome Res. 9:234 [1999]). This calculation was done by permuting parent alleles while fixing the IBD status of sibs within a family. Hardy-Weinberg equilibrium was tested using a likelihood ratio test. The likelihood of the unrelated CD genotypes was calculated both under Hardy-Weinberg restrictions and  
10 general genotype frequencies. The significance of the log-likelihood ratio statistic was assessed using a chi-square distribution with one degree of freedom. The ratio of the 3020InsC homozygous penetrance to the heterozygous penetrance was estimated by assuming that the 3020InsC is in Hardy-Weinberg equilibrium in the general population. The frequency of the genotypes in the affected individuals was estimated from 416  
15 unrelated CD patients.

For the case-control analysis, genotyping of one CD individual from 416 independent families was performed and the allele frequency among all groups was 8.2% (Table 2). The allele frequencies are comparable in the two main ethnic subgroups, Jewish (8.4%) and non-Jewish Caucasians (8.1%). Among case controls (Table 2), the  
20 allele frequency in four separate Caucasian cohorts of 4.0% was significantly lower than in CD patients ( $p = 0.0018$ , by the large sample approximations to a two sample binomial test). A similar value for the 3020InsC allele frequency (8.3%) was estimated from all 797 CD individuals from all families. The allele frequency of the 3020InsC among 182 unrelated UC patients was 3.0%, and was significantly lower than the frequency among  
25 CD patients ( $p = 0.0010$ ). Because the allele frequencies in the separate control groups are comparable, it is not expected that the significantly higher frequency of the 3020InsC in CD affected individuals is caused by population substructure.

30

<b>Table 2</b>					
<b>Allele Frequency in Unrelated Crohn's Disease Patients and Controls</b>					
Crohn's disease			Controls		
Source	Sample Size	3020InsC*	Source	Sample Size	3020InsC*
Univ of Chicago	212	7.3	Chicago	65	3.8
Johns Hopkins	88	6.8	Baltimore	46	3.2
Univ of Pittsburgh	116	10.8	San Francisco	81	3.1
			Germany	94	5.3
Total	416	8.2	Total	287	4.0

\* Percent allele frequency.

To further test that the observed differences between CD and control individuals are not due to population differences, analysis by the transmission disequilibrium test (TDT) was performed. Using only one CD patient per independent family, preferential transmission of the 3020InsC, with 39 transmissions and 17 nontransmissions from heterozygous parents to affected children ( $p = 0.0046$ ) was observed (Table 2). Using all available parent-child trios, 68 transmissions and 33 nontransmissions were observed (Table 3). By sib-TDT (Teng and Risch, Genome Res. 9:234 [1999]), which calculates empirical probabilities for chi squared statistics and accurately reflects association independent of linkage within families, the empirical p-value was 0.00071. The family based association test (Lake *et al.*, Am J Hum Genet 67:1515 [2000]) (which tests for association under the null hypothesis of linkage but no association) estimates the p-value at 0.0014.

In sequencing 36 unrelated CD individuals, an additional amino acid polymorphism was identified, C802T, which results in a proline to serine substitution at codon 268. The allele frequency of the C802T allele is 32.9% in CD patients compared to 25.8% in case-controls ( $p = 0.008$ ). This difference is at least partially driven by the (C802T-3020InsC) haplotype. While the transmission disequilibrium odds ratio [O.R. = probability (transmission)/1-probability(transmission)] in CD patients for the (C802T-3020InsC) haplotype is 2.29 ( $p = 0.0033$ ), it is not significantly increased (O.R. = 1.23,  $p = 0.20$ ) for the (C802T-3020wild-type) haplotype.

The genotype frequencies obtained by using unrelated CD individuals were 11 3020InsC homozygotes, 46 3020InsC heterozygotes and 359 wild-type homozygotes. Among case controls, there were 23 heterozygote individuals, with the remaining being wild-type homozygotes. There was significant deviation from Hardy-Weinberg equilibrium among CD patients ( $p = 1.46 \times 10^{-5}$ , based on a likelihood ratio test). The relative disease penetrance of 3020InsC homozygous compared to 3020InsC heterozygous is approximately 11.5, suggesting that the 3020InsC mutation alone can function in a recessive fashion.

Table 3 TDT Demonstrates Preferential Transmission of the 3020InsC to CD Patients					
One CD Patient Per Family				All CD Patients	
Source	Transmitted	Not Transmitted	p-value	Transmitted	Not Transmitted
Univ of Chicago	21	10		32	16
Johns Hopkins	4	4		10	8
Univ of Pittsburgh	14	3		26	9

Total	39	17	0.0046	68	33
-------	----	----	--------	----	----

#### D. Expression Plasmids and Immunoblotting

The expression plasmids pcDNA3-Nod2, pcDNA3-TLR4, and pcDNA3-MD-2 have been described. The expression plasmid producing the 3020InsC Nod2 mutant was generated by a PCR method and cloned into pcDNA3 (Invitrogen). The authenticity of the construct was confirmed by DNA sequencing. Expression of untagged Nod2 proteins in transfected cells was determined by immunoblotting using affinity purified rabbit anti-Nod2 antibody, as described above (See methodology section). To raise the antibody, recombinant Nod2 protein (residues 28-301) was overexpressed in E. coli strain BL21(DE3) using the pET-30a vector (Novagen). Recombinant Nod2 protein containing a C-terminal histidine tag was purified using a nickel column (Novagen) and injected into rabbits.

#### E. NF- $\kappa$ B Activation Assay

NF- $\kappa$ B activation assays were performed as described above (Example 4 and methodology section). Briefly, HEK293T cells were co-transfected with 12 ng of the reporter construct pBVI-Luc, plus indicated amounts of each expression plasmid and 120 ng of pEF-BOS- $\beta$ -gal in triplicate in the presence or absence of LPS. LPS from various sources was obtained from Sigma (St Louis, MO) or from several investigators. Twenty four hours post-transfection, cell extracts were prepared and the relative luciferase activity was measured as described above. Results were normalized for transfection efficiency to values obtained with pEF-BOS- $\beta$ -gal.

Nod2 has been shown to activate NF- $\kappa$ B and to confer responsiveness to bacterial lipopolysaccharides (See Example 8 above). To test the ability of wild-type and mutant Nod2 to activate NF- $\kappa$ B, human embryonic kidney (HEK) 293T cells were transiently cotransfected with wild-type or 3020InsC Nod2 plasmids and a NF- $\kappa$ B reporter construct. In the absence of LPS, expression of both wild-type and mutant Nod2 induced NF- $\kappa$ B activation (Fig. 19a). Importantly, equivalent levels of wild-type and mutant Nod2 protein expression (as assessed by immunoblotting of total lysates) resulted in similar



levels of NF- $\kappa$ B activation (Fig. 19a). Like Nod2, cytosolic plant R proteins have C-terminal LRRs that are critical for the recognition of pathogen components and induction of pathogen-specific responses (Pamiske *et al.*, Cell 91: 821 [1997]; Ellis *et al.*, Plant Cell. 11:495 [1999]; Dixon *et al.*, [2000], *supra*). Because the 3020InsC disrupts an LRR from Nod2, the ability of wild-type and mutant Nod2 proteins to induce NF- $\kappa$ B activity in response to LPS was assayed. Since overexpression of Nod2 induces potent NF- $\kappa$ B activation (Fig. 19a), the cells were transfected with low amounts of wild-type and mutant Nod2 plasmids to induce similar levels of protein expression and basal NF- $\kappa$ B activity (Fig. 19a). The ability of Nod2 proteins to enhance NF- $\kappa$ B activation after incubation with LPS from several bacteria was then tested. LPS from various bacteria induced NF- $\kappa$ B activation in cells expressing wild-type Nod2, whereas no significant induction of reporter gene activity was observed in cells transfected with control plasmid (Fig. 19b). The ability of Nod2 mutant to confer responsiveness to LPS was greatly diminished when compared to wild-type Nod2 (Fig. 19b). Neither wild-type nor mutant Nod2 enhanced NF- $\kappa$ B activation induced by LPS from *Salmonella minnesota*, *Neisseria meningitidis* and *Hemophilus influenzae*, suggesting that there is differential regulation of Nod2 function by LPS from different bacteria. In control experiments shown in Fig. 19b, all LPS preparations tested induced NF- $\kappa$ B activation in cells transfected with Toll-like receptor-4 (TLR4), a cell surface receptor for LPS. Thus, Nod2 appears to have differential preference for LPS from certain bacteria and the NF- $\kappa$ B activity induced by LPS is markedly diminished in Nod2 with 3020InsC.

### Example 10

#### Additional Crohn's Disease Alleles

This example describes the identification of additional mutations in the Nod2 gene as well as the association of additional mutations with Crohn's disease.

##### A. Identification of Additional Crohn's Alleles

Figure 26 shows additional polymorphisms that were identified in the Nod2 gene (SEQ ID NOs:1 and 33). The 3020InsC mutation was identified as described in Example 9 above. Additional mutations were identified by direct sequencing. Figure 26 describes the 3020InsC/Nod2 $\Delta$ 33 mutation as well as 7 additional polymorphisms that were

identified. Figure 27 describes allele frequencies for each haplotype identified. Positions of polymorphisms are indicated using the numbering of the Nod2a transcript and protein.

**B. Significant Association of Nod2 $\Delta$ 33, G908R, and R702W with Crohn's**

**5 Disease**

The transmission disequilibrium test (described in Example 9 above) was used to demonstrate transmission of three alleles suspected of being associated with Crohn's disease. The polymorphisms investigated were identified as described above. Table 4 below demonstrates the results of the transmission disequilibrium test (TDT) for the three  
10 associated variants, using either one CD patient per 416 independent CD families, or by counting all trios. Counting all independent nuclear families using the sib-TDT test demonstrates comparable p-values: Nod2 $\Delta$ 33 ( $p = 0.0007$ ), G908R ( $p = 0.0005$ ), and R702W ( $p = 0.0005$ ).

Additional support for disease association was obtained by case control analysis,  
15 where significantly higher allele frequencies were observed in CD patients compared to case controls. Table 5 describes the results of case control analysis for unrelated Crohn's disease patients.

Table 6 describes the genotype relative risks for heterozygous and homozygous risk alleles. The genotypic relative risks (GRR) are defined as the ratio of the marginal  
20 penetrance of the risk homozygote and heterozygote genotypes to the wild type homozygotes. Using Bayes rule, the GRR can be expressed as a function of the allele frequencies in the case and control groups. For the control group, it is assumed that the alleles are in Hardy-Weinberg equilibrium. Note that the estimates for G908R are somewhat skewed due to its very low allele frequency among non-Ashkenazim.

25 The population attributable risk among the non-Ashkenazim for Nod2 $\Delta$ 33, G908R, and R702W were 6.18%, 4.35% and 12.76% respectively. The population attributable risk was calculated as  $(K - K_w)/K$ , where  $K$  is the prevalence of Crohn's in the general population and  $K_w$  is the prevalence of Crohn's in the subpopulation consisting in individuals homozygous for the wild type allele at the specified variant.

This example demonstrates that multiple polymorphisms exist in the Nod2 gene and that at least 3 of the polymorphisms are associated with an increased prevalence and risk of developing Crohn's disease.

<b>Table 4</b>					
<b>TDT Demonstrates Preferential Transmission of Nod2 Polymorphisms</b>					
	<b>One CD per family</b>			<b>All CD trios</b>	
<b>Polymorphism</b>	<b>Transmitted</b>	<b>Not Transmitted</b>	<b>p-value</b>	<b>Transmitted</b>	<b>Not Transmitted</b>
Nod2Δ33	39	17	0.0046	68	33
G908R	34	12	0.0016	53	20
R702W	43	16	0.00060	78	34

5

<b>Table 5</b>			
<b>Allele Frequency (%) in Unrelated Crohn's Disease Patients and Controls</b>			
<b>Polymorphism</b>	<b>CD patients (n=416)</b>	<b>Controls (n= 287)</b>	<b>p-value</b>
Nod2Δ33	8.2	1.0	0.0018
G908R	5.9	1.7	0.00010
R702W	8.5	4.0	0.0010

10

<b>Table 6</b> <b>Genotype Relative Risks for Non-Ashkenazim</b>		
<b>Polymorphism</b>	<b>Heterozygous</b>	<b>Homozygous</b>
Nod2 $\Delta$ 33	1.5	17.6
G908R	2.0	34.5
R702W	2.6	14.3

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in molecular biology, genetics, or related fields are intended to be within the scope of the following claims.

## CLAIMS

What is claimed is:

- 5           1.    A method of identifying subjects at risk of developing Crohn's disease comprising:
- a)    providing
- i)    nucleic acid from a subject, wherein said nucleic acid comprises a Nod2 gene; and
- 10                   b)    detecting the presence or absence of one or more variations in said Nod2 gene.
2.    The method of Claim 1, further comprising step c) determining if said subject is at risk of developing Crohn's disease based on the presence or absence of said
- 15    one or more variations.
3.    The method of Claim 2, wherein said determining of step c) comprises determining a genotype relative risk for said subject.
- 20           4.    The method of Claim 2, wherein said determining of step c) comprises determining a population attributable risk for said subject.
5.    The method of claim 1, wherein said variation is a mutation.
- 25           6.    The method of Claim 1, wherein said variation is a polymorphism.
7.    The method of claim 1, wherein said variation results in increased NF- B activation.
- 30           8.    The method of Claim 5, wherein said mutation is a cytosine residue insertion.

9. The method of Claim 5, wherein said mutation causes a deletion of at least one LRR repeat of Nod2.

5 10. The method of Claim 1, wherein said one or more variations are selected from the group consisting of the nucleic acid sequences described by SEQ ID NOs: 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88.

11. The method of Claim 1, wherein said detecting in step (b) is accomplished  
10 by hybridization analysis.

12. The method of Claim 1, wherein said detecting in step (b) comprises comparing the sequence of said nucleic acid to the sequence of a wild-type Nod2 nucleic acid.

15

13. A kit for determining if a subject is at risk of developing Crohn's disease comprising:

- a) a detection assay, wherein said detection assay is capable of specifically detecting a variant Nod2 allele; and  
20 b) instructions for determining if the subject is at increased risk of developing Crohn's disease.

14. The kit of Claim 13, wherein said detection assay comprises a nucleic acid probe that hybridizes under stringent conditions to a nucleic acid sequence selected from  
25 the group consisting of SEQ ID NOs: 70-83.

15. An isolated nucleic acid comprising a sequence encoding a polypeptide selected from the group consisting of SEQ ID NOs: 55, 57, 59, 61, 63, 65, 67, 69, 85, 87, and 89.

30

16. The nucleic acid sequence of Claim 15, wherein said sequence is operably linked to a heterologous promoter.

17. The nucleic acid sequence of Claim 16, wherein said sequence is  
5 contained within a vector.

18. A host cell comprising the vector of Claim 17.

19. The host cell of Claim 18, wherein said host cell is located in an organism  
10 selected from the group consisting of a plant and an animal.

20. An isolated nucleic acid sequence selected from the group consisting of  
SEQ ID NOs: 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88.

15 21. A computer readable medium encoding a representation of the nucleic  
acid sequence of claim 20.

22. An isolated polypeptide selected from the group consisting of SEQ ID  
NOs: 55, 57, 59, 61, 63, 65, 67, 69, 85, 87, and 89.

20

23. A computer readable medium encoding a representation of the polypeptide  
of claim 22.

24. A computer implemented method of determining a patient's risk of  
25 developing Crohn's disease comprising:

a) providing:

i) nucleic acid from a patient, wherein said nucleic acid  
comprises a Nod2 gene; and

ii) a computer comprising software for the prediction of a  
30 patient's risk of developing Crohn's disease; and

- b) detecting the presence of one or more variations in said patient's Nod2 gene to generate genetic variation information;
- c) entering said genetic variation information into said computer; and
- d) calculating said patient's risk with said software.

5

25. The method of claim 24, further comprising step e) displaying said patient's risk.

26. The method of Claim 24, wherein said risk comprises a genotype relative risk.

10

27. The method of Claim 24, wherein said risk comprises a population attributable risk.

28. The method of Claim 24, wherein said variation is a polymorphism.

15

29. The method of Claim 24, wherein said variation is a mutation.

30. The method of Claim 29, wherein said mutation is a cytosine residue insertion.

20

31. The method of Claim 30, wherein said mutation causes a deletion of at least one LRR repeat of Nod2.

32. The method of Claim 24, wherein said one or more variations are selected from the group consisting of the nucleic acid sequences described by SEQ ID NOs: 33, 54, 56, 58, 60, 62, 64, 66, 68, 84, 86, and 88.

25

33. The method of Claim 24, wherein said detecting in step (b) comprises comparing the sequence of said nucleic acid to the sequence of a wild-type Nod2 nucleic acid.

30






Figure 1





Figure 2






Figure 4





Figure 5



### Figure 6




Figure 7




Figure 8






Figure 9




Figure 10

# Figure 11

## SEQ ID NO:33

### Nod2 cDNA sequence

```

gtagacagat ccaggctcac cagtccctgtg ccactgggct tttggcgctt tgcacaaggc      60
ctaccgcgag atgccatgcc tgctccccc gctaataagg ctttgatggg ggaagagggt      120
ggttcagcct ctacagatga ggaggaaaga gcaagtgtcc tcctcggaca ttctccgggt      180
tgtgaaatgt gctcgcagga ggcttttcag gcacagagga gccagctggt cgagctgctg      240
gtctcagggt ccctggaagg cttcgagagt gtcctggact ggctgctgtc ctgggaggtc      300
ctctcctggg aggactacga gggcttccac ctctgggcc agcctctctc ccacttgccc      360
aggcgccctt tggacaccgt ctggaataag ggtacttggg cctgtcagaa gctcatcgcg      420
gtgcccgaag aagcccaggc cgacagccag tcccccaagc tgcatggctg ctgggacccc      480
cactcgtctc acccagcccc agacctgcag agtcaccggc cagccattgt caggaggctc      540
cacagccatg tggagaacat gctggacctg gcatgggagc ggggtttcgt cagccagtat      600
gaatgtgatg aaatcagggt gccgatcttc acacogtccc agagggcaag aaggctgctt      660
gatcttgcca cggtgaaagc gaatggattg gctgccttcc ttctacaaca tgttcaggaa      720
ttaccagtcc cattggccct gcctttggaa gctgccacat gcaagaagta tatggccaag      780
ctgaggacca cgggtgtctgc tcagtctcgc ttctcagta cctatgatgg agcagagacg      840
ctctgcctgg aggacatata cacagagaat gtctcggagg tctgggcaga tgtgggcatg      900
gctggacccc cgcagaagag cccagccacc ctgggcctgg aggagctctt cagcaccctt      960
ggccacctca atgacgatgc ggacactgtg ctggtggtgg gtgaggcggg cagtggcaag      1020
agcacgctcc tgcagcggct gcacttgctg tgggctgcag ggcaagactt ccaggaattt      1080
ctctttgtct tcccattcag ctgccggcag ctgcagtgc tggccaaacc actctctgtg      1140
cggactctac tctttgagca ctgctgttgg cctgatgttg gtcaagaaga catcttccag      1200
ttactccttg accaccctga ccgtgtcctg ttaacctttg atggctttga cgagttcaag      1260
ttcaggttca cggatcgtga acgccactgc tccccgaccg accccacctc tgtccagacc      1320

```

ctgctcttca accttctgca gggcaacctg ctgaagaatg cccgcaagggt ggtgaccagc	1380
cgtccggccg ctgtgtcggc gttcttcagg aagtacatcc gcaccgagtt caacctcaag	1440
ggcttctctg aacagggcat cgagctgtac ctgaggaagc gccatcatga gcccggggtg	1500
gcggaccgcc tcatccgcct gtcceaagag acctcagccc tgcacggttt gtgccacctg	1560
cctgtcttct catggatggg gtccaaatgc caccaggaac tgttgctgca ggaggggggg	1620
tccccaaaga ccactacaga tatgtacctg ctgattctgc agcattttct gctgcatgcc	1680
acccccccag actcagcttc ccaaggctct ggaccagtc ttcttcgggg ccgcctcccc	1740
accctctctg acctgggcag actggctctg tggggcctgg gcatgtgctg ctacgtgttc	1800
tcagcccagc agctccaggc agcacaggtc agcctgatg acattttctt tggcttctctg	1860
gtgctgtcca aagggtgctg gccagggagt acggcgcccc tggaaatctt tcacatcact	1920
ttccagtgtt tctttgccgc gttctacctg gcactcagt ctgatgtgcc accagctttg	1980
ctcagacacc tcttcaattg tggcaggcca ggcaactcac caatggccag gctcctgccc	2040
acgatgtgca tccaggcctc ggagggaaag gacagcagcg tggcagcttt gctgcagaag	2100
gccgagccgc acaaccttca gatcacagca gccttcctgg cagggtgtt gtcccgggag	2160
cactggggcc tgettgctga gtgccagaca tctgagaagg ccctgctccg gcgccaggcc	2220
tgtgcccgtt ggtgtctggc ccgcagcctc cgcaagcact tccactccat ccgcccagct	2280
gcaccgggtg aggccaaag cgtgcatgcc atgcccgggt tcatctggct catccggagc	2340
ctgtacgaga tgcaggagga gcggctggct cggaaggctg cacgtggcct gaatgttggg	2400
cacctcaagt tgacattttg cagtgtgggc cccactgagt gtgtgcccct ggcctttgtg	2460
ctgcagcacc tccggcgccc cgtggccctg cagctggact acaactctgt gggtgacatt	2520
ggcgtggagc agctgctgcc ttgccttggg gtctgcaagg ctctgtattt gcgcgataac	2580
aatatctcag accgaggcat ctgcaagctc attgaatgtg ctcttcactg cgagcaattg	2640
cagaagttag ctctattcaa caacaaattg actgacggct gtgcacactc catggctaag	2700
ctccttgcac gcaggcagaa cttcttggca ttgaggctgg ggaataacta catcactgcc	2760
gcgggagccc aagtgtggc cgaggggctc cgaggcaaca cctccttgca gttcttggga	2820
ttctggggca acagagtggg tgacgagggg gcccgagccc tggctgaagc cttgggtgat	2880
caccagagct tgaggtggct cagcctgggt gggaaacaaca ttggcagtgt gggtgcccaa	2940
gccttggcac tgatgtggc aaagaacgtc atgctagaag aactctgcct ggaggagaa	3000
catctccagg atgaagtggt atgttctctc gcagaaggac tgaagaaaaa ttcaagtttg	3060
aaaatcctga agttgtccaa taactgcac accctacctag gggcagaagc cctcctgcag	3120

gccccctgaaa ggaatgacac catcctggaa gtctggctcc gagggaaacac tttctctcta	3180
gaggaggttg acaagctcgg ctgcaggac accagactct tgctttgaag tctccgggag	3240
gatgttcgtc tcagtttgtt tgtgagcagg ctgtgagttt gggccccaga ggctgggtga	3300
catgtgttgg cagcctcttc aaaatgagcc ctgtcctgcc taaggctgaa cttgttttct	3360
gggaacacca taggtcacct ttattctggc agaggagga gcatcagtgc cctccaggat	3420
agacttttcc caagcctact tttgccattg acttcttccc aagattcaat cccaggatgt	3480
acaaggacag cccctcctcc atagtatggg actggcctct gctgatcctc ccaggcttcc	3540
gtgtgggtca gtggggccca tggatgtgct tgttaactga gtgccttttg gtggagaggc	3600
ccggcctctc acaaaagacc ccttaccact gctctgatga agaggagtac acagaacaca	3660
taattcagga agcagctttc cccatgtctc gactcatcca tccaggccat tccccgtctc	3720
tggttcctcc cctcctcctg gactcctgca cagctcctt cctctgaggc tgaaattcag	3780
aatattagtg acctcagctt tgatatttca cttacagcac cccaaccct ggcacccagg	3840
gtgggaaggg ctacacctta gcctgccctc ctttcgggtg ttttaagacat ttttggaagg	3900
ggacacgtga cagccgtttg ttccccaaga cattctaggt ttgcaagaaa aatatgacca	3960
cactccagct gggatcacat gtggactttt atttccagtg aaatcagtta ctcttcagtt	4020
aagccttttg aaacagctcg actttaaaaa gctccaaatg cagctttaaa aaattaatct	4080
gggccagaat ttcaaacggc ctactaggc ttctggttga tgcctgtgaa ctgaactctg	4140
acaacagact tctgaaatag acccacaaga ggcagttcca tttcatttgt gccagaatgc	4200
tttaggatgt acagttagg attgaaagtt tacaggaaaa aaaattaggc cgttccttca	4260
aagcaaatgt ctctctggat tattcaaaat gatgtatgtt gaagcctttg taaattgtca	4320
gatgctgtgc aaatgttatt attttaaaca ttatgatgtg tgaaaactgg ttaatattta	4380
taggtcactt tgttttactg tcttaagttt atactcttat agacaacatg gccgtgaact	4440
ttatgctgta aataatcaga ggggaataaa ctgttgagtc aaaac	4485

## Figure 12

### SEQ ID NO:1

#### Nod2 cDNA sequence

```

gtagacagat ccaggctcac cagtctctgtg ccactgggct tttggcgctt tgcacaaggc      60
ctaccgcgag atgccatgcc tgetccccca gcctaattggg ctttgatggg ggaagagggg      120
ggttcagcct ctcacgatga ggaggaaaga gcaagtgtcc tcctcggaca ttctccgggt      180
tgtgaaatgt gctcgcagga ggcttttcag gcacagagga gccagctggt cgagctgctg      240
gtctcagggt ccctggaagg ctctcgagagt gtcttggaact ggctgctgtc ctgggaggtc      300
ctctcctggg aggactacga gggcttccac ctctgggcc agcctctctc ccacttggcc      360
aggcgccctt tggacaccgt ctggaataag ggtacttggg cctgtcagaa gctcatcgcg      420
gtgccccaa gagccaggc cgacagccag tcccccaagc tgcatggctg ctgggacccc      480
cactcgctcc acccagccc agacctgcag agtcaccggc cagccattgt caggaggctc      540
cacagccatg tggagaacat gctggacctg gcatgggagc ggggtttcgt cagccagtat      600
gaatgtgatg aaatcagggt gccgatcttc acaccgtccc agagggcaag aagctgctt      660
gatcttgcca cggtgaaage gaatggattg gctgccttcc ttctacaaca tgttcaggaa      720
ttaccagtec cattggccct gcctttggaa gctgccacat gcaagaagta tatggccaag      780
ctgaggacca cgggtgtctgc tcagtctcgc ttctcagta cctatgatgg agcagagacg      840
ctctgcctgg aggacatata cacagagaat gtcttgagg tctgggcaga tgtgggcatg      900
gctggacccc cgcagaagag ccagccacc ctgggcctgg aggagctctt cagcaccctt      960
ggccacotca atgacgatgc ggacactgtg gtggtggtgg gtgaggcggg cagtggcaag      1020
agcacgctcc tgcagcgggt gcacttgctg tgggctgcag ggcaagactt ccaggaattt      1080
ctctttgtct tcccatcag ctgccggcag ctgcagtga tggccaaacc actctctgtg      1140
cggactctac tctttgagca ctgctgttgg cctgatgttg gtcaagaaga catcttccag      1200
ttaactcttg accaccctga ccgtgtcctg ttaacctttg atggctttga cgagttcaag      1260
ttcaggttca cggatcgtga acgccaactgc tccccgaccg accccacctc tgtccagacc      1320

```

ctgctcttca accttctgca gggcaacctg ctgaagaatg cccgcaagggt ggtgaccagc	1380
cgtccggcgc ctgtgtcgcc gtctctcagg aagtacatcc gcaccgagtt caacctcaag	1440
ggcttctctg aacagggcat cgagctgtac ctgaggaagc gccatcatga gcccgggggtg	1500
gcggaccgcc tcatccgcct gctccaagag acctcagccc tgcacggttt gtgccacctg	1560
cctgtcttct catggatggt gtccaaatgc caccaggaac tgttgctgca ggaggggggg	1620
tccccaaaga ccaactacaga tatgtacctg ctgattctgc agcattttct gctgcatgcc	1680
acccccccag actcagcttc ccaaggctcg ggaccagtc ttcttcgggg ccgcctcccc	1740
accctctgc acctgggcag actggctctg tggggcctgg gcatgtgctg ctacgtgttc	1800
tcagcccagc agctccaggc agcacaggtc agcctgatg acatttctct tggcttctctg	1860
gtgctgcca aagggtgctg gccaggaggt acggcgcccc tgggaattct tcacatcact	1920
ttccagtgtc tctttgccgc gttctacctg gcactcagtg ctgatgtgcc accagctttg	1980
ctcagacacc tcttcaattg tggcaggcca ggcaactcac caatggccag gtcctgccc	2040
acgatgtgca tccaggcctc ggagggaaag gacagcagcg tggcagcttt gctgcagaag	2100
gccgagccgc acaaccttca gatcacagca gccttcctgg cagggtgtgt gtcccgggag	2160
cactggggcc tgcgtgctga gtgccagaca tctgagaagg ccttgctccg gcgccaggcc	2220
tgtgcccgtg ggtgtctggc ccgcagcctc cgcaagcact tccactccat cccgccagct	2280
gcaccgggtg agccaagag cgtgcatgcc atgcccgggt tcatctggct catccggagc	2340
ctgtacgaga tgcaggagga gcggctggct cggaaggctg cacgtggcct gaatgttggg	2400
cacctcaagt tgacattttg cagtgtgggc cccactgagt gtgtgcccct ggcccttctg	2460
ctgcagcacc tccggcggcc cgtggccctg cagctggact acaactctgt gggtgacatt	2520
ggcgtggagc agctgctgcc ttgccttggg gtctgcaagg ctctgtattt gcgcgataac	2580
aatatctcag accgaggcat ctgcaagctc attgaatgtg ctcttctctg cgagcaattg	2640
cagaagttag ctctattcaa caacaaattg actgacggct gtgcacactc catcggttaag	2700
ctccttgcat gcaggcagaa cttcttggca ttgaggctgg ggaataacta catcactgcc	2760
gcgggagccc aagtgtggc cgaggggctc cgaggcaaca cctccttgca gttcctggga	2820
ttctggggca acagagtggg tgacgagggg gcccaggccc tggctgaagc cttgggtgat	2880
caccagagct tgaggtggct cagcctgggt gggaacaaca ttggcagtgt gggtgcccaa	2940
gccttggcac tgatgtggc aaagaacgtc atgctagaag aactctgcct ggaggagaac	3000
catctccagg atgaagtggt atgttctctc gcagaaggac tgaagaaaaa ttcaagtttg	3060
aaaatcctga agttgtccaa taactgcac acctacctag gggcagaagc cctcctgcag	3120

gcccttgaaa ggaatgacac catcctggaa gtctggctcc gagggaaacac tttctctcta	3180
gaggagggttg acaagctcgg ctgcaggac accagactct tgctttgaag tctccgggag	3240
gatgttcgtc tcagtttgtt tgtgagcagg ctgtgagttt gggccccaga ggctgggtga	3300
catgtgttgg cagcctcttc aaaatgagcc ctgtcctgcc taaggctgaa cttgttttct	3360
gggaacacca taggtcacct ttattctggc agaggaggga gcatcagtc cctccaggat	3420
agacttttcc caagcctact ttgcccattg acttcttccc aagattcaat cccaggatgt	3480
acaaggacag cccctcctcc atagtatggg actggcctct gctgatcctc ccaggcttcc	3540
gtgtgggtca gtggggccca tggatgtgct tgtaactga gtgccttttg gtggagaggc	3600
ccggcctctc aaaaaagacc ccttaccact gctctgatga agaggagtac acagaacaca	3660
taattcagga agcagctttc cccatgtctc gactcatcca tccaggccat tccccgtctc	3720
tggttcctcc cctcctcctg gactcctgca cagctcctt cctctgagge tgaaattcag	3780
aatattagtg acctcagctt tgatatttca cttacagcac ccccaacctt ggcaccagg	3840
gtgggaaggg ctacacctta gcctgccctc ctttccggtg ttttaagacat ttttgggaagg	3900
ggacacgtga cagccgtttg ttccccaaga cattctaggt ttgcaagaaa aatatgacca	3960
cactccagct gggatcacat gtggactttt atttccagtg aaatcagtta ctcttcagtt	4020
aagccttttg aaacagctcg actttaaaaa gctccaaatg cagctttaaa aaattaatct	4080
gggccagaat ttcaaacggc ctactaggc ttctgggtga tgctgtgaa ctgaactctg	4140
acaacagact tetgaaatag acccacaaga ggcagttcca ttctatttgt gccagaatgc	4200
tttaggatgt acagttatgg attgaaagt tacaggaaaa aaaattaggc cgttccttca	4260
aagcaaatgt ctctctggat tattcaaaat gatgtatgtt gaagcctttg taaattgtca	4320
gatgctgtgc aaatgttatt attttaaaca ttatgatgtg tgaaaactgg ttaatatatta	4380
taggtcactt tgttttactg tcttaagttt atactcttat agacaacatg gccgtgaact	4440
ttatgctgta aataatcaga ggggaataaa ctgttgagtc aaaac	4485



# Figure 13

## SEQ ID NO:2

MGEEGGSASH DEEERASVLL GHSPGCEMCS QEAFQAQRSQ LVELLVSGSL EGFESVLDWL  
 LSWEVLSWED YEGFHLLGQP LSHLARRLLD TVWNKGTWAC QKLIAAAQEA QADSQSPKLH  
 GCWDPHSLHP ARDLQSHRPA IVRRLHSHVE NMLDLAWERG FVSQYECDEI RLPITFPSQR  
 ARRLDLATV KANGLAAFL LQHVEQLPVPL ALPLEAATCK KYMAKLRTTV SAQSRFLSTY  
 DGAETLCLED IYTEENVLEVW ADVGMAGPPQ KSPATLGLEE LFSTPGHLND DADTVLVVGE  
 AGSGKSTLLQ RLHLLWAAGQ DFQEFLLVFP FSCRQLQCMA KPLSVRTLLF EHCCWPDVGO  
 EDIFQLLLDH PDRVLLTFDG FDEFKFRFTD RERHCSPTDP TSVQTLLEFN LQGNLLKNAR  
 KVVTSRPAAV SAFLRKYIRT EFNKGFSEQ GIELYLKRKH HEPGVADRLL RLLQETSALH  
 GLCHLPVFSW MVSCHQELL LQEGGSPKTT TDMYLLILQH FLLHATPPDS ASQGLGPSLL  
 RGRLLPTLLH LRLALWGLGM CCYVFSQQ LQAQVSPDDI SLGFLVRAKG VVPGSTAPLE  
 FLHITFQCF AAFYLALSAD VPPALLRHLF NCGRPGNSPM ARLLPTMCIQ ASEKDSVA  
 ALLQKAEPHN LQITAAFLAG LLSREHWGLL AECQTSEKAL LRRQACARWC LARSLRKHFH  
 SIPPAPAGEA KSVHAMPFI WLIRSLYEMQ EERLARKAAR GLNVGHLKLT FCSVGPTCA  
 ALAFVLQHLR RPVALQLDYN SVGDIGVEQL LPCLGVCKAL YLRDNNISDR GICKLIECAL  
 HCEQLQKLAL FNNKLTGCA HSMAKLLACR QNFLALRLGN NYITAAGA QV LAEGLRGNTS  
 LQFLGFWGNR VGDEGAQALA EALGDHQLR WLSLVGNNIG SVGAQALALM LAKNVMLEEL  
 CLEENHLQDE GVCSLAELK KNSSLKILKL SNNCITYLGA EALLQALERN DTILEVWLRG  
 NTFSLEEVDK LGCRDTRLLL \*

## Figure 14

## SEQ ID NO:3

MCSQEAFQAA RSQVVELLVS GSLEGFESVL DWLLSWEVLS WEDYEGFHLL GQPLSHLARR  
LLDTVWNKGT WACQKLIAAA QEAQADSQSP KLHGCWDPHS LHPARDLQSH RPAIVRRLLHS  
HVENMLDLAW ERGFVSQYEC DEIRLPIFTP SQRARRLLDL ATVKANGLAA FLLQHVQELP  
VPLALPLEAA TCKKYMALR TTVSAQSRFL STYDGAETLC LEDIYTENVL EVWADVGMAG  
PPQKSPATLG LEELFSTPGH LNDDADTVLV VGEAGSGKST LLQRLHLLWA AGQDFQEFLE  
VFPFSCRQLQ CMAKPLSVRT LLFEHCCWPD VGQEDIFQLL LDHPDRVLLT FDGFDEFKFR  
FTDRERHCSP TDPTSVQTLL FNLLQGNLLK NARKVTSRP AAVSAFLRKY IRTEFNLKGF  
SEQGIELYLR KRHHEPGVAD RLIRLLQETS ALHGLCHLPV FSWMVSKCHQ ELLLQEGGSP  
KTTTDMYLLI LQHFLHATP PDSASQGLGP SLLRGRLPTL LHLGRLALWG LGMCCYVFA  
QQLQAAQVSP DDISLGFLVR AKGVVPGSTA PLEFLHITFQ CFFAAFYAL SADVPPALLR  
HLFNCGRPGN SPMARLLPTM CIQASEGKDS SVAALLQKAE PHNLQITAAF LAGLLSREHW  
GLLAECQTSE KALLRRQACA RWCLARSLRK HFHSIPPAAP GEAKSVHAMP GFIWLIRSLY  
EMQEERLARK AARGLNVGHL KLTFCVSGPT ECAALAFVLQ HLRRPVALQL DYNSVGDIGV  
EQLLPCLGVC KALYLRDNNI SDRGICKLIE CALHCEQLQK LALFNNKLTG GCAHSMALL  
ACRQNFALR LGNNYITAAG AQVLAEGLRG NTSLQFLGFW GNRVGDEGAQ ALAEALGDHQ  
SLRWLSLVGN NIGSVGAQAL ALMLAKNVM EELCLEENHL QDEGVCSLAE GLKKNSSLKI  
LKLSNNCITY LGAEALLQAL ERNDTILEVW LRGNTFSLEE VDKLGCRDTR LLL\*

Figure 15  
SEQ ID NO:34

Nod2a AA sequence, Mutant

MGEEGGSASH DEEERASVLL GHSPGCEMCS QEAFQAQRSQ LVELLVSGSL EGFESVLDWL  
LSWEVLSWED YEGFHLLGQP LSHLARRLLD TVWNKGTWAC QKLIAAAQEA QADSQSPKLH  
GCWDPHSLHP ARDLQSHRPA IVRRLHSHVE NMLDLAWERG FVSQYECDEI RLPIFTSPQR  
ARRLLDLATV KANGLAAFL L QHVQELPVPL ALPLEAATCK KYMAKLRTTV SAQSRFLSTY  
DGAETLCLED IYTENVLEW ADVGMAGPPQ KSPATLGLEE LFSTPGHLND DADTVLVVGE  
AGSGKSTLLQ RLHLLWAAGQ DFQEFLEFVP FSCRQLQCMA KPLSVRTLLE EHCCWPDVGO  
EDIFQLLLDH PDRVLLTFDG FDEFKFRFTD RERHCSPTDP TSVQTLLFNL LQGNLLKNAR  
KVVTSRPAAV SAFLRKYIRT EFNKGFSEQ GIELYLKRKH HEPGVADR LI RLLQETSALH  
GLCHLPVFSW MVSCKHQELL LQEGGSPKTT TDMYLLILQH FLLHATPPDS ASQGLGPSLL  
RGR LPTLLHL GRLALWGLGM CCYVFSQQ L QAAQVSPDDI SLGFLVRAKG VVPGSTAPLE  
FLHITFCQFF AAFYLALSAD VPPALLRHLE NCGRPGNSPM ARLLPTMCIQ ASEGKDSSVA  
ALLQKAEPHN LQITAAFLAG LLSREHWGLL AECQTSEKAL LRRQACARWC LARSLRKHFH  
SIPPAAPGEA KSVHAMPGFI WLIRSLYEMQ EERLARKAAR GLNVGHLKLT FCSVGPTeca  
ALAFVLQHLR RPVALQLDYN SVGDIGVEQL LPCLGVCKAL YLRDNNISDR GICKLIECAL  
HCEQLQKLAL FNNKLTGCA HSMAKLLACR QNFLALRLGN NYITAAGA QV LAEGLRGNTS  
LQFLGFWGNR VGDEGAQALA EALGDHQLSR WLSLVGNNIG SVGAQALALM LAKNVMLEEL  
CLEENHLQDE GVCSLAEGLK KNSSLKILKL SNNCITYLGA EALLQAP\*

**FIGURE 16****Nod2 Exon11, Wild type**

cagacatgag caggatgtgt ctaagggaca ggtgggcttc agtagactgg ctaactcctg

cagtctcttt aactggacag tttcaagagg aaaaccaaga atccttgaag ctcaccattg

tatcttcttt tccagGTGT CCAATAACTG CATCACCTAC CTAGGGGCAG AAGCCCTCCT

L S N N C I T Y L G A E A L L

GCAGGCCCTT GAAAGGAATG ACACCATCCT GGAAGTCTGg taaggccctt gggcaggcct

Q A L E R N D T I L E V

gttttagctc tccgaacctc agtttttcta tctgtaaaat ggggtgacgg gagagaggaa

tggcagaatt ttgaggatcc cttctgattc tgacattcag tgagaatgat tctgcatgtg

**Nod2 Exon11, Mutant**

cagacatgag caggatgtgt ctaagggaca ggtgggcttc agtagactgg ctaactcctg

cagtctcttt aactggacag tttcaagagg aaaaccaaga atccttgaag ctcaccattg

tatcttcttt tccagGTGT CCAATAACTG CATCACCTAC CTAGGGGCAG AAGCCCTCCT

L S N N C I T Y L G A E A L L

GCAGGCCCTT TGAAAGGAAT GACACCATCC TGGAAGTCTG gtaaggcccc tgggcaggcc

Q A P \*

tgtagct ctccgaacct cagtttttct atctgtaaaa tggggtgacg ggagagagga

atggcagaat ttgaggatc ccttctgatt ctgacattca gtgagaatga ttctgcatgt

g





Figure 17



**Figure 18**




Figure 19



# Figure 20

## SEQ ID NO: 53

atgggggaagagggtggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggacattctccgggttgga  
aatgtgctcgcaggagggttttcaggcacagaggagccagctgggtcgagctgctgggtctcaggggtccctggaaggcttcg  
agagtgtcctggactggctgctgctcctgggaggtcctcctcctgggaggactacgaggggttccacctcctgggcccagcct  
ctctcccacttgccaggcgccttctggacaccgtctggaataagggtacttgggcctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcacccaagctgcatggctgtcgggacccccactcgtccacccagcccagacc  
tgcagagtaccggccagccattgtcaggagggtccacagccatgtggagaacatgctggacctggcatgggagcgggggt  
ttcgtcagccagtatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagagggaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttcttctacaacatgttcaggaattaccagtccttggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagtcctcgcttctcagtcacctat  
gatggagcagagacgctctgcctggaggacatatacacagagaatgtcctggagggtctgggcatgtgggcatggctgg  
acccccgcagaagagcccagccacctggggtcggaggagctcttcagacccccctggccacctcaatgacgatgcggaca  
ctgtgctgggtgggtggggtgaggcggcagtgaggcaagagcacgctcctgcagcgggtgcacttgctgagggtgcagggcaa  
gacttcagggaatttctcttctcctccattcagctgcccggcagctgcagtgcatggccaaacctctctgtgcggac  
tctactctttgagcactgctgttggcctgatggttggtcaagaagacatcttccagttactccttgaccacctgaccgtg  
tctgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagacctgctcttcaaccttctgcagggaacctgctgaagaatgcccgcaagggtggtgaccagccgtcc  
ggccgctgtgtcggcgttctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggtcatcgagc  
tgtacctgagggaagcgccatcatgagccgggggtggcggaccgcctcatccgctgctccaagagacctcagccctgcac  
ggtttgtgccacctgcctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggttccc  
aaagaccactacagatatgtacctgctgattctgcagcattttctgctgcatgccacccccccagactcagcttccaag  
gtctgggacccagctcttctcggggcgccctccccacctcctgcacctgggcagactggctctgtggggcctgggcatg  
tgctgctacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggcttctcgtgctg  
tgccaaagggtgtcgtgccagggtacggcgccctggaattccttcacatcactttccagtgcttcttgcgcggttct  
acctggcactcagtgctgatgtgccaccagcttctgctcagacaccttcaatttggtggcaggccaggcaactcaccaatg  
gccagggtcctgcccacgatgtgcatccaggcctcggagggaaggacagcagcgtggcagcttctgctgcagaaggccga  
gccgcacaaccttcagatcacagcagccttctcggcagggtgtgttctccgggagcactggggcctgctggctgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtgggtgtctggcccgagcctccgcaagcacttcac  
tccatcccggcagctgcaccgggtgaggccaagagcgtgcatgccatgccgggttcatctggctcatccggagcctgta  
cgagtgcaggaggagcggctggctcggaagggtgcaggtggcctgaatgttgggcacctcaagttgacatttgcagtg  
tgggccccactgagtgctgctgcctggccttctgtgctgcagcacctccggcgcccggtggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgccttgcttgggtgtctgcaaggctctgtatttgcgcgataacaatat  
ctcagaccgaggcatctgcaagctcattgaatgtgctcttctcagcgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgcccggggagcccaagtgtggccgagggggtccgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtggtgacgagggggccaggccctggctgaagccttgggtgatcaccagagcttgaggtggctcagcc  
tggtggggaacaacattggcagtggtgggtgccccaggccttggaagccttgggtgatcaccagagcttgaggtggctcagcc  
tgccctggaggagaacctctccaggatgaaggtgtatgttctctgcagaaggactgaagaaaaattcaagtttgaaaaat  
cctgaagttgtccaataactgcatacctacctaggggcagaagccctcctgcaggcccttgaaaggatgacaccatcc  
tggaagtctggctccgagggaacactttctcttagaggaggttgacaagctcggctgcagggaaccagactcttgctt  
tga

# Figure 21

## SEQ ID NO: 54

atgggggaagaggggtggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggacattctccgggttggtga  
aatgtgctcgcaggagggttttcaggcacagaggagccagctgggtcgagctgctgggtctcagggtccctggaaggcttcg  
agagtgtcctggactgggtgctgtcctgggaggtcctctcctgggaggactacgaggggtccacctcctgggcccagcct  
ctctccacttgccaggcgcttcttgacacccgtctggaataagggtacttgggctgtcagaagctcatcgggctgc  
ccaagaagcccaggccgacagccagtcctcccaagctgcatggctgctgggaccccccactcgtccaccagcccagagacc  
tgcagagtccacggccagccattgtcaggaggctccacagccatgtggagaacatgctggacctggcatgggagcggggt  
ttcgtcagccagtgatgaatgtgatgaaatcaggttgcgcatcttcacaccgtcccagagggcaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttctctacaacatgttcaggaattaccagtcccatggccctgcctt  
tgggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagctcctcctcagtaacctat  
gatggagcagagacgctctgcctggaggacatatacacagagaatgtcctggaggtctgggagatgtgggcatggctgg  
atccccgcagaagagcccagccacctgggctggaggagctcttcagcaccctggccacctcaatgacgatgcccaga  
ctgtgctgggtgggtgggtgagggcggtcagtggaagagcacgctcctgcagcggtgcacttgctgtgggtgcaggggaa  
gactccaggaatttctcttctccattcagctgcggcagctgcagtgcatggccaaaccactctctgtgcggac  
tctactctttgagcactgctgttggcctgatgttggtaagaagacatcttcagttactccttgaccacctgaccgtg  
tctgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagacctgctcttcaaccttctgcagggcaacctgctgaagaatgcccgcgaagggtgggtgaccagccgtcc  
ggcgcgtgtgtcggcgttccctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggcatcgagc  
tgtacctgaggaagcgccatcatgagcccggggtggcgagccgcctcatccgcctgctccaagagacctcagccctgcac  
ggtttgtgccacctgcctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggggggggtcccc  
aaagaccactacagatatgtacctgctgattctcggggcccctccccacctcctgcacctgggcagactgggtctgtggggcctgggcatg  
gtctgggagccagctcttctcggggcccctccccacctcctgcacctgggcagactgggtctgtggggcctgggcatg  
tgctgctacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttctctgggtgcg  
tgccaaagggtgtcgtgccagggtacggcgccccctggaattccttcacatcactttccagtgcttctttgccgcgttct  
acctggcactcagtgctgatgtgccaccagctttgtcagacacctcttcaattgtggcaggccaggcaactcaccaatg  
gccaggtcctcctgccacgatgtgcatccaggcctcggagggaaggacagcagcgtggcagctttgctgcagaaggccga  
gccgcacaaccttcagatcacagcagccttctcggcagggtgtgttctccgggagcactggggcctgctggctgagtgc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtggtgtctggcccgagcctccgcaagcactccac  
tccatcccgcagctgcacgggtgagggcaagagcgtgcatgccatgcccggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggtgggtcggaagggtgcacgtggcctgaatgttgggcacctcaagttagcattttgagtg  
tgggccccactgagtgctgctgccttggtgtgtcagcacctccggcgcccggtggcctgagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgccttgcttgggtgtctgcaaggctctgtatttgccgataacaatat  
ctcagaccgaggtcctgcaagctcattgaatgtgctcttctcagcagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcatgcaggcagaacttcttggtcattgaggtggggaat  
aactacatcactgcccgcgggagcccaagtgctggcgagggggtccgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtggttgacgagggggccaggccctggctgaagccttgggtgatcaccagagcttgaggtgggtcagcc  
tggtggggaacaacattggcagtggtgggtgcccagccttggcactgatgtggcaagaacgtcatgctagaagaactc  
tgcttgaggagaaccatctccaggtgaaggtgtatgttctctgcagaaggactgaagaaaaattcaagttgaaaat  
cctgaagttgtccaataactgcatacctacctaaggggcagaagccctcctgcaggcccttgaaaggaatgacaccatc  
ctggaagtctgggtccgagggaacacttctctctagaggaggttgacaagctcggctgcagggaaccagactcttgct  
ttga

**Figure 22**  
**SEQ ID NO: 55**

MGEEGGSASH DEERASVLL GHSPGCEMCS QEAFQAQRSQ LVELLVSGSL EGFESVLDWL  
60  
LSWEVLSWED YEGFHLLGQP LSHLARRLLD TVWNKGTWAC QKLIAAAQEA QADSQSPKLH  
120  
GCWDPHSLHP ARDLQSHRPA IVRRLHSHVE NMLDLAWERG FVSQYECDEI RLPIFTSPQR  
180  
ARRLLDLATV KANGLAAFL QHVQELPVPL ALPLEAATCK KYMAKLRTTV SAQSRFLSTY  
240  
DGAETLCLED IYTENVLEVW ADVGMAGSPQ KSPATLGLEE LFSTPGHLND DADTVLVVGE  
300  
AGSGKSTLLQ RLHLLWAAGQ DFQEFLLVFP FSCRQLQCMA KPLSVRTLIF EHCCWPDVQG  
360  
EDIFQLLLDH PDRVLLTFDG FDEFKFRFTD RERHCSPTDP TSVQTLLENL LQGNLLKNAR  
420  
KVVTSRPAAV SAFLRKYIRT EFNKGFSEQ GIELYLRKRH HEPGVADRLI RLLQETSALH  
480  
GLCHLPVFSW MVSKCHQELL LQEGGSPKTT TDMYLLILQH FLLHATPPDS ASQGLGPSLL  
540  
RGRLPTLLHL GRLALWGLGM CCYVFSQQQL QAAQVSPDDI SLGFLVRAKG VVPGSTAPLE  
600  
FLHITFQCFE AAFYLALSAD VPPALLRHLEF NCGRPGNSPM ARLLPTMCIQ ASEGKDSSVA  
660  
ALLQKAEPHN LQITAAFLAG LLSREHWGLL AECQTSEKAL LRRQACARWC LARSLRKHFH  
720  
SIPPAAPGEA KSVHAMPFI WLIRSLYEMQ EERLARKAAR GLNVGHLKLT FCSVGPTECA  
780  
ALAFVLQHLR RPVALQLDYN SVGDIGVEQL LPCLGVCKAL YLRDNNISDR GICKLIECAL  
840  
HCEQLQKLAL FNNKLTGCA HSMAKLLACR QNFLALRLGN NYITAAGAQV LAEGLRGNTS  
900  
LQFLGFWGNR VGDEGAQALA EALGDHQLR WLSLVGNNIG SVGAQALALM LAKNVMLEEL  
960  
CLEENHLQDE GVCSLAEGK KNSSLKILKL SNNCITYLGA EALLOAP\*  
1007

**Figure 23**  
**SEQ ID NO: 56**

atgggggaagaggggtggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggacattctccgggttgatga  
aatgtgctcgcaggaggcttttcaggcacagaggagccagctggctcgagctgctggctcaggggtccctggaaggcttcg  
agagtgtcctggactggctgctgctcctgggaggtcctcctcctgggaggactacgagggttccacctcctgggccagcct  
ctctcccacttggccaggcgcttcttggaacacgtctggaataaagggtacttgggcctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcaccccaagctgcatggctgctgggacccccactcgctccaccagcccagagacc  
tgcagagtcaccggccagccattgtcaggaggctccacagccatgtggagaacatgctggacctggcagggagcgggt  
ttcgtcagccagtatgaatgtgatgaaatcaggttggcagatcttcacaccgtcccagagggaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttctctacaacatgttcaggaattaccagtccattggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacggtgtctgctcagtcctcctcagtacctat  
gatggagcagagacgctctgctcggaggacatatacacagagaatgtcctggaggctctgggcagatgtgggcatggctgg  
acccccgcagaagagcccagccacctgggcctggaggagctcttcagcacccctggccacctcaatgacgatgcggaca  
ctgtgctgggtgggtgaggcgggcagtgaggcaagagcacgctcctgcagcggctgcacttgcctggtgggtgcagggcaa  
gacttccaggaatttctcttcttctcctcctcagctgcggcgagctgcagtgcatggccaaaccactctctgtgcggac  
tctactctttgagcagctgtgtggcctgatgttggtcaagaagacatcttccagttactccttgaccacctgaccgtg  
tctgtttaacctttgatggcttgcagagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagacctgctcttcaaccttctgcagggaacctgtgaagaatgcccgcaagggtggtgaccagccgtcc  
ggccgctgtgtcggcgttctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggtcatcgagc  
tgtacctgaggaaagcgccatcatgagcccggggtggcggaccgctcatccgcctgctccaagagacctcagccctgcac  
ggtttgtgccacctgcctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgcctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcatttctgctgcatgccacccccagactcagcttcccaag  
gtctgggacccagctcttctcggggcgccctccccacctcctgcacctgggcagactggctctgtggggcctgggcatg  
tgtgctacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctctggcttctcgtgctg  
tgccaaagggtgtcgtgccagggtacggcgccctggaattccttcacatcacttccagtgcttcttgcgcgttct  
acctggcactcagtgctgatgtgccaccagcttgcctcagacacctcttcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgccacgatgtgcatccaggcctcggagggaaggacagcagcgtggcagcttgcctgcagaaggccga  
gccgcacaaccttcagatcacagcagccttctcggcagggtgtgtcccgggagcactggggcctgctggctgagtgcc  
agacatctgagaaggccctgctctggcgccaggcctgtgcccgtgggtgtctggcccgagcctccgcaagcacttccac  
tccatcccgcagctgcacgggtgaggccaagagcgtgcatgccatgccgggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggctggctcggaaggctgcagtggtgctggtgacactcaagttgacatttgcagtg  
tgggccccactgagtgctgctgccttggccttgcctgctgcagcactccggcgcccgctggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgccttgccttgggtgtctgcaaggctctgtatttgcgcgataacaatat  
ctcagaccgaggcatctgcaagctcattgaatgtgctcttactgcgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcagtcaggcagaacttcttggcatgaggctggggaat  
aactacatcactgcccggggagcccaagtgtggccgaggggctccgaggcaacacctccttgcagttcctgggattctg  
gggcaacagagtgggtgacgagggggccaggccctggctgaagccttgggtgatcaccagagcttgagggtggctcagcc  
tggtgggggaacaacattggcagtggtggtgcccagccttggcactgatgtggcagaagactgaagaaaaattcaagttgaaat  
tgccctggaggagaacctctccaggatgaaggtgtatgttctctcgcagaaggactgaagaaaaattcaagttgaaat  
cctgaagttgtccaataactgcatacctacctaggggcagaagccctcctgcaggcccttgaaaggaatgacaccatcc  
tggaagctcggctccgagggaacacttctctctagaggaggttgacaagctcggctgcagggaacaccagactcttgctt  
tga

## Figure 24

### SEQ ID NO: 57

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQVLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTSPQRARRLLDLATVKANGLAAFLQHVQELPVPLALPLEAATCKKYMALRRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFLHATPPDSASQGLGPSLLRGRLLPTLLHLGRLALWGLGM  
CCYVFSAAQLQAAQVSPDDISLGLVRAKGVVPGSTAPLEFLHITFQCFFAAYLALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLWRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGNLNVGHLKLTFCSVGPTCAALAFVLQHLRRPVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLDRDNNISDRGICKLIECALHCEQLQKLALFNNKLTGCAHSMAKLLACRQNFALRLGN  
NYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSRLWLSLVGNNIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

**Figure 25**  
**SEQ ID NO: 58**

atgggggaagaggggtggttcagcctctcacgatgaggaggaagagcaagtgtcctcctcggacattctccgggttgga  
aatgtgctcgcaggaggttttcaggcacagaggagcagctgggtcgagctgctgggtctcagggtccctggaaggcttcg  
agagtgtcctggactggctgctgtcctgggaggtcctctcctgggaggactacgagggcttccacctcctgggagcct  
ctctcccacttggccaggcgccttctggacaccgtctggaataagggtaacttgggctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcccccaagctgcatgggtgctgggacccccactcgtccaccagcccagagacc  
tgcagagtcccgccagccatttgtcaggaggtccacagccatgtggagaacatgctggacctggcatgggagcggggt  
ttcgtcagccagtatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagagggcaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgcttcttctacaacatgttcaggaattaccagtcctattggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagttaggaccacggtgtcgtcagtcctcgttctcagtacctat  
gatggagcagagacgctctgcctggaggacatatcacagagaatgtcctggaggtctgggagatgtgggcatggctgg  
acccccgcagaagagcccatcatgagcccggtgggctggaggagctcttcagcaccctggccacctcaatgacgatgcggaca  
ctgtgctgggtgggtgggtgaggcgggcagtggaagagcacgctcctgcagcggctgcacttgctgtgggctgcagggcaa  
gacttccaggaatttctcttcttcttccattcagctgcccgcagctgcagtgcatggccaaacctctctgtgcggac  
tctactctttgagcactgtgttggcctgatgttggtcaagaagacatcttccagttactccttgaccacctgaccgtg  
tccgttaacctttgatggcttggacgagtcaagttcaggttcagggttcaggatcgtgaacgccactgctccccgaccgaccc  
acctctgtccagacctgctcttcaaccttctgcagggcaacctgctgaagaatgcccgcagggtggtagaccgctcc  
ggcgctgtgtcggcgcttccctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacaggcatcgagc  
tgtaacctgaggaagcgcctcatgagcccggtggcgaccgctcatccgctgctccaagagacctcagccctgcac  
ggtttgtgccacctgcctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgatctgcagcatttctgctgcagtcacccccccagactcagcttcccaag  
gtctgggaccagctcttctcggggcgccctccccacctcctgcacctgggagactggctctgtgggctgggcatg  
tgctgctacgtgttctcagccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttccctgggtgcg  
tgccaaagggtgctgctgcccaggagtagggcgccccctggaattccttcacatcacttccagtgcttcttggcggttct  
acctggcactcagtgctgatgtgccaccagcttctgcagacacctcttcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgccacgatgtgcacccagcctcggagggaagagacagcagcgtggcagcttctgtgcagaaggccga  
gcccacaaaccttcagatcacagcagccttctggcagggtgtgtgtccgggagcactggggctgctgggtgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtgggtgtctggccgcagcctccgcaagcacttccac  
tccatcccgcagctgcaccgggtgaggccaagagcgtgcagtcacatgcccgggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggctggctcggaaggctgcacgtggcctgaatgttgggacacctcaagttgacatttgcagtg  
tgggccccactgagtgctgctgcccctggccttctgtgctgcagcacctccggcgcccggtggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgcttgccttgggtgtctgcaaggctctgtatttgcgcgataaacaat  
ctcagaccgaggcatctgcaagctcattgaatgtgctcttcaactgcaggaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcatgcaggcagaacttcttggcattgaggtggggaat  
aactacatcactgcccggggagcccaagtgctggccgaggggtccgaggcaacacctccttgagttcctgggattctg  
gcgcaacagagtgggtgacgagggggccaggccctggctgaagccttgggtgatcaccagagcttgaggtgggtcagcc  
tggtggggaaacaacattggcagtggtgggtgcccgaagccttggcactgatgctggcaagaacgtcatgtagaagaactc  
tgcttgaggagaaacatctccaggatgaaggtgtatgttctctcgcagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataactgcatcacctacctaggggcagaagccctcctgcaggcccttgaaaggaatgacaccatcc  
tggaggtcggctccgagggaacacttctctctagaggaggttgacaagctcggctgcagggaaccagactcttgctt  
tga

SNP	Allele	SNP Sequence*	AA Polymorphism	AA Location	cDNA Location				
SNP4	1	GGCAGATGTGGGATGGCTGGACCC; SEQ ID NO:70	P	P 268 S	nt 802				
	2	GGCAGATGTGGGATGGCTGGATCC; SEQ ID NO:71	S						
SNP20	1	AGACATCTGAGAAGGCCCTGCTCCGG; SEQ ID NO:72	R	R 702 W	nt 2104				
	2	AGACATCTGAGAAGGCCCTGCTCIGG; Seq ID NO:73	W						
SNP7	1	CTGCAGCACCTCCGGCGGCCCGTG; SEQ ID NO:74	V	V 793 M	nt 2377				
	2	CTGCAGCACCTCCGGCGGCCCATG; SEQ ID NO:75	M						
SNP18	1	TTGCAGAAGTTAGCTCTATTCAAC; SEQ ID NO:76	N	N 852 S	nt 2555				
	2	TTGCAGAAGTTAGCTCTATTACAGC; SEQ ID NO:77	S						
SNP25	1	ACTGACGGCTGTGCACACTCCATG; SEQ ID NO:78	M	M 863 V	nt 2587				
	2	ACTGACGGCTGTGCACACTCCGTG; SEQ ID NO:79	V						
SNP17	1	TGCAGTTCCTGGGATTCTGGGGC; SEQ ID NO:80	G	G 908 R	nt 2722				
	2	TGCAGTTCCTGGGATTCTGGGGC; SEQ ID NO:81	R						
SNP23	1	CACTGATGCTGGCAAGAAGACGTC; SEQ ID NO:82	V	V 955 I	nt 2863				
	2	CACTGATGCTGGCAAGAAGACATC; SEQ ID NO:83	I						
3020C Ins	1	GGGCAGAAAGCCCTCCTGCAGGGCCCT; SEQ ID NO:90	wild-type		nt 3020				
	2	GGGCAGAAAGCCCTCCTGCAGGGCCCT; SEQ ID NO:91	frameshift mutation	Δ33.					
		*Underlined is mutated base							
		*Nucleotide/amino acid numbers designate the positions in Nod2a as reported by Ogura et al. J. Biol. Chem. 276:4812 [2001]							
		AA = amino acid							
		SNP= single nucleotide polymorphism							

Figure 26

snp4	snp20	snp7	snp18	snp17	snp23	3020insC	comment
1	1	1	1	1	1	1	common
2	1	1	1	1	1	1	about 10% allele frequency in controls
2	2	1	1	1	1	1	about 4% allele frequency in controls
2	1	1	1	2	1	1	about 1-2% allele frequency in controls
2	1	1	1	1	1	2	about 3-4% allele frequency in controls
1	1	1	1	1	1	1	very rare: 4/400 patients are heterozygous; occurs on allele 1 of snp4
1	1	2	1	1	1	1	very rare: arms not working
2	1	1	2	1	1	1	very rare: arms working
1	1	1	1	1	2	1	very rare: arms working

## Figure 27



**Figure 28**  
**SEQ ID NO: 59**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQVLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTSPQRARRLLDLATVKANGLAAFLQHVVQELPVPLALPLEAATCKKYMAKLRRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRILIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLQEGGSPKTTTDMYLLILQHFLHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGM  
CCYVFSAAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAFYLAALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTCAALAFVLQHLRRPVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTGCAHSMAKLLACRQNFLALRLGN  
NYITAAGAQVLAEGLRGNTSLQFLGFWRNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAELLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

**Figure 29**  
**SEQ ID NO: 60**

atgggggaagagggtgggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcgacattctccgggttgga  
aatgtgctcgaggaggttttccaggcacagaggagccagctgggtcgagctgctgggtctcagggtccctggaaggttcg  
agagtgtcctggactggctgctgtcctgggagggtcctctcctgggaggactacgagggttccacctcctgggcccagcct  
ctctcccacttggccaggcgcttctggacaccgtctggaataagggtaacttgggcctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcctcccaagctgcatggctgctgggacccccactcgctccaccagcccagacc  
tgcagagtccacggccagccattgtcaggaggtccacagccatgtggagaacatgctggacctggcatgggagcgggt  
ttcgtcagccagtatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagagggcaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttcttacaacatgttcaggaattaccagtcctatggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccaggtgtctgctcagttctcgcttctcagttacat  
gatggagcagagacgctctgcctggaggacatatcacagagaatgtcctggaggtctgggcagatgtgggcatggctgg  
atccccgcagaagagcccagccaccctgggctggaggagctcttcagcaccctggccacctcaatgacgatgaggaca  
ctgtgctgggtgggtgggtgaggcgggagtggaagagcacgctcctgcagcggctgcacttgctgtgggtgcagggcaa  
gacttccaggaatttctcttcttctcctcattcagctgcccgcagctgcagtgcatggccaaaccactctctgtgaggac  
tctactctttgagcactgctgttggcctgatgttggtcaagaagacatcttcagttactccttgaccaccctgaccgtg  
tccgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctcccggaccgacccc  
acctctgtccagaccctgctcttcaaccttctgcagggcaacctgctgaagaatgcccgaagggtgggtgaccagcgtcc  
ggcgtgctgtgctggcgttctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggtcatcgagc  
tgtacctgaggaagcgccatcatgagccgggggtggcggaccgctcatccgcctgctccaagagacctcagccctgcac  
ggtttgtgccacctgctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcattttctgctgcatgccacccccccagactcagcttcccaag  
gtctgggaccagctcttctcggggcgccctccccacctcctgcacctgggcagactgggtctgtggggcctgggcatg  
tgctgctacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggcttcttgggtgcg  
tgccaaagggtgctgctgcccaggagtagcggcgccccctggaattccttcacatcacttccagtgcttcttggcgggtct  
acctggcactcagtgctgatgtgccaccagcttctgctcagacacctctcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgccacgatgtgcatccaggcctcggagggaaggacagcagcgtggcagctttgctgcagaaggccga  
gccgcacaaccttcagatcacagcagccttctggcagggtgtgtgtccgggagcactggggcctgctggctgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtggtgtctggcccgagcctccgcaagcacttccac  
tccatccccccagctgcaccgggtgaggccaagagcgtgcatgccatgccggggttcatctgggtcatccggagcctgta  
cgagatgcaggaggagcggctgggtcggaaggctgcagtggtgctgaatgttgggcacctcaagttgacatttgcagtg  
tgggccccactgagtgctgctgcccggccttctgtgctgcagcacctccggcgcccggtggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgcttgccttgggtgtctgcaaggctctgtatttgcgcgataacaatat  
ctcagaccgaggcatctgcaagctcattgaatgtgctcttctcagtgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgcccgggagcccaagtgtggtggcagggtcctcgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtggtgacgagggggccaggccctgggtgaagccttgggtgatcaccagagcttgaggtggctcagcc  
tggtggggaacaacattggcagtggtggtgcccagccttggcactgatgctggcaagaacgtcatgctagaagaactc  
tgcttgaggagaacctctccaggatgaaggtgtatgttctctcgcagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataactgcatcacctacctaggggcagaagccctcctgcaggcccttgaaaggaatgacaccatcc  
tggaagtctgctccgagggaacacttctctctagaggaggttgacaagctcgggtgcagggaaccagactcttgctt  
tga

**Figure 30**  
**SEQ ID NO: 61**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLI AAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTSPQRARRLLDLATVKANGLAAFLQLQHVQELPVPLALPLEAATCKKYM AKLRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGSPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKG FSEQGIELYLKRHHEPGVADRLLIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLQEGGSPKTTTDMYLLILQHFL LHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGM  
CCYVFSAAQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAFYLA LSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAAGLNVGHLKLTFCSVGPTCAALAFVLQHLRRPVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLT DGAHSMAKLLACRQNFALRLGN  
NYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

# Figure 31

## SEQ ID NO: 62

atgggggaagaggggtgggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggacattctccgggttgga  
aatgtgctcgcaggaggcttttcaggcacagaggagccagctgggtcgagctgctgggtctcaggggtccctggaaggcttcg  
agagtgtcctggactggctgctgtcctgggaggtcctcctcctgggaggactacgagggcttcacactcctgggcccagcct  
ctctcccacttggccaggcgcttcttggaacccgtctggaataagggtaacttgggctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcctcccaagctgcatgggtgctgggacccccactcgctccacccagcccagagacc  
tgcagagtccacggccagccattgtcaggaggctccacagccatgtggagaacatgctggacctggcatgggagcgggggt  
ttcgtcagccagtgatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagagggaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattgggtgccttccttctacaacatgttcagggaattaccagtcctattggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagtcctcgcttctcagtaacctat  
gatggagcagagacgctctgcctggaggacatatcacagagaatgtcctggaggctcgggagatgtgggcatgggtgg  
acccccgcagaagagcccatcatgagccgggtggcgaggagctcttcagcaccctggccacctcaatgacgatgggaca  
ctgtgctgggtgggtgggtgaggcgggcagtggaagagcacgctcctgcagcgggtgcacttgctgtgggtgcagggcaa  
gacttccaggaatttctcttctgtcttccattcagctgcccgcagctgcagtgcatggccaaacctctctgtgcggac  
tctactctttgagcactgctgttgccctgatgttggtcaagaagacatcttcagttactccttgaccacctgaccgtg  
tctgttaacctttgatgggtttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagacctgctcttcaaccttctgcagggcaacctgctgaagaatgcccgaagggtggtagccagccgtcc  
ggcgctgtgtcggcggttccctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggcatcgagc  
tgtacctcaggaagagcccatcatgagccgggtggcgaggagcctcatccgctgctccaagagacctcagccctgcac  
ggtttgtgccacctgcctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcattttctgctgcagtcacccccccagactcagcttcccaag  
gtctgggaccagctcttctcggggccgcctccccacctcctgcacctgggcagactgggtctgtggggcctgggcatg  
tgctgctacgtgttctcagccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttctcctgggtgcg  
tgccaaagggtgtcgtgccaggagtagggcgccctggaattccttcacatcacttccagtgcttcttggcggttct  
acctggcactcagtgctgatgtgccaccagcttctcagacacctcttcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgccacgatgtgcacccagcctcggagggaagagcagcagcgtggcagcttctgctcagaaggccga  
ggcgacacaccttcagatcacagcagccttctggcagggtgtgttccgggagcactggggcctgctgggtgagtgc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtgggtgtctggcccgagcctccgcaagcacttccac  
tccatcccgcagctgcaccgggtgaggccaagagcgtgcagtcacatgcccgggttcatctgggtcatccggagcctgta  
cgagatgcaggaggagcgggtgggtcgggaaggctgcacgtggcctgaatgttgggcacctcaagttgacattttgcagtg  
tgggccccactgagtgctgctccctggccttctgtgctgcagcacctccggcgggccatggccctgcagctggactacaac  
tctgtgggtgacattggcggtggagcagctgctgccttgcttgggtgtctgcaaggctctgtatttgcgcgataacaatat  
ctcagaccgaggcatctgcaagctcattgaatgtgctcttcaactgcgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgccgcgggagcccaagtgtggccgagggggtccgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtggtgacgagggggccaggccctgggtgaagccttgggtgatcaccagagcttgaggtgggtcagcc  
tggtggggaacaacattggcagtggtgggtgccaaagccttggcactgatgctggcaagaacgtcatgctagaagaactc  
tgcttgaggagaacctctccaggatgaaggtgtatgttctctcgagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataactgcatcacctacctaggggcagaagcctcctgcaggcccttgaaaggaatgacaccatcc  
tggaagtctggctccgagggaacacttctctctagaggaggttgacaagctcgggtgcagggaaccagactcttgctt  
tga

**Figure 32**  
**SEQ ID NO: 63**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQVLELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLI AAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERG  
FVSQYECDEIRLP IFTPSQRARRLLDLATVKANGLAAFL LQH VQELPVPLALPLEAATCKKYM AKLR TTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLEVFVFFSCRQLQCMAPLSVRTLLFEHCCWPDVQGEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHPEPGVADR LIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFL LHATPPDSASQGLGPSLLRGR LPTLLHLGR LALWGLGM  
CCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAAGRLNVGHLKLTFC SVGPTECAALAFVLQHLRRPMALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLT DGCAHSM AKLLACRQNFLALRLGN  
NYITAAGAVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

**Figure 33**  
**SEQ ID NO: 64**

atgggggaagaggggtggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggaattctccgggttgga  
aatgtgctcgcaggaggcttttcaggcacagaggagccagctggtcgagctgctggtctcaggggtccctggaaggcttcg  
agagtgtcctggactggctgctgtcctgggaggtcctcctgggaggactacgagggttccacctctggggccagcct  
ctctcccacttggccaggcgcttctggacaccgtctggaataagggtaacttgggcctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcacccaagctgcatggctgctgggacccccactcgctccaccagcccagagacc  
tgcagagtaccggccagccattgtcaggagggtccacagccatgtggagaacatgctggacctggcatgggagcggggt  
ttcgtcagccagtatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagagggaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttccttctacaacatgttcaggaattaccagtcctattggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagctctcgcttccctcagtacctat  
gatggagcagagacgctctgcctggaggacatatcacagagaatgtcctggagggtctgggcagatgtgggcatggctgg  
acccccgcagaagagcccagccaccctgggcctggaggagctcttcagcaccctggccacctcaatgacgatgggaca  
ctgtgctggtgggtgggtgaggcgggcagtggaagagcacgctctcgcagcggtgcacttgctgtggggtgcagggcaa  
gacttccaggaatttctcttctgtcttccattcagctgcccggcagctgcagtgcatggccaaacctctctgtgcccga  
tctactctttgagcactgctgttggcctgatgttggtcaagaagacatcttccagttactccttgaccacctgaccgtg  
tccgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagacctgctcttcaaccttctgcagggaacctgctgaagaatgcccgaagggtgggtaaccagcctcc  
ggcgcgtgtgtcgccgttccctcaggaagtacatccgacccaggttcaacctcaagggttctctgaacagggtcatcgagc  
tgtacctgaggaagcgcctcatgagccggggtggcggaccgctcatccgctgctccaagagacctcagccctgcac  
gggttggtgccacctgcctgtcttctcatggatgggtgccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcatttctgctgcatgccacccccccagactcagcttcccaag  
gtctgggaccagctcttctcggggccgcctccccacctcctgcacctgggcagactggctctgtggggcctgggcatg  
tgctgctacgtgttctcagcccagcagctccaggcagcacagggtcagccctgatgacatttctcttggcttccctgggtgcg  
tgccaaagggtgtcgtgccaggagtagggcgccctgggaattccttcacatcacttccagtgcttcttggcgcgttct  
acctggcactcagtgctgatgtgccaccagcttctgtcagacaccttcaattgtggcaggccaggcaactcaccaatg  
gccaggtccttcccacgatgtgcatccaggcctcggagggaaggacagcagcgtggcagctttgctgcagaaggccga  
gccgcacaaccttcagatcacagcagccttctggcagggtgtgtgtcccgaggacactggggcctgctgggtgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtgtgtgtggtgctggcccgagcctccgcaagcacttccac  
tccatcccgcagctgcaccgggtgaggccaagagcgtgcatgccatgcccggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggctggctcggaagggtgcagtggtgctgaatgtgggcacctcaagttgacatttgcagtg  
tgggccccactgagtgctgctccctggccttctgtgctgcagcacctccggcgcccggtggcctgagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgccttgccttgggtgtctgcaaggctctgtatttgccgataacaatat  
ctcagaccgaggtcatctgcaagctcattgaatgtgctcttcaactgcagcaattgcaagtttagctctattcagcaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgccgcccagcccaagtgctggccgaggggtccgaggcaacacctccttgagttcctgggttctg  
gggcaacagagtgggtgacgagggggcccaggccctggctgaagccttgggtgatcaccagagcttgaggtggctcagcc  
tggtggggaacaacattggcagtggtgggtgcccgaagccttggcactgatgctggcaagaacgtcatgctagaagaactc  
tgccctggaggagaacctctccaggatgaaggtgtatgttctctgcagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataactgcatcacctacctaggggcagaagccctcctgcaggcccttgaaagggaatgacaccatcc  
tggaagtctggctccgagggaacacttctctctagaggaggttgacaagctcggctgcagggaacaccagactcttgctt  
tga

**Figure 34**  
**SEQ ID NO: 65**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFAQQRSQVLELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLI AAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLLOHVQELPVPLALPLEAATCKKYM AKLR TTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVT SRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRILIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLLOEGGSPKTTTDMYLLILQHFL LHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGM  
CCYVFSAAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAYLALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLI RSLYEMQEERLARKAARGLNVGHLKLTFC SVGPTECAALAFVLQHLRRPVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFSNKLTDGCAHSMAKLLACRQNF LALRLGN  
NYITAAGAQLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGN NIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

**Figure 35**  
**SEQ ID NO: 66**

atgggggaagaggggtggttcagcctctcacgatgaggaggaagagcaagtgtcctcctcgacattctccgggttgta  
aatgtgctcgcaggaggcttttcaggcacagaggagccagctgggtcgagctgctgggtctcagggtccctggaaggcttcg  
agagtgtcctggactggctgctgtcctgggaggtcctctcctgggaggactacgagggtccacctcctgggcccagcct  
ctctcccacttggccaggcgcttcttgacaccgtctggaataagggtaacttgggcctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagctccccaagctgcatggctgctgggacccccactcgctccacccagcccagacc  
tgcagagtcccgccagccattgtcaggaggctccacagccatgtggagaacatgctggacctggcatgggagcgggtg  
ttcgtcagccagtatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagagggcaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttccttctacaacatgttcaggaattaccagctccattggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagtcctcgcttccctcagtacctat  
gatggagcagagacgctcctgctggagacatatacacagagaatgtcctggaggtctgggcagatgtgggcatggctgg  
acccccgcagaagcgcacccctgggctggaggagctcttcagcaccctggccacctcaatgacgatgcccagaca  
ctgtgctgggtgggtgggtgagggggcagtgccaagagcacgctcctgcagcggctgcacttgctgtgggctgcagggcaa  
gacttcaggaatttctcttcttctccattcagctgcccgcagctgcagtgcatggccaaacctctctgtgcccagc  
tctactctttgagcactgctgttggcctgatgttggtcaagaagacatcttcaggttaactccttgaccacctgaccgtg  
tccgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagacctgctcttcaaccttctgcagggcaacctgctgaagaatgcccgcagggtgggtgaccagcctcc  
ggcgctgtgtcggttccctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggtcagc  
tgtacctgaggaagcgcacatcatgagcccgggtggcgaccgcctcatccgcctgctccaagagacctcagccctgcac  
ggtttgtgccacctgctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgatctgcagcatttctgctgcatgccacccccagactcagcttcccaag  
gtctgggacccagctctctcggggccgcctccccacctcctgcacctgggcagactggctctgtggggcctgggcatg  
tgctgtacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttccctgggtgcg  
tgccaaagggtgtcgtgccaggagtagggcgccctggaattccttcacatcactttccagtgcttcttggccggttct  
acctggcactcagtgctgatgtgccaccagctttgctcagacacctcttcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgcccacgatgtgcatccaggcctcggaaggaaaggacagcagcgtggcagcttctgtgcagaaggccga  
gcccacaaaccttcagatcacagcagccttccctggcagggtgtgtgtccgggagcactggggcctgctggctgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtggtgtctggccgcagcctccgcaagcacttccac  
tccatcccgcagctgcaccgggtgaggccaagagcgtgcatgccatggccgggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggctgggtcggaaggctgcacgtggcctgaatgttgggcacctcaagttgacatttgcagtg  
tgggccccactgagtgctgcccctggccttctgtgtgcagcacctccggcgcccggtggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgccccttgggtgtctgcaaggctctgtatttgcgcgataacaatat  
ctcagaccgaggtcatctgcaagctcattgaatgtgctcttctcagtgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgccgcgggagcccaagtgtggccgaggggtccgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtggtgacgagggggccaggccctgggtgaagccttgggtgatcaccagagcttgaggtgggtcagcc  
tggtggggaacaacattggcagtggtgggtgcccgaagccttggcactgatgctggcaagaacatcatgtagaagaactc  
tgccctggaggagaacctctccaggtatgaaggtgtatgttctctgcagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataactgcatcacctacctaggggcagaagccctcctgcaggcccttgaaagggaatgacaccatcc  
tggaagttcgggtccgagggaacactttctctctagaggaggttgacaagctcgggtgcagggaaccagactcttgctt  
tga



**Figure 36**  
**SEQ ID NO: 67**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFAQRSQVLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLI AAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTSPQRARRLLDLATVKANGLAAFLQHVQELPVPLALPLEAATCKKYM AKLRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHHEPGVADRILRLQETSALH  
GLCHLPVFSWMVSKCHQELLQEGGSPKTTTDMYLLILQHFLHATPPDSASQGLGPSLLRGRPLTLLHLGRLALWGLGM  
CCYVFSQAQQLQAAQVSPDDISLGFLVRAGVVPGSTAPLEFLHITFCFFA AFYLALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFC SVGPTCAALAFVLQHLRRPVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLT DGC AHSMAKLLACRQNFLALRLGN  
NYITAAGAQLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNIMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL

\*

**Figure 37**  
**SEQ ID NO: 68**

atgggggaagaggggtgggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggaacattctccgggttgga  
aatgtgctcgcaggaggcttttcaggcacagaggagccagctggctcgagctgctggctcaggggtccctggaaaggcttcg  
agagtgtcctggactggctgctgtcctgggaggtcctcctcctgggaggactacgagggcttcacacctcctgggcccagcct  
ctctcccacttgagcaggcgcccttctggacaccgtctggaataagggtaacttgggcctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcacccaagctgcatggctgctgggacccccactcgctccaccagcccagagacc  
tgcagagtccacggccagccattgtcaggaggctccacagccatgtggagaacatgctggacctggcatgggagcgggggt  
ttcgtcagccagtatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagagggaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttccttctacaacatgttcaggaattaccagtcaccttggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagtcctcgcttcctcagtacctat  
gatggagcagagacgctctgcctggaggacatatcacagagaatgtcctgaaggctcctgggaggtcctgggcagatgtgggcatggctgg  
acccccgagaagagcccagccacccctgggctggaggagctcttcagcaccctggccacctcaatgacgatgaggaca  
ctgtgctgggtgggtgggtgaggcgggcagtggaagagcacgctcctgcagcggctgcacttgcctgtgggtgcaggggcaa  
gacttccaggaatttctcttcttctccttcattcagctgcgggcagctgcagtgcatggccaaaccactctctgtgcggac  
tctactctttgagcactgctgttggcctgatgttggtcaagaagacatcttcagttactccttgaccacctgaccgtg  
tcctgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagacctgctcttcaaccttctgcagggaacctgctgaagaatgcccgcaagggtggtagcagccgtcc  
ggccgctgtgtcggcgttcctcaggaagtacatccgcaccgagtcaacctcaagggttctctgaacagggcatcgagc  
tgtacctgaggaagcgcacatcatgagcccggtggcgagccgctcatccgcctgctccaagagacctcagccctgcac  
gggttggtgccacctgcctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcatttctgctgcagccacccccagactcagcttcccaag  
gtctgggaccagctcttctcggggcgccctccccacctcctgcacctgggcagactggctctgtggggcctgggcatg  
tgctgctacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttctctgggtgcg  
tgccaaagggtgtcgtgccaggagtagggcgccctggaattccttcacatcactttccagtgcttcttgcgcgttct  
acctggcactcagtgctgatgtgccaccagcttctcagacacctcttcaattgtggcaggccaggaactcaccaatg  
gccaggctcctgccacgatgtgcatccaggcctcggagggaagagacagcagcgtggcagctttgctgcagaaggccga  
gccgcacaaccttcagatcacagcagccttcctggcagggtgtgtgtccgggagcactggggcctgctggctgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgtggtgtctggcccgagcctccgcaagcacttccac  
tccatcccgccagctgcaccgggtgaggccaagagcgtgcatgccatgcccggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggctggctcggaaggctgcacgtggcctgaatgttgggcacctcaagttgacattttgcagtg  
tgggccccactgagtgctgctgcctggccttctgtgctgcagcactccggcgcccgctggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgccttgcttgggtgtctgcaaggctctgtatttgccgataacaatat  
ctcagaccgagcatctgcaagctcattgaatgtgctcttcactgcgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccgtggctaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgccgcccagcccaagtgtgcccagggggctccgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtgggtgacgagggggccaggccctggctgaagccttgggtgatcaccagagcttgaggtggctcagcc  
tggtggggaacaacattggcagtggtgggtgcccgaagccttggcactgatgctggcaagaacgtcatgctagaagaactc  
tgcttgaggagaacctctccaggatgaagggtgatgttctctcgcagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataactgcacacctaggggcagaagcctcctgcaggcccttgaaaggaatgacaccatcc  
tggaagtctggctccgagggaacacttctctctagaggaggttgacaagctcggctgcagggacaccagactcttgctt  
tga

**Figure 38**  
**SEQ ID NO: 69**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLI AAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLQLHVQELPVPLALPLEAATCKKYMALRRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHPEPGVADRLLIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLQEGGSPKTTTDMYLLILQHFLHATPPDSASQGLGPSLLRGRLLPTLLHLGRLLALWGLGM  
CCYVFSAAQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFCFFAIFYLALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTCAALAFVLQHLRRPVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTGCAHSVAKLLACRQNFLALRLGN  
NYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSRLWLSLVGNNIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLCRDTRLLL

\*

# Figure 39

## SEQ ID NO: 84

atgggggaagaggggtggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggacattctccgggttgga  
aatgtgctcgcaggaggttttcaggcacagaggagccagctgggtcgagctgctgggtctcagggtccctggaaggcttcg  
agagtgtcctggactggctgctgtcctgggaggtcctctcctgggaggactacgagggcttcacctcctgggccagcct  
ctctccacttgggcaggcgcttcttgacaccgtctggaataagggtaactgggctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagctccccaagctgcatggctgctgggacccccactcgtccacccagcccagagacc  
tgcagagtccacggccagccattgtcaggaggctccacagccatgtggagaacatgctggacctggcatgggagcgggt  
ttcgtcagccagatgaatgtgatgaaatcagggtgcccgtcttcacaccgtcccagagggcaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttcttacaacatgttcagggaattaccagtcctattggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagctctcgttctcagtacctat  
gatggagcagagacgctctgcctggaggacatatacacagagaatgtcctggaggtctgggcagatgtgggcagtggtgg  
atccccgcagaagagcccagccaccctgggctggaggagctcttcagcaccctggccacctcaatgacgatgaggaca  
ctgtgctgggtgggtgggtgagggcggtgaggaagagcacgctcctgcagcggtgcacttgctgtgggctgcagggcaa  
gacttcagggaatttctcttcttctccattcagctgcccgcagctgcagtgcatggccaaacctctctgtgaggac  
tctactctttgagcactgctgttggcctgatgttggtcaagaagacatcttcaggttactccttgaccacctgaccgtg  
tcctgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacggcactgctccccggcagcccc  
acctctgtccagacctgctctcaaccttctgcagggcaacctgctgaagaatgcccgcaaggctgggacagcgctcc  
ggcgcctgtgtcggttctcctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggcatcgagc  
tgtacctgaggaagcgccatcatgagccggggtggcgaccgctcatccgctgctccaagagacctcagccctgcac  
ggtttgtgccacctgctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcatttctgctgcatgccacccccccagactcagcttcccaag  
gtctgggacccagctctcttcggggcgctccccacctcctgcacctgggcagactggctctgtgggctgggcatg  
tgctgtcagtggttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttctctgggtgcg  
tgccaaagggtgtcgtgccaggagtagcgccccctggaattccttcacatcactttccagtgcttcttgccgcttct  
acctggcactcagtgctgatgtgccaccagctttgctcagacacctcttcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgccacgatgtgcatccaggcctcgaggaggaaaggacagcagcgtggcagctttgctgcagaaggccga  
gccgcacaaccttcagatcacagcagccttctggcagggtgtgtgtccgggagcactggggcctgctgggtgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgccgctgggtgtctggcccgagcctccgcaagcacttccac  
tccatcccgccagctgcacgggtgaggccaagagcgtgcatgccatgccgggttcatctgggtcatccggagcctgta  
cgagatgcaggaggagcggtgggtcggaaggctgcagtggtgctgaatgttgggcacctcaagttgacattttgcagtg  
tgggccccactgagtgctgctgcttggccttctgtgctgcagcacctccggcgccgctggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgcttgccttgggtgtctgcaaggctctgtatttgccgataacaatat  
ctcagaccgaggtcatctgcaagctcattgaatgtgcttctcagtgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcatgcaggcagaacttcttggtattgaggtgggtgagc  
aactacatcactgccgaggagcccaagtgctggcgagggggtccgaggcaacacctccttgagttcctgggtattctg  
gagcaacagagtggtgacgagggggccaggccctggctgaagccttggtgatcaccagagcttgaggtgggtcagcc  
tggtggggaacaacattggcagtggtgggtgcccaggccttggtgactgatgctggcaagaacgtcatgctagaagaactc  
tgcttgaggagaacctctccaggatgaagtgatgttctctcgcagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataaactgcacacctagggggcagaagccctcctgcaggcccttgaaaggaatgacaccatcc  
tggaagcttggtccgagggaacaccttctctctagaggaggttgacaagctcggtgcagggaacaccagactcttgctt  
tga

**Figure 40**  
**SEQ ID NO: 85**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAQFQAQRSQVLELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTSPQRARRLLDLATVKANGLAAFLQHVQELPVPLALPLEAATCKKYMALRRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGSPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLLVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLFNLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLQEGGSPKTTTDMYLLILQHFLHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGM  
CCYVFSQQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAYLALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTCAALAFVLQHLRRPVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTGCAHSMALLACRQNFALRLGN  
NYITAAGAQVLAEGLRGNTSLQFLGFWRNRVGDEGAQALAEALGDHQSRLWLSLVGNNGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

# Figure 41

## SEQ ID NO: 86

atgggggaagaggggtgggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggacattctccgggttgatga  
aatgtgctcgcaggagggcttttcaggcacagaggagccagctgggtcgagctgctgggtctcagggtccctggaaggcttcg  
agagtgtcctggactgggtgctgtcctgggaggtcctctcctgggaggactacgagggctccacctcctgggcccagcct  
ctctcccacttgccaggcgccttctggacaccgtctggaataagggtaacttgggcctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcccccaagctgcatgggtgctgggacccccactcgctccacccagcccgagacc  
tgcagagtcccgccagccattgtcaggaggtccacagccatgtggagaacatgctggacctggcatgggagcgggggt  
ttcgtcagccagtatgaatgtgatgaaatcagggtgcccgtcttcacaccgtcccagagggcaagaaggctgcttgatct  
tgccacgggtgaaagcgaatggattgggtgccttccttctacaacatgttcaggaattaccagtcccatggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagtcctcgcttctcagttacctat  
gatggagcagagacgctctgctggaggacatatacacagagaatgtcctggaggctctgggagatgtgggagcgggtg  
atcccgcagaagagcccacccctgggaggtccttcagcaccctggccacctcaatgacgatgcccagaca  
ctgtgctgggtgggtgggtgaggcgggagtggaagagcacgctcctgcagcgggtgcacttgctgtgggtgcagggcaa  
gacttccaggaatttctcttcttctccattcagctgcccgcagctgcagtgcatggccaaccactctctgtgcggac  
tctactctttgagcactgctgttggcctgatgttggtcaagaagacatcttccagttactccttgaccacccctgaccgtg  
tcctgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctgtgtccagacctgctcttcaaccttctgcagggcaacctgctgaagaatgcccgcgaagggtggtagccagccgtcc  
ggcgcgtgtgtcggcgttctcaggaagtacatccgcacaggttcaacctcaagggttctctgaacagggcatcgagc  
tgtacctgaggaagcccacatcatgagccggggtggcggagcctcatccgcctgctccaagagacctcagccctgcac  
ggtttgtgccacctgctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcatttctgctgcatgccacccccccagactcagcttcccaag  
gtctgggacccagctcttctcggggccgctccccaccctcctgcacctgggcagactggctctgtggggcctgggcatg  
tgctgtacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttctcgtggtgcg  
tgccaaagggtgtcgtgccaggagtagcgcccccctggaattccttcacatcactttccagtgcttcttggccggttct  
acctggcactcagtgctgatgtgccaccagcttctgctcagacaccttcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgccacgatgtgcatccaggcctcggagggaaggacagcagcgtggcagcttctgtgcagaaggccga  
gcccgcacaaccttcagatcacagcagccttctggcagggtgtgtgtccgggagcactggggcctgctgggtgagtgcc  
agacatctgagaaggccctgctccggcgccaggcctgtgcccgcgtgggtgtctggcccgcagcctccgcaagcactccac  
tccatcccgcagctgcaccgggtgaggccaagagcgtgcatgccatgcccggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggctggctcggaaaggctgcacgtggcctgaatgttgggcacctcaagttgacattttgcagtg  
tgggccccactgagtgctgcccctggcctttgtgctgcagcacctccggcgcccggtggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgcttgccttgggtgtctgcaaggctctgtatttgcgcgataacaatat  
ctcagaccgagggcatctgcaagctcattgaatgtgctcttactgcgagcaattgcagaagttagctctattcagcaaca  
aattgactgacggctgtgcacactccatggctaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgccgcgggagcccaagtgctggccgagggggtccgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtggtgacgagggggccaggccctggctgaagccttgggtgatcaccagagcttgaggtgggtcagcc  
tggtggggaacaacattggcagtggtgggtgcccgaagccttggcactgatgctggcaagaacgtcatgctagaagaactc  
tgcctggaggagaacctctccaggatgaaggtgatgttctctgcagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataaactgcatacctacctaggggcagaagccctcctgcaggcccttgaaagggaatgacacccatcc  
tggaggtctggctccgaggggaacactttctcttagaggaggttgacaagctcggctgcagggaacaccagactcttgctt  
tga

**Figure 42**  
**SEQ ID NO: 87**

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQVLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLI AAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTSPQRARRLLDLATVKANGLAAFLQH VQELPVPLALPLEAATCKKYM AKLRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGSPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEGGIELYLKRHHHEPGVADRLLIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFL LHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGM  
CCYVFS AQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFCFFAAFY LALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTCAALAFVLQHLRRPV ALQLDYN  
SVGDIGVEQLLPCLGVCKALYL RDNNISDRGICKLIECALHCEQLQKLALFSNKLTGCAHSMAKLLACRQNFLALRLGN  
NYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

**Figure 43**  
**SEQ ID NO: 88**

atgggggaagaggggtgggttcagcctctcacgatgaggaggaaagagcaagtgtcctcctcggaattctccgggttgga  
aatgtgctcgcaggaggcttttcaggcacagaggagccagctggctcgagctgctgggtctcagggtccctggaaggcttcg  
agagtgtcctggactggctgctgtcctgggaggtcctctcctgggaggactacgagggctccacctcctgggcccagcct  
ctctcccacttggccaggcgccttcttggaaccgtctggaataagggtaacttgggctgtcagaagctcatcgcggtgc  
ccaagaagcccaggccgacagccagtcctcccaagctgcatggctgctgggacccccactcgctccaccagcccgagacc  
tgcagagtcaacggccagccattgtcaggaggtccacagccatgtggagaacatgctggacctggcatgggagcgggt  
ttcgtcagccagtatgaatgtgatgaaatcaggttgccgatcttcacaccgtcccagaggggaagaaggctgcttgatct  
tgccacggtgaaagcgaatggattggctgccttccttctacaacatgttcaggaattaccagtccttggccctgcctt  
tggaagctgccacatgcaagaagtatatggccaagctgaggaccacgggtgtctgctcagtcctcgcttctcagtacctat  
gatggagcagagacgctctgcctggaggacatatacacagagaatgtcctggaggtctgggagatgtgggcatggctgg  
atccccgcagaagagcgcacccctgggaggtccttcagcaccctggccacctcaatgacgatgcccagaca  
ctgtgctgggtgggtgggtgaggcgggcagtggaagagcacgctcctgcagcgggtgcacttgcctggtgggtgcagggcaa  
gacttccaggaatttctcttcttcttccattcagctgcccgcagctgcagtgcatggccaaaccactctctgtgcggac  
tctactctttgagcactgctgttggcctgatgttggtcaagaagacatcttccagttactccttgaccaccctgaccgtg  
tcctgttaacctttgatggctttgacgagttcaagttcaggttcacggatcgtgaacgccactgctccccgaccgacccc  
acctctgtccagaccctgctcttcaaccttctgcagggcaacctgctgaagaatgcccgaagggtgtagccagccgctc  
ggcgcgtgtgctggcgttccctcaggaagtacatccgcaccgagttcaacctcaagggttctctgaacagggcatcgagc  
tgacctgcaggaagcgcacatgagcccggggtggcgagccctcatccgctgctccaagagacctcagccctgcac  
ggtttgtgccacctgcctgtcttctcatggatgggtgtccaaatgccaccaggaactgttgctgcaggaggggggtcccc  
aaagaccactacagatatgtacctgctgattctgcagcatttctgctgcatgccacccccagactcagcttcccaag  
gtctgggacccagctcttctcggggccgcctccccaccctcctgcacctgggcagactggctctgtggggcctgggcatg  
tgctgctacgtgttctcagcccagcagctccaggcagcacaggtcagccctgatgacatttctcttggttctctgggtgcg  
tgccaaagggtgtcgtgccaggagtagggcgccctggaattccttcacatcactttccagtgcttcttggcgcgttct  
acctggcactcagtgctgatgtgccaccagcttgcctcagacacctcttcaattgtggcaggccaggcaactcaccaatg  
gccaggctcctgcccacgatgtgcacccagcctcggagggaaggacagcagcgtggcagcttgcctgcagaaggccga  
gcccacaaaccttcagatcacagcagccttctggcagggtgtgtgtccgggagcactggggcctgctggctgagtgcc  
agacatctgagaaggccctgctctggcgccaggcctgtgcccgcgtgggtgtctggcccgcagcctccgcaagcactccac  
tccatccccgcagctgcaccgggtgaggccaagagcgtgcatgccatgcccgggttcatctggctcatccggagcctgta  
cgagatgcaggaggagcggctggctcggaaggctgcacgtggcctgaatgttgggcacctcaagttgacattttgcagtg  
tgggccccactgagtgctgctgcctggccttgcctgctgcagcactccggcgggcccggtggccctgcagctggactacaac  
tctgtgggtgacattggcgtggagcagctgctgccttgcttgggtgtctgcaaggctctgtatttgcgcgataaacaat  
ctcagaccgaggcatctgcaagctcattgaatgtgctcttctcactgcgagcaattgcagaagttagctctattcaacaaca  
aattgactgacggctgtgacactccatggctaaagctccttgcatgcaggcagaacttcttggcattgaggctggggaat  
aactacatcactgcccggggagcccaagtgctggccgaggggtccgaggcaacacctccttgagttcctgggattctg  
gggcaacagagtggtgacgagggggccaggccctggctgaagccttgggtgatcaccagagcttgaggtgggtcagcc  
tggtggggaacaacattggcagtggtgggtgcccgaagccttggcactgatgctggcaagaacgtcatgtagaagaactc  
tgcttgaggagaaacatctccaggatgaaggtgatgttctctcgagaaggactgaagaaaaattcaagtttgaaaat  
cctgaagttgtccaataactgcatcacctacctaggggcagaagccctcctgcaggcccttgaaaggaatgacaccatcc  
tggaggtcggctccgagggaacactttctctctagaggaggttgacaagctcggctgcagggaaccagactcttgctt  
tga



**Figure 44**  
**SEQ ID NO: 89**

MGEEGGSASHDEERASVLLGHSPGCEMCSQEAFAQRSQQLVELLVSGSLEGFESVLDWLLSWEVLWEDYEGFHLLGQP  
LSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERG  
FVSQYECDEIRLPIFTSPQRARRLLDLATVKANGLAAFLQHVQELPVPLALPLEAATCKKYMALRTTVSAQSRFLSTY  
DGAETLCLEDIYTENVLEVWADVGMAGSPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQ  
DFQEFLFVFPFSCRQLQCMAPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP  
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALH  
GLCHLPVFSWMVSKCHQELLQEGGSPKTTTDMYLLILQHFLHATPPDSASQGLGPSLLRGRPLTLLHLGRLALWGLGM  
CCYVPSAQQQAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAYLALSADVPPALLRHLFNCGRPGNSPM  
ARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLWRQACARWCLARSLRKHFH  
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSSVGPTECAALAFVLQHLRRPVVALQLDYN  
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTGCAHSMAKLLACRQNFALRLGN  
NYITAAGAVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEEL  
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL  
\*

## SEQUENCE LISTING

5 <110> Nunez, Gabriel  
 Inohara, Naohiro  
 Ogur, Yasunori  
 10 Cho, Judy  
 Nicolae, Dan L  
 15 Bonen, Denise

<120> NOD2 Nucleic Acids and Proteins  
 20

<130> UM-06646  
 25

<160> 99  
 30

<170> PatentIn version 3.1

35 <210> 1  
 <211> 4485  
 <212> DNA  
 40 <213> Homo sapiens

45 <400> 1  
 gtagacagat ccagggtcac cagtcctgtg ccactgggct tttggcggtc tgcacaaggc 60  
 ctacccgcag atgccatgcc tgctcccca gcctaattggg ctttgatggg ggaagagggt 120  
 50 gggttcagcct ctcacgatga ggaggaaaga gcaagtgtcc tcctcggaca ttctccgggt 180  
 tgtgaaatgt gctcgcagga ggcttttcag gcacagagga gccagctggt cgagctgctg 240  
 gtctcagggt ccctggaagg cttcgagagt gtctggact ggctgctgtc ctgggagggtc 300  
 55 ctctcctggg aggactacga gggcttcac ctctgggcc agcctctctc ccacttggcc 360

	aggcgcccttc tggacaccgt ctggaataag ggtacttggg cctgtcagaa gctcatcgcg	420
	gctgccccaaag aagcccaggc cgacagccag tcccccaagc tgcattggctg ctgggacccc	480
5	cactcgctcc acccagcccc agacctgcag agtcaccggc cagccattgt caggaggctc	540
	cacagccatg tggagaacat gctggacctg gcatgggagc ggggtttcgt cagccagtat	600
10	gaatgtgatg aaatcagggt gccgatcttc acaccgtccc agagggcaag aaggctgctt	660
	gatcttgcca cggtgaaagc gaatggattg gctgccttcc ttctacaaca tgttcaggaa	720
	ttaccagtcc cattggccct gcctttggaa gctgccacat gcaagaagta tatggccaag	780
15	ctgaggacca cgggtgtctgc tcagtctcgc ttcttcagta cctatgatgg agcagagacg	840
	ctctgcctgg aggacatata cacagagaat gtcctggagg tctgggcaga tgtgggcatg	900
20	gctggacccc cgcagaagag cccagccacc ctgggcctgg aggagctctt cagcaccctt	960
	ggccacctca atgacgatgc ggacactgtg ctggtggtgg gtgaggcggg cagtggcaag	1020
	agcacgctcc tgcagcggct gcacttgctg tgggctgcag ggcaagactt ccaggaattt	1080
25	ctctttgtct tccattcag ctgccggcag ctgcagtgca tggccaaacc actctctgtg	1140
	cggactctac tctttgagca ctgctgttg cctgatgttg gtcāagaaga catcttcag	1200
30	ttactccttg accacctga cegtgtcctg ttaacctttg atggctttga cgagttcaag	1260
	ttcaggttca cggatcgtga acgccactgc tccccgaccg accccacctc tgtccagacc	1320
	ctgctcttca acctctgcga gggcaacctg ctgaagaatg cccgcaagggt ggtgaccagc	1380
35	cgtccggccg ctgtgtcggc gttcctcagg aagtacatcc gcaccgagtt caacctcaag	1440
	ggcttctctg aacagggcat cgagctgtac ctgaggaagc gccatcatga gcccggggtg	1500
40	gcggaccgcc tcatccgcct gctccaagag acctcagccc tgcacggttt gtgccacctg	1560
	cctgtcttct catggatggt gtccaaatgc caccaggaac tgttgctgca ggaggggggg	1620
	tccccaaaga ccactacaga tatgtacctg ctgattctgc agcattttct gctgcatgcc	1680
45	acccccccag actcagcttc ccaaggctct ggaccagtc ttcttcgggg ccgcctcccc	1740
	acctctctgc acctgggcag actggctctg tggggcctgg gcatgtgctg ctacgtgttc	1800
50	tcagcccagc agctccaggc agcacaggtc agccctgatg acattttctt tggttctctg	1860
	gtgcgtgcca aagggtgctg gccagggagt acggcgcccc tggaattcct tcacatcact	1920
	ttccagtgtt tctttgccgc gttctacctg gcactcagtg ctgatgtgcc accagctttg	1980
55	ctcagacacc tcttcaattg tggcaggcca ggcaactcac caatggccag gtcctgccc	2040
	acgatgtgca tccaggcctc ggagggaaag gacagcagcg tggcagcttt gctgcagaag	2100

	gccgagccgc acaaccttca gatcacagca gccttcctgg cagggctggt gtcccgaggag	2160
5	cactggggcc tgctggctga gtgccagaca tctgagaagg ccctgctccg gcgccaggcc	2220
	tgtgcccgt ggtgtctggc cgcagcctc cgcaagcact tccactccat cccgccagct	2280
	gcaccgggtg aggccaagag cgtgcatgcc atgccgggt tcatctggct catccggagc	2340
10	ctgtacgaga tgcaggagga gcggtggct cggaaggctg cacgtggcct gaatgttggg	2400
	cacctcaagt tgacattttg cagtgtgggc cccactgagt gtgctgccct ggcctttgtg	2460
15	ctgcagcacc tccggcggcc cgtggccctg cagctggact acaactctgt ggggtgacatt	2520
	ggcgtggagc agctgctgcc ttgccttggg gtctgcaagg ctctgtattt gcgcgataac	2580
	aatatctcag accgaggcat ctgcaagctc attgaatgtg ctcttactg cgagcaattg	2640
20	cagaagttag ctctattcaa caacaaattg actgacggct gtgcacactc catggctaag	2700
	ctccttgcag gcaggcagaa cttcttggca ttgaggctgg ggaataacta catcactgcc	2760
25	gcgggagccc aagtgtggc cgaggggctc cgaggcaaca cctccttgca gttcctggga	2820
	ttctggggca acagagtggg tgacgagggg gccaggccc ttggtgaagc cttgggtgat	2880
	caccagagct tgagggtggc cagcctggtg gggaacaaca ttggcagtgt ggggtgccc	2940
30	gccttggcac tgatgctggc aaagaacgtc atgctagaag aactctgcct ggaggagaac	3000
	catctccagg atgaagggt atgttctctc gcagaaggac tgaagaaaaa ttcaagttt	3060
35	aaaatcctga agttgtccaa taactgcac acctacctag gggcagaagc cctcctgcag	3120
	gcccttgaaa ggaatgacac catcctggaa gtctggctcc gagggaaacac tttctctcta	3180
	gaggagggtg acaagctcgg ctgcagggac accagactct tgctttgaag tctccgggag	3240
40	gatgttcgtc tcagtttggt tgtgagcagg ctgtgagttt gggcccaga ggctgggtga	3300
	catgtgttg cagcctcttc aaaatgagcc ctgtcctgcc taaggctgaa cttgttttct	3360
45	gggaacacca taggtcacct ttattctggc agaggaggga gcatcagtgc cctccaggat	3420
	agacttttcc caagcctact tttgccattg acttcttccc aagattcaat cccaggatgt	3480
	acaaggacag cccctcctcc atagtatggg actggcctct gctgacctc ccaggcttcc	3540
50	gtgtgggtca gtggggccca tggatgtgct tgttaactga gtgccttttg gtggagaggc	3600
	ccggcctctc aaaaaagacc ccttaccact gctctgatga agaggagtac acagaacaca	3660
55	taattcagga agcagctttc cccatgtctc gactcatcca tccaggccat tccccgtctc	3720
	tggttcctcc cctcctcctg gactcctgca cacgtcctt cctctgaggc tgaaattcag	3780

aatattagtg acctcagctt tgatatttca cttacagcac cccaaccct ggcacccagg 3840  
 gtgggaaggg ctacacctta gcctgccctc ctttccggtg ttttaagacat ttttggaagg 3900  
 5 ggacacgtga cagccgtttg ttccccaaga cattctaggt ttgcaagaaa aatatgacca 3960  
 cactccagct gggatcacat gtggactttt atttccagtg aaatcagtta ctcttcagtt 4020  
 aagccttttg aaacagctcg actttaaaaa gctccaaatg cagctttaaa aaattaatct 4080  
 10 gggccagaat ttcaaacggc ctactaggc ttctggttga tgctgtgaa ctgaactctg 4140  
 acaacagact tctgaaatag acccacaaga ggcagttcca tttcatttgt gccagaatgc 4200  
 15 tttaggatgt acagttatgg attgaaagtt tacaggaaaa aaaattaggc cgttccttca 4260  
 aagcaaatgt cttcctggat tattcaaaat gatgtatgtt gaagcctttg taaattgtca 4320  
 gatgctgtgc aaatgttatt attttaaaca ttatgatgtg tgaaaactgg ttaatattta 4380  
 20 taggtcactt tgttttactg tcttaagttt atactcttat agacaacatg gccgtgaact 4440  
 ttatgctgta aataatcaga ggggaataaa ctgttgagtc aaaac 4485  
 25  
 <210> 2  
 <211> 1040  
 30 <212> PRT  
 <213> Homo sapiens  
 35  
 <400> 2  
 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 40 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 45 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 50 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 55 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80

Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 5 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 10 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 15 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 20 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 25 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190  
 30 Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val  
 195 200 205  
 35 Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala  
 210 215 220  
 Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr  
 225 230 235 240  
 40 Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val  
 245 250 255  
 45 Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser  
 260 265 270  
 50 Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu  
 275 280 285  
 Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly  
 290 295 300  
 55 Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln

	305		310		315		320
5	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu	325		330		335	
10	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His	340		345		350	
15	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu	355		360		365	
20	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe	370		375		380	
25	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro	385		390		395	400
30	Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu	405		410		415	
35	Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala	420		425		430	
40	Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser	435		440		445	
45	Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly	450		455		460	
50	Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His	465		470		475	480
55	Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His	485		490		495	
60	Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp	500		505		510	
65	Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro	515		520		525	
70	Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu	530		535		540	

5      Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
       545                        550                        555                        560

Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser  
                                  565                        570                        575

10      Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val  
                                  580                        585                        590

15      Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys  
                                  595                        600                        605

20      Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
                                  610                        615                        620

25      Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
                                  625                        630                        635                        640

Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
                                  645                        650                        655

30      Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
                                  660                        665                        670

35      Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
                                  675                        680                        685

40      Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln  
                                  690                        695                        700

45      Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
                                  705                        710                        715                        720

Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
                                  725                        730                        735

50      Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
                                  740                        745                        750

55      Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
                                  755                        760                        765



Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780  
 5  
 Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800  
 10 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 15 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830  
 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845  
 20 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860  
 25 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880  
 30 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895  
 35 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910  
 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925  
 40 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940  
 45 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960  
 50 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975  
 55 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990

Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
 995 1000 1005

5 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020

10 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035

Leu Leu  
 1040

15

<210> 3

<211> 1013

20 <212> PRT

<213> Homo sapiens

25

<400> 3

30 Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu  
 1 5 10 15

Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp  
 20 25 30

35

Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His  
 35 40 45

40

Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr  
 50 55 60

45 Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala  
 65 70 75 80

50 Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp  
 85 90 95

Asp Pro His Ser Leu His Pro Ala Arg Asp Leu Gln Ser His Arg Pro  
 100 105 110

55

Ala Ile Val Arg Arg Leu His Ser His Val Glu Asn Met Leu Asp Leu

	115	120	125
5	Ala Trp Glu Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg 130 135 140		
10	Leu Pro Ile Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu 145 150 155 160		
15	Ala Thr Val Lys Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val 165 170 175		
20	Gln Glu Leu Pro Val Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys 180 185 190		
25	Lys Lys Tyr Met Ala Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg 195 200 205		
30	Phe Leu Ser Thr Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile 210 215 220		
35	Tyr Thr Glu Asn Val Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly 225 230 235 240		
40	Pro Pro Gln Lys Ser Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser 245 250 255		
45	Thr Pro Gly His Leu Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly 260 265 270		
50	Glu Ala Gly Ser Gly Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu 275 280 285		
55	Trp Ala Ala Gly Gln Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe 290 295 300		
	Ser Cys Arg Gln Leu Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr 305 310 315 320		
	Leu Leu Phe Glu His Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile 325 330 335		
	Phe Gln Leu Leu Leu Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp 340 345 350		

Gly Phe Asp Glu Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys  
 355 360 365  
 5

Ser Pro Thr Asp Pro Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu  
 370 375 380

10

Gln Gly Asn Leu Leu Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro  
 385 390 395 400

15

Ala Ala Val Ser Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn  
 405 410 415

20

Leu Lys Gly Phe Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg  
 420 425 430

25

His His Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu  
 435 440 445

Thr Ser Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser Trp Met  
 450 455 460

30

Val Ser Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro  
 465 470 475 480

35

Lys Thr Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu  
 485 490 495

40

His Ala Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu  
 500 505 510

45

Leu Arg Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu  
 515 520 525

Trp Gly Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln  
 530 535 540

50

Ala Ala Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg  
 545 550 555 560

55

Ala Lys Gly Val Val Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His  
 565 570 575

Ile Thr Phe Gln Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala  
 580 585 590  
 5 Asp Val Pro Pro Ala Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro  
 595 600 605  
 10 Gly Asn Ser Pro Met Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala  
 610 615 620  
 15 Ser Glu Gly Lys Asp Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu  
 625 630 635 640  
 20 Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser  
 645 650 655  
 Arg Glu His Trp Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala  
 660 665 670  
 25 Leu Leu Arg Arg Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu  
 675 680 685  
 30 Arg Lys His Phe His Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys  
 690 695 700  
 35 Ser Val His Ala Met Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr  
 705 710 715 720  
 40 Glu Met Gln Glu Glu Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn  
 725 730 735  
 Val Gly His Leu Lys Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys  
 740 745 750  
 45 Ala Ala Leu Ala Phe Val Leu Gln His Leu Arg Arg Pro Val Ala Leu  
 755 760 765  
 50 Gln Leu Asp Tyr Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu  
 770 775 780  
 55 Pro Cys Leu Gly Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile  
 785 790 795 800

Ser Asp Arg Gly Ile Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu  
 805 810 815  
 5 Gln Leu Gln Lys Leu Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys  
 820 825 830  
 10 Ala His Ser Met Ala Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala  
 835 840 845  
 15 Leu Arg Leu Gly Asn Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu  
 850 855 860  
 Ala Glu Gly Leu Arg Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp  
 865 870 875 880  
 20 Gly Asn Arg Val Gly Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu  
 885 890 895  
 25 Gly Asp His Gln Ser Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile  
 900 905 910  
 30 Gly Ser Val Gly Ala Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val  
 915 920 925  
 35 Met Leu Glu Glu Leu Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly  
 930 935 940  
 Val Cys Ser Leu Ala Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile  
 945 950 955 960  
 40 Leu Lys Leu Ser Asn Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu  
 965 970 975  
 45 Leu Gln Ala Leu Glu Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg  
 980 985 990  
 50 Gly Asn Thr Phe Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp  
 995 1000 1005  
 55 Thr Arg Leu Leu Leu  
 1010

<210> 4  
 <211> 1040  
 5 <212> PRT  
 <213> Homo sapiens

10  
 <400> 4

Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 15  
 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 20  
 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 25  
 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 30  
 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80  
 35  
 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 40  
 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 45  
 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 50  
 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 55  
 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 60  
 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala

	180	185	190
5	Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val 195 200 205		
10	Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala 210 215 220		
15	Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr 225 230 235 240		
20	Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val 245 250 255		
25	Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser 260 265 270		
30	Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu 275 280 285		
35	Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly 290 295 300		
40	Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln 305 310 315 320		
45	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu 325 330 335		
50	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His 340 345 350		
55	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu 355 360 365		
60	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe 370 375 380		
65	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro 385 390 395 400		
70	Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu 405 410 415		



5	Lys	Asn	Ala	Arg	Lys	Val	Val	Thr	Ser	Arg	Pro	Ala	Ala	Val	Ser	Ala	420	425	430
10	Phe	Leu	Arg	Lys	Tyr	Ile	Arg	Thr	Glu	Phe	Asn	Leu	Lys	Gly	Phe	Ser	435	440	445
15	Glu	Gln	Gly	Ile	Glu	Leu	Tyr	Leu	Arg	Lys	Arg	His	His	Glu	Pro	Gly	450	455	460
20	Val	Ala	Asp	Arg	Leu	Ile	Arg	Leu	Leu	Gln	Glu	Thr	Ser	Ala	Leu	His	465	470	475
25	Gly	Leu	Cys	His	Leu	Pro	Val	Phe	Ser	Trp	Met	Val	Ser	Lys	Cys	His	485	490	495
30	Gln	Glu	Leu	Leu	Leu	Gln	Glu	Gly	Gly	Ser	Pro	Lys	Thr	Thr	Thr	Asp	500	505	510
35	Met	Tyr	Leu	Leu	Ile	Leu	Gln	His	Phe	Leu	Leu	His	Ala	Thr	Pro	Pro	515	520	525
40	Asp	Ser	Ala	Ser	Gln	Gly	Leu	Gly	Pro	Ser	Leu	Leu	Arg	Gly	Arg	Leu	530	535	540
45	Pro	Thr	Leu	Leu	His	Leu	Gly	Arg	Leu	Ala	Leu	Trp	Gly	Leu	Gly	Met	545	550	555
50	Cys	Cys	Tyr	Val	Phe	Ser	Ala	Gln	Gln	Leu	Gln	Ala	Ala	Gln	Val	Ser	565	570	575
55	Pro	Asp	Asp	Ile	Ser	Leu	Gly	Phe	Leu	Val	Arg	Ala	Lys	Gly	Val	Val	580	585	590
60	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	Leu	His	Ile	Thr	Phe	Gln	Cys	595	600	605
65	Phe	Phe	Ala	Ala	Phe	Tyr	Leu	Ala	Leu	Ser	Ala	Asp	Val	Pro	Pro	Ala	610	615	620
70	Leu	Leu	Arg	His	Leu	Phe	Asn	Cys	Gly	Arg	Pro	Gly	Asn	Ser	Pro	Met	625	630	635

Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
 645 650 655  
 5  
 Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670  
 10 Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685  
 15 Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg His Gln  
 690 695 700  
 20 Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720  
 Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735  
 25 Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750  
 30 Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765  
 35 Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780  
 40 Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800  
 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 45 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830  
 50 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845  
 55 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860

Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880

5 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895

10 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910

15 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925

Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940

20 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960

25 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975

30 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990

35 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
 995 1000 1005

Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020

40 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035

45 Leu Leu  
 1040

50 <210> 5  
 <211> 97  
 <212> PRT

55 <213> Homo sapiens

<400> 5

5 Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu  
1 5 10 15

10 Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp  
20 25 30

15 Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His  
35 40 45

20 Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr  
50 55 60

25 Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala  
65 70 75 80

30 Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp  
85 90 95

30 Asp

<210> 6

35 <211> 94

<212> PRT

40 <213> Homo sapiens

<400> 6

45 Ser Leu His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val  
1 5 10 15

50 Arg Arg Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu  
20 25 30

55 Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile  
35 40 45

Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val

	50		55		60
5	Lys 65	Ala Asn Gly Leu 70	Ala Ala Phe Leu Leu 75	Gln His Val Gln Glu Leu 80	
10	Pro Val Pro Leu 85	Ala Leu Pro Leu Glu 90	Ala Ala Thr Cys Lys		
15	<210> 7				
	<211> 305				
	<212> PRT				
	<213> Homo sapiens				
20	<400> 7				
25	Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu 1 5 10 15				
30	Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly 20 25 30				
35	Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln 35 40 45				
40	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu 50 55 60				
45	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His 65 70 75 80				
50	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu 85 90 95				
55	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe 100 105 110				
	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro 115 120 125				
	Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu 130 135 140				

[illegible]

Arg Ser Leu Tyr Glu Met Gln Glu Glu Arg Leu Ala Arg Lys Ala Ala  
 1 5 10 15

5 Arg Gly Leu Asn Val Gly His Leu Lys Leu Thr Phe  
 20 25

10 <210> 9  
 <211> 28  
 <212> PRT  
 15 <213> Homo sapiens

20 <400> 9  
 Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe Val Leu Gln  
 1 5 10 15

25 His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr  
 20 25

30 <210> 10  
 <211> 25  
 <212> PRT  
 35 <213> Homo sapiens

40 <400> 10  
 Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly  
 1 5 10 15

45 Val Cys Lys Ala Leu Tyr Leu Arg Asp  
 20 25

50 <210> 11  
 <211> 28  
 <212> PRT  
 55 <213> Homo sapiens

<400> 11  
 5 Asn Asn Ile Ser Asp Arg Gly Ile Cys Lys Leu Ile Glu Cys Ala Leu  
 1 5 10 15  
 10 His Cys Glu Gln Leu Gln Lys Leu Ala Leu Phe Asn  
 20 25  
 <210> 12  
 15 <211> 28  
 <212> PRT  
 20 <213> Homo sapiens  
 <400> 12  
 25 Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala Lys Leu Leu Ala  
 1 5 10 15  
 30 Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 20 25  
 <210> 13  
 35 <211> 28  
 <212> PRT  
 40 <213> Homo sapiens  
 <400> 13  
 45 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 1 5 10 15  
 50 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly  
 20 25  
 <210> 14  
 55 <211> 28



<212> PRT  
 <213> Homo sapiens  
 5  
 <400> 14  
 10 Asn Arg Val Gly Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly  
 1 5 10 15  
 Asp His Gln Ser Leu Arg Trp Leu Ser Leu Val Gly  
 15 20 25  
 <210> 15  
 <211> 28  
 20 <212> PRT  
 <213> Homo sapiens  
 25  
 <400> 15  
 30 Asn Asn Ile Gly Ser Val Gly Ala Gln Ala Leu Ala Leu Met Leu Ala  
 1 5 10 15  
 Lys Asn Val Met Leu Glu Glu Leu Cys Leu Glu Glu  
 35 20 25  
 <210> 16  
 <211> 28  
 40 <212> PRT  
 <213> Homo sapiens  
 45  
 <400> 16  
 50 Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala Glu Gly Leu Lys  
 1 5 10 15  
 Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 55 20 25

<210> 17  
<211> 28  
5 <212> PRT  
<213> Homo sapiens  
10  
<400> 17  
Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
1 5 10 15  
15  
Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly  
20 25  
20  
<210> 18  
<211> 7  
25 <212> PRT  
<213> Homo sapiens  
30  
<400> 18  
Glu Ala Gly Ser Gly Lys Ser  
1 5  
35  
<210> 19  
<211> 5  
40 <212> PRT  
<213> Homo sapiens  
45  
<400> 19  
Leu Leu Thr Phe Asp  
50 1 5  
<210> 20  
55 <211> 92

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

5

&lt;400&gt; 20

10 Glu Ser His Pro His Ile Gln Leu Leu Lys Ser Asn Arg Glu Leu Leu  
1 5 10 15

15 Val Thr His Ile Arg Asn Thr Gln Cys Leu Val Asp Asn Leu Leu Lys  
20 25 30

20 Asn Asp Tyr Phe Ser Ala Glu Asp Ala Glu Ile Val Cys Ala Cys Pro  
35 40 45

25 Thr Gln Pro Asp Lys Val Arg Lys Ile Leu Asp Leu Val Gln Ser Lys  
50 55 60

30 Gly Glu Glu Val Ser Glu Phe Phe Leu Tyr Leu Leu Gln Gln Leu Ala  
65 70 75 80

35 Asp Ala Tyr Val Asp Leu Arg Pro Trp Leu Leu Glu  
85 90

&lt;210&gt; 21

35 &lt;211&gt; 92

&lt;212&gt; PRT

40 <213> Homo sapiens

&lt;400&gt; 21

45 Gly Ile Ala Gln Gln Trp Ile Gln Ser Lys Arg Glu Asp Ile Val Asn  
1 5 10 15

50 Gln Met Thr Glu Ala Cys Leu Asn Gln Ser Leu Asp Ala Leu Leu Ser  
20 25 30

55 Arg Asp Leu Ile Met Lys Glu Asp Tyr Glu Leu Val Ser Thr Lys Pro  
35 40 45

Thr Arg Thr Ser Lys Val Arg Gln Leu Leu Asp Thr Thr Asp Ile Gln

50                                      55                                      60  
 Gly Glu Glu Phe Ala Lys Val Ile Val Gln Lys Leu Lys Asp Asn Lys  
 5      65                                      70                                      75                                      80  
 Gln Met Gly Leu Gln Pro Tyr Pro Glu Ile Leu Val  
 10                                      85                                      90  
 <210> 22  
 <211> 93  
 15      <212> PRT  
 <213> Homo sapiens  
 20  
 <400> 22  
 Glu Arg Pro Ser Glu Thr Ile Asp Arg Glu Arg Lys Arg Leu Val Glu  
 25      1                                      5                                      10                                      15  
 Thr Leu Gln Ala Asp Ser Gly Leu Leu Leu Asp Ala Leu Val Ala Arg  
 30                                      20                                      25                                      30  
 Gly Val Leu Thr Gly Pro Glu Tyr Glu Ala Leu Asp Ala Leu Pro Asp  
 35                                      35                                      40                                      45  
 Ala Glu Arg Arg Val Arg Arg Leu Leu Leu Leu Val Gln Ser Lys Gly  
 50                                      55                                      60  
 Glu Ala Ala Cys Gln Glu Leu Leu Arg Cys Ala Gln Gln Thr Val Ser  
 40      65                                      70                                      75                                      80  
 Met Pro Asp Pro Ala Trp Asp Trp Gln His Val Gly Pro  
 45                                      85                                      90  
 <210> 23  
 50      <211> 94  
 <212> PRT  
 <213> Homo sapiens  
 55

<400> 23  
 Met Glu Ala Arg Asp Lys Gln Val Leu Arg Ser Leu Arg Leu Glu Leu  
 1 5 10 15  
 5  
 Gly Ala Glu Val Leu Val Glu Gly Leu Val Leu Gln Tyr Leu Tyr Gln  
 20 25 30  
 10  
 Glu Gly Ile Leu Thr Glu Asn His Ile Gln Glu Ile Asn Ala Gln Thr  
 35 40 45  
 15 Thr Gly Leu Arg Lys Thr Met Leu Leu Leu Asp Ile Leu Pro Ser Arg  
 50 55 60  
 20 Gly Pro Lys Ala Phe Asp Thr Phe Leu Asp Ser Leu Gln Glu Phe Pro  
 65 70 75 80  
 Trp Val Arg Glu Lys Leu Lys Lys Ala Arg Glu Glu Ala Met  
 85 90  
 25  
 <210> 24  
 <211> 91  
 30  
 <212> PRT  
 <213> Homo sapiens  
 35  
 <400> 24  
 Met His Pro His His Gln Glu Thr Leu Lys Lys Asn Arg Val Val Leu  
 1 5 10 15  
 40  
 Ala Lys Gln Leu Leu Leu Ser Glu Leu Leu Glu His Leu Leu Glu Lys  
 20 25 30  
 45  
 Asp Ile Ile Thr Leu Glu Met Arg Glu Leu Ile Gln Ala Lys Val Gly  
 35 40 45  
 50  
 Ser Phe Ser Gln Asn Val Glu Leu Leu Asn Leu Leu Pro Lys Arg Gly  
 50 55 60  
 55 Pro Gln Ala Phe Asp Ala Phe Cys Glu Ala Leu Arg Glu Thr Lys Gln  
 65 70 75 80

Gly His Leu Glu Asp Met Leu Leu Thr Thr Leu  
 85 90

5  
 <210> 25  
 <211> 91

10 <212> PRT  
 <213> Homo sapiens

15  
 <400> 25  
 Met Arg Gln Asp Arg Arg Ser Leu Leu Glu Arg Asn Ile Met Met Phe  
 1 5 10 15

20 Ser Ser His Leu Lys Val Asp Glu Ile Leu Glu Val Leu Ile Ala Lys  
 20 25 30

25 Gln Val Leu Asn Ser Asp Asn Gly Asp Met Ile Asn Ser Cys Gly Thr  
 35 40 45

30 Val Arg Glu Lys Arg Arg Glu Ile Val Lys Ala Val Gln Arg Arg Gly  
 50 55 60

35 Asp Val Ala Phe Asp Ala Phe Tyr Asp Ala Leu Arg Ser Thr Gly His  
 65 70 75 80

40 Glu Gly Leu Ala Glu Val Leu Glu Pro Leu Ala  
 85 90

45  
 <210> 26  
 <211> 90  
 <212> PRT  
 <213> Homo sapiens

50  
 <400> 26  
 Leu Cys Glu Ile Glu Cys Arg Ala Leu Ser Thr Ala His Thr Arg Leu  
 5 10 15

Ile His Asp Phe Glu Pro Arg Asp Ala Leu Thr Tyr Leu Glu Gly Lys  
                   20                  25                  30

5 Asn Ile Phe Thr Glu Asp His Ser Glu Leu Ile Ser Lys Met Ser Thr  
           35                  40                  45

10 Arg Leu Glu Arg Ile Ala Asn Phe Leu Arg Ile Tyr Arg Arg Gln Ala  
       50                  55                  60

15 Ser Glu Leu Gly Pro Leu Ile Asp Phe Phe Asn Tyr Asn Asn Gln Ser  
       65                  70                  75                  80

His Leu Ala Asp Phe Leu Glu Asp Tyr Ile  
                   85                  90

20 <210> 27  
       <211> 93

25 <212> PRT  
       <213> Homo sapiens

30 <400> 27

35 Met Asp Glu Ala Asp Arg Arg Leu Leu Arg Arg Cys Arg Leu Arg Leu  
       1                  5                  10                  15

Val Glu Glu Leu Gln Val Asp Gln Leu Trp Asp Val Leu Leu Ser Arg  
                   20                  25                  30

40 Glu Leu Phe Arg Pro His Met Ile Glu Asp Ile Gln Arg Ala Gly Ser  
           35                  40                  45

45 Gly Ser Arg Arg Asp Gln Ala Arg Gln Leu Ile Ile Asp Leu Glu Thr  
       50                  55                  60

50 Arg Gly Ser Gln Ala Leu Pro Leu Phe Ile Ser Cys Leu Glu Asp Thr  
       65                  70                  75                  80

Gly Gln Asp Met Leu Ala Ser Phe Leu Arg Thr Asn Arg  
                   85                  90

55

<210> 28  
 <211> 93  
 5 <212> PRT  
 <213> Homo sapiens

10  
 <400> 28  
 Met Asp Ala Lys Ala Arg Asn Cys Leu Leu Gln His Arg Glu Ala Leu  
 1 5 10 15  
 15  
 Glu Lys Asp Ile Lys Thr Ser Tyr Ile Met Asp His Met Ile Ser Asp  
 20 25 30  
 20  
 Gly Phe Leu Thr Ile Ser Glu Glu Glu Lys Val Arg Asn Glu Pro Thr  
 35 40 45  
 25  
 Gln Gln Gln Arg Ala Ala Met Leu Ile Lys Met Ile Leu Lys Lys Asp  
 50 55 60  
 30  
 Asn Asp Ser Tyr Val Ser Phe Tyr Asn Ala Leu Leu His Glu Gly Tyr  
 65 70 75 80  
 35  
 Lys Asp Leu Ala Ala Leu Leu His Asp Gly Ile Pro Val  
 85 90  
 40  
 <210> 29  
 <211> 92  
 40 <212> PRT  
 <213> Homo sapiens

45  
 <400> 29  
 Met Ala Ser Asp Asp Leu Ser Leu Ile Arg Lys Asn Arg Met Ala Leu  
 50 1 5 10 15  
 55  
 Phe Gln Gln Leu Thr Cys Val Leu Pro Ile Leu Asp Asn Leu Leu Lys  
 20 25 30  
 60  
 Ala Asn Val Ile Asn Lys Gln Glu His Asp Ile Ile Lys Gln Lys Thr



35                                      40                                      45  
 5    Gln Ile Pro Leu Gln Ala Arg Glu Leu Ile Asp Thr Ile Trp Val Lys  
      50                                      55                                      60  
 10   Gly Asn Ala Ala Ala Asn Ile Phe Lys Asn Cys Leu Lys Glu Ile Asp  
      65                                      70                                      75                                      80  
 15   Ser Thr Leu Tyr Lys Asn Leu Phe Val Asp Lys Asn  
                                           85                                      90  
 20   <210> 30  
      <211> 320  
      <212> PRT  
      <213> Homo sapiens  
 25   <400> 30  
 30   Asn Glu Ser Leu Gly Ser Leu Asn Ser Leu Ala Cys Leu Leu Asp His  
      1                                      5                                      10                                      15  
      Thr Thr Gly Ile Leu Asn Glu Gln Gly Glu Thr Ile Phe Ile Leu Gly  
                                     20                                      25                                      30  
 35   Asp Ala Gly Val Gly Lys Ser Met Leu Leu Gln Arg Leu Gln Ser Leu  
                                     35                                      40                                      45  
 40   Trp Ala Thr Gly Arg Leu Asp Ala Gly Val Lys Phe Phe Phe His Phe  
      50                                      55                                      60  
 45   Arg Cys Arg Met Phe Ser Cys Phe Lys Glu Ser Asp Arg Leu Cys Leu  
      65                                      70                                      75                                      80  
 50   Gln Asp Leu Leu Phe Lys His Tyr Cys Tyr Pro Glu Arg Asp Pro Glu  
                                     85                                      90                                      95  
      Glu Val Phe Ala Phe Leu Leu Arg Phe Pro His Val Ala Leu Phe Thr  
                                     100                                      105                                      110  
 55   Phe Asp Gly Leu Asp Glu Leu His Ser Asp Leu Asp Leu Ser Arg Val  
      115                                      120                                      125

[illegible]

&lt;213&gt; Homo sapiens

5 <400> 31  
 Pro Val Val Phe Val Thr Arg Lys Lys Leu Val Asn Ala Ile Gln Gln  
 1 5 10 15  
 10 Lys Leu Ser Lys Leu Lys Gly Glu Pro Gly Trp Val Thr Ile His Gly  
 20 25 30  
 15 Met Ala Gly Cys Gly Lys Ser Val Leu Ala Ala Glu Ala Val Arg Asp  
 35 40 45  
 20 His Ser Leu Leu Glu Gly Cys Phe Pro Gly Gly Val His Trp Val Ser  
 50 55 60  
 Val Gly Lys Gln Asp Lys Ser Gly Leu Leu Met Lys Leu Gln Asn Leu  
 65 70 75 80  
 25 Cys Thr Arg Leu Asp Gln Asp Glu Ser Phe Ser Gln Arg Leu Pro Leu  
 85 90 95  
 30 Asn Ile Glu Glu Ala Lys Asp Arg Leu Arg Ile Leu Met Leu Arg Lys  
 100 105 110  
 35 His Pro Arg Ser Leu Leu Ile Leu Asp Asp Val Trp Asp Ser Trp Val  
 115 120 125  
 40 Leu Lys Ala Phe Asp Ser Gln Cys Gln Ile Leu Leu Thr Thr Arg Asp  
 130 135 140  
 Lys Ser Val Thr Asp Ser Val Met Gly Pro Lys Tyr Val Val Pro Val  
 145 150 155 160  
 45 Glu Ser Ser Leu Gly Lys Glu Lys Gly Leu Glu Ile Leu Ser Leu Phe  
 165 170 175  
 50 Val Asn Met Lys Lys Ala Asp Leu Pro Glu Gln Ala His Ser Ile Ile  
 180 185 190  
 55 Lys Glu Cys Lys Gly Ser Pro Leu Val Val Ser Leu Ile Gly Ala Leu  
 195 200 205

Leu Arg Asp Phe Pro Asn Arg Trp Glu Tyr Tyr Leu Lys Gln Leu Gln  
 210 215 220  
 5  
 Asn Lys Gln Phe Lys Arg Ile Arg Lys Ser Ser Ser Tyr Asp Tyr Glu  
 225 230 235 240  
 10 Ala Leu Asp Glu Ala Met Ser Ile Ser Val Glu Met Leu Arg Glu Asp  
 245 250 255  
 15 Ile Lys Asp Tyr Tyr Thr Asp Leu Ser Ile Leu Gln Lys Asp Val Lys  
 260 265 270  
 20 Val Pro Thr Lys Val Leu Cys Ile Leu Trp Asp Met Glu Thr Glu Glu  
 275 280 285  
 Val Glu Asp Ile Leu Gln Glu Phe Val Asn Lys Ser Leu Leu Phe Cys  
 290 295 300  
 25 Asp Arg Asn Gly  
 305  
 30 <210> 32  
 <211> 315  
 <212> PRT  
 35 <213> Homo sapiens  
 40 <400> 32  
 Met Thr Cys Tyr Ile Arg Glu Tyr His Val Asp Arg Val Ile Lys Lys  
 1 5 10 15  
 45 Leu Asp Glu Met Cys Asp Leu Asp Ser Phe Phe Leu Phe Leu His Gly  
 20 25 30  
 50 Arg Ala Gly Ser Gly Lys Ser Val Ile Ala Ser Gln Ala Leu Ser Lys  
 35 40 45  
 55 Ser Asp Gln Leu Ile Gly Ile Asn Tyr Asp Ser Ile Val Trp Leu Lys  
 50 55 60

Asp Ser Gly Thr Ala Pro Lys Ser Thr Phe Asp Leu Phe Thr Asp Ile  
 65 70 75 80

5 Leu Leu Met Leu Lys Ser Glu Asp Asp Leu Leu Asn Phe Pro Ser Val  
 85 90 95

10 Glu His Val Thr Ser Val Val Leu Lys Arg Met Ile Cys Asn Ala Leu  
 100 105 110

15 Ile Asp Arg Pro Asn Thr Leu Phe Val Phe Asp Asp Val Val Gln Glu  
 115 120 125

Glu Thr Ile Arg Trp Ala Gln Glu Leu Arg Leu Arg Cys Leu Val Thr  
 130 135 140

20 Thr Arg Asp Val Glu Ile Ser Asn Ala Ala Ser Gln Thr Cys Glu Phe  
 145 150 155 160

25 Ile Glu Val Thr Ser Leu Glu Ile Asp Glu Cys Tyr Asp Phe Leu Glu  
 165 170 175

30 Ala Tyr Gly Met Pro Met Pro Val Gly Glu Lys Glu Glu Asp Val Leu  
 180 185 190

35 Asn Lys Thr Ile Glu Leu Ser Ser Gly Asn Pro Ala Thr Leu Met Met  
 195 200 205

Phe Phe Lys Ser Cys Glu Pro Lys Thr Phe Glu Lys Met Ala Gln Leu  
 210 215 220

40 Asn Asn Lys Leu Glu Ser Arg Gly Leu Val Gly Val Glu Cys Ile Thr  
 225 230 235 240

45 Pro Tyr Ser Tyr Lys Ser Leu Ala Met Ala Leu Gln Arg Cys Val Glu  
 245 250 255

50 Val Leu Ser Asp Glu Asp Arg Ser Ala Leu Ala Phe Ala Val Val Met  
 260 265 270

55 Pro Pro Gly Val Asp Ile Pro Val Lys Leu Trp Ser Cys Val Ile Pro  
 275 280 285

Val Asp Ile Cys Ser Asn Glu Glu Glu Gln Leu Asp Asp Glu Val Ala

	290	295	300	
5	Asp Arg Leu Lys Arg	Leu Ser Lys Arg Gly	Ala	
	305	310	315	
	<210>	33		
10	<211>	4486		
	<212>	DNA		
15	<213>	Homo sapiens		
	<400>	33		
20	gtagacagat ccaggctcac cagtcctgtg ccactgggct tttggcgctc tgcacaaggc		60	
	ctaccgcgag atgccatgcc tgctccccc gcctaattggg ctttgatggg ggaagaggg		120	
	ggttcagcct ctacagatga ggaggaaaga gcaagtgtcc tcctcggaca ttctccgggt		180	
25	tgtgaaatgt gctcgcagga ggcttttcag gcacagagga gccagctggt cgagctgctg		240	
	gtctcagggg ccctggaagg cttcgagagt gtcctggact ggctgctgtc ctgggaggtc		300	
	ctctcctggg aggactacga gggcttcac ctctcgggcc agcctctctc ccacttggcc		360	
30	aggcgccttc tggacaccgt ctggaataag ggtacttggg cctgtcagaa gctcatcgcg		420	
	gctgcccag aagcccaggc cgacagccag tcccccaagc tgcattggctg ctgggacccc		480	
35	cactcgctcc acccagcccg agacctgcag agtcaccggc cagccattgt caggaggctc		540	
	cacagccatg tggagaacat gctggacctg gcatgggagc ggggtttcgt cagccagtat		600	
	gaatgtgatg aaatcaggtt gccgatcttc acaccgtccc agagggcaag aaggctgctt		660	
40	gatcttgcca cggtgaaagc gaatggattg gctgccttcc ttctacaaca tgttcaggaa		720	
	ttaccagtcc cattggccct gcctttggaa gctgccacat gcaagaagta tatggccaag		780	
45	ctgaggacca cgggtgtctgc tcagtctcgc ttctcagta cctatgatgg agcagagacg		840	
	ctctgcctgg aggacatata cacagagaat gtcctggagg tctgggcaga tgtgggcatg		900	
	gctggacccc cgcagaagag ccagccacc ctgggcctgg aggagctctt cagcaccct		960	
50	ggccacctca atgacgatgc ggacactgtg ctggtggtgg gtgaggcggg cagtggcaag		1020	
	agcacgtcc tgcagcggct gcacttctgt tgggctgcag ggcaagactt ccaggaattt		1080	
55	ctctttgtct tccattcag ctgccggcag ctgcagtga tggccaaacc actctctgtg		1140	
	cggactctac tctttgagca ctgctgttgg cctgatgttg gtcaagaaga catcttccag		1200	

	ttactccttg accaccctga ccgtgtcctg ttaacctttg atggctttga cgagttcaag	1260
5	ttcaggttca cggatcgtga acgccactgc tccccgaccg accccacctc tgtccagacc	1320
	ctgctcttca accttctgca gggcaacctg ctgaagaatg cccgcaaggt ggtgaccagc	1380
	cgccggccg ctgtgtcggc gttcctcagg aagtacatcc gcaccgagtt caacctcaag	1440
10	ggcttctctg aacagggcat cgagctgtac ctgaggaagc gccatcatga gcccggggtg	1500
	gcggaccgcc tcatccgctt gtcctcaagag acctcagccc tgcacggttt gtgccacctg	1560
15	cctgtcttct catggatggt gtccaaatgc caccaggaac tgttgctgca ggaggggggg	1620
	tccccaaaga ccactacaga tatgtacctg ctgattctgc agcattttct gctgcatgcc	1680
	acccccccag actcagcttc ccaaggctct ggaccagtc ttcttcgggg ccgcctcccc	1740
20	acctcctgc acctgggcag actggctctg tggggcctgg gcatgtgctg ctacgtgttc	1800
	tcagcccagc agctccaggc agcacaggtc agccctgatg acatttctct tggcttcctg	1860
25	gtgcgtgcca aagggtgctg gccaggaggt acggcgcccc tggaattcct tcacatcact	1920
	ttccagtgtt tctttgccgc gttctacctg gcactcagtg ctgatgtgcc accagctttg	1980
	ctcagacacc tcttcaattg tggcaggcca ggcaactcac caatggccag gctcctgccc	2040
30	acgatgtgca tccaggcctc ggaggaaag gacagcagcg tggcagcttt gctgcagaag	2100
	gccgagccgc acaaccttca gatcacagca gccttcctgg cagggtgtt gtcccgggag	2160
35	cactggggcc tgctggctga gtgccagaca tctgagaagg ccctgctccg gcgccaggcc	2220
	tgtgcccgtt ggtgtctggc ccgcagcctc cgcaagcact tccactccat cccgccagct	2280
	gcaccgggtg aggccaaag cgtgcatgcc atgccgggtt tcactctggt catccggagc	2340
40	ctgtacgaga tgcaggagga gcggctggct cggaaggctg cacgtggcct gaatgttggg	2400
	cacctcaagt tgacattttg cagtgtgggc cccactgagt gtgctgccct ggcctttgtg	2460
45	ctgcagcacc tccggcggcc cgtggccctg cagctggact acaactctgt gggtgacatt	2520
	ggcgtggagc agctgctgcc ttgccttggg gtctgcaagg ctctgtattt gcgcgataac	2580
	aatatctcag accgaggcat ctgcaagctc attgaatgtg ctcttactg cgagcaattg	2640
50	cagaagttag ctctattcaa caacaaattg actgacggct gtgcacactc catggctaag	2700
	ctccttgcat gcaggcagaa cttcttggca ttgaggctgg ggaataacta catcactgcc	2760
55	gcgggagccc aagtgtggc cgaggggctc cgaggcaaca cctccttgca gttcctggga	2820
	ttctggggca acagagtggg tgacgagggg gccaggccc tggctgaagc cttgggtgat	2880

caccagagct tgagggtggct cagcctggtg gggaacaaca ttggcagtggt ggggtgccccaa 2940  
 gccttggcac tgatgctggc aaagaacgctc atgctagaag aactctgcct ggaggagaac 3000  
 5 catctccagg atgaaggtgt atgttctctc gcagaaggac tgaagaaaaa ttcaagtttg 3060  
 aaaatcctga agttgtccaa taactgcctc acctacctag gggcagaagc cctcctgcag 3120  
 10 gccccttgaa aggaatgaca ccctcctgga agtctggctc cgagggaaca ctttctctct 3180  
 agaggaggtt gacaagctcg gctgcaggga caccagactc ttgctttgaa gtctccggga 3240  
 ggatgttcgt ctcaagttgt ttgtgagcag gctgtgagtt tgggccccag aggctgggtg 3300  
 15 acatgtgttg gcagcctctt caaaatgagc cctgtcctgc ctaaggctga acttgttttc 3360  
 tgggaacacc ataggtcacc tttattctgg cagaggaggg agcatcagtg ccctccagga 3420  
 tagacttttc ccaagcctac ttttgccatt gacttcttcc caagattcaa tcccaggatg 3480  
 20 tacaaggaca gcccctctc catagtatgg gactggcctc tgctgatcct cccaggcttc 3540  
 cgtgtgggtc agtggggccc atggatgtgc ttgttaactg agtgcctttt ggtggagagg 3600  
 25 cccggcctct cacaaaagac cccttaccac tgctctgatg aagaggagta cacagaacac 3660  
 ataattcagg aagcagcttt ccccatgtct cgactcatcc atccaggcca ttccccgtct 3720  
 ctggttcctc cctcctcctt ggactcctgc acacgctcct tcctctgagg ctgaaattca 3780  
 30 gaatattagt gacctcagct ttgatatttc acttacagca ccccaaccc tggcacccag 3840  
 ggtgggaagg gctacacctt agcctgccct cctttccggt gtttaagaca tttttggaag 3900  
 35 gggacacgtg acagccggtt gttccccaag acattctagg ttgcaagaa aaatatgacc 3960  
 aactccagc tgggatcaca tgtggacttt tatttccagt gaaatcagtt actcttcagt 4020  
 taagcctttg gaaacagctc gactttaaaa agctccaaat gcagctttaa aaaattaatc 4080  
 40 tgggccagaa tttcaaacgg cctcactagg cttctggttg atgcctgtga actgaactct 4140  
 gacaacagac ttctgaaata gaccacaag aggcagttcc atttcatttg tgccagaatg 4200  
 45 ctttaggatg tacagttatg gattgaaagt ttacaggaaa aaaaattagg ccgttccttc 4260  
 aaagcaaatg tcttcctgga ttattcaaaa tgatgtatgt tgaagccttt gtaaattgtc 4320  
 50 agatgctgtg caaatgttat tattttaaac attatgatgt gtgaaaactg gttaatatct 4380  
 ataggtcact ttgttttact gtcttaagtt tatactctta tagacaacat ggccgtgaac 4440  
 tttatgctgt aaataatcag aggggaataa actgttgagt caaaac 4486  
 55 <210> 34



<211> 1007  
 <212> PRT  
 5 <213> Homo sapiens

<400> 34  
 10 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 15 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 20 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 25 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 30 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80  
 35 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 40 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 45 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 50 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 55 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 60 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 65 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190

Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val  
 195 200 205  
 5  
 Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala  
 210 215 220  
 10  
 Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr  
 225 230 235 240  
 15  
 Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val  
 245 250 255  
 20  
 Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser  
 260 265 270  
 Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu  
 275 280 285  
 25  
 Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly  
 290 295 300  
 30  
 Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln  
 305 310 315 320  
 35  
 Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu  
 325 330 335  
 40  
 Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His  
 340 345 350  
 Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu  
 355 360 365  
 45  
 Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe  
 370 375 380  
 50  
 Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro  
 385 390 395 400  
 55  
 Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu  
 405 410 415

Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala  
 420 425 430

5 Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser  
 435 440 445

10 Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly  
 450 455 460

15 Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His  
 465 470 475 480

Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
 485 490 495

20 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
 500 505 510

25 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
 515 520 525

30 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
 530 535 540

35 Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
 545 550 555 560

Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser  
 565 570 575

40 Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val  
 580 585 590

45 Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys  
 595 600 605

50 Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
 610 615 620

55 Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
 625 630 635 640

Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp

	645	650	655
5	Ser Ser Val 660	Ala Ala Leu Leu Gln Lys 665	Ala Glu Pro His Asn Leu Gln 670
10	Ile Thr Ala Ala Phe Leu Ala 675	Gly Leu Leu Ser Arg 680	Glu His Trp Gly 685
15	Leu Leu Ala Glu Cys Gln Thr 690	Ser Glu Lys Ala Leu Leu Arg Arg Gln 695	
20	Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser 705	Leu Arg Lys His Phe His 710	
25	Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met 725		735
30	Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu 740		745
35	Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys 755		760
40	Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe 770		775
45	Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn 785		790
50	Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val 805		810
55	Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile 820		825
60	Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu 835		840
65	Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala 850		855
70	Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn 865		870

5 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895  
 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910  
 10 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925  
 15 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940  
 20 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960  
 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975  
 25 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990  
 30 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Pro  
 995 1000 1005  
 35 <210> 35  
 <211> 360  
 <212> DNA  
 40 <213> Homo sapiens  
 45 <400> 35  
 cagacatgag caggatgtgt ctaagggaca ggtgggcttc agtagactgg ctaactcctg 60  
 cagtctcttt aactggacag tttcaagagg aaaaccaaga atccttgaag ctaccattg 120  
 50 tatcttcttt tccaggttgt ccaataactg catcacctac ctaggggcag aagccctcct 180  
 gcaggccctt gaaaggaatg acaccatcct ggaagtctgg taaggcccct gggcaggcct 240  
 gtttttagctc tccgaacctc agtttttcta tctgtaaaat ggggtgacgg gagagaggaa 300  
 55 tggcagaatt ttgaggatcc cttctgattc tgacattcag tgagaatgat tctgcatgtg 360

5      <210> 36  
       <211> 361  
       <212> DNA  
       <213> Homo sapiens  
 10  
       <400> 36  
       cagacatgag caggatgtgt ctaagggaca ggtgggcttc agtagactgg ctaactcctg      60  
 15      cagtctcttt aactggacag tttcaagagg aaaaccaaga atccttgaag ctcaccattg      120  
       tatcttcttt tccaggttgt ccaataactg catcacctac ctaggggcag aagccctcct      180  
 20      gcaggccctt tgaaaggaat gacaccatcc tggaggtctg gtaaggcccc tgggcaggcc      240  
       tgttttagct ctccgaacct cagtttttct atctgtaaaa tggggtgacg ggagagagga      300  
       atggcagaat tttgaggatc ccttctgatt ctgacattca gtgagaatga ttctgcatgt      360  
 25      g      361  
  
       <210> 37  
 30      <211> 27  
       <212> DNA  
       <213> Artificial Sequence  
 35  
       <220>  
 40      <223> Synthetic  
       <400> 37  
       atgtgctcgc aggaggcttt tcaggca      27  
 45  
       <210> 38  
       <211> 26  
 50      <212> DNA  
       <213> Artificial Sequence  
 55  
       <220>

<223> Synthetic

<400> 38  
cgcttcaccc accaccagca cagtgt 26

5

<210> 39

<211> 28

10 <212> DNA

<213> Artificial Sequence

15

<220>

<223> Synthetic

20 <400> 39

catggctgga ccccccgcaga agagccca 28

<210> 40

<211> 28

<212> DNA

30 <213> Artificial Sequence

<220>

<223> Synthetic

<400> 40

40 catgcccggtggttcacatctggc tcatccgg 28

<210> 41

<211> 27

<212> DNA

<213> Artificial Sequence

50

<220>

<223> Synthetic

<400> 41

gccatgcccg ggttcacctg gctcatc 27

5 <210> 42  
<211> 28  
<212> DNA

10 <213> Artificial Sequence

15 <220>  
<223> Synthetic

<400> 42  
tgagtcgaga catggggaaa gctgcttc 28

20

<210> 43

25 <211> 27  
<212> DNA  
<213> Artificial Sequence

30

<220>  
<223> Synthetic

35 <400> 43  
agcagctcga ccagctggct cctctgt 27

40 <210> 44  
<211> 27  
<212> DNA

45 <213> Artificial Sequence

50 <220>  
<223> Synthetic

<400> 44  
55 gacaggccca agtaccctta ttccaga 27



<210> 45  
<211> 27  
5 <212> DNA  
<213> Artificial Sequence  
10  
<220>  
<223> Synthetic  
15 <400> 45  
atgtgctcgc aggaggcttt tcaggca 27  
20  
<210> 46  
<211> 26  
<212> DNA  
25 <213> Artificial Sequence  
30  
<220>  
<223> Synthetic  
35 <400> 46  
cgcttcaccc accaccagca cagtgt 26  
40  
<210> 47  
<211> 27  
<212> DNA  
<213> Artificial Sequence  
45  
<220>  
<223> Synthetic  
50 <400> 47  
atgtgctcgc aggaggcttt tcaggca 27  
55 <210> 48

<211> 26  
<212> DNA  
5 <213> Artificial Sequence

10 <220>  
<223> Synthetic  
<400> 48  
15 cgcctcaccc accaccagca cagtgt 26

<210> 49  
<211> 22  
20 <212> DNA  
<213> Artificial Sequence

25 <220>  
<223> Synthetic  
30 <400> 49  
gagtcaacgg atttggtcgt at 22

35 <210> 50  
<211> 21  
<212> DNA  
40 <213> Artificial Sequence

45 <220>  
<223> Synthetic  
<400> 50  
50 agtcttctcgg gtggcagtga t 21

<210> 51  
55 <211> 20

<212> DNA  
 <213> Artificial Sequence  
 5  
 <220>  
 <223> Synthetic  
 10  
 <400> 51  
 ctgagccttt gttgatgagc 20  
 15 <210> 52  
 <211> 20  
 <212> DNA  
 20 <213> Artificial Sequence  
 25 <220>  
 <223> Synthetic  
 <400> 52  
 30 tcttcaacca catccccatt 20  
 <210> 53  
 35 <211> 3123  
 <212> DNA  
 <213> Homo sapiens  
 40  
 <400> 53  
 45 atgggggaag aggggtggttc agcctctcac gatgaggagg aaagagcaag tgtcctcctc 60  
 ggacattctc cgggttggtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
 ctggctcgagc tgctgggtctc agggtcctcg gaaggcttcg agagtgtcct ggactggctg 180  
 50 ctgtcctggg aggtcctctc ctgggaggac tacgagggt tccacctcct gggccagcct 240  
 ctctcccact tggccaggcg cttctctggac accgtctgga ataagggtac ttgggcctgt 300  
 cagaagctca tcgcggctgc ccaagaagcc caggccgaca gccagtcccc caagctgcat 360  
 55 ggctgctggg acccccactc gctccaccca gcccgagacc tgcagagtca ccggccagcc 420

	attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcggggt	480
	ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg	540
5	gcaagaaggc tgcttgatct tgccacgggtg aaagcgaatg gattggctgc cttccttcta	600
	caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag	660
10	aagtatatgg ccaagctgag gaccacgggtg tctgctcagt ctcgcttcct cagtacctat	720
	gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg	780
	gcagatgtgg gcatggctgg acccccgcag aagagcccag ccaccctggg cctggaggag	840
15	ctcttcagca cccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag	900
	gcgggcagtg gcaagagcac gtcctgcag cggctgcact tgctgtgggc tgcagggcaa	960
20	gacttcagg aatttctctt tgtcttccca ttcagctgcc ggagctgca gtgcatggcc	1020
	aaaccactct ctgtgcggac tctactcttt gagcactgct gttggcctga tgttggtcaa	1080
	gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc	1140
25	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
	acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgcccgc	1260
30	aagggtggtga ccagccgtcc ggccgctgtg tcggcggttc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggctt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat	1380
	catgagcccc ggggtggcga ccgcctcctc cgctgctcc aagagacctc agccctgcac	1440
35	ggtttgtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500
	ctgcaggagg gggggtcccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
40	tttctgctgc atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt	1620
	cggggccgcc tccccacct cctgcacctg ggagactgg ctctgtgggg cctgggcatg	1680
	tgctgctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
45	tctcttggtt tcctggtgcg tgccaaagggt gtcgtgccag ggagtacggc gccctggaa	1800
	ttccttcaca tcaacttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
50	gtgccaccag ctttgtcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
	gccaggtccc tgcccacgat gtgcatccag gcctcgagg gaaaggacag cagcgtggca	1980
	gctttgctgc agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
55	ctgttgctccc gggagcactg gggcctgctg gctgagtgcc agacatctga gaaggccctg	2100
	ctccggcgcc aggcctgtgc ccgtggtgt ctggcccgca gcctccgcaa gcacttcac	2160

	tccatccccg cagctgcacc ggggtgaggcc aagagcgtgc atgcatgcc cgggttcac	2220
5	tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcggaa ggctgcacgt	2280
	ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct	2340
	gccctggcct ttgtgctgca gcacctccgg cggcccgtgg ccctgcagct ggactacaac	2400
10	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
	tatttgcgcg ataacaatat ctacagccga ggcatctgca agctcattga atgtgtctt	2520
15	cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca	2580
	cactccatgg ctaagctcct tgcattgcagg cagaacttct tggcattgag gctggggaat	2640
	aactacatca ctgccgcggg agcccaagtg ctggccgagg ggctccgagg caacacctcc	2700
20	ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct	2760
	gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc	2820
25	agtgtgggtg cccaagcctt ggcaactgat ctggcaaaga acgtcatgct agaagaactc	2880
	tgccctggagg agaaccatct ccaggatgaa ggtgtatgtt ctctcgaga aggactgaag	2940
	aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcatcaccta cctaggggca	3000
30	gaagccctcc tgcaggccct tgaaaggaat gacaccatcc tggaagtctg gctccgaggg	3060
	aacactttct ctctagagga gggtgacaag ctcggtgca gggacaccag actcttgctt	3120
35	tga	3123
	<210> 54	
40	<211> 3124	
	<212> DNA	
	<213> Homo sapiens	
45		
	<400> 54	
	atgggggaag aggggtggtc agcctctcac gatgaggagg aaagagcaag tgcctcctc	60
50	ggacattctc cgggttggtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag	120
	ctggtcgagc tgctggtctc agggtcctcg gaaggcttcg agagtgtcct ggactggctg	180
55	ctgtcctggg aggtcctctc ctgggaggac tacgagggt tccacctcct gggccagcct	240
	ctctccact tggccaggcg cttctggac accgtctgga ataagggtac ttgggcctgt	300

	cagaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcccc caagctgcat	360
	ggctgctggg acccccactc gctccacca gcccgagacc tgcagagtca ccggccagcc	420
5	attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcgggg	480
	ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg	540
10	gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta	600
	caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag	660
	aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctcgcttctt cagtacctat	720
15	gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg	780
	gcagatgtgg gcatggctgg atccccgcag aagagcccag ccaccctggg cctggaggag	840
20	ctcttcagca cccttgcca cctcaatgac gatgcggaca ctgtgctggg ggtgggtgag	900
	gcgggcagtg gcaagagcac gctcctgcag cggtgcact tgctgtgggc tgcagggcaa	960
	gacttccagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc	1020
25	aaaccactct ctgtgcggac tctactcttt gagcactgct gttggcctga tgttggtcaa	1080
	gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc	1140
30	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
	acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgccgc	1260
	aaggtggtga ccagccgtcc ggccgctgtg tcggcgttcc tcaggaagta catccgcacc	1320
35	gagttcaacc tcaagggtct ctctgaacag ggcacgcagc tgtacctgag gaagcgccat	1380
	catgagcccc ggggtggcga ccgcctcatc cgctgtctcc aagagacctc agccctgcac	1440
40	ggtttggtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500
	ctgcaggagg gggggtcccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgtgc atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt	1620
45	cggggccgcc tccccacct cctgcacctg ggcagactgg ctctgtgggg cctgggcatg	1680
	tgctgctaag tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
50	tctcttggtt tcctggtgcg tgccaaaggt gtcgtgccag ggagtacggc gccctggaa	1800
	ttccttcaca tcactttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
	gtgccaccag ctttgctcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
55	gccaggctcc tgccacgat gtgcatccag gcctcggagg gaaaggacag cagcgtggca	1980
	gctttgctgc agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040

ctgttgcccc gggagcactg gggcctgctg gctgagtgcc agacatctga gaaggccctg 2100  
 5 ctccggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgcaa gcacttccac 2160  
 tccatcccgc cagctgcacc gggtagaggcc aagagcgtgc atgccatgcc cgggttcac 2220  
 tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcggaa ggctgcacgt 2280  
 10 ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct 2340  
 gccctggcct ttgtgtgca gcacctccg cgcccgtgg ccctgcagct ggactacaac 2400  
 15 tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg 2460  
 tatttgcgcg ataacaatat ctcagacoga ggcattctga agctcattga atgtgtctt 2520  
 cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca 2580  
 20 cactccatgg ctaagctcct tgcattgcagg cagaacttct tggcattgag gctggggaat 2640  
 aactacatca ctgccgcggg agcccaagtg ctggccgagg ggctccgagg caacacctcc 2700  
 25 ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggcctggct 2760  
 gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc 2820  
 agtgtgggtg cccaagcctt ggcactgatg ctggcaaaga acgtcatgct agaagaactc 2880  
 30 tgcttgagg agaaccatct ccaggatgaa ggtgtatgtt ctctgcaga aggactgaag 2940  
 aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcatcaccta cctaggggca 3000  
 35 gaagccctcc tgcaggcccc ttgaaaggaa tgacaccatc ctggaagtct ggctccgagg 3060  
 gaacactttc tctctagagg aggttgacaa gctcggctgc agggacacca gactcttgct 3120  
 ttga 3124  
 40  
 <210> 55  
 <211> 1007  
 45 <212> PRT  
 <213> Homo sapiens  
 50  
 <400> 55  
 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 55 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu

	20	25	30
5	Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly 35 40 45		
10	Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu 50 55 60		
15	Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro 65 70 75 80		
20	Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly 85 90 95		
25	Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala 100 105 110		
30	Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu 115 120 125		
35	His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg 130 135 140		
40	Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly 145 150 155 160		
45	Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr 165 170 175		
50	Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala 180 185 190		
55	Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val 195 200 205		
60	Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala 210 215 220		
65	Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr 225 230 235 240		
70	Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val 245 250 255		



5	Leu	Glu	Val	Trp	Ala	Asp	Val	Gly	Met	Ala	Gly	Ser	Pro	Gln	Lys	Ser
				260					265					270		
10	Pro	Ala	Thr	Leu	Gly	Leu	Glu	Glu	Leu	Phe	Ser	Thr	Pro	Gly	His	Leu
			275					280					285			
15	Asn	Asp	Asp	Ala	Asp	Thr	Val	Leu	Val	Val	Gly	Glu	Ala	Gly	Ser	Gly
		290					295					300				
20	Lys	Ser	Thr	Leu	Leu	Gln	Arg	Leu	His	Leu	Leu	Trp	Ala	Ala	Gly	Gln
	305					310					315					320
25	Asp	Phe	Gln	Glu	Phe	Leu	Phe	Val	Phe	Pro	Phe	Ser	Cys	Arg	Gln	Leu
					325					330					335	
30	Gln	Cys	Met	Ala	Lys	Pro	Leu	Ser	Val	Arg	Thr	Leu	Leu	Phe	Glu	His
				340					345					350		
35	Cys	Cys	Trp	Pro	Asp	Val	Gly	Gln	Glu	Asp	Ile	Phe	Gln	Leu	Leu	Leu
			355					360					365			
40	Asp	His	Pro	Asp	Arg	Val	Leu	Leu	Thr	Phe	Asp	Gly	Phe	Asp	Glu	Phe
		370					375					380				
45	Lys	Phe	Arg	Phe	Thr	Asp	Arg	Glu	Arg	His	Cys	Ser	Pro	Thr	Asp	Pro
	385					390					395					400
50	Thr	Ser	Val	Gln	Thr	Leu	Leu	Phe	Asn	Leu	Leu	Gln	Gly	Asn	Leu	Leu
					405					410					415	
55	Lys	Asn	Ala	Arg	Lys	Val	Val	Thr	Ser	Arg	Pro	Ala	Ala	Val	Ser	Ala
				420					425					430		
60	Phe	Leu	Arg	Lys	Tyr	Ile	Arg	Thr	Glu	Phe	Asn	Leu	Lys	Gly	Phe	Ser
			435					440					445			
65	Glu	Gln	Gly	Ile	Glu	Leu	Tyr	Leu	Arg	Lys	Arg	His	His	Glu	Pro	Gly
		450					455					460				
70	Val	Ala	Asp	Arg	Leu	Ile	Arg	Leu	Leu	Gln	Glu	Thr	Ser	Ala	Leu	His
	465					470					475					480

Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
 485 490 495  
 5  
 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
 500 505 510  
 10 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
 515 520 525  
 15 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
 530 535 540  
 20 Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
 545 550 555 560  
 Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser  
 565 570 575  
 25 Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val  
 580 585 590  
 30 Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys  
 595 600 605  
 35 Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
 610 615 620  
 40 Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
 625 630 635 640  
 Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
 645 650 655  
 45 Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670  
 50 Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685  
 55 Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln  
 690 695 700

Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720

5 Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735

10 Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750

15 Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765

20 Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780

25 Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800

30 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815

35 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830

40 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845

45 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860

50 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880

55 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895

Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910

Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925

Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala

	930	935	940
5	Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu 945 950 955 960		
10	Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala 965 970 975		
15	Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn 980 985 990		
20	Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Pro 995 1000 1005		
25	<210> 56 <211> 3123 <212> DNA <213> Homo sapiens		
30	<400> 56 atgggggaag aggggtggttc agcctctcac gatgaggagg aaagagcaag tgtcctcctc ggacattctc cgggttggtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag	60	120
35	ctggctcgagc tgctggtctc aggggtccctg gaaggcttcg agagtgtcct ggactggctg ctgtcctggg aggtcctctc ctgggaggac tacgagggtt tccacctcct gggccagcct	180	240
40	ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtac ttgggcctgt cagaagctca tcgcggctgc ccaagaagcc caggccgaca gccagtcccc caagctgcat ggctgctggg acccccactc gctccaccca gcccagagacc tgcagagtca ccggccagcc	300	360
45	attgtcagga ggctccacag ccatgtggag aacatgtctg acctggcatg ggagcggggt ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta	480	540
50	caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctgcttcct cagtacctat gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg	600	660
55	gcagatgtgg gcatggctgg acccccgcag aagagcccag ccacctggg cctggaggag	720	780
			840

	ctcttcagca cccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag	900
5	gcgggcagtg gcaagagcac gctcctgcag cggctgcact tgctgtgggc tgcagggcaa	960
	gacttcagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc	1020
	aaaccactct ctgtgcggac tctactcttt gagcactgct gttggcctga tgttggtcaa	1080
10	gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc	1140
	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
15	acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgccgc	1260
	aaggtggtga ccagccgtcc ggccgctgtg tcggcgttcc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggtt ctctgaacag ggcacgcagc tgtacctgag gaagcgccat	1380
20	catgagcccg ggggtggcga ccgcctcatc cgctgctcc aagagacctc agccctgcac	1440
	ggtttggtgc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500
25	ctgcaggagg ggggggtccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgctgc atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt	1620
	cggggccgoc tccccaccct cctgcacctg ggcagactgg ctctgtgggg cctgggcatg	1680
30	tgctgctaag tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
	tctcttggtt tcctggtgcg tgccaaaggt gtcgtgccag ggagtacggc gcccctggaa	1800
35	ttccttcaca tcactttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
	gtgccaccag ctttgcctcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
	gccaggctcc tgcccacgat gtgcatccag gcctcggagg gaaaggacag cagcgtggca	1980
40	gctttgctgc agaagggcga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
	ctgttgctccc gggagcactg gggcctgctg gctgagtgcc agacatctga gaaggccctg	2100
45	ctctggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgcaa gcacttcac	2160
	tccatccccg cagctgcacc gggtagggcc aagagcgtgc atgccatgcc cgggttcac	2220
	tggtcatcc ggagcctgta cgagatgcag gaggagcggc tggtcggaa ggctgcacgt	2280
50	ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggcccccac tgagtgtgct	2340
	gccctggcct ttgtgctgca gcacctccg cgcccgtgg ccctgcagct ggactacaac	2400
55	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
	tatttgcgcg ataacaatat ctcagaccga ggcacatgca agctcattga atgtgctctt	2520

cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca 2580  
 cactccatgg ctaagctcct tgcattgcagg cagaacttct tggcattgag gctggggaat 2640  
 5 aactacatca ctgccgcggg agcccaagtg ctggccgagg ggctccgagg caacacctcc 2700  
 ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct 2760  
 gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc 2820  
 10 agtgtgggtg cccaagcctt ggcactgatg ctggcaaaga acgtcatgct agaagaactc 2880  
 tgcctggagg agaaccatct ccaggatgaa ggtgtatggt ctctcgaga aggactgaag 2940  
 15 aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcatcaccta cctaggggca 3000  
 gaagccctcc tgcaggccct tgaaggaat gacaccatcc tggaagtctg gctccgagg 3060  
 aacactttct ctctagagga ggttgacaag ctcggtgca gggacaccag actcttgctt 3120  
 20 tga 3123

25 <210> 57

<211> 1040

<212> PRT

30 <213> Homo sapiens

35 <400> 57

Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15

40 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30

45 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45

50 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60

Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80

55 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95

5 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 10 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 15 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 20 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190  
 25 Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val  
 195 200 205  
 30 Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala  
 210 215 220  
 35 Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr  
 225 230 235 240  
 40 Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val  
 245 250 255  
 Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser  
 260 265 270  
 45 Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu  
 275 280 285  
 50 Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly  
 290 295 300  
 55 Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln  
 305 310 315 320

Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu  
 325 330 335  
 5  
 Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His  
 340 345 350  
 10  
 Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu  
 355 360 365  
 15  
 Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe  
 370 375 380  
 20  
 Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro  
 385 390 395 400  
 Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu  
 405 410 415  
 25  
 Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala  
 420 425 430  
 30  
 Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser  
 435 440 445  
 35  
 Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly  
 450 455 460  
 40  
 Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His  
 465 470 475 480  
 Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
 485 490 495  
 45  
 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
 500 505 510  
 50  
 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
 515 520 525  
 55  
 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
 530 535 540



Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
 545 550 555 560

5 Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser  
 565 570 575

10 Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val  
 580 585 590

15 Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys  
 595 600 605

Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
 610 615 620

20 Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
 625 630 635 640

25 Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
 645 650 655

30 Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670

35 Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685

Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Trp Arg Gln  
 690 695 700

40 Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720

45 Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735

50 Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750

Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765

55 Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe

	770	775	780
5	Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn 785 790 795 800		
10	Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val 805 810 815		
15	Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile 820 825 830		
20	Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu 835 840 845		
25	Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala 850 855 860		
30	Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn 865 870 875 880		
35	Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg 885 890 895		
40	Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly 900 905 910		
45	Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser 915 920 925		
50	Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala 930 935 940		
55	Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu 945 950 955 960		
	Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala 965 970 975		
	Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn 980 985 990		
	Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu 995 1000 1005		

[illegible]

	gacttccagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc	1020
	aaaccactct ctgtgcggac tctactcttt gagcactgct gttggcctga tgttgggtcaa	1080
5	gaagacatct tccagttact ccttgaccac cctgaccgtg tctgttaac ctttgatggc	1140
	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
10	acctctgtcc agaccctgct cttcaacctt ctgcaggcca acctgctgaa gaatgccgcg	1260
	aagggtggtga ccagccgtcc ggccgctgtg tggcgcttcc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggett ctctgaacag ggcacgcagc tgtacctgag gaagcgccat	1380
15	catgagcccc ggggtggcga ccgcctcatc cgctgctcc aagagacctc agccctgcac	1440
	ggtttgtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500
20	ctgcaggagg ggggggtcccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgtgc atgccacccc ccagactca gttcccaag gtctgggacc cagtcttctt	1620
	cggggcgccc tccccacct cctgcacctg ggcagactgg ctctgtgggg cctgggcatg	1680
25	tgctgctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
	tctcttggt tctggtgcg tgccaaagg gtcgtgccag ggagtacggc gccctggaa	1800
30	ttccttcaca tcactttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
	gtgccaccag ctttgctcag acacctcttc aattgtggca ggccaggcaa ctaccaatg	1920
	gccaggctcc tgcccacgat gtgcatccag gcctcggagg gaaaggacag cagcgtggca	1980
35	gctttgtgc agaaggcca gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
	ctgttgctcc gggagcactg gggcctgctg gctgagtgcc agacatctga gaaggccctg	2100
40	ctccggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgcaa gcacttccac	2160
	tccatccccg cagctgcacc ggggtaggcc aagagcgtgc atgcatgcc cgggttcac	2220
	tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcgaa ggctgcacgt	2280
45	ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct	2340
	gccctggcct ttgtgctgca gcacctccg cgcccgtgg ccctgcagct ggactacaac	2400
50	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
	tatttgcgcg ataacaatat ctgagaccga ggcacatgca agctcattga atgtgctctt	2520
	cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca	2580
55	cactccatgg ctaagctcct tgcagtcagg cagaacttct tggcattgag gctggggaat	2640
	aactacatca ctgccgcggg agcccaagt ctggccgagg ggctccgagg caacacctcc	2700

ttgcagttcc tgggattctg ggcgaacaga gtgggtgacg agggggccca ggccttggt 2760  
 5 gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc 2820  
 agtgtgggtg cccaagcctt ggcactgatg ctggcaaaga acgtcatgct agaagaactc 2880  
 tgcctggagg agaaccatct ccaggatgaa ggtgtatggt ctctcgaga aggactgaag 2940  
 10 aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcatcaccta cctaggggca 3000  
 gaagccctcc tgcaggccct tgaaaggaat gacaccatcc tggaagtctg gctccgaggg 3060  
 15 aacactttct ctctagagga ggttgacaag ctcggctgca gggacaccag actcttgctt 3120  
 tga 3123

20 <210> 59

<211> 1040

<212> PRT

25 <213> Homo sapiens

30 <400> 59

Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15

35 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30

40 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45

45 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60

Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80

50 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95

55 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110

Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 5 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 10 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 15 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 20 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190  
 Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val  
 195 200 205  
 25 Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala  
 210 215 220  
 30 Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr  
 225 230 235 240  
 35 Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val  
 245 250 255  
 40 Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser  
 260 265 270  
 Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu  
 275 280 285  
 45 Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly  
 290 295 300  
 50 Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln  
 305 310 315 320  
 55 Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu  
 325 330 335

Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His  
                             340                            345                            350

5 Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu  
                             355                            360                            365

10 Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe  
                             370                            375                            380

15 Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro  
                             385                            390                            395                            400

Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu  
                             405                            410                            415

20 Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala  
                             420                            425                            430

25 Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser  
                             435                            440                            445

30 Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly  
                             450                            455                            460

35 Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His  
                             465                            470                            475                            480

Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
                             485                            490                            495

40 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
                             500                            505                            510

45 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
                             515                            520                            525

50 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
                             530                            535                            540

55 Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
                             545                            550                            555                            560

Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser

	565	570	575
5	Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val 580 585 590		
10	Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys 595 600 605		
15	Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala 610 615 620		
20	Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met 625 630 635 640		
25	Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp 645 650 655		
30	Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln 660 665 670		
35	Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly 675 680 685		
40	Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln 690 695 700		
45	Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His 705 710 715 720		
50	Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met 725 730 735		
55	Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu 740 745 750		
60	Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys 755 760 765		
65	Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe 770 775 780		
70	Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn 785 790 795 800		



5 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830  
 10 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845  
 15 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860  
 20 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880  
 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895  
 25 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Arg Asn Arg Val Gly  
 900 905 910  
 30 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925  
 35 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940  
 40 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960  
 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975  
 45 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990  
 50 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
 995 1000 1005  
 55 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020

Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035

5 Leu Leu  
 1040

10 <210> 60  
 <211> 3123  
 <212> DNA  
 15 <213> Homo sapiens

20 <400> 60  
 atgggggaag aggggtggttc agcctctcac gatgaggagg aaagagcaag tgtcctcctc 60  
 ggacattctc cgggttgtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
 25 ctggtcgagc tgctggtctc agggtcctcg gaaggcttcg agagtgtcct ggactggctg 180  
 ctgtcctggg aggtcctctc ctgggaggac tacgagggtt tccacctcct gggccagcct 240  
 ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtac ttgggcctgt 300  
 30 cagaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcccc caagctgcat 360  
 ggctgctggg acccccactc gctccacca gcccgagacc tgcagagtca ccggccagcc 420  
 35 attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcggggt 480  
 ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg 540  
 gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta 600  
 40 caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag 660  
 aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctgcttcct cagtacctat 720  
 45 gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggctctg 780  
 gcagatgtgg gcatggctgg atccccgag aagagcccag ccaccctggg cctggaggag 840  
 ctcttcagca cccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag 900  
 50 gcgggcagtg gcaagagcac gctcctgag cggtgcact tgctgtgggc tgcagggcaa 960  
 gacttcagag aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc 1020  
 55 aaaccactct ctgtgcggac tctactcttt gagcactgct gttggcctga tgttggtcaa 1080  
 gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc 1140

	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
5	acctctgtcc agaccctgct cttcaacctt ctgcaggcca acctgctgaa gaatgcccgc	1260
	aaggtggtga ccagccgtcc ggccgctgtg tcggcggtcc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggctt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat	1380
10	catgagcccc ggggtggcga ccgcctcctc cgctgctcc aagagacctc agccctgcac	1440
	ggtttgtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500
15	ctgcaggagg gggggctccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgctgc atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt	1620
	cggggccgcc tccccacct cctgcacctg ggagactgg ctctgtgggg cctgggcatg	1680
20	tgctgctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
	tctcttggtt tcttggtgcg tgccaaaggt gtcgtgccag ggagtacggc gccctggaa	1800
25	ttccttcaca tcaacttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
	gtgccaccag ctttgctcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
	gccaggctcc tgcccacgat gtgcatccag gcctcgagg gaaaggacag cagcgtggca	1980
30	gctttgctgc agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
	ctgttgctcc gggagcactg gggcctgctg gctgagtgcc agacatctga gaaggccctg	2100
35	ctccggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgaa gcacttcac	2160
	tccatcccgcc cagctgcacc gggtagggcc aagagcgtgc atgccatgcc cgggttcctc	2220
	tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcggaa ggctgcacgt	2280
40	ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct	2340
	gccctggcct ttgtgctgca gcacctccgg cggcccgtgg ccctgcagct ggactacaac	2400
45	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
	tatttgcgcg ataacaatat ctcagaccga ggcatctgca agctcattga atgtgctctt	2520
	cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca	2580
50	cactccatgg ctaagctcct tgcattgcagg cagaacttct tggcattgag gctggggaat	2640
	aactacatca ctgccgcggg agcccaagtg ctggccgagg ggctccgagg caacacctcc	2700
55	ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct	2760
	gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc	2820

agtgtgggtg cccaagcctt ggcaactgatg ctggcaaaga acgtcatgct agaagaactc 2880  
 tgcctggagg agaaccatct ccaggatgaa ggtgtatggt ctctcgcaga aggactgaag 2940  
 5 aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcatcaccta cctaggggca 3000  
 gaagccctcc tgcaggccct tgaaggaat gacaccatcc tggaagtctg gctccgaggg 3060  
 aacactttct ctctagagga ggttgacaag ctcggctgca gggacaccag actcttgctt 3120  
 10 tga 3123

15 <210> 61

<211> 1040

<212> PRT

20 <213> Homo sapiens

25 <400> 61

Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15

30 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30

35 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45

40 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60

Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80

45 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95

50 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110

55 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125

His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140

5 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160

10 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175

15 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190

Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val  
 195 200 205

20 Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala  
 210 215 220

25 Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr  
 225 230 235 240

30 Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val  
 245 250 255

35 Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Ser Pro Gln Lys Ser  
 260 265 270

Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu  
 275 280 285

40 Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly  
 290 295 300

45 Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln  
 305 310 315 320

50 Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu  
 325 330 335

55 Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His  
 340 345 350

Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu

	355		360		365
5	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe				
	370		375		380
10	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro				
	385		390		395 400
15	Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu				
		405		410	415
20	Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala				
		420		425	430
25	Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser				
		435		440	445
30	Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly				
		450		455	460
35	Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His				
	465		470		475 480
40	Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His				
		485		490	495
45	Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp				
		500		505	510
50	Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro				
		515		520	525
55	Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu				
		530		535	540
60	Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met				
	545		550		555 560
65	Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser				
		565		570	575
70	Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val				
		580		585	590

5	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	Leu	His	Ile	Thr	Phe	Gln	Cys
			595					600					605			
10	Phe	Phe	Ala	Ala	Phe	Tyr	Leu	Ala	Leu	Ser	Ala	Asp	Val	Pro	Pro	Ala
	610						615					620				
15	Leu	Leu	Arg	His	Leu	Phe	Asn	Cys	Gly	Arg	Pro	Gly	Asn	Ser	Pro	Met
	625					630					635					640
20	Ala	Arg	Leu	Leu	Pro	Thr	Met	Cys	Ile	Gln	Ala	Ser	Glu	Gly	Lys	Asp
					645					650					655	
25	Ser	Ser	Val	Ala	Ala	Leu	Leu	Gln	Lys	Ala	Glu	Pro	His	Asn	Leu	Gln
				660					665					670		
30	Ile	Thr	Ala	Ala	Phe	Leu	Ala	Gly	Leu	Leu	Ser	Arg	Glu	His	Trp	Gly
			675					680						685		
35	Leu	Leu	Ala	Glu	Cys	Gln	Thr	Ser	Glu	Lys	Ala	Leu	Leu	Arg	Arg	Gln
	690						695					700				
40	Ala	Cys	Ala	Arg	Trp	Cys	Leu	Ala	Arg	Ser	Leu	Arg	Lys	His	Phe	His
	705					710					715					720
45	Ser	Ile	Pro	Pro	Ala	Ala	Pro	Gly	Glu	Ala	Lys	Ser	Val	His	Ala	Met
					725					730					735	
50	Pro	Gly	Phe	Ile	Trp	Leu	Ile	Arg	Ser	Leu	Tyr	Glu	Met	Gln	Glu	Glu
				740					745					750		
55	Arg	Leu	Ala	Arg	Lys	Ala	Ala	Arg	Gly	Leu	Asn	Val	Gly	His	Leu	Lys
			755					760					765			
60	Leu	Thr	Phe	Cys	Ser	Val	Gly	Pro	Thr	Glu	Cys	Ala	Ala	Leu	Ala	Phe
	770						775					780				
65	Val	Leu	Gln	His	Leu	Arg	Arg	Pro	Val	Ala	Leu	Gln	Leu	Asp	Tyr	Asn
	785					790					795					800
70	Ser	Val	Gly	Asp	Ile	Gly	Val	Glu	Gln	Leu	Leu	Pro	Cys	Leu	Gly	Val
					805					810					815	

Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830  
 5  
 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845  
 10 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860  
 15 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880  
 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895  
 20 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910  
 25 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925  
 30 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940  
 35 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960  
 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975  
 40 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990  
 45 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
 995 1000 1005  
 50 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020  
 55 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035



Leu Leu  
1040

5 <210> 62  
<211> 3123  
<212> DNA  
10 <213> Homo sapiens

15 <400> 62  
atgggggaag aggggtggttc agcctctcac gatgaggagg aaagagcaag tgtcctcctc 60  
ggacattctc cgggttggtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
20 ctggtcgagc tgctggtctc agggtcctcg gaaggcttcg agagtgtcct ggactggctg 180  
ctgtcctggg aggtcctctc ctgggaggac tacgagggtt tccacctcct gggccagcct 240  
ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtac ttgggcctgt 300  
25 cagaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcccc caagctgcat 360  
ggctgctggg acccccactc gctccaccca gcccgagacc tgcagagtca ccggccagcc 420  
30 attgtcagga ggctccacag ccatgtggag aacatgtcgg acctggcatg ggagcggggt 480  
ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg 540  
gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta 600  
35 caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag 660  
aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctgcttcct cagtacctat 720  
40 gatggagcag agacgtctcg cctggaggac atatacacag agaatgtcct ggaggtctgg 780  
gcagatgtgg gcatggctgg acccccgagc aagagcccag ccacctggg cctggaggag 840  
ctcttcagca cccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag 900  
45 gcgggcagtg gcaagagcac gctcctgcag cggctgcact tgctgtgggc tgcagggcaa 960  
gacttcagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc 1020  
50 aaaccactct ctgtgcggac tctactctt gagcactgct gttggcctga tgttggtcaa 1080  
gaagacatct tccagttact ccttgaccac cctgaccgtg tctgttaac ctttgatggc 1140  
tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc 1200  
55 acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgccgcg 1260

aaggtggtga ccagccgtcc ggccgctgtg tcggcggtcc tcaggaagta catccgcacc 1320  
 gagttcaacc tcaagggctt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat 1380  
 5 catgagcccc ggggtggcga ccgcctcatc cgctgtctcc aagagacctc agccctgcac 1440  
 ggtttgtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg 1500  
 10 ctgcaggagg ggggtgcccc aaagaccact acagatatgt acctgctgat tctgcagcat 1560  
 tttctgtgc atgccacccc ccagactca gttcccaag gtctgggacc cagtcttctt 1620  
 cggggcccgc tccccacct cctgcacctg ggagactgg ctctgtgggg cctgggcatg 1680  
 15 tgctgtacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt 1740  
 tctcttggt tcctggtgcg tgccaaagg gtctgtccag ggagtacggc gcccctggaa 1800  
 ttccttcaca tcactttcca gtgcttcttt gccggttct acctggcact cagtgtgat 1860  
 20 gtgccaccag ctttgtcag acacctctc aattgtggca ggccaggcaa ctcaccaatg 1920  
 gccaggtcc tgcccacgat gtgcatccag gcctcgagg gaaaggacag cagcgtggca 1980  
 25 gctttgtgc agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg 2040  
 ctgttgtccc gggagcactg gggcctgtg gctgagtgc agacatctga gaaggccctg 2100  
 ctccggcgcc aggcctgtgc ccgctggtgt ctggcccga gcctccgaa gcacttcac 2160  
 30 tccatcccgc cagctgcacc gggtagggc aagagcgtgc atgcatgcc cgggttcac 2220  
 tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcgaa ggctgcacgt 2280  
 35 ggctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct 2340  
 gccctggct ttgtgtgca gcacctccg cggccatgg cctgcagct ggactacaac 2400  
 tctgtgggtg acattggcgt ggagcagctg ctgccttgc ttggtgtctg caaggctctg 2460  
 40 tatttgccg ataacaatat ctgagaccga ggcatctgca agctcattga atgtgtctt 2520  
 cactgcgagc aattgcagaa gttagcteta ttcaacaaca aattgactga cggctgtgca 2580  
 45 cactccatgg ctaagctcct tgcatgcagg cagaacttct tggcattgag gctggggaat 2640  
 aactacatca ctgccgcgg agcccaagt ctggccgagg ggctccgagg caacacctcc 2700  
 ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct 2760  
 50 gaagccttg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc 2820  
 agtgtgggtg cccaagcctt ggactgatg ctggcaaaga acgtcatgct agaagaactc 2880  
 55 tgcctggagg agaaccatct ccaggatgaa ggtgtatgtt ctctgcaga aggactgaag 2940  
 aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcacaccta cctaggggca 3000

gaagccctcc tgcaggccct tgaaaggaat gacaccatcc tggaagtctg gctccgaggg 3060  
 aacactttct ctctagagga gggttgacaag ctcggctgca gggacaccag actcttgctt 3120  
 5 tga 3123  
  
 <210> 63  
 10 <211> 1040  
 <212> PRT  
 15 <213> Homo sapiens  
  
 <400> 63  
 20 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 25 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 30 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 35 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80  
 40 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 45 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 50 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 55 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly

	145		150		155		160
5	Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr	165		170		175	
10	Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala	180		185		190	
15	Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val	195		200		205	
20	Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala	210		215		220	
25	Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr	225		230		235	240
30	Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val	245		250		255	
35	Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser	260		265		270	
40	Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu	275		280		285	
45	Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly	290		295		300	
50	Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln	305		310		315	320
55	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu	325		330		335	
60	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His	340		345		350	
65	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu	355		360		365	
70	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe	370		375		380	

5	Lys	Phe	Arg	Phe	Thr	Asp	Arg	Glu	Arg	His	Cys	Ser	Pro	Thr	Asp	Pro	385	390	395	400
10	Thr	Ser	Val	Gln	Thr	Leu	Leu	Phe	Asn	Leu	Leu	Gln	Gly	Asn	Leu	Leu	405	410	415	
15	Lys	Asn	Ala	Arg	Lys	Val	Val	Thr	Ser	Arg	Pro	Ala	Ala	Val	Ser	Ala	420	425	430	
20	Phe	Leu	Arg	Lys	Tyr	Ile	Arg	Thr	Glu	Phe	Asn	Leu	Lys	Gly	Phe	Ser	435	440	445	
25	Glu	Gln	Gly	Ile	Glu	Leu	Tyr	Leu	Arg	Lys	Arg	His	His	Glu	Pro	Gly	450	455	460	
30	Val	Ala	Asp	Arg	Leu	Ile	Arg	Leu	Leu	Gln	Glu	Thr	Ser	Ala	Leu	His	465	470	475	480
35	Gly	Leu	Cys	His	Leu	Pro	Val	Phe	Ser	Trp	Met	Val	Ser	Lys	Cys	His	485	490	495	
40	Gln	Glu	Leu	Leu	Leu	Gln	Glu	Gly	Gly	Ser	Pro	Lys	Thr	Thr	Thr	Asp	500	505	510	
45	Met	Tyr	Leu	Leu	Ile	Leu	Gln	His	Phe	Leu	Leu	His	Ala	Thr	Pro	Pro	515	520	525	
50	Asp	Ser	Ala	Ser	Gln	Gly	Leu	Gly	Pro	Ser	Leu	Leu	Arg	Gly	Arg	Leu	530	535	540	
55	Pro	Thr	Leu	Leu	His	Leu	Gly	Arg	Leu	Ala	Leu	Trp	Gly	Leu	Gly	Met	545	550	555	560
60	Cys	Cys	Tyr	Val	Phe	Ser	Ala	Gln	Gln	Leu	Gln	Ala	Ala	Gln	Val	Ser	565	570	575	
65	Pro	Asp	Asp	Ile	Ser	Leu	Gly	Phe	Leu	Val	Arg	Ala	Lys	Gly	Val	Val	580	585	590	
70	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	Leu	His	Ile	Thr	Phe	Gln	Cys	595	600	605	

Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
 610 615 620  
 5  
 Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
 625 630 635 640  
 10 Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
 645 650 655  
 15 Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670  
 20 Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685  
 Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln  
 690 695 700  
 25 Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720  
 30 Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735  
 35 Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750  
 40 Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765  
 Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780  
 45 Val Leu Gln His Leu Arg Arg Pro Met Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800  
 50 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 55 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830

Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845  
 5 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860  
 10 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880  
 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895  
 15 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910  
 20 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925  
 25 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940  
 30 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960  
 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975  
 35 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990  
 40 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
 995 1000 1005  
 45 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020  
 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035  
 Leu Leu  
 1040  
 55

<210> 64  
 <211> 3123  
 5 <212> DNA  
 <213> Homo sapiens

10  
 <400> 64  
 atgggggaag aggggtggttc agcctctcac gatgaggagg aaagagcaag tgcctcctc 60  
 ggacattctc cgggttgtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
 15 ctggtcgagc tgctggtctc aggggtccctg gaaggcttcg agagtgtcct ggactggctg 180  
 ctgtcctggg aggtcctctc ctgggaggac tacgagggtt tccacctcct gggccagcct 240  
 20 ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtac ttgggcctgt 300  
 cagaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcccc caagctgcat 360  
 ggctgctggg acccccactc gctccacca gccgagacc tgcagagtc cggccagcc 420  
 25 attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcgggt 480  
 ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg 540  
 30 gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc ctctcttcta 600  
 caacatgttc aggaattacc agtcccattg gcctgcctt tggaagctgc cacatgcaag 660  
 aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctcgcttct cagtacctat 720  
 35 gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg 780  
 gcagatgtgg gcatggctgg acccccgcag aagagcccag ccaccctggg cctggaggag 840  
 40 ctcttcagca cccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag 900  
 gcgggcagtg gcaagagcac gctcctgcag cggctgcaact tgctgtgggc tgcagggcaa 960  
 gacttcagag aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggc 1020  
 45 aaaccactct ctgtgcggac tctactctt gagcactgct gttggcctga tgttggtcaa 1080  
 gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc 1140  
 50 tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc 1200  
 acctctgtcc agaccctgct cttcaacctt ctgcaggga acctgctgaa gaatgcccgc 1260  
 aagggtgtga ccagccgtcc ggccgctgtg tcggcgctcc tcaggaagta catccgcacc 1320  
 55 gagttcaacc tcaagggtt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat 1380



	catgagcccg	gggtggcgga	ccgcctcatc	cgctgtctcc	aagagacctc	agccctgcac	1440
	ggtttgtgcc	acctgcctgt	cttctcatgg	atggtgtcca	aatgccacca	ggaactgttg	1500
5	ctgcaggagg	gggggtcccc	aaagaccact	acagatatgt	acctgctgat	tctgcagcat	1560
	tttctgctgc	atgccacccc	cccagactca	gcttcccaag	gtctgggacc	cagtcttctt	1620
	cggggcccgc	tccccaccct	cctgcacctg	ggcagactgg	ctctgtgggg	cctgggcatg	1680
10	tgctgctacg	tgttctcage	ccagcagctc	caggcagcac	aggtcagccc	tgatgacatt	1740
	tctcttggtt	tcctggtgcg	tgccaaaggt	gtcgtgccag	ggagtacggc	gcccctggaa	1800
15	ttccttcaca	tcactttcca	gtgcttcttt	gccgcgttct	acctggcact	cagtgtctgat	1860
	gtgccaccag	ctttgctcag	acacctcttc	aattgtggca	ggccaggcaa	ctcaccaatg	1920
	gccaggctcc	tgcccacgat	gtgcatccag	gcctcggagg	gaaaggacag	cagcgtggca	1980
20	gctttgtctg	agaaggccga	gccgcacaac	cttcagatca	cagcagcctt	cctggcaggg	2040
	ctgttgtccc	gggagcactg	gggcctgctg	gctgagtgcc	agacatctga	gaaggccctg	2100
25	ctccggcgcc	aggcctgtgc	ccgtggtgt	ctggcccgca	gcctccgcaa	gcacttcac	2160
	tccatccgcg	cagctgcacc	gggtgaggcc	aagagcgtgc	atgccatgcc	cgggttcac	2220
	tggctcatcc	ggagcctgta	cgagatgcag	gaggagcggc	tggctcgga	ggctgcacgt	2280
30	ggcctgaatg	ttgggcacct	caagttgaca	ttttgcagtg	tgggccccac	tgagtgtgct	2340
	gccctggcct	ttgtgctgca	gcacctccgg	cggcccgtgg	ccctgcagct	ggactacaac	2400
35	tctgtgggtg	acattggcgt	ggagcagctg	ctgccttgcc	ttggtgtctg	caaggctctg	2460
	tatttgcgcg	ataacaatat	ctcagaccga	ggcatctgca	agctcattga	atgtgtcttt	2520
	cactgcgagc	aattgcagaa	gttagctcta	ttcagcaaca	aattgactga	cggctgtgca	2580
40	cactccatgg	ctaagctcct	tgcatgcagg	cagaacttct	tggcattgag	gctggggaat	2640
	aactacatca	ctgccgcggg	agcccaagtg	ctggccgagg	ggctccgagg	caacacctcc	2700
45	ttgcagttcc	tgggattctg	gggcaacaga	gtgggtgacg	agggggccca	ggccctggct	2760
	gaagccttgg	gtgatcacca	gagcttgagg	tggctcagcc	tgggtgggaa	caacattggc	2820
	agtgtgggtg	cccaagcctt	ggcactgatg	ctggcaaaga	acgtcatgct	agaagaactc	2880
50	tgctggagg	agaaccatct	ccaggatgaa	ggtgtatgtt	ctctcgaga	aggactgaag	2940
	aaaaattcaa	gtttgaaaat	cctgaagttg	tccaataact	gcatcaccta	cctaggggca	3000
55	gaagccctcc	tgcaggccct	tgaaggaat	gacaccatcc	tgggaagtctg	gctccgaggg	3060
	aacactttct	ctctagagga	ggttgacaag	ctcggtgca	gggacaccag	actcttgctt	3120

tga

3123

5 <210> 65  
 <211> 1040  
 <212> PRT  
 10 <213> Homo sapiens

15 <400> 65  
 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 20 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 25 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 30 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 35 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80  
 40 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 45 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 50 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 55 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 60 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 65 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr

	165	170	175
5	Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala 180 185 190		
10	Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val 195 200 205		
15	Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala 210 215 220		
20	Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr 225 230 235 240		
25	Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val 245 250 255		
30	Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser 260 265 270		
35	Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu 275 280 285		
40	Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly 290 295 300		
45	Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln 305 310 315 320		
50	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu 325 330 335		
55	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His 340 345 350		
60	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu 355 360 365		
65	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe 370 375 380		
70	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro 385 390 395 400		

5 Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu  
 405 410 415  
 Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala  
 420 425 430  
 10 Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser  
 435 440 445  
 15 Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly  
 450 455 460  
 20 Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His  
 465 470 475 480  
 Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
 485 490 495  
 25 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
 500 505 510  
 30 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
 515 520 525  
 35 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
 530 535 540  
 40 Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
 545 550 555 560  
 Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser  
 565 570 575  
 45 Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val  
 580 585 590  
 50 Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys  
 595 600 605  
 55 Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
 610 615 620

Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
 625 630 635 640  
 5  
 Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
 645 650 655  
 10 Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670  
 15 Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685  
 20 Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln  
 690 695 700  
 Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720  
 25 Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735  
 30 Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750  
 35 Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765  
 40 Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780  
 Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800  
 45 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 50 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830  
 55 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845

Ala Leu Phe Ser Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
850 855 860

5 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
865 870 875 880

10 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
885 890 895

15 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
900 905 910

20 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
915 920 925

25 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
930 935 940

30 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
945 950 955 960

35 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
965 970 975

40 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
980 985 990

45 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
995 1000 1005

50 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
1010 1015 1020

55 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
1025 1030 1035

Leu Leu  
1040

<210> 66

<211> 3123

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

5

&lt;400&gt; 66

	atgggggaag aggggtggtc agcctctcac gatgaggagg aaagagcaag tgtcctcctc	60
10	ggacattctc cgggttggtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag	120
	ctggtcgagc tgctggtctc aggggccctg gaaggcttcg agagtgtcct ggactggctg	180
	ctgtcctggg aggtcctctc ctgggaggac tacgagggct tccacctcct gggccagcct	240
15	ctctcccact tggccaggcg ctttctggac accgtctgga ataagggtac ttgggcctgt	300
	cagaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcccc caagctgcat	360
20	ggctgctggg acccccactc gctccacca gcccgagacc tgcagagtca ccggccagcc	420
	attgtcagga ggctccacag ccatgtggag aacatgtctg acctggcatg ggagcggggt	480
	ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg	540
25	gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta	600
	caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag	660
30	aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctgcttcct cagtacctat	720
	gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg	780
	gcagatgtgg gcatggctgg acccccgcag aagagcccag ccacctggg cctggaggag	840
35	ctcttcagca cccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag	900
	gcgggcagtg gcaagagcac gctcctgcag cggtgcact tgctgtgggc tgcagggcaa	960
40	gacttccagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc	1020
	aaaccactct ctgtgctggac tctactcttt gagcactgct gttggcctga tgttggtcaa	1080
	gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc	1140
45	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
	acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgcccgc	1260
50	aaggtggtga ccagccgtcc ggccgctgtg tcggcggtcc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggtt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat	1380
	catgagcccg ggggtggcga ccgcctcatc cgctgctcc aagagacctc agccctgcac	1440
55	ggtttggtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500

	ctgcaggagg gggggtcccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgctgc atgccacccc cccagactca gttcccaag gtctgggacc cagtcttctt	1620
5	cggggcccgc tccccacct cctgcacctg ggcagactgg ctctgtgggg cctgggcatg	1680
	tgctgctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
10	tctcttggtt tcttggtgcg tgccaaaggt gtcgtgccag ggagtacggc gcccttgaa	1800
	ttccttcaca tcactttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
	gtgccaccag ctttgctcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
15	gccaggctcc tgcccacgat gtgcatccag gcctcggagg gaaaggacag cagcgtggca	1980
	gctttgctgc agaaggccga gccgcacaa cttcagatca cagcagcctt cctggcaggg	2040
20	ctgttgctcc gggagcactg gggcctgctg gctgagtgcc agacatctga gaaggccctg	2100
	ctccggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgcaa gcacttcac	2160
	tccatccgc cagctgcacc ggggtaggcc aagagcgtgc atgccatgcc cgggttcac	2220
25	tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcggaa ggctgcacgt	2280
	ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct	2340
30	gccctggcct ttgtgctgca gcacctccgg cggcccgtgg ccctgcagct ggactacaac	2400
	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
	tatttgcgcg ataacaatat ctcagaccga ggcatctgca agctcattga atgtgctctt	2520
35	cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca	2580
	cactccatgg ctaagctcct tgcattgcagg cagaacttct tggcattgag gctggggaat	2640
40	aactacatca ctgccgcggg agcccaagtg ctggccgagg ggctccgagg caacacctcc	2700
	ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct	2760
	gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc	2820
45	agtgtgggtg cccaagcctt ggcactgatg ctggcaaaga acatcatgct agaagaactc	2880
	tgcttgagg agaaccatct ccaggatgaa ggtgtatgtt ctctcgaga aggactgaag	2940
50	aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcatcaccta cctaggggca	3000
	gaagccctcc tgcaggccct tgaaaggaat gacaccatcc tggaagtctg gctccgaggg	3060
	aacactttct ctctagagga gggtgacaag ctcggtgca gggacaccag actcttgctt	3120
55	tga	3123



<210> 67  
 <211> 1040  
 5 <212> PRT  
 <213> Homo sapiens

10  
 <400> 67  
 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 15 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 20 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 25 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 30 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80  
 35 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 40 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 45 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 50 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 55 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 55 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala

	180	185	190
5	Asn Gly Leu Ala Ala Phe Leu	Leu Gln His Val Gln Glu Leu Pro Val	
	195	200	205
10	Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala		
	210	215	220
15	Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr		
	225	230	235
20	Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val		
	245	250	255
25	Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser		
	260	265	270
30	Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu		
	275	280	285
35	Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly		
	290	295	300
40	Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln		
	305	310	315
45	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu		
	325	330	335
50	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His		
	340	345	350
55	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu		
	355	360	365
60	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe		
	370	375	380
65	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro		
	385	390	395
70	Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu		
	405	410	415

5 Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala  
 420 425 430  
 Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser  
 435 440 445  
 10 Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly  
 450 455 460  
 15 Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His  
 465 470 475 480  
 20 Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
 485 490 495  
 25 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
 500 505 510  
 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
 515 520 525  
 30 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
 530 535 540  
 35 Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
 545 550 555 560  
 40 Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser  
 565 570 575  
 45 Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val  
 580 585 590  
 Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys  
 595 600 605  
 50 Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
 610 615 620  
 55 Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
 625 630 635 640

Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
 645 650 655  
 5 Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670  
 10 Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685  
 15 Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln  
 690 695 700  
 20 Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720  
 Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735  
 25 Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750  
 30 Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765  
 35 Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780  
 40 Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800  
 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 45 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830  
 50 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845  
 55 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860

Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880

5 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895

10 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910

15 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925

Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940

20 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Ile Met Leu Glu Glu Leu  
 945 950 955 960

25 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975

30 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990

35 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala'Leu Glu  
 995 1000 1005

Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020

40 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035

45 Leu Leu  
 1040

50 <210> 68  
 <211> 3123  
 <212> DNA

55 <213> Homo sapiens

<400> 68  
 5 atgggggaag aggggtgggtc agcctctcac gatgaggagg aaagagcaag tgtcctcctc 60  
 ggacattctc cgggttgtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
 ctgggtcgagc tgctgggtctc aggggtccctg gaaggcttcg agagtgtcct ggactggctg 180  
 10 ctgtcctggg aggtcctctc ctgggaggac tacgagggct tccacctcct gggccagcct 240  
 ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtac ttgggcctgt 300  
 cagaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcccc caagctgcat 360  
 15 ggctgctggg acccccactc gctccacca gcccgagacc tgcagagtca ccggccagcc 420  
 attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcgggg 480  
 20 ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg 540  
 gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc ctctcttcta 600  
 caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag 660  
 25 aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctcgcttcct cagtacctat 720  
 gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg 780  
 30 gcagatgtgg gcatggctgg acccccgcag aagagcccag ccaccctggg cctggaggag 840  
 ctcttcagca cccttgcca cctcaatgac gatgcggaca ctgtgctggg ggtgggtgag 900  
 gcgggcagtg gcaagagcac gctcctgcag cggtgcact tgctgtgggc tgcagggcaa 960  
 35 gacttccagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc 1020  
 aaaccactct ctgtgcggac tctactcttt gagcactgct gttggcctga tgttggtcaa 1080  
 40 gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc 1140  
 tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc 1200  
 acctctgtcc agaccctgct ctccaacctt ctgcagggca acctgctgaa gaatgccgc 1260  
 45 aaggtggtga ccagccgtcc ggccgctgtg tcggcgctcc tcaggaagta catccgcacc 1320  
 gagttcaacc tcaagggtt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat 1380  
 50 catgagcccc ggggtggcga ccgcctcatc cgctgctcc aagagacctc agccctgcac 1440  
 ggtttgtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg 1500  
 ctgcaggagg ggggggtcccc aaagaccact acagatatgt acctgctgat tctgcagcat 1560  
 55 tttctgctgc atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt 1620

	cggggcccgc tccccaccct cctgcacctg ggcagactgg ctctgtgggg cctgggcatg	1680
	tgctgctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
5	tctcttggtc tcctggtgcg tgccaaaggt gtcgtgccag ggagtacggc gccctggaa	1800
	ttccttcaca tcactttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
10	gtgccaccag ctttgctcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
	gccaggctcc tgcccacgat gtgcatccag gcctcggagg gaaaggacag cagcgtggca	1980
	gctttgtgc agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
15	ctgttgctcc gggagcaactg gggcctgctg gctgagtgcc agacatctga gaaggccctg	2100
	ctccggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgcaa gcacttcac	2160
20	tccatccgc cagctgcacc gggtagaggc aagagcgtgc atgcatgcc cgggttcac	2220
	tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcgga ggctgcacgt	2280
	ggcctgaatg ttgggcacct caagttgaca ttttgacgtg tgggccccac tgagtgtgct	2340
25	gccctggcct ttgtgctgca gcacctccgg cggcccgtgg ccctgcagct ggactacaac	2400
	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
30	tatttgcgcg ataacaatat ctcagaccga ggcattgca agctcattga atgtgtctt	2520
	cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca	2580
	cactccgtgg ctaagctcct tgcattgcagg cagaacttct tggcattgag gctggggaat	2640
35	aactacatca ctgccgcggg agcccaagtg ctggccgagg ggctccgagg caacacctcc	2700
	ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct	2760
40	gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc	2820
	agtgtgggtg cccaagcctt ggcactgatg ctggcaaaga acgtcatgct agaagaactc	2880
	tgcttgagg agaaccatct ccaggatgaa ggtgtatgtt ctctgcaga aggactgaag	2940
45	aaaaattcaa gtttgaaaat cctgaagttg tocaataact gcatcaccta cctaggggca	3000
	gaagccctcc tgcaggccct tgaaaggaat gacaccatcc tggaagtctg gctccgaggg	3060
50	aacactttct ctctagagga ggttgacaag ctcggtgca gggacaccag actcttgctt	3120
	tga	3123
55	<210> 69	
	<211> 1040	

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

5

&lt;400&gt; 69

10 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 15 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 20 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 25 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 30 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80  
 35 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 40 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 45 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 50 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 55 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 60 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 65 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190  
 70 Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val



	195	200	205
5	Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala 210 215 220		
10	Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr 225 230 235 240		
15	Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val 245 250 255		
20	Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Pro Pro Gln Lys Ser 260 265 270		
25	Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu 275 280 285		
30	Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly 290 295 300		
35	Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln 305 310 315 320		
40	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu 325 330 335		
45	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His 340 345 350		
50	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu 355 360 365		
55	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe 370 375 380		
60	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro 385 390 395 400		
65	Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu 405 410 415		
70	Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala 420 425 430		

5 Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser  
     435                                    440                    445  
 10 Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly  
     450                                    455                    460  
 15 Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His  
     465                                    470                    475                    480  
 20 Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
                                     485                    490                    495  
 25 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
                                     500                    505                    510  
 30 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
                                     515                    520                    525  
 35 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
     530                                    535                    540  
 40 Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
     545                                    550                    555                    560  
 45 Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser  
                                     565                    570                    575  
 50 Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val  
                                     580                    585                    590  
 55 Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys  
                                     595                    600                    605  
 60 Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
     610                                    615                    620  
 65 Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
     625                                    630                    635                    640  
 70 Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
                                     645                    650                    655

Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670

5

Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685

10

Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln  
 690 695 700

15

Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720

20

Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735

Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750

25

Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765

30

Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780

35

Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800

40

Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815

Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830

45

Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845

50

Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Val Ala  
 850 855 860

55

Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880

Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
                             885                            890                            895

5 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
                             900                            905                            910

10 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
                             915                            920                            925

15 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
                             930                            935                            940

Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
                             945                            950                            955                            960

20 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
                             965                            970                            975

25 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
                             980                            985                            990

30 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
                             995                            1000                            1005

35 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
                             1010                            1015                            1020

Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
                             1025                            1030                            1035

40 Leu Leu  
                             1040

45 <210> 70  
       <211> 25  
       <212> DNA

50 <213> Homo sapiens

55 <400> 70  
       ggcagatgtg ggcattggctg gacccc

25

5     <210> 71  
      <211> 25  
      <212> DNA  
      <213> Homo sapiens  
10  
      <400> 71  
      ggcagatgtg ggcattggctg gatcc 25  
15  
      <210> 72  
      <211> 26  
20     <212> DNA  
      <213> Homo sapiens  
25  
      <400> 72  
      agacatctga gaaggccctg ctccgg 26  
30     <210> 73  
      <211> 26  
      <212> DNA  
35     <213> Homo sapiens  
40     <400> 73  
      agacatctga gaaggccctg ctctgg 26  
45     <210> 74  
      <211> 24  
      <212> DNA  
50     <213> Homo sapiens  
55     <400> 74  
      ctgcagcacc tccggcggcc cgtg 24

<210> 75  
<211> 24  
5 <212> DNA  
<213> Homo sapiens  
10  
<400> 75  
ctgcagcacc tccggcggcc catg 24  
15 <210> 76  
<211> 24  
<212> DNA  
20 <213> Homo sapiens  
25 <400> 76  
ttgcagaagt tagctctatt caac 24  
30 <210> 77  
<211> 24  
<212> DNA  
35 <213> Homo sapiens  
40 <400> 77  
ttgcagaagt tagctctatt cagc 24  
<210> 78  
45 <211> 24  
<212> DNA  
<213> Homo sapiens  
50  
<400> 78  
55 actgacggct gtgcacactc catg 24

<210> 79  
<211> 24  
5 <212> DNA  
<213> Homo sapiens

10  
<400> 79  
actgacggct gtgcacactc cgtg 24

15 <210> 80  
<211> 23  
<212> DNA  
20 <213> Homo sapiens

25 <400> 80  
tgcagttcct gggattctgg ggc 23

30 <210> 81  
<211> 23  
<212> DNA  
35 <213> Homo sapiens

40 <400> 81  
tgcagttcct gggattctgg cgc 23

<210> 82  
45 <211> 23  
<212> DNA  
<213> Homo sapiens  
50

<400> 82  
55 cactgatgct ggcaaagaac gtc 23

<210> 83  
 <211> 23  
 5 <212> DNA  
 <213> Homo sapiens  
 10  
 <400> 83  
 cactgatgct ggcaaagaac atc 23  
 15 <210> 84  
 <211> 3123  
 <212> DNA  
 20 <213> Homo sapiens  
 25 <400> 84  
 atgggggaag aggggtggtc agcctctcac gatgaggagg aaagagcaag tgtcctcctc 60  
 ggacattctc cgggttggtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
 30 ctgggtcgagc tgcgtgtctc aggggtccctg gaaggcttcg agagtgtcct ggactggctg 180  
 ctgtcctggg aggtcctctc ctgggaggac tacgagggtt tccacctcct gggccagcct 240  
 ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtac ttgggcctgt 300  
 35 cagaagctca tcgcggctgc ccaagaagcc caggccgaca gccagtcccc caagctgcat 360  
 ggctgctggg acccccactc gctccacca gcccgagacc tgcagagtca ccggccagcc 420  
 40 attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcggggg 480  
 ttctgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg 540  
 gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta 600  
 45 caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag 660  
 aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctgcttcct cagtacctat 720  
 50 gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg 780  
 gcagatgtgg gcatggctgg atccccgag aagagcccag ccaccctggg cctggaggag 840  
 ctcttcagca cccctggcca cctcaatgac gatgcggaca ctgtgctggg ggtgggtgag 900  
 55 gcgggcagtg gcaagagcac gctcctgcag cggctgcact tgctgtgggc tgcagggcaa 960



	gacttccagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc	1020
	aaaccactct ctgtgcggac tctactcttt gagcactgct gttggcctga tgttggtcaa	1080
5	gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc	1140
	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
10	acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgccgcg	1260
	aaggtggtga ccagccgtcc ggccgctgtg tcggcgctcc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggctt ctctgaacag ggcacgcagc tgtacctgag gaagcgccat	1380
15	catgagcccg ggggtggcga ccgcctcatc cgctgctcc aagagacctc agccctgcac	1440
	ggtttgtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500
20	ctgcaggagg ggggggtccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgctgc atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt	1620
	cggggccgcc tccccacct cctgcacctg ggcagactgg ctctgtgggg cctgggcatg	1680
25	tgtgctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
	tctcttggtt tcctggtgcg tgccaaaggt gtcgtgccag ggagtacggc gcccctggaa	1800
	ttccttcaca tcactttcca gtgcttcttt gccgcgttct acctggcact cagtgtgat	1860
30	gtgccaccag ctttgctcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
	gccaggctcc tgcccacgat gtgcatccag gcctcgagg gaaaggacag cagcgtggca	1980
35	gctttgctgc agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
	ctggtgtccc gggagcactg gggcctgctg gctgagtgcc agacatctga gaaggccctg	2100
40	ctccggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgcaa gcacttcac	2160
	tccatcccg cagctgcacc ggggtaggcc aagagcgtgc atgccatgcc cgggttcac	2220
	tggctcatcc ggagcctgta cgagatgcag gaggagcggc tggctcgaa ggctgcacgt	2280
45	ggcctgaatg ttgggcacct caagttgaca ttttgacgtg tgggccccac tgagtgtgct	2340
	gccctggcct ttgtgctgca gcacctccgg cggcccgtgg ccctgcagct ggactacaac	2400
50	tctgtgggtg acattggcgt ggagcagctg ctgccttgc ttggtgtctg caaggctctg	2460
	tatttgcgcg ataacaatat ctacagccga ggcactgca agctcattga atgtgctctt	2520
	cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggtgtgca	2580
55	cactccatgg ctaagctcct tgcacgcagg cagaacttct tggcattgag gctggggaat	2640
	aactacatca ctgccgcggg agcccaagt ctggccgagg ggctccgagg caacacctcc	2700

ttgcagttcc tgggattctg ggcgaacaga gtgggtgacg agggggccca ggccctggct 2760  
 5 gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtggggaa caacattggc 2820  
 agtgtgggtg cccaagcctt ggcactgatg ctggcaaaga acgtcatgct agaagaactc 2880  
 tgcctggagg agaaccatct ccaggatgaa ggtgtatggt ctctcgaga aggactgaag 2940  
 10 aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcatcaccta cctaggggca 3000  
 gaagccctcc tgcaggccct tgaaaggaat gacaccatcc tggaagtctg gctccgaggg 3060  
 15 aacactttct ctctagagga ggttgacaag ctcggctgca gggacaccag actcttgctt 3120  
 tga 3123

<210> 85  
 20 <211> 1040  
 <212> PRT  
 25 <213> Homo sapiens

<400> 85  
 30 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15

35 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30

40 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45

45 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60

Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80

50 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95

55 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110

Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 5  
 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 10 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160  
 15 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175  
 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190  
 20 Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val  
 195 200 205  
 25 Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala  
 210 215 220  
 30 Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr  
 225 230 235 240  
 35 Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val  
 245 250 255  
 40 Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Ser Pro Gln Lys Ser  
 260 265 270  
 Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu  
 275 280 285  
 45 Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly  
 290 295 300  
 50 Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln  
 305 310 315 320  
 55 Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu  
 325 330 335

Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His  
 340 345 350

5 Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu  
 355 360 365

10 Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe  
 370 375 380

15 Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro  
 385 390 395 400

Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu  
 405 410 415

20 Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala  
 420 425 430

25 Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser  
 435 440 445

30 Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly  
 450 455 460

35 Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His  
 465 470 475 480

Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His  
 485 490 495

40 Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp  
 500 505 510

45 Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro  
 515 520 525

50 Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu  
 530 535 540

55 Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met  
 545 550 555 560

Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser

	565	570	575
5	Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val 580 585 590		
10	Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln Cys 595 600 605		
15	Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala 610 615 620		
20	Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met 625 630 635 640		
25	Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp 645 650 655		
30	Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln 660 665 670		
35	Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly 675 680 685		
40	Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg Gln 690 695 700		
45	Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His 705 710 715 720		
50	Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met 725 730 735		
55	Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu 740 745 750		
60	Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys 755 760 765		
65	Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe 770 775 780		
70	Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn 785 790 795 800		

5 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830  
 10 Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845  
 15 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860  
 20 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880  
 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895  
 25 Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Arg Asn Arg Val Gly  
 900 905 910  
 30 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925  
 35 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940  
 40 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960  
 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975  
 45 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990  
 50 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
 995 1000 1005  
 55 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020

Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035

5 Leu Leu  
 1040

10 <210> 86  
 <211> 3123  
 <212> DNA  
 15 <213> Homo sapiens

20 <400> 86  
 atgggggaag aggggtggttc agcctctcac gatgaggagg aaagagcaag tgtcctcctc 60  
 ggacattctc cgggttgtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
 25 ctggtcgagc tgctgggtctc aggggtccctg gaaggcttcg agagtgtcct ggactggctg 180  
 ctgtcctggg aggtcctctc ctgggaggac tacgagggtt tccacctcct gggccagcct 240  
 ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtag ttgggcctgt 300  
 30 cagaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcctc caagctgcat 360  
 ggctgctggg accccactc gctccacca gcccgagacc tgcagagtca ccggccagcc 420  
 35 attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcggggt 480  
 ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg 540  
 gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta 600  
 40 caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag 660  
 aagtatatgg ccaagctgag gaccacggtg tctgctcagt ctgcttcct cagtacctat 720  
 45 gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg 780  
 gcagatgtgg gcatggctgg atccccgag aagagcccag ccaccctggg cctggaggag 840  
 ctcttcagca ccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag 900  
 50 gcgggcagtg gcaagagcac gctcctgcag cggctgcact tgctgtgggc tgcagggcaa 960  
 gacttccagg aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc 1020  
 55 aaaccactct ctgtgcggac tetactcttt gagcactgct gttggcctga tgttggtcaa 1080  
 gaagacatct tccagttact ccttgaccac cctgaccgtg tcctgttaac ctttgatggc 1140

	tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc	1200
5	acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgcccgc	1260
	aaggtggtga ccagccgtcc ggccgctgtg tggcggttcc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggctt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat	1380
10	catgagcccg ggggtggcgga ccgcctcatc cgctgctcc aagagacctc agccctgcac	1440
	ggtttgtgcc acctgcctgt cttctcatgg atgggtgtcca aatgccacca ggaactgttg	1500
15	ctgcaggagg ggggggtcccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgtgc atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt	1620
	cggggcgccc tccccacct cctgcacctg ggagactgg ctctgtgggg cctgggcatg	1680
20	tgctgctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
	tctcttggct tcctggtgcg tgccaaaggt gtcgtgccag ggagtacggc gccctggaa	1800
25	ttccttcaca tcactttcca gtgcttcttt gccggttct acctggcact cagtgtgat	1860
	gtgccaccag ctttgcctcag acacctctt aattgtggca ggccaggcaa ctcaccaatg	1920
	gccaggctcc tgcccacgat gtgcatccag gcctcggagg gaaaggacag cagcgtggca	1980
30	gctttgtgc agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
	ctgttgtccc gggagcactg gggcctgtg gctgagtgcc agacatctga gaaggccctg	2100
35	ctccggcgcc aggcctgtgc ccgctggtgt ctggcccgca gcctccgaa gcacttcac	2160
	tccatccgc cagctgcacc ggggtgaggcc aagagcgtgc atgccatgcc cgggttcac	2220
	tggtcatcc ggagcctgta cgagatgcag gaggagcggc tggctcgaa ggctgcacgt	2280
40	ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct	2340
	gccctggcct ttgtgctgca gcacctccgg cggcccgtgg ccctgcagct ggactacaac	2400
45	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
	tatttgcgcy ataacaatat ctcagaccga ggcatctgca agctcattga atgtgctctt	2520
	cactgcgagc aattgcagaa gttagctcta ttcagcaaca aattgactga cggtgtgca	2580
50	cactccatgg ctaagctcct tgcatgcagg cagaacttct tggcattgag gctggggaat	2640
	aactacatca ctgccgcggg agcccaagtg ctggccgagg ggctccgagg caacacctcc	2700
55	ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct	2760
	gaagccttgg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc	2820



```

      agtgtgggtg cccaagcctt ggcactgatg ctggcaaaga acgtcatgct agaagaactc 2880
      tgcttgagg agaaccatct ccaggatgaa ggtgtatgtt ctctcgaga aggactgaag 2940
5     aaaaattcaa gtttgaatat cctgaagttg tccaataact gcatcaccta cctaggggca 3000
      gaagccctcc tgcaggccct tgaaaggaat gacaccatcc tggaagtctg gctccgaggg 3060
      aacactttct ctctagagga ggttgacaag ctcggtgca gggacaccag actcttgctt 3120
10    tga
                                           3123

```

15 <210> 87

<211> 1040

<212> PRT

20 <213> Homo sapiens

25 <400> 87

```

Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala
1           5           10           15

```

```

30 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu
           20           25           30

```

```

35 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly
           35           40           45

```

```

40 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu
           50           55           60

```

```

Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro
65           70           75           80

```

```

45 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly
           85           90           95

```

```

50 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala
           100          105          110

```

```

55 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu
           115          120          125

```

His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140

5 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly  
 145 150 155 160

10 Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr  
 165 170 175

15 Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala  
 180 185 190

Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val  
 195 200 205

20 Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala  
 210 215 220

25 Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr  
 225 230 235 240

30 Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val  
 245 250 255

35 Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Ser Pro Gln Lys Ser  
 260 265 270

Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu  
 275 280 285

40 Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly  
 290 295 300

45 Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln  
 305 310 315 320

50 Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu  
 325 330 335

55 Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His  
 340 345 350

Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu

	355		360		365
5	Asp His Pro Asp Arg Val	Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe			
	370	375	380		
10	Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro				
	385	390	395	400	
	Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu				
		405	410	415	
15	Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala				
		420	425	430	
20	Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser				
		435	440	445	
25	Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly				
		450	455	460	
30	Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His				
		465	470	475	480
	Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His				
		485	490	495	
35	Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp				
		500	505	510	
40	Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro				
		515	520	525	
45	Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu				
		530	535	540	
50	Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met				
		545	550	555	560
	Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser				
		565	570	575	
55	Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val Val				
		580	585	590	

5	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	Leu	His	Ile	Thr	Phe	Gln	Cys	595	600	605
10	Phe	Phe	Ala	Ala	Phe	Tyr	Leu	Ala	Leu	Ser	Ala	Asp	Val	Pro	Pro	Ala	610	615	620
15	Leu	Leu	Arg	His	Leu	Phe	Asn	Cys	Gly	Arg	Pro	Gly	Asn	Ser	Pro	Met	625	630	635
20	Ala	Arg	Leu	Leu	Pro	Thr	Met	Cys	Ile	Gln	Ala	Ser	Glu	Gly	Lys	Asp	645	650	655
25	Ser	Ser	Val	Ala	Ala	Leu	Leu	Gln	Lys	Ala	Glu	Pro	His	Asn	Leu	Gln	660	665	670
30	Ile	Thr	Ala	Ala	Phe	Leu	Ala	Gly	Leu	Leu	Ser	Arg	Glu	His	Trp	Gly	675	680	685
35	Leu	Leu	Ala	Glu	Cys	Gln	Thr	Ser	Glu	Lys	Ala	Leu	Leu	Arg	Arg	Gln	690	695	700
40	Ala	Cys	Ala	Arg	Trp	Cys	Leu	Ala	Arg	Ser	Leu	Arg	Lys	His	Phe	His	705	710	715
45	Ser	Ile	Pro	Pro	Ala	Ala	Pro	Gly	Glu	Ala	Lys	Ser	Val	His	Ala	Met	725	730	735
50	Pro	Gly	Phe	Ile	Trp	Leu	Ile	Arg	Ser	Leu	Tyr	Glu	Met	Gln	Glu	Glu	740	745	750
55	Arg	Leu	Ala	Arg	Lys	Ala	Ala	Arg	Gly	Leu	Asn	Val	Gly	His	Leu	Lys	755	760	765
60	Leu	Thr	Phe	Cys	Ser	Val	Gly	Pro	Thr	Glu	Cys	Ala	Ala	Leu	Ala	Phe	770	775	780
65	Val	Leu	Gln	His	Leu	Arg	Arg	Pro	Val	Ala	Leu	Gln	Leu	Asp	Tyr	Asn	785	790	795
70	Ser	Val	Gly	Asp	Ile	Gly	Val	Glu	Gln	Leu	Leu	Pro	Cys	Leu	Gly	Val	805	810	815

Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
                     820                    825                    830

5

Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
                     835                    840                    845

10

Ala Leu Phe Ser Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
                     850                    855                    860

15

Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
                     865                    870                    875                    880

20

Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
                     885                    890                    895

25

Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
                     900                    905                    910

30

Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
                     915                    920                    925

35

Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
                     930                    935                    940

40

Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
                     945                    950                    955                    960

45

Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
                     965                    970                    975

50

Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
                     980                    985                    990

55

Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
                     995                    1000                    1005

Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
                     1010                    1015                    1020

Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
                     1025                    1030                    1035

Leu Leu  
1040

5 <210> 88  
<211> 3123  
<212> DNA  
10 <213> Homo sapiens

15 <400> 88  
atgggggaag aggggtggttc agcctctcac gatgaggagg aaagagcaag tgcctcctc 60  
ggacattctc cgggttggtga aatgtgctcg caggaggctt ttcaggcaca gaggagccag 120  
20 ctggtcgagc tgctggtctc agggtcctcg gaaggcttcg agagtgtcct ggactggctg 180  
ctgtcctggg aggtcctctc ctgggaggac tacgagggt tccacctcct gggccagcct 240  
ctctcccact tggccaggcg ccttctggac accgtctgga ataagggtac ttgggcctgt 300  
25 cágaagctca tcgcggtgc ccaagaagcc caggccgaca gccagtcccc caagctgcat 360  
ggctgctggg acccccactc gctccacca gcccgagacc tgcagagtca ccggccagcc 420  
30 attgtcagga ggctccacag ccatgtggag aacatgctgg acctggcatg ggagcgggt 480  
ttcgtcagcc agtatgaatg tgatgaaatc aggttgccga tcttcacacc gtcccagagg 540  
gcaagaaggc tgcttgatct tgccacggtg aaagcgaatg gattggctgc cttccttcta 600  
35 caacatgttc aggaattacc agtcccattg gccctgcctt tggaagctgc cacatgcaag 660  
aagtatatgg ccaagctgag gaccacggtg tctgtcagt ctgcttctc cagtacctat 720  
40 gatggagcag agacgctctg cctggaggac atatacacag agaatgtcct ggaggtctgg 780  
gcagatgtgg gcatggctgg atccccgag aagagcccag ccacctggg cctggaggag 840  
ctcttcagca ccctggcca cctcaatgac gatgcggaca ctgtgctggt ggtgggtgag 900  
45 gcgggcagtg gcaagagcac gctcctgcag cggctgcact tgctgtggg tgcagggcaa 960  
gacttcagag aatttctctt tgtcttccca ttcagctgcc ggcagctgca gtgcatggcc 1020  
50 aaaccactct ctgtgctggac tctactctt gagcactgct gttggcctga tgttggtcaa 1080  
gaagacatct tccagttact ccttgaccac cctgaccgtg tctgtttaac ctttgatggc 1140  
tttgacgagt tcaagttcag gttcacggat cgtgaacgcc actgctcccc gaccgacccc 1200  
55 acctctgtcc agaccctgct cttcaacctt ctgcagggca acctgctgaa gaatgccgc 1260

	aaggtggtga ccagccgtcc ggccgctgtg tcggcggttc tcaggaagta catccgcacc	1320
	gagttcaacc tcaagggctt ctctgaacag ggcatcgagc tgtacctgag gaagcgccat	1380
5	catgagcccg ggggtggcga ccgcctcatc cgcctgtctc aagagacctc agccctgcac	1440
	ggtttgtgcc acctgcctgt cttctcatgg atggtgtcca aatgccacca ggaactgttg	1500
10	ctgcaggagg gggggtcccc aaagaccact acagatatgt acctgctgat tctgcagcat	1560
	tttctgtctg atgccacccc ccagactca gcttcccaag gtctgggacc cagtcttctt	1620
	cggggcccgc tccccacct cctgcacctg ggagactgg ctctgtgggg cctgggcatg	1680
15	tgtgtctacg tgttctcagc ccagcagctc caggcagcac aggtcagccc tgatgacatt	1740
	tctcttggtc tcctggtgcg tgccaaaggt gtcgtgccag ggagtaaggc gcccctggaa	1800
	ttccttcaca tcactttcca gtgcttcttt gccgcgttct acctggcact cagtgtctgat	1860
20	gtgccaccag ctttgctcag acacctcttc aattgtggca ggccaggcaa ctcaccaatg	1920
	gccaggtccc tgcccacgat gtgcatccag gcctcgagg gaaaggacag cagcgtggca	1980
25	gctttgtctg agaaggccga gccgcacaac cttcagatca cagcagcctt cctggcaggg	2040
	ctgttggtccc gggagcactg gggcctgtgt gctgagtgcc agacatctga gaaggccctg	2100
30	ctctggcgcc aggcctgtgc ccgctggtgt ctggcccga gcctccgcaa gcacttccac	2160
	tccatcccgc cagctgcacc gggtagggcc aagagcgtgc atgccatgcc cgggttcac	2220
	tggtcatcc ggagcctgta cgagatgcag gaggagcggc tggctcgaa ggctgcacgt	2280
35	ggcctgaatg ttgggcacct caagttgaca ttttgagtg tgggccccac tgagtgtgct	2340
	gccctggcct ttgtgtgca gcacctccgg cggcccgtgg ccctgcagct ggactacaac	2400
40	tctgtgggtg acattggcgt ggagcagctg ctgccttgcc ttggtgtctg caaggctctg	2460
	tatttgccgcg ataacaatat ctcagaccga ggcatctgca agctcattga atgtgtctt	2520
	cactgcgagc aattgcagaa gttagctcta ttcaacaaca aattgactga cggctgtgca	2580
45	cactccatgg ctaagctcct tgcattgcag cagaacttct tggcattgag gctggggaat	2640
	aactacatca ctgccgcggg agcccaagt ctggccgagg ggctccgagg caacacctcc	2700
50	ttgcagttcc tgggattctg gggcaacaga gtgggtgacg agggggccca ggccctggct	2760
	gaagccttg gtgatcacca gagcttgagg tggctcagcc tgggtgggaa caacattggc	2820
	agtgtgggtg cccaagcctt ggactgatg ctggcaaaga acgtcatgct agaagaactc	2880
55	tgcctggagg agaaccatct ccaggatgaa ggtgtatgtt ctctcgaga aggactgaag	2940
	aaaaattcaa gtttgaaaat cctgaagttg tccaataact gcacaccta cctaggggca	3000

gaagccctcc tgcaggccct tgaaggaat gacaccatcc tggaagtctg gctccgaggg 3060  
 aacactttct ctctagagga ggttgacaag ctcggctgca gggacaccag actcttgctt 3120  
 5 tga 3123  
  
 <210> 89  
 10 <211> 1040  
 <212> PRT  
 15 <213> Homo sapiens  
  
 <400> 89  
 20 Met Gly Glu Glu Gly Gly Ser Ala Ser His Asp Glu Glu Glu Arg Ala  
 1 5 10 15  
 25 Ser Val Leu Leu Gly His Ser Pro Gly Cys Glu Met Cys Ser Gln Glu  
 20 25 30  
 30 Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser Gly  
 35 40 45  
 35 Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp Glu  
 50 55 60  
 Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln Pro  
 65 70 75 80  
 40 Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys Gly  
 85 90 95  
 45 Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln Ala  
 100 105 110  
 50 Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser Leu  
 115 120 125  
 His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg  
 130 135 140  
 55 Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly



	145		150		155		160
5	Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr	165		170		175	
10	Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala	180		185		190	
15	Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val	195		200		205	
20	Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met Ala	210		215		220	
25	Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr Tyr	225		230		235	240
30	Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn Val	245		250		255	
35	Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Ser Pro Gln Lys Ser	260		265		270	
40	Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His Leu	275		280		285	
45	Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly	290		295		300	
50	Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln	305		310		315	320
55	Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu	325		330		335	
	Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His	340		345		350	
	Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu	355		360		365	
	Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe	370		375		380	

5	Lys	Phe	Arg	Phe	Thr	Asp	Arg	Glu	Arg	His	Cys	Ser	Pro	Thr	Asp	Pro	385	390	395	400
	Thr	Ser	Val	Gln	Thr	Leu	Leu	Phe	Asn	Leu	Leu	Gln	Gly	Asn	Leu	Leu		405	410	415
10	Lys	Asn	Ala	Arg	Lys	Val	Val	Thr	Ser	Arg	Pro	Ala	Ala	Val	Ser	Ala		420	425	430
15	Phe	Leu	Arg	Lys	Tyr	Ile	Arg	Thr	Glu	Phe	Asn	Leu	Lys	Gly	Phe	Ser		435	440	445
20	Glu	Gln	Gly	Ile	Glu	Leu	Tyr	Leu	Arg	Lys	Arg	His	His	Glu	Pro	Gly		450	455	460
25	Val	Ala	Asp	Arg	Leu	Ile	Arg	Leu	Leu	Gln	Glu	Thr	Ser	Ala	Leu	His		465	470	475
30	Gly	Leu	Cys	His	Leu	Pro	Val	Phe	Ser	Trp	Met	Val	Ser	Lys	Cys	His		485	490	495
35	Gln	Glu	Leu	Leu	Leu	Gln	Glu	Gly	Gly	Ser	Pro	Lys	Thr	Thr	Thr	Asp		500	505	510
40	Met	Tyr	Leu	Leu	Ile	Leu	Gln	His	Phe	Leu	Leu	His	Ala	Thr	Pro	Pro		515	520	525
45	Asp	Ser	Ala	Ser	Gln	Gly	Leu	Gly	Pro	Ser	Leu	Leu	Arg	Gly	Arg	Leu		530	535	540
50	Pro	Thr	Leu	Leu	His	Leu	Gly	Arg	Leu	Ala	Leu	Trp	Gly	Leu	Gly	Met		545	550	555
55	Cys	Cys	Tyr	Val	Phe	Ser	Ala	Gln	Gln	Leu	Gln	Ala	Ala	Gln	Val	Ser		565	570	575
60	Pro	Asp	Asp	Ile	Ser	Leu	Gly	Phe	Leu	Val	Arg	Ala	Lys	Gly	Val	Val		580	585	590
65	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	Leu	His	Ile	Thr	Phe	Gln	Cys		595	600	605

Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro Ala  
 610 615 620  
 5  
 Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro Met  
 625 630 635 640  
 10 Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys Asp  
 645 650 655  
 15 Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu Gln  
 660 665 670  
 20 Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp Gly  
 675 680 685  
 Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Trp Arg Gln  
 690 695 700  
 25 Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe His  
 705 710 715 720  
 30 Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala Met  
 725 730 735  
 35 Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu  
 740 745 750  
 40 Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu Lys  
 755 760 765  
 Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala Phe  
 770 775 780  
 45 Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn  
 785 790 795 800  
 50 Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly Val  
 805 810 815  
 55 Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly Ile  
 820 825 830

Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys Leu  
 835 840 845

5 Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met Ala  
 850 855 860

10 Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly Asn  
 865 870 875 880

15 Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg  
 885 890 895

Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly  
 900 905 910

20 Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser  
 915 920 925

25 Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala  
 930 935 940

30 Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu  
 945 950 955 960

35 Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala  
 965 970 975

40 Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser Asn  
 980 985 990

Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu  
 995 1000 1005

45 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe  
 1010 1015 1020

50 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu  
 1025 1030 1035

Leu Leu  
 1040

55

<210> 90  
<211> 25  
5 <212> DNA  
<213> Homo sapiens  
  
10 <400> 90  
gggcagaagc cctcctgcag gccct 25  
  
15 <210> 91  
<211> 26  
<212> DNA  
20 <213> Homo sapiens  
  
25 <400> 91  
gggcagaagc cctcctgcag gccct 26  
  
30 <210> 92  
<211> 22  
<212> DNA  
35 <213> Artificial Sequence  
  
40 <220>  
<223> Synthetic  
<400> 92  
45 cagaagccct cctgcaggcc ct 22  
  
50 <210> 93  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
55

<220>  
<223> Synthetic  
5 <400> 93  
cgcggtgtcat tcctttcatg gggc 24  
  
10 <210> 94  
<211> 20  
<212> DNA  
15 <213> Artificial Sequence  
  
20 <220>  
<223> Synthetic  
<400> 94  
25 agtgcacagc ttgtgaatgg 20  
  
<210> 95  
<211> 27  
30 <212> DNA  
<213> Artificial Sequence  
35  
  
<220>  
<223> Synthetic  
40 <400> 95  
cgcgggcaga tgtgggcatg gctagac 27  
  
45 <210> 96  
<211> 19  
<212> DNA  
50 <213> Artificial Sequence  
  
55 <220>  
<223> Synthetic

<400> 96  
 gcagctgaat gggaagaca 19

5  
 <210> 97  
 <211> 26

10 <212> DNA  
 <213> Artificial Sequence

15  
 <220>  
 <223> Synthetic

20 <400> 97  
 gccgtggctg ggctcttctg cgagga 26

25 <210> 98  
 <211> 27  
 <212> PRT

30 <213> Homo sapiens

35 <400> 98  
 Leu Ser Asn Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln  
 1 5 10 15

40 Ala Leu Glu Arg Asn Asp Thr Ile Leu Glu Val  
 20 25

45 <210> 99  
 <211> 18  
 <212> PRT

50 <213> Homo sapiens

55 <400> 99  
 Leu Ser Asn Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln  
 1 5 10 15

Ala Pro